<SEC-DOCUMENT>0000939767-21-000097.txt : 20211102
<SEC-HEADER>0000939767-21-000097.hdr.sgml : 20211102
<ACCEPTANCE-DATETIME>20211102161847
ACCESSION NUMBER:		0000939767-21-000097
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20211001
FILED AS OF DATE:		20211102
DATE AS OF CHANGE:		20211102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		211371566

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20211001.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52,d:7e2d69fbadd646bd8aed87fedd3d018c--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:exel="http://www.exelixis.com/20211001" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20211001</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M18yLTEtMS0xLTA_6ae81369-d6cf-4ecb-88f8-8e8acd7e7c22">false</ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M180LTEtMS0xLTA_78d11355-35b2-4c7a-a7f4-a33320b1df9b">2021</ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M181LTEtMS0xLTA_b8508a82-36f9-4144-8869-3a4c33e0c88c">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M182LTEtMS0xLTA_0573daf1-6541-4324-93de-6deef93998fb">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M183LTEtMS0xLTA_05dfb2f8-64e4-4391-92de-bdff1ca5e752">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20211001.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia9f82e383c694af98e6ab4c223730d0f_I20211025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide163890188b441d915e37fe3b4e3038_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65446bf2aefe4b8b84374a8e8278071d_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd49a4943be041879f2e79978071f89b_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518c57cfc2514e6599b766ac488ba69f_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3cacefb1924a19b321562f6cc1c50f_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15e8da8abd24a81a7bb05a35813d724_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe73b8c15e74b31812388266b3b6221_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e12bec23f4e45b9b13fab2a662de8d6_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef3dfbd7d00493facc23c12218a5c77_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93fec9e93714e5e8df46aa0e36139b7_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4355be7a9b5344b3b5089274a3522b2c_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e1c3a859c9742a09f45706125e87b43_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a199c9648744541be4de3d34bb7e362_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide320c4815644a62a658d3862311595c_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47efd87d077d432f81f34c8bf9b33d22_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4646f21cac644933a185200c07101315_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198373947b4145e597fec4495ee48f55_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44a54e568514d1cba61fe6a37c6f581_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa21b82a225453a9b5b3197b7945bb2_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ddb6bce36184f08be45c8955d58a6fe_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f35a35374542268bc2759496673a02_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c9d55484894ea1b4af267e9c70eb4d_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cdd133e47d04123866777ff9abd71d2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ab773d1d894523a26a2a3ceb10fe3e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451f3b4d1aa14a1bbcb5d26014d13efc_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c8618c9439454b8cb846aaed306eaa_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048c97d67ba14a7e9c9166ecce15a78f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccbb310782fb42fea3375eb6a1ccf6a8_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ee09a03bec4322b0b7c0889fe08791_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d66ad81fc247a8856e28f96b5e71b4_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe7efeffe4d4f2fa1c6ab83e7c2abd3_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c0fbefe45c4bddad088d3948fec4d4_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:context id="ib422db6657d447b49fd7f409b08a14d0_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7652c419cd5e434ebdaf01060d9d1b55_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic5cb6b35aa834afe81197ed5f5a2983b_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1d06f401ca4330abe2df73ad44d932_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300f361eb7ac41089fb4dcbbbaa0b22c_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d98f6b265ec4941b70dd37ca3904b2d_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399cf68a318047d4b6e4fe4633d1e94f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb3578547994d3fb6471e6ac46c8ae1_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83bf53370dce463db3d2184cc9abeeed_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1a4766b133423c94f7ac43bee70be1_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66848fd649d4aa3b3af5f75c759ed57_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c6d26551a848e69c150ea689520c0c_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf8e62d4ceae407da69dddd7a401315a_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5701273b195d4b8fa25b28e5eaf36b88_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f8a9eb0dca41b09aaedd7f9d03c606_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7eaebb9b56c4a4da079b1660c8ec3cb_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e11bac7372644709417934e0ca155a5_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916390b099cf490a8faaf1f1536bb941_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27140a762b04420283d20b05a3483f19_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd6869dd7354422821f089dadf50b8c_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82fd13f9c484bcd90d7acca51198b90_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19e6f8ceb3d4193a62ed61fe70f30d2_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d11b7619ee4ffdb9ca1f1ae9dcfcce_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43aff9879b254a2bb8d73b57aaad937d_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748062d52a79415b951264743fd8a262_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333ba041ae564029967d730948f966a1_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533ba6a6b82e4d4b9cb2b6bf9f6227d8_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab832c59885481194024af60a61d1df_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094984ccbfca4e3fac09b15012e1be74_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237d077e560b4407af980d2b6dbb5351_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf27c022f00045578983d2cd05cefd50_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfefd582d8584f539f09611fe980f68f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96da6fb9308c4441a6c7e0e9966c1d83_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef660618700414f8dcbfb860da76a87_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1e2a62f0694219aade24fac80d1c5e_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9326972b57124d95b7c72df93cabd3e1_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie773f2a3a13f4701a26b5a39d5d1daee_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33755e44bf94f1da1da6239ce61afce_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1034b890c344f2187aff9b841e56da4_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b6af8835eb4a388447fefe69add707_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f554670ff6b4145bbceb659e8d31cee_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362468d981744887840c7c13b4494a7b_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4a5f75f1f84d7cb2773b54773806d1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a51cab5342b4f589598449b9d53e45a_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe7a926c38a46a6a1270839bca439ab_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e56e167d51d4361a27af591b87356ee_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae0fe3ee92a4735919e62e7c773d8f8_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac98a4d51cd54e6993377fc838bb765a_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31062813c13140b7b457913dd4852e78_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5422d1856079466bbb9f65186f532193_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0cbb1bbb9c8465c8eaa7264a9c37ea6_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic620d2de433e40fca7e2944d830c2bda_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b511d5be3cc42d6a46455b239456426_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210d874da4ec4ad2b439ac379d882d7c_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebc613892384a1e81978aadc22bc1fd_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id076f77c6811421996bf94e07e9611b6_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf26fde834484f20a6cb7803fb0e1cd7_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d721a4a024409b8e51b7763addb8a4_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6cabd3bc8aa4381abca308dce1cb94b_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2514fa13b9413db7b3f86827a216cc_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ed7af7a5b8432dad75ddaa4bc98d77_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886d9164ed4647cf9aab2503a662e148_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43ea83781f046ea919b9cbceae39832_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c6af5351c04591a3a684eaf231d711_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1fd8c412d841c9b9361bc3a6ccd5d4_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37bf6ef982543208fd55d26c3a8d017_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb4d4519bbd45b58964c21b78d81e64_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92ef125dfb745409eb663f06a66015c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i347244ecea174e2b84d7115e9117517a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecec3a46caf04b9bb463218152250078_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc219e31879f4e968543b9a4acc1c6bd_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f92052702c84e3da6d1adf2f5d4712a_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299213a2fe8a44d19010980daaddadd2_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e6809b452b4c0d91e76fccd77f2f8c_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c12de1d32146d68e9fb7edd1441d2d_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e4ab99fdb34795911040b0e2097e76_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3beaad32f58b469c90e2e895a020fed6_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8050e574dc1c4db78e12b097abdec6dc_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ebdacb1fea40dd827669ddd4d97f01_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabc23478b384ed9851e76ca8df34e39_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c088daadd8a408f89a19ef83a3570ed_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41488a2e36454734af6a6a327ecb17cf_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0256d26fd34b138fadf3cd0c240a78_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c65d788a4d64260968ac3714dcfe64f_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7183ea49abb44619f51586094019e9f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i303d549538f2427bba2cce5280974392_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59abfa55299448e3a17334e501e602fd_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ef9a35f9714d0baf8ee7a1bf5fa4f9_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46630f5e17e048d6958cfa0d603db35f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf65eae8d34c44368baa6edb4df56a64_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id970f743dae1483e88e2ddd200c78c24_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d005b00a57d4883b8ae4d21dc6bde0b_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5db0c4605f84fbdb15d0ac333e9c674_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5376f2dae7f547e9b48251e30c8efb87_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e1880501a749b483269275293c21a5_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227171c03dd7470ab777a1c62dda82f1_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3992056ab144b1b9917c48ab7ac95cf_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893a51123e7c4016962a39929c139bff_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180e76bcc0744dceb497bede8877d6bc_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33937ce988840acb055192972fe7d0e_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3f26725f7e469ab88cddcff11f5119_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19bb8d1b724e4bd8a470e35512bff9e4_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb6246a347b47a29f0ec6969990a643_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>exel:target</xbrli:measure></xbrli:unit><xbrli:context id="i42c64fd2685d49a09c1aaa714e8a71b5_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab15a25bff164a59ba9db9bb00ba2c21_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e81c19802d8419abd05b32afb361529_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8f21157bbf4e7a88b78baa89878020_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d54e684ac234965a52c3f8147a489f2_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f3b300dd384295b48111fb3de48dc8_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dce2e60a7dd497a8e784207c60eda67_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1603788af44df89cb2501d143c508e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d33b9db55634d2f8dd4b55f547600b6_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia937163ad2774ba59a4a97202dd4f1d3_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic704aa165c1c46d4ae28412336d3f23c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522e306d776042df8fab951f97ebaf9e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e0f0514bbc24b8596206e4a278f05c9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7942a0d26aa2410493571fbd1d1a1d40_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="i57f02cd5c10e458e843d55805a3431fd_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba2574066cf4ff6a9f6e4150f0d9a59_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbe7cfb8d5147028098fffe5f993314_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0747067a48245fc8dc26066c743c9d3_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262de96d6b8744ae924a3782d09bacc8_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia884675fcb614de78f41b988cfa85253_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788e7100b3c44fc79ba7388a22d4be54_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f49a14a38b4618a641e7062e9a8119_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib852bbac7c2b4dae935d9ace85587f2b_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2116aaf10cba486e9ea0a92a908bcf3f_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac31bdedd8347f4a54d5329d8341508_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6aee20093514a7c908b61d8a427f82f_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85113d3b2cbb42bea2638a8879a3bc44_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f7ba7484824fdfb1bf032ab871ce77_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1060b811968c481ebf2bbc36128837fb_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b53fa939094dbc9d03652f7ae327cd_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice95d1289bb548b3a198fedcadd68f9c_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0713852efdf4c9b8596061c2371f8c5_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2720023a476a45c4ad1b14dea520df26_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f50cbeebde04173b4d76512c9e37178_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce21a7f43c44e3f961a96a70156939e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358c92e2bfaf46b3bda44418ad4ddff9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eee75baece241f6bc83d598c6a8dce5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b60ddc46614de198e0d20fcc2e0d40_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice80f13753ab4747b55be1f290360a38_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a068b43a44e4e71aed4fab765a9a10d_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4197a386017d4ce4b80b50397cde9f66_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74bd879c428e43e38d7c190fb00c13bd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b26d8ad0e0c4ab9b2ddc26c19baf207_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06308a04850340b581f089fa2d42d8ab_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a9bdf6dc464c5f9f939b05d8db8a62_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3bb879c1144c2b8f21d8d76daa2611_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b9dabe918ed4a75984789a54fabbc52_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576f4d76f4844ef59140fad75b749351_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f14e7d83ac24bc0934f3ce817815377_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie604d7023f6448e9bfdea6430b029c7d_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3d41a820d64c68a08dc8510596f5bc_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc806a4586494bdea73d4d8ca8067226_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5366d5070d44918ed8a0165ebd5ab0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="forward_contract"><xbrli:measure>exel:forward_contract</xbrli:measure></xbrli:unit><xbrli:context id="i68ac30fd607b41bc80b50c13706647e4_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0936cbe6a0f84d479d483892d24f6d55_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib720450b2a1a4fc8a2cdcdb63baed576_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db00f27c60d4842a7a2bce3d6d547e1_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia41fd2edf3a14dd7bf6bb33de4813ccc_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafa823dcfbd4c2a9d8b8df5d69e150d_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bdb2309e0e5446b87b31a0eb6c99f2c_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67eaaa8ffdc4407780e4e29e54ed4917_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b8058d357f34b1db293a0ba18c7b0e4_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff8c10e09a74083a913c8dd829db3e3_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133709ff0a1b4c138d61663fd033397e_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b5f2d2f5d3425586df0611b0cd3dbb_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4accc8a979184a968b8b082d620fbf50_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e09d7534be4b2999db1628207e2de6_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7299aa4e8d1145f896fecef97ca01e59_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08eb8dd6d816445da416b2e82bf72356_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0381b7e4bd74829a0a31d3bf8871cf0_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bef1feb8ca440608a019e77cde78bae_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d30612661b1407c8474216f06f0d220_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808843dbbc3c44908e48a431eb1f24d0_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb2d7629149a482f9cc826940879689f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1460d3b96640419a83156ab690e99fb1_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50addfcd8acf48179fe0db096adfbc86_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838699b122594d4f9e99ff8f3d9dbddd_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a6530ae4124dd299a7574226b98393_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fce6ed1b2045eb851578aba3348c9a_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a75f9432ff64e73a1ac73574ddcfa54_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1dc7061a4104e0b8aeb478b3078f095_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf64fa313b794183bf4faf469cfd0c06_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aaa7d8a46a34b038a5d053b7701b533_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id421b19fea1b414c8e38865109ab0e73_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535221d9dcc64cd9a6a8c6fdc118809a_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165ca677164a4242b9e75babf9daaee0_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b3a70674fc4636bc068b030241f7ab_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedAndProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e23ec3c3e84835ad5b3e3b31152b22_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2972daa1c2964506955e6854b99b0bd8_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74264c148104da28095c53746f7d4fe_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6OTUxYjE2YTJlYTg3NDA3ZmIxYjY3MzIwYzcwNTYzZWIvdGFibGVyYW5nZTo5NTFiMTZhMmVhODc0MDdmYjFiNjczMjBjNzA1NjNlYl8wLTEtMS0xLTA_0ec99e8d-7110-4612-809b-f7c3ffe0d04c">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ODRlNjc2M2Q0M2ZlNDNlY2E0MTc1NzBkOTgyYmNkYjMvdGFibGVyYW5nZTo4NGU2NzYzZDQzZmU0M2VjYTQxNzU3MGQ5ODJiY2RiM18wLTAtMS0xLTA_79a29efc-d2ce-4c28-b875-a69f312e4bb3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18zMjk4NTM0ODg1Mjg0_a49fed01-a2d9-4af7-be06-aa7533fe9e7e">October 1, 2021</ix:nonNumeric></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6M2QyZmU4MzU0ZjljNGI4Yzg3OGE2OTcyNWQ2NTZkMDQvdGFibGVyYW5nZTozZDJmZTgzNTRmOWM0YjhjODc4YTY5NzI1ZDY1NmQwNF8wLTAtMS0xLTA_39f4197a-fba1-4e23-a90e-560b01a52c2a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODcy_bdbf2759-e470-408c-a074-608f94aeb4ef">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20211001_g1.jpg" alt="exel-20211001_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NDc4ZGViOGZiYWRmNDg3YjkxMmFlMWM2YjNjMDVkYzUvdGFibGVyYW5nZTo0NzhkZWI4ZmJhZGY0ODdiOTEyYWUxYzZiM2MwNWRjNV8xLTAtMS0xLTA_39ffb2d5-19d2-4370-92c0-45c7295cfb14">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NmExNzg0MmE4YjkxNDVkNDkzYjgzODhhNDFhZjc1NjUvdGFibGVyYW5nZTo2YTE3ODQyYThiOTE0NWQ0OTNiODM4OGE0MWFmNzU2NV8wLTAtMS0xLTA_e9bfcd9f-e078-48b4-bd1d-2e49f60bbf42">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NmExNzg0MmE4YjkxNDVkNDkzYjgzODhhNDFhZjc1NjUvdGFibGVyYW5nZTo2YTE3ODQyYThiOTE0NWQ0OTNiODM4OGE0MWFmNzU2NV8wLTEtMS0xLTA_55e5ffbd-ea45-4796-9bf0-27350de8a2de">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODcz_fdbd1b8d-5c44-4c79-bff4-979c9a9bc6f8">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc5_ea0c287a-c546-4ff3-a72a-13b7b92a485a">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODgw_f8ae221d-406f-4afe-8833-dff178c902d3">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc0_5296291b-9cff-4e9f-9a2f-9aede2ebdf3b">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc1_9ea08894-52c3-47e7-b74a-9d71c11b1049">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc2_2b31e832-5fe0-4491-b750-c60270e28093">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTAtMS0xLTA_cfa8d593-7863-465a-862f-3931dc014404">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTEtMS0xLTA_d4cc3907-4b07-446c-9d95-ffd3d38d4f39">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTItMS0xLTA_14086888-f8e0-4ff1-b428-9d60093c3a38">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODgx_22e20b35-9ecf-4bcc-ade6-8a1eba92c99b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc3_2535097c-c3f1-487e-805a-9a17e4a6ac43">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8wLTAtMS0xLTA_8f27ca95-0388-47fa-a027-ec6665272191">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8xLTQtMS0xLTA_e40d127b-2cc2-47d1-a2fa-4a971e431880">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8yLTEtMS0xLTA_ba4e9160-bba9-4584-94f7-187219614e4e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc4_20572e20-1f84-4aa6-a055-cd99915aad36">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October&#160;25, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ia9f82e383c694af98e6ab4c223730d0f_I20211025" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODE3_37f3346d-f93f-4ac4-a26f-bddf93ad8456">316,397,360</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_16">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_19">Condensed Consolidated Statements of Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_22">Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_28">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_64">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_79">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_82">36</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_85">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_91">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_94">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_97">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_100">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_103">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_103">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_106">57</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_109">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNy0xLTEtMS0w_5d8f92c7-594b-40ac-a242-33b57d90abe0">567,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNy0zLTEtMS0w_d55ec1c9-ca63-44ae-8d5c-15bcfc215c99">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOC0xLTEtMS0w_63404abe-77ef-4b23-94e4-fd9debf3283b">835,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOC0zLTEtMS0w_3575c0da-fcc3-49d3-a81d-29e9dfa1a17d">887,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOS0xLTEtMS0w_2d6992d2-feaf-4084-95d8-8130cf6e7e77">179,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOS0zLTEtMS0w_9f1357ec-99d0-4810-9722-7741f9ac4584">160,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTAtMS0xLTEtMA_7976117f-3aeb-4b32-8bd5-aa24c087b73e">28,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTAtMy0xLTEtMA_ab2bf300-087e-410d-a7e8-f76d4fafcc6a">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTItMS0xLTEtMA_fe12a199-abe3-4dde-9834-c82444e696ef">51,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTItMy0xLTEtMA_0c048b74-da84-4593-8df1-f41dac430751">57,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTMtMS0xLTEtMA_2a500f5b-37e7-4bd5-b2be-9768c8080a1b">1,662,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTMtMy0xLTEtMA_a4684479-b93d-4749-8342-4405e5c73f39">1,445,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTQtMS0xLTEtMA_bc92c52b-a233-4081-bec9-3ce473d2586a">362,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTQtMy0xLTEtMA_89ce001b-0f88-44b3-9ab1-71301070f9bb">330,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTUtMS0xLTEtMA_e1fcba99-8c0a-4558-9da8-fe4869af47dc">99,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTUtMy0xLTEtMA_fac8e37d-7c43-49aa-ad3d-b923f31cb859">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTYtMS0xLTEtMA_51bf3d5a-e7d2-41d9-bf0b-9e04f51e6c02">125,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTYtMy0xLTEtMA_d4e7d35c-79c2-4933-b8cd-7bc515f387fa">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTctMS0xLTEtMA_0922e084-1c9a-45ca-ab7d-611eaa95ab9c">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTctMy0xLTEtMA_e1acb485-618b-4cb0-97b0-864144020ada">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTgtMS0xLTEtMA_f686649f-7243-4abf-b0a2-77a44fc4e368">134,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTgtMy0xLTEtMA_ec6b0426-4165-458b-a502-6edd475dbbf5">73,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTktMS0xLTEtMA_5b908855-cad6-477e-aa42-df989a120d12">2,447,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTktMy0xLTEtMA_523da919-6d83-4a56-923d-6ca97fc0878b">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjItMS0xLTEtMA_6c73b39f-1af8-4018-9cea-ad0d0bcc1c7f">24,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjItMy0xLTEtMA_d36e2b70-29ff-4d8b-9ff6-dc7fef65b5b4">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjMtMS0xLTEtMA_04dde1e9-abbd-48b5-ad8f-e244782c9f92">53,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjMtMy0xLTEtMA_be84b3c9-e344-462d-bee1-421d1668f2c0">51,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjQtMS0xLTEtMA_15a511fc-3aa0-4e88-ba4f-fdb6c3d3a33d">70,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjQtMy0xLTEtMA_14d0fef0-f25e-40a3-a04e-45c6bd06f474">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjUtMS0xLTEtMA_aaea9336-e7e1-422a-a62f-bbad88805278">31,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjUtMy0xLTEtMA_132d217b-55b7-4830-add4-c14cda1dc6e3">20,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjYtMS0xLTEtMA_14bdf128-1f1b-4f1f-b938-53053d218ddc">35,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjYtMy0xLTEtMA_8fe9e4cc-c645-42e3-9364-c99e1eec89c9">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjgtMS0xLTEtMA_1631f0bb-6d7b-404c-96c2-f3f50fa447d1">54,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjgtMy0xLTEtMA_91932d84-d81c-4607-9648-9e082797b8bc">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjktMS0xLTEtMA_83393950-eea6-4710-a404-f3b7e397abab">269,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjktMy0xLTEtMA_58eaec3d-2f31-4f80-80ca-eeab07d8c577">204,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzAtMS0xLTEtMA_47b20cc8-b928-4cf1-82a5-6e2b32756279">9,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzAtMy0xLTEtMA_8a4f8791-8ab7-4138-aa3f-6636426170e6">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzEtMS0xLTEtMA_d1c71c35-1302-4be4-9132-0fe34719d0b6">52,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzEtMy0xLTEtMA_23d6d40b-b2ff-4337-bc6a-f2b21ea00050">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzItMS0xLTEtMA_3bf46fd3-64b8-41c2-8011-8c1ef84397b0">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzItMy0xLTEtMA_c090237f-0981-4677-a5ae-3a4bde6fde73">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzMtMS0xLTEtMA_d273161d-6ed7-4d29-98a5-31b73c3b4741">335,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzMtMy0xLTEtMA_99481dff-5031-4136-912e-fb8da22738d4">258,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzQtMS0xLTEtMA_4e338356-8a53-473c-a670-db09d5b67b9c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzQtMy0xLTEtMA_376b1ddb-cf65-479d-bd12-f68ea1f6d8a0"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzIx_2a071ec1-b0c4-4667-b768-a1f50723ba3b"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzIx_37343c4a-f02b-47cd-9241-16411ddeb55e">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzM1_191f9632-6b98-4d80-be67-5a4f8fed32ce"><ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzM1_f0f6c149-ea2e-48de-a10e-4b2493ac1b09">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzYw_1c297645-f262-424c-96a4-ccad78eb625d"><ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzYw_3e1445e6-ae1a-466b-bd69-a13fa450d62e">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMS0xLTEtMA_adaf8321-9a86-4766-aee9-b3fd94652971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMy0xLTEtMA_67cf1537-8e93-41d3-a1c6-91a9f4254319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzE4_1c29d531-b605-445f-96c6-c45d3ec04823"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzE4_22015caa-3c3f-4e16-b1bd-0df8d3b3a3ad">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMy_0a785c16-4bf4-4288-ac74-f0c4b4fefdc5"><ix:nonFraction unitRef="shares" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMy_f3d30448-e064-421e-9ce6-d242315a378f">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMyOTg1MzQ4ODM0ODM_1f0840cf-b356-4567-a6b0-dc73f6f47476"><ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMyOTg1MzQ4ODM0ODM_8c6ae5ae-af28-4f01-af61-e6ec4130a6fc">316,305</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzEwOTk1MTE2Mjc5MDA_0efd639a-093d-4986-9b55-a8b2f064c1c0"><ix:nonFraction unitRef="shares" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzEwOTk1MTE2Mjc5MDA_68d08d64-bda5-47a2-8086-131b5a8940a4">311,627</ix:nonFraction></ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMS0xLTEtMA_019b8789-f285-4ee9-8c62-d202dffe8f5d">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMy0xLTEtMA_61caa702-2527-48fb-a7a4-a756bcdd6af6">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzgtMS0xLTEtMA_134bada4-2c4e-47a6-bb00-d19c19723dd4">2,422,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzgtMy0xLTEtMA_66556e0c-3988-4185-8fb3-5ca8c65db0e4">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzktMS0xLTEtMA_60701b39-5ffd-4529-9a2e-2f8bd3152fd1">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzktMy0xLTEtMA_74d669b0-c5f4-4729-8c09-9d203a336107">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDAtMS0xLTEtMA_72c96fff-56b8-4782-aacb-e7f5e80271f2">311,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDAtMy0xLTEtMA_d2f1be3d-642b-40fe-9a17-253977f58ef4">447,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDEtMS0xLTEtMA_153d92fa-7cef-46ef-9aae-0cbda906f14a">2,112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDEtMy0xLTEtMA_12f365d6-f06d-4619-b8f1-dad4c81868ec">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDItMS0xLTEtMA_88ceaf62-93d0-438f-b92c-6c99c0edc541">2,447,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDItMy0xLTEtMA_74582a24-b4b7-4636-b70b-0c8e4c04505d">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy0xLTEtMS0w_a31b5224-e4b9-43b1-8188-e8b6e91334fc">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy0zLTEtMS0w_c5f8b58d-8ce9-456c-add0-bfa3c1abae37">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy01LTEtMS0w_9f046351-9bbf-42bf-b528-68208008e6be">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy03LTEtMS0w_9730b25e-7620-49a9-9cac-38419dfef73c">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC0xLTEtMS0w_3b1ef0c9-b136-4389-9a28-4a28eb73fde0">49,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC0zLTEtMS0w_d3b52731-7a23-4e93-91ce-5b423161b31f">33,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC01LTEtMS0w_f682ad28-82a5-40f5-9e2e-035914cf93d3">116,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC03LTEtMS0w_585a4b31-d8ea-4eff-9835-45bcbb4edd97">113,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS0xLTEtMS0w_3db50703-463d-4a90-b331-d8e26f6120d6">15,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS0zLTEtMS0w_e165ab2a-f7bb-4c6a-b810-407080510a14">29,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS01LTEtMS0w_e070fe31-1520-45da-ba32-862b67817fc5">92,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS03LTEtMS0w_1e23b9b5-5cf3-425f-a992-0d0c05d3007c">62,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi0xLTEtMS0w_a3542f78-9185-478e-8aca-c408fa0d776a">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi0zLTEtMS0w_98d2a79a-959f-4a9f-9b7e-22755b99438d">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi01LTEtMS0w_44b3934c-ab1d-4870-969d-4d0344153ea7">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi03LTEtMS0w_83941c97-30e8-4f23-b142-a666157d021f">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC0xLTEtMS0w_2f02bc13-8614-402a-a9d9-a15e9459e94a">11,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC0zLTEtMS0w_5db81e3e-8768-425a-8685-fbc88ef9b164">8,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC01LTEtMS0w_49f2dd26-c7a7-4282-9797-7442c47ce8ad">39,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC03LTEtMS0w_5aa88188-e74a-4e41-a646-d2df48b854e5">27,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS0xLTEtMS0w_e6bb5d6b-d476-4d4f-b2d4-6c2c36c6e896">163,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS0zLTEtMS0w_8a302c45-ed13-4b67-80d6-c48260526dfb">176,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS01LTEtMS0w_84778e22-a86f-482c-a4e9-2c2949adeeff">471,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS03LTEtMS0w_f141793c-989a-4bb4-906f-740616015205">393,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtMS0xLTEtMA_b9d3ecf0-e454-4173-a399-e4d750067d11">101,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtMy0xLTEtMA_8cf6d2e6-cefa-4cf9-8be7-7340cb0d339f">88,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtNS0xLTEtMA_b58ec43b-24d0-468a-b86d-fb2c1dab5e12">302,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtNy0xLTEtMA_1c26a477-c09d-4916-a23d-3a5180a226d9">210,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtMS0xLTEtMA_0789091c-d42c-4925-b635-1ac5fa99a42f">276,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtMy0xLTEtMA_682eb8ba-a84a-4593-a9b7-3492fa022128">273,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtNS0xLTEtMA_6ac20d0e-452d-483a-8f2c-8b910ba66530">813,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtNy0xLTEtMA_7d37d2eb-701d-4c8b-9f58-76a1ffa3ba35">631,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItMS0xLTEtMA_7a85ec2d-0363-4b07-a11f-87aee6e6a7a2">51,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItMy0xLTEtMA_403fa1a0-d129-4c7b-a9f5-27d2cfb3b1cd">42,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItNS0xLTEtMA_59ce7e52-153c-48f4-8e42-3e2ec78b180a">170,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItNy0xLTEtMA_a22b3022-c9f8-4e8a-bf26-8d8d57c1e083">85,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtMS0xLTEtMA_43096d93-7225-47ea-8624-811f27eb49c7">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtMy0xLTEtMA_07a16425-9d7c-4c3e-b8d5-3b1848f572a5">3,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtNS0xLTEtMA_f4723d7b-fe30-4b7d-86c0-ebd67b49836d">6,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtNy0xLTEtMA_0c7ca7fc-7539-4559-b2b6-88426edb80c9">16,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtMS0xLTEtMA_8ef39262-ceac-4a44-adf8-ec9d3895b101">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtMy0xLTEtMA_94e9fafe-1a67-4ef1-810b-5b4c89f5d7a3">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtNS0xLTEtMA_e5db7f63-a8e2-422d-9ad2-34d63b0d8079">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtNy0xLTEtMA_4f81ea16-07ba-4e92-9f63-14c144633207">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtMS0xLTEtMA_76ddbf98-8ea5-4ece-a87b-53f49918e890">53,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtMy0xLTEtMA_bccd7d13-a13e-46ff-a750-9a1057081bb7">38,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtNS0xLTEtMA_2ae1b0af-8ef0-46ae-84ba-da577bc3921d">176,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtNy0xLTEtMA_a9b5f637-7f65-41ed-8a64-8d2253d6a185">102,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtMS0xLTEtMA_2813745d-caf6-444c-8161-fc12ff5d1f8c">15,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtMy0xLTEtMA_c060d4c6-a336-46b2-974c-dc750185c69f">5,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtNS0xLTEtMA_122353dc-9681-441a-8de2-d1f0a09fdf5a">40,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtNy0xLTEtMA_4d3d5a63-4aec-43f4-a20b-42095533c49b">19,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctMS0xLTEtMA_eec64939-0628-4e1c-bef4-c7b332cf51c0">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctMy0xLTEtMA_5d74a91b-5ae2-4e97-840e-aa9fcb148c02">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctNS0xLTEtMA_af656ecd-b39a-4c5e-9561-2871623aafe6">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctNy0xLTEtMA_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktMS0xLTEtMA_38da336a-0b48-4091-9f1b-b15377dcee25">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktMy0xLTEtMA_8b8e09d1-d48a-4a50-aaf6-b8bf422d0d94">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktNS0xLTEtMA_aedf411c-0d8e-4f3a-9f7f-1ddf85cea199">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktNy0xLTEtMA_35726889-ce55-4d4b-bfd6-8861946f4c03">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtMS0xLTEtMA_dc73123c-dd75-4f8b-99d5-4ae2b7551ae2">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtMy0xLTEtMA_78fa6d13-2825-4eaf-81b3-644fc6613684">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtNS0xLTEtMA_26e7c67d-b597-44ff-be84-100e1db36ea8">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtNy0xLTEtMA_aff28865-8246-4a52-9a73-333948fa63c7">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItMS0xLTEtMA_f6a3bb63-8a07-4e3d-bd06-dd3045edbc4a">315,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItMy0xLTEtMA_c35715b6-078b-4c39-8cfa-7297534d1b34">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItNS0xLTEtMA_68c773f3-238e-40db-af17-a503d176dd9c">313,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItNy0xLTEtMA_bdfd78bb-b9ed-4a2e-a3d9-6a4692a22022">307,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtMS0xLTEtMA_fd8c778b-b113-4c4a-baa1-499b24073763">322,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtMy0xLTEtMA_bbb87449-9592-4f7a-9873-cea3f5a5a616">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtNS0xLTEtMA_6d8cb68d-a799-4b19-9b8b-f885f2dc8de9">322,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtNy0xLTEtMA_98453d27-5604-456c-8efc-96eae6bdd965">317,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_22"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi0xLTEtMS0w_eec64939-0628-4e1c-bef4-c7b332cf51c0">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi0zLTEtMS0w_5d74a91b-5ae2-4e97-840e-aa9fcb148c02">32,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi01LTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi03LTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfOTY_92dc79b0-cd21-45d0-8148-f3e5dd4763e0">193</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTAx_aa0a952b-6532-43bf-a7a1-e6c9d340fae9">453</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTA2_d211cbd9-5fde-4691-8a46-aa03b2fb55e7">949</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTE0_ae5a243c-7670-4a23-88a9-8432a0c58689">893</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0xLTEtMS0w_963078fa-6e35-4278-ab30-2453bfc43a43">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0zLTEtMS0w_e2ffebfa-e929-4d02-8ae4-e29fca626df3">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC01LTEtMS0w_6a137331-c53e-45e2-abb0-86d8417f1a38">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC03LTEtMS0w_38870f69-f5e6-4ff0-9685-87e79c2b991d">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi0xLTEtMS0w_8c5a5aa8-396c-4ecc-ad78-3af5faad074c">37,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi0zLTEtMS0w_d52325b9-a698-4945-a3c9-f341dc31f130">33,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi01LTEtMS0w_9f0cdf87-1834-4823-b12c-b3dc3710d258">132,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi03LTEtMS0w_f195f119-a241-414f-9d10-7759fca82809">86,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.232%"><tr><td style="width:1.0%"></td><td style="width:41.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65446bf2aefe4b8b84374a8e8278071d_I20210702" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMS0xLTEtMA_4cd249e3-7075-4d67-9fc9-eb1fd7283548">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65446bf2aefe4b8b84374a8e8278071d_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMy0xLTEtMA_8e3216c0-a051-4f75-a55d-979173597fe5">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd49a4943be041879f2e79978071f89b_I20210702" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtNS0xLTEtMA_56fbe028-5d9a-4b30-953b-17c2575522b4">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518c57cfc2514e6599b766ac488ba69f_I20210702" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtNy0xLTEtMA_16c05371-4267-46ea-99ee-03fb7d84e402">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3cacefb1924a19b321562f6cc1c50f_I20210702" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtOS0xLTEtMA_c1af744b-c065-427d-b795-c834ad44e741">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15e8da8abd24a81a7bb05a35813d724_I20210702" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMTEtMS0xLTA_7c53826f-f0e5-4788-b4fa-6b2d1df62e49">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe73b8c15e74b31812388266b3b6221_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjQtOS0xLTEtMA_695a354d-dbdd-4a82-bf6d-0f7bbb7008c0">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjQtMTEtMS0xLTA_800ac956-088f-459a-b6c8-54242ee51e7c">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e12bec23f4e45b9b13fab2a662de8d6_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjUtNy0xLTEtMA_ad98fc27-9368-47b2-8010-780b590751d4">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjUtMTEtMS0xLTA_3f2088a9-9b84-4f48-a4a2-bb63e62af074">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMS0xLTEtMA_8fa4aaae-7827-4838-9353-472b6dc5ac0b">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMy0xLTEtMA_45915857-ee1a-4b44-aae9-f4b45944d8cf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtNS0xLTEtMA_9c0b541b-1b4c-49ed-a9ff-8929845a721b">3,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMTEtMS0xLTA_add759d4-0800-4ea7-9d21-7e983e56b80f">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjctNS0xLTEtMA_1ac7afc7-69b3-411d-ba75-f4a43fc816ac">5,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjctMTEtMS0xLTA_037e81c6-1f51-4033-ba32-2175d75785da">5,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjgtNS0xLTEtMA_ebd187a5-6229-4cb0-8f68-49df5cba2242">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjgtMTEtMS0xLTA_9061eb8b-8c93-4149-9dc9-1a7b9a235de9">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMS0xLTEtMA_5f43d558-da1e-4129-8d03-6475ae1418ac"><ix:nonFraction unitRef="shares" contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMS0xLTEtMA_9d9ec062-c9e7-4be4-a6ae-5e03c4ac4fbb">316,305</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMy0xLTEtMA_6cafb514-9742-42ee-a7df-f2c8d41a908e">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93fec9e93714e5e8df46aa0e36139b7_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktNS0xLTEtMA_099f1faf-8c71-4535-9e31-733718a444e1">2,422,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktNy0xLTEtMA_aff693b5-38de-4b27-bfc0-4725de8c0924">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktOS0xLTEtMA_2ea2bae8-4970-414d-bf21-0e03eac5b49c">311,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMTEtMS0xLTA_3aca33c4-eb9f-4d58-9092-3aa88509f955">2,112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2020</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMS0xLTEtMA_7af61aa7-2c42-46e3-bab5-db2bf578e83e">308,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMy0xLTEtMA_51364f83-93bf-40d5-817f-2268367ab27e">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4355be7a9b5344b3b5089274a3522b2c_I20200703" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtNS0xLTEtMA_c7d45e1e-07fd-48a6-8309-1ca3d26e6f7e">2,269,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1c3a859c9742a09f45706125e87b43_I20200703" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtNy0xLTEtMA_9e01167f-479d-44c8-84b1-0ba89634b490">7,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a199c9648744541be4de3d34bb7e362_I20200703" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtOS0xLTEtMA_a3d46e91-e8ff-4ae1-81c8-b64643320e21">443,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide320c4815644a62a658d3862311595c_I20200703" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMTEtMS0xLTA_01bbb9f8-6ca6-4230-8306-43eb2e1e61b3">1,833,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47efd87d077d432f81f34c8bf9b33d22_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjUtOS0xLTEtMA_495328f5-6d4d-4dfb-86e6-e73543f59efa">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjUtMTEtMS0xLTA_29a06051-37c7-44b5-ae92-2560f4c45adf">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4646f21cac644933a185200c07101315_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjYtNy0xLTEtMA_79445059-f2fe-41ee-b8bf-64fe8e3f88bf">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjYtMTEtMS0xLTA_b5eee533-424d-469a-a954-c50869752959">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMS0xLTEtMA_d92df501-d70b-486f-86f1-0b45a4e25f01">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMy0xLTEtMA_522d31cb-edf4-41aa-8500-5243fdc4a543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctNS0xLTEtMA_d3216b7b-ade3-408e-a653-307d0741b6e9">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMTEtMS0xLTA_d3519021-5fb6-4730-887f-4bee649730c6">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjgtNS0xLTEtMA_a0b37bda-4b74-4604-a4ec-34aed5743018">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjgtMTEtMS0xLTA_716e7f0c-3af4-4410-adf2-aab73a29dd79">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjktNS0xLTEtMA_b1748ddf-dc5a-4586-bfcc-ce2ad8950a6e">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjktMTEtMS0xLTA_0264b537-7ec3-4c82-840a-fcec5736b658">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at September&#160;30, 2020</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i198373947b4145e597fec4495ee48f55_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMS0xLTEtMA_a45898cf-26a6-4d7e-8fc5-188941e8d2d7">309,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198373947b4145e597fec4495ee48f55_I20201002" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMy0xLTEtMA_1787b8be-6dea-43df-8c6b-4fbc77c3c35d">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44a54e568514d1cba61fe6a37c6f581_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtNS0xLTEtMA_88e2c08b-8fc2-40bd-a6bc-0b5f617d45e7">2,321,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtNy0xLTEtMA_3672f4ac-9e17-4dc3-a0c1-cf93625a5ca5">6,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa21b82a225453a9b5b3197b7945bb2_I20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtOS0xLTEtMA_752a60b3-a8ef-4209-89da-21b388c2f81c">475,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMTEtMS0xLTA_77dd8760-9601-4b7d-865f-91140bd1c45d">1,852,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued on next page</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.451%"><tr><td style="width:1.0%"></td><td style="width:42.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5f35a35374542268bc2759496673a02_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMS0xLTEtMA_404edfb1-ecce-4d53-9a80-05f01633ba29">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f35a35374542268bc2759496673a02_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMy0xLTEtMA_19d9850c-9a5b-44df-a702-9c0bce5a6f02">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6c9d55484894ea1b4af267e9c70eb4d_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtNS0xLTEtMA_66cb538c-699b-4484-a78f-1b9747af834b">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdd133e47d04123866777ff9abd71d2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtNy0xLTEtMA_80c0d9fd-2801-4a7b-8607-e7dfbf4ea876">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15ab773d1d894523a26a2a3ceb10fe3e_I20210101" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtOS0xLTEtMA_068a0f32-948c-4615-85c6-846f3fff5c19">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMTEtMS0xLTA_b2944140-0699-42e6-ab97-84ca1bba9520">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjQtOS0xLTEtMA_af656ecd-b39a-4c5e-9561-2871623aafe6">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjQtMTEtMS0xLTA_62ed2ce1-7d9c-40d4-b889-51cf27170dd3">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i451f3b4d1aa14a1bbcb5d26014d13efc_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjUtNy0xLTEtMA_012dfb7a-c905-404b-9d91-e7481689572b">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjUtMTEtMS0xLTA_8302e0e3-6e31-4073-9525-19a2654e8d5c">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMS0xLTEtMA_307acd8b-aa37-4058-ba85-80c721516f96">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMy0xLTEtMA_3ea38f70-b3f1-4de3-ae08-93f97a149923">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtNS0xLTEtMA_6ee1a5ca-319f-42ac-adde-8a37d8ebe9ff">18,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMTEtMS0xLTA_aa9e71e0-441e-40eb-b228-85bf59022b64">18,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjctNS0xLTEtMA_645fd383-4960-4b87-b204-2992570d0e38">15,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjctMTEtMS0xLTA_c72c89b4-9fdf-4ad7-a295-0ffac76a0d64">15,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjgtNS0xLTEtMA_9d928c07-c881-4f63-8b40-4dfd982da71a">97,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjgtMTEtMS0xLTA_513b3d9d-b8c6-41eb-846c-ca7ecd6ecdf9">97,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMS0xLTEtMA_5f43d558-da1e-4129-8d03-6475ae1418ac"><ix:nonFraction unitRef="shares" contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMS0xLTEtMA_9d9ec062-c9e7-4be4-a6ae-5e03c4ac4fbb">316,305</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMy0xLTEtMA_6cafb514-9742-42ee-a7df-f2c8d41a908e">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93fec9e93714e5e8df46aa0e36139b7_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktNS0xLTEtMA_dd702cf3-897a-477e-8b88-e05ff8bceb3a">2,422,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktNy0xLTEtMA_aff693b5-38de-4b27-bfc0-4725de8c0924">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktOS0xLTEtMA_2ea2bae8-4970-414d-bf21-0e03eac5b49c">311,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMTEtMS0xLTA_a3eb767e-9994-41d7-b43f-b32fd1549137">2,112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.903%"><tr><td style="width:1.0%"></td><td style="width:42.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62c8618c9439454b8cb846aaed306eaa_I20200103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMS0xLTEtMA_b0dfcd5a-23d8-47e5-a34f-a67ee2a1ba36">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c8618c9439454b8cb846aaed306eaa_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMy0xLTEtMA_0975785c-c51e-461e-924e-ff3dbae3110f">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048c97d67ba14a7e9c9166ecce15a78f_I20200103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtNS0xLTEtMA_b845800a-8a7c-4ab0-b30d-a5620b9aff4b">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccbb310782fb42fea3375eb6a1ccf6a8_I20200103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtNy0xLTEtMA_23930714-6148-450c-a741-10a28a8402ea">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ee09a03bec4322b0b7c0889fe08791_I20200103" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtOS0xLTEtMA_ccd22d99-e116-4440-aa56-547df39b8562">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d66ad81fc247a8856e28f96b5e71b4_I20200103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMTEtMS0xLTA_a3c548bf-091d-41b0-9555-f0fffd6c6bd9">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe7efeffe4d4f2fa1c6ab83e7c2abd3_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjQtOS0xLTEtMA_42a3ba4b-0d88-4769-8c64-68ba25f9299f">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjQtMTEtMS0xLTA_e8e4102a-726e-4a1b-b09c-1e55366d525c">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c0fbefe45c4bddad088d3948fec4d4_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjUtNy0xLTEtMA_49429602-f338-45b4-ab2c-b07d3728f07b">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjUtMTEtMS0xLTA_a8f7fb3d-0c8b-482a-9934-f117da03e640">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMS0xLTEtMA_578014af-d639-4b10-ad28-b3629708fac9">4,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMy0xLTEtMA_eb5d524c-a2a1-4734-9af6-bcb3fa814aed">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtNS0xLTEtMA_326fdfb8-fb22-47c5-afbe-04900f60321d">19,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMTEtMS0xLTA_f12792c2-7dce-4e0c-8733-cd647390cad9">19,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjctNS0xLTEtMA_83bb0933-1085-40f8-a4f2-502f789dc627">26,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjctMTEtMS0xLTA_bf5cd2d6-8097-4372-be6d-5f8bc5e15a58">26,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjgtNS0xLTEtMA_e0208267-5df8-49d0-bf2d-fd24f3a06cb7">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjgtMTEtMS0xLTA_c20ebe55-d7da-4e73-bf5f-f8d618117601">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i198373947b4145e597fec4495ee48f55_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMS0xLTEtMA_a45898cf-26a6-4d7e-8fc5-188941e8d2d7">309,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198373947b4145e597fec4495ee48f55_I20201002" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMy0xLTEtMA_1787b8be-6dea-43df-8c6b-4fbc77c3c35d">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44a54e568514d1cba61fe6a37c6f581_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktNS0xLTEtMA_88e2c08b-8fc2-40bd-a6bc-0b5f617d45e7">2,321,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktNy0xLTEtMA_3672f4ac-9e17-4dc3-a0c1-cf93625a5ca5">6,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa21b82a225453a9b5b3197b7945bb2_I20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktOS0xLTEtMA_752a60b3-a8ef-4209-89da-21b388c2f81c">475,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMTEtMS0xLTA_77dd8760-9601-4b7d-865f-91140bd1c45d">1,852,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMi0xLTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMi0zLTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNC0xLTEtMS0w_aaedc619-5cdf-4ef8-a0ae-429bcac9a1b7">11,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNC0zLTEtMS0w_c9189f0e-1013-4e96-baf8-6f68074ed391">6,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNS0xLTEtMS0w_737f832e-270f-47d6-959a-a50e653ba959">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNS0zLTEtMS0w_8f189f15-2238-4258-b199-8cc07657aef8">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNi0xLTEtMS0w_5c6ef68f-ed7e-4ad2-8d7f-e551bdefc19e">3,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNi0zLTEtMS0w_19da72b0-d868-4e05-b64f-6ff510e1d839">3,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNy0xLTEtMS0w_417ff460-ce9a-4df6-9e92-36aff2e1ef7c">32,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNy0zLTEtMS0w_7b90575b-223e-4746-a6ba-c113804d5e0b">15,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfOC0xLTEtMS0w_02b8ef9e-b9ff-4883-ac08-b5f9d37ff694">35,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfOC0zLTEtMS0w_8b0f8a33-b165-4c3f-a3b3-a7bc6cbba68f">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTAtMS0xLTEtMA_0646ac28-e20c-4deb-9402-be9fd29af82f">20,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTAtMy0xLTEtMA_90e4677c-76f0-4185-a448-c2e03dde79ab">47,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTEtMS0xLTEtMA_23400ba1-bf91-4f06-9ff7-1a236a7c7b70">26,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTEtMy0xLTEtMA_1c4e86f5-f64f-48e1-8215-9fc19a7603e2">13,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTMtMS0xLTEtMA_1c64cb45-7e15-4b15-9ab8-95df9c462ee2">24,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTMtMy0xLTEtMA_079a087e-1c3f-47bd-9d0f-df9cbf5f5aa7">15,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTUtMS0xLTEtMA_ca96c156-c144-4fdf-9f8d-4866c0bcc728">11,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTUtMy0xLTEtMA_957d7e65-fdea-414b-a25a-1ef780503267">4,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTYtMS0xLTEtMA_a9d09a44-6446-4bf8-9efb-face6049889c">47,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTYtMy0xLTEtMA_cc368bba-cc2f-4c71-a67f-348d571819b4">51,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTctMS0xLTEtMA_4ba5a6fb-4c2d-41f6-a483-1cde9bcaf61d">304,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTctMy0xLTEtMA_9b15f680-9dd8-4ffe-9446-e3cd2274676d">175,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTktMS0xLTEtMA_fd0347b4-fbbb-4b9b-97db-cc8ee7d789e5">48,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTktMy0xLTEtMA_402d4b28-597b-4355-aac6-fa6c152db194">16,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjEtMS0xLTEtMA_e7a11f39-5e12-4d7c-9a54-b039dc57ef36">1,077,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjEtMy0xLTEtMA_e7266415-e51c-4c8d-9665-1f2c64bb0b1e">866,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjItMS0xLTEtMA_86621ce4-5ad5-44d4-902e-a343532d610a">1,095,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjItMy0xLTEtMA_e337dc78-bef2-4335-bf78-46de393b8e89">781,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjMtMS0xLTEtMA_daae5b61-5cc3-4ad4-a489-998013842e09">29,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjMtMy0xLTEtMA_193ab283-e609-4c34-87e3-01a10963c6f1">101,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjUtMS0xLTEtMA_69e41f7f-e56d-404a-aa00-26692454f0f5">18,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjUtMy0xLTEtMA_6fc7a907-a433-4667-b024-4b6a80d38dc8">19,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjYtMS0xLTEtMA_8e037889-9a7a-483c-b8ea-993f27cfe6e3">15,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjYtMy0xLTEtMA_3dbb2809-3b6a-407b-b12d-658df1036e5c">26,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjktMS0xLTEtMA_2a61ef8d-4b5f-4748-b7f9-3755cbedafa9">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjktMy0xLTEtMA_9526d8fb-e01d-4202-83ed-5c2a48e63abf">6,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzAtMS0xLTEtMA_28c6d279-005b-4c3f-ab17-deb2d6b19580">277,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzAtMy0xLTEtMA_ca06ae5b-c938-4fc1-8161-4eb0d867cc3f">67,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzEtMS0xLTEtMA_ff386474-cc5a-402e-b03c-be5acda8da4b">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d66ad81fc247a8856e28f96b5e71b4_I20200103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzEtMy0xLTEtMA_691f427c-2d6a-49ae-ab90-d42cffe1af28">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzItMS0xLTEtMA_dac59af9-aaac-4255-ac22-92c39e2a8c8f">598,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzItMy0xLTEtMA_53b14c49-f613-40b1-8895-32457a2fd6c1">335,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzctMS0xLTEtMA_d9c72316-8529-4241-9f31-e2f53f6cb969">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzctMy0xLTEtMA_93944947-1c93-4a55-b038-fca13f019391">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzktMS0xLTEtMA_0f50d609-ed52-439a-87dd-be005c43f470">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzktMy0xLTEtMA_5d1f2a9d-764e-4abd-9c53-9bcabc470cdc">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred in asset acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNDAtMS0xLTEtMA_31029412-b01c-4a1f-bfd2-287528aa9d03">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNDAtMy0xLTEtMA_63fa4c49-cf1f-4bcf-92da-530ef78061a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1MA_546cc494-4c1c-4641-90b8-9b538597f5fb" continuedAt="ide3231c112a147aeab58034eb3c68c8b" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ide3231c112a147aeab58034eb3c68c8b" continuedAt="i4bcfbd45411746d0936009c01a4a7b81"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 1994, <ix:nonFraction unitRef="product" contextRef="ib422db6657d447b49fd7f409b08a14d0_D20210102-20211001" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfNjMw_d873235c-76c0-4524-9746-c1b30b044dff">four</ix:nonFraction> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC) and, in the U.S. only, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i7652c419cd5e434ebdaf01060d9d1b55_D20210102-20211001" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfMTUxMg_098a6cae-2c1c-4d49-9028-3005ad3eafd1">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1MQ_4afb3437-4ba4-40ac-acd4-71644b09f022" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1Mg_cb79c548-bcfa-4260-ae5e-6b1426435def" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU0Nw_a4c46ecd-8a62-436b-9943-c35612b12819" continuedAt="iee6194520fb742a7827b83ee6b131b7b" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iee6194520fb742a7827b83ee6b131b7b">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i4bcfbd45411746d0936009c01a4a7b81" continuedAt="ic01e10f5fd444285943a17c26af0e0ca"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3NA_4c058857-219d-4945-891a-78df12221863" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfNDIwNw_5fee590f-cd3b-4796-a08c-1e87a57bc356">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3NQ_e8091265-00be-434b-800a-b33183f94e64" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3Nw_064eb144-9dae-4488-8846-bef8e2ddb74f" continuedAt="i05842f15f167490b8f7c59ca2d0301a7" escape="true">Reclassifications</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05842f15f167490b8f7c59ca2d0301a7">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income (loss) from operations, net income (loss), total assets, total liabilities or total stockholders&#8217; equity.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1Mw_d1fd0267-5ac9-4733-bdd9-1835d9fd6b2b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income (Loss).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3OQ_06f16e8b-db5d-4b6b-b790-8b16fef98af4" continuedAt="if606e9d75fd94832a0d813c825dfd360" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="ic01e10f5fd444285943a17c26af0e0ca"><ix:continuation id="if606e9d75fd94832a0d813c825dfd360"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI3OQ_875b35dd-5662-4d10-a278-e31f37dac66f" continuedAt="ida05a2b51dd14d7a801ce87df9b548cb" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ida05a2b51dd14d7a801ce87df9b548cb" continuedAt="i3eee0d413ed641a8bd30104f7bd78ba4"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI4Mw_bfb0411a-1f72-40a2-85cb-4e55ecc85593" continuedAt="i3f7c254a5b6049abb1eed28675dfa3fb" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5cb6b35aa834afe81197ed5f5a2983b_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy0xLTEtMS0w_173add81-4513-41d5-8e51-2971b874c7c7">357,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1d06f401ca4330abe2df73ad44d932_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy0zLTEtMS0w_00e8983c-64c7-49dd-98ff-0845ce8e3602">220,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i300f361eb7ac41089fb4dcbbbaa0b22c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy01LTEtMS0w_b2499a3e-15f5-4bb4-8e28-da562e4befe5">1,051,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d98f6b265ec4941b70dd37ca3904b2d_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy03LTEtMS0w_66d23f3a-962a-4f2c-ba84-1e9722657011">702,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399cf68a318047d4b6e4fe4633d1e94f_D20210703-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC0xLTEtMS0w_436fde0b-ba48-4589-8acc-7789f6fd4d9f">94,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bb3578547994d3fb6471e6ac46c8ae1_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC0zLTEtMS0w_838ffbfe-9f06-4e51-9599-e14cb8948e7f">51,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83bf53370dce463db3d2184cc9abeeed_D20210102-20211001" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC01LTEtMS0w_7f16a07f-c46c-4ef4-b292-7ae72a896db3">277,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife1a4766b133423c94f7ac43bee70be1_D20200104-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC03LTEtMS0w_27a29d45-399c-423c-a347-1887be1816e3">161,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS0xLTEtMS0w_a31b5224-e4b9-43b1-8188-e8b6e91334fc">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS0zLTEtMS0w_c5f8b58d-8ce9-456c-add0-bfa3c1abae37">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS01LTEtMS0w_9f046351-9bbf-42bf-b528-68208008e6be">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS03LTEtMS0w_9730b25e-7620-49a9-9cac-38419dfef73c">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy0xLTEtMS0w_3b1ef0c9-b136-4389-9a28-4a28eb73fde0">49,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy0zLTEtMS0w_d3b52731-7a23-4e93-91ce-5b423161b31f">33,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy01LTEtMS0w_f682ad28-82a5-40f5-9e2e-035914cf93d3">116,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy03LTEtMS0w_585a4b31-d8ea-4eff-9835-45bcbb4edd97">113,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC0xLTEtMS0w_3db50703-463d-4a90-b331-d8e26f6120d6">15,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC0zLTEtMS0w_e165ab2a-f7bb-4c6a-b810-407080510a14">29,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC01LTEtMS0w_e070fe31-1520-45da-ba32-862b67817fc5">92,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC03LTEtMS0w_1e23b9b5-5cf3-425f-a992-0d0c05d3007c">62,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66848fd649d4aa3b3af5f75c759ed57_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS0xLTEtMS0w_ab4f63e5-5379-4071-accf-923cb0ab3d68">65,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c6d26551a848e69c150ea689520c0c_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS0zLTEtMS0w_41fc3bf7-f5c5-4725-8514-343b52f61e92">62,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8e62d4ceae407da69dddd7a401315a_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS01LTEtMS0w_c9cf5bae-bf24-4429-a48c-2b4b29cf7387">209,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5701273b195d4b8fa25b28e5eaf36b88_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS03LTEtMS0w_468e9f42-54d3-4981-afd9-d580bef22a95">176,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtMS0xLTEtMA_a3542f78-9185-478e-8aca-c408fa0d776a">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtMy0xLTEtMA_98d2a79a-959f-4a9f-9b7e-22755b99438d">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtNS0xLTEtMA_44b3934c-ab1d-4870-969d-4d0344153ea7">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtNy0xLTEtMA_83941c97-30e8-4f23-b142-a666157d021f">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5NQ_9ef8b030-f2a8-46d4-818e-952dd52092b4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi0xLTEtMS0w_6cbc135a-baeb-4764-9867-e9e6654eaa0d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84f8a9eb0dca41b09aaedd7f9d03c606_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi0zLTEtMS0w_a9160fdd-3a89-4fa8-937e-d091c8f8f0dd">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7eaebb9b56c4a4da079b1660c8ec3cb_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi01LTEtMS0w_dccf70f7-dafc-4214-aa7a-a1ed433082de">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e11bac7372644709417934e0ca155a5_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi03LTEtMS0w_7b32cc81-551d-4c9a-b276-7987c909f120">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i916390b099cf490a8faaf1f1536bb941_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy0xLTEtMS0w_c7d6593d-5883-4687-824d-a6465813692e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27140a762b04420283d20b05a3483f19_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy0zLTEtMS0w_7491d2c5-e4cb-4ba9-b2ca-6338cf5d13ed">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdd6869dd7354422821f089dadf50b8c_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy01LTEtMS0w_c5972a48-fe20-4a11-afa7-3e55bb5f2993">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib82fd13f9c484bcd90d7acca51198b90_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy03LTEtMS0w_298ec37b-1452-4b05-b688-248ff0db0fe2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id19e6f8ceb3d4193a62ed61fe70f30d2_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC0xLTEtMS0w_b0c54e6f-c9a0-4c1b-8a6f-4f142b922047">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85d11b7619ee4ffdb9ca1f1ae9dcfcce_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC0zLTEtMS0w_cbb0a9d4-6a45-4f7e-a670-c716e2231cdb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43aff9879b254a2bb8d73b57aaad937d_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC01LTEtMS0w_5ca7da7b-7007-49a2-b0b6-5f04c8cbcf60">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i748062d52a79415b951264743fd8a262_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC03LTEtMS0w_9bc488ee-e479-4ce9-9736-dac2451ea243">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i333ba041ae564029967d730948f966a1_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS0xLTEtMS0w_6e7f548d-eda0-4c8b-b4ff-2c8465a00c5d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i533ba6a6b82e4d4b9cb2b6bf9f6227d8_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS0zLTEtMS0w_11d08a9a-0560-4714-a3ce-11d795117a23">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icab832c59885481194024af60a61d1df_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS01LTEtMS0w_08e27025-dbb7-4a86-ba04-fe9c32f15ab1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i094984ccbfca4e3fac09b15012e1be74_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS03LTEtMS0w_f0cbae35-a98e-432d-bb81-47c09c3305d7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i237d077e560b4407af980d2b6dbb5351_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi0xLTEtMS0w_f93efa01-84c1-43cf-a2be-a5f02a2a2028">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf27c022f00045578983d2cd05cefd50_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi0zLTEtMS0w_f26c2ae9-c2a2-465d-9eb8-a2f00ae2db57">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfefd582d8584f539f09611fe980f68f_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi01LTEtMS0w_f464bb80-9f60-446b-a8f4-8b4bedb5c955">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96da6fb9308c4441a6c7e0e9966c1d83_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi03LTEtMS0w_67db7558-90ff-4aa0-85f3-906931a54b70">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idef660618700414f8dcbfb860da76a87_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC0xLTEtMS0w_7b397668-6776-4b72-b195-cdef22700e35">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa1e2a62f0694219aade24fac80d1c5e_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC0zLTEtMS0w_1147789a-f15f-446e-b719-8d16fe86834f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9326972b57124d95b7c72df93cabd3e1_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC01LTEtMS0w_e0f94e77-fb17-407f-8e11-f858e62eca39">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie773f2a3a13f4701a26b5a39d5d1daee_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC03LTEtMS0w_966c6ba7-953b-4ccf-b5d6-2714914e6fa4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia33755e44bf94f1da1da6239ce61afce_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMS0xLTEtMS0w_4880df0e-3066-4b51-85a4-53dc80f56bc6">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1034b890c344f2187aff9b841e56da4_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMS0zLTEtMS0w_e5fdb826-6908-46d5-8bba-4aecf57009f8">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8b6af8835eb4a388447fefe69add707_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMi0xLTEtMS0w_85cb694c-2b0f-450f-9577-3d743d5a9ec8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f554670ff6b4145bbceb659e8d31cee_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMi0zLTEtMS0w_39568caa-bb5c-41c9-a715-80fef6e544b9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i362468d981744887840c7c13b4494a7b_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMy0xLTEtMS0w_b87f2087-cce2-4bcf-8a2c-060badb51873">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife4a5f75f1f84d7cb2773b54773806d1_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMy0zLTEtMS0w_d800b7e1-2ac0-4c9f-b516-faa4ec522499">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a51cab5342b4f589598449b9d53e45a_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNC0xLTEtMS0w_b5d5527a-2478-4b09-9252-f6b45a560fea">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fe7a926c38a46a6a1270839bca439ab_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNC0zLTEtMS0w_03ada757-bdfd-4011-965c-12eaa2776866">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e56e167d51d4361a27af591b87356ee_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNS0xLTEtMS0w_6906ac86-0f3d-4d78-a614-fbaf45b6456a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaae0fe3ee92a4735919e62e7c773d8f8_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNS0zLTEtMS0w_b8ef8fb8-b6a2-46f2-b299-c80c79b9c744">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5MQ_ce8ad047-da59-43fc-b059-6e4691245cc3" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac98a4d51cd54e6993377fc838bb765a_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi0xLTEtMS0w_70e3f27d-12a3-487f-8565-43939e843af2">266,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31062813c13140b7b457913dd4852e78_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi0zLTEtMS0w_0ae7ec58-f612-4883-8de0-fe39068a30ca">171,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5422d1856079466bbb9f65186f532193_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi01LTEtMS0w_2bb1619f-0b75-4fc2-869e-75931ef24cce">783,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cbb1bbb9c8465c8eaa7264a9c37ea6_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi03LTEtMS0w_46f4a963-914d-4afa-a85e-f0dbcf474a07">549,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic620d2de433e40fca7e2944d830c2bda_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy0xLTEtMS0w_dd65bfb8-b417-4152-b7ac-ab08c248b8a1">38,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b511d5be3cc42d6a46455b239456426_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy0zLTEtMS0w_f0542b6f-1fec-40b8-9c23-f76fc8f1ee48">36,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210d874da4ec4ad2b439ac379d882d7c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy01LTEtMS0w_8b50088d-6f81-4f3d-b257-01284f95a684">162,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebc613892384a1e81978aadc22bc1fd_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy03LTEtMS0w_74d8e3df-f33b-40e0-9b09-911d3b8cb544">117,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id076f77c6811421996bf94e07e9611b6_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC0xLTEtMS0w_dba68782-a68f-4452-9c73-51e0782d63fc">23,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf26fde834484f20a6cb7803fb0e1cd7_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC0zLTEtMS0w_e6197e16-e564-4453-bcdc-9d38322ba45e">23,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d721a4a024409b8e51b7763addb8a4_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC01LTEtMS0w_b72a6cb1-cd92-43cb-868c-23b148413c72">37,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6cabd3bc8aa4381abca308dce1cb94b_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC03LTEtMS0w_d2ad1f16-a73e-4e0f-8133-e473a61dd542">50,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS0xLTEtMS0w_529019e6-e35e-4d54-971b-589e21c93047">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS0zLTEtMS0w_ca79663f-6e73-4ccd-9e7e-da790d41e914">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS01LTEtMS0w_97af7416-3830-4653-83aa-fd43caa13c61">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS03LTEtMS0w_32787fea-9872-4914-9c55-8cea9274aceb">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i3eee0d413ed641a8bd30104f7bd78ba4" continuedAt="i64a9a55544ff4c3380cc3fb8c6f850b4"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI4NQ_b46950c6-f64a-4467-8700-014a7c33b270" continuedAt="if8a353d011ce485289c4906a7ea6c18e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div></ix:nonNumeric><ix:continuation id="i3f7c254a5b6049abb1eed28675dfa3fb"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2514fa13b9413db7b3f86827a216cc_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi0xLTEtMS0w_30ea9611-8061-40f2-9fce-4bf8d9e6152a">259,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ed7af7a5b8432dad75ddaa4bc98d77_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi0zLTEtMS0w_e9ce1009-7ca8-4fea-b3b5-a32a2274f03d">159,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886d9164ed4647cf9aab2503a662e148_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi01LTEtMS0w_6d8f548c-cde8-4720-96e2-ca5ceed0f1a2">759,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43ea83781f046ea919b9cbceae39832_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi03LTEtMS0w_24817ef6-e6c9-4548-b71d-df43fc0b0271">522,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c6af5351c04591a3a684eaf231d711_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy0xLTEtMS0w_d58ef229-fa97-435c-b347-3c60c9c5c745">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1fd8c412d841c9b9361bc3a6ccd5d4_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy0zLTEtMS0w_e2f0e254-76c9-46da-b1b9-6711e88438e7">9,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37bf6ef982543208fd55d26c3a8d017_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy01LTEtMS0w_5bf0a2b3-9125-4bfb-a3e1-a887fcfa0879">15,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb4d4519bbd45b58964c21b78d81e64_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy03LTEtMS0w_87b2e9b9-e487-4cdc-af61-0c8e5d7bd2d9">18,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC0xLTEtMS0w_9b774a79-1f7f-4ea5-9455-043123aeb78f">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC0zLTEtMS0w_497fa6a5-17ed-446e-a189-13d88c90aab1">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC01LTEtMS0w_5658e17a-d949-4e92-b9ea-3cdecaf0041f">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC03LTEtMS0w_8ebc4ca6-17cb-4129-becb-33e7727e1d7a">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5OA_c86bbeee-e402-4415-9b3d-0c8a4c14b498" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:41.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92ef125dfb745409eb663f06a66015c_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS0xLTEtMS0w_3f8c50e6-0127-40a7-9676-6b69a3d2ed21">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347244ecea174e2b84d7115e9117517a_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS0zLTEtMS0w_c574b52c-8c06-4d9a-bf83-abe158a7ab7d">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecec3a46caf04b9bb463218152250078_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS01LTEtMS0w_99c469f4-ff36-476b-95d8-06046d1741f4">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS05LTEtMS0w_fd36fff4-684a-4f59-98de-74a72397a8cd">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy0xLTEtMS0w_ef441f16-17ed-4584-b965-ca13a6d309bf">178,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy0zLTEtMS0w_ea6f22f8-a25c-4ea8-a62b-f12975cd8761">22,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy01LTEtMS0w_4bd43313-5ecf-468d-925c-8b65ead482be">74,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy05LTEtMS0w_59787200-10fe-4b38-98f4-6ed0db6c86e8">275,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC0xLTEtMS0w_b01296d8-d6ff-433c-a1b4-6181ffd6d929">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC0zLTEtMS0w_2f8db0c0-2156-4bdf-9168-d6c6dfbbab5b">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC01LTEtMS0w_5807bfe9-2a2a-4226-9bf8-879db3afcbae">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC05LTEtMS0w_b110690c-4d91-4f9e-b858-9b526c5b8505">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS0xLTEtMS0w_786ff62e-5f59-489e-a8cb-dd13f9703238">171,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS0zLTEtMS0w_6d18787c-fb2d-4a12-997f-ab6b1326c292">18,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS01LTEtMS0w_c5a3d412-9373-451e-960e-2f04dde2105b">70,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS05LTEtMS0w_97eba886-199a-4e31-a912-94df070df238">260,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc219e31879f4e968543b9a4acc1c6bd_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi0xLTEtMS0w_27139e91-111c-4095-8898-9be180ed094d">16,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f92052702c84e3da6d1adf2f5d4712a_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi0zLTEtMS0w_ab551e4d-29ba-4a73-8d01-b55191e36625">7,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299213a2fe8a44d19010980daaddadd2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi01LTEtMS0w_52d40783-a605-4638-810b-3d0e9124f31b">23,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi05LTEtMS0w_f2b8fd8a-4212-42b0-abc1-4ebe17cca377">47,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="if8a353d011ce485289c4906a7ea6c18e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets were <ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNzE0NjgyNTU4Njk3Mw_4d662736-3da9-4c2c-ae24-bce92a607099"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNzE0NjgyNTU4Njk3Mw_d9edb405-899f-4141-b15e-067f8f4cc7ad">zero</ix:nonFraction></ix:nonFraction> as of September 30, 2021 and December 31, 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities as of September 30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i64a9a55544ff4c3380cc3fb8c6f850b4"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5Mw_5f2754bc-69e0-4d2e-9f40-8bd592fb4fa5" continuedAt="id23d021e93934e1687e5aa584d8dfcd7" escape="true">Contract liabilities were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="id23d021e93934e1687e5aa584d8dfcd7" continuedAt="i0c3ca57cc5724d6f82676805d5edadf0"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfNy0xLTEtMS0w_4961e843-2d0a-41ef-944c-1cad7c1ae753">7,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfNy0zLTEtMS0w_143b7f85-500b-463e-b2b4-df1c894b2bcd">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOC0xLTEtMS0w_e4c7e80e-c129-4b1d-861f-e94669e43810">9,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOC0zLTEtMS0w_6895c262-6d90-4e31-b17b-cd36ae89fe6d">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOS0xLTEtMS0w_9d71572b-a22e-44c3-8a0b-3a203b1673f8">16,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOS0zLTEtMS0w_9fe2733e-2e5e-4928-b0b1-e74b3dae373a">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:continuation id="i0c3ca57cc5724d6f82676805d5edadf0" continuedAt="i34e758b61a104e538d79a56fe8a449f5">(1)</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i34e758b61a104e538d79a56fe8a449f5">&#160;&#160;&#160;&#160;Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-5" format="ixt:num-dot-decimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDI1Ng_2d9082a9-cc21-4ada-9f61-9b00cc5982c5"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDI1Ng_e0647e83-a1b8-45d7-a820-ebe87357d016">6.8</ix:nonFraction></ix:nonFraction> million in revenues in each of the nine months ended September&#160;30, 2021 and 2020, that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDQwNg_50ca8bac-407e-4ece-b374-3aba93e57e06">48.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDQxMw_9cdbfd03-dbd0-452e-99a7-c789c00f55f3">116.2</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDUxNw_b95abcba-1980-4a15-8f22-ace158305a75">33.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDUyNA_4b148db8-a688-4c21-ac75-0841802e90a9">115.3</ix:nonFraction> million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDc3NA_a94755c3-0dd5-4fd1-b335-d2029d9946dd">86.5</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNzAwMw_bfd90d17-290b-46e5-8f63-440ae163e24e" continuedAt="i01d8030f9db8404c8d7b24ccd14923e8" escape="true">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i01d8030f9db8404c8d7b24ccd14923e8" continuedAt="i826fa72e2b1b4476888cf7a8666fe9a5"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i826fa72e2b1b4476888cf7a8666fe9a5" continuedAt="i358db05e547d43858e732933cb764b66"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, collaboration services revenues for the nine months ended September&#160;30, 2021, includes a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period.</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNzAwNQ_b42a56cd-733e-4299-aab5-a6d590a99aa8" continuedAt="icb94b087da574d359c026c6f4dc7c12e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e6809b452b4c0d91e76fccd77f2f8c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi0xLTEtMS0w_4d44c815-e9ba-4255-9423-c505b5769399">25,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c12de1d32146d68e9fb7edd1441d2d_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi0zLTEtMS0w_e7ff58b2-7f81-4a8e-81f3-96a5857bfb11">19,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e4ab99fdb34795911040b0e2097e76_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi01LTEtMS0w_c83b5118-3cb7-400d-ba62-b83ed124fe95">81,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3beaad32f58b469c90e2e895a020fed6_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi03LTEtMS0w_ea3368c7-a9b4-4a66-8a1b-d86aca996cc8">71,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8050e574dc1c4db78e12b097abdec6dc_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy0xLTEtMS0w_9655fa2d-89e6-4b32-a243-4ee399ea748b">12,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ebdacb1fea40dd827669ddd4d97f01_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy0zLTEtMS0w_c5b8e14c-cdb9-457d-930a-352ef3884324">16,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabc23478b384ed9851e76ca8df34e39_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy01LTEtMS0w_f7da5fa0-6625-422f-a9a1-d1f9074eb738">81,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c088daadd8a408f89a19ef83a3570ed_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy03LTEtMS0w_6d27c294-6879-4b23-afad-d482ba9edcf7">46,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41488a2e36454734af6a6a327ecb17cf_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC0xLTEtMS0w_e60e3764-3db0-4f20-b851-c05a6fb671f2">38,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0256d26fd34b138fadf3cd0c240a78_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC0zLTEtMS0w_08cb184e-f3da-492c-90b6-450acbb659e6">36,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC01LTEtMS0w_7148ffd8-313b-4a96-a6b3-c962f575e771">162,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c65d788a4d64260968ac3714dcfe64f_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC03LTEtMS0w_991a5492-633b-4507-b0ad-e987d0e2c7d7">117,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the nine months ended September 30, 2021 included $<ix:nonFraction unitRef="usd" contextRef="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjM4MQ_641f434d-23c4-45c7-8d8e-0b3e72166750">11.9</ix:nonFraction>&#160;million recognized in connection with a $<ix:nonFraction unitRef="usd" contextRef="ia7183ea49abb44619f51586094019e9f_D20210403-20210702" decimals="-5" format="ixt:num-dot-decimal" name="exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjM5Ng_a5cfac8d-708f-4588-adfc-55f02f29015c">12.5</ix:nonFraction>&#160;million regulatory milestone we determined was probable of achievement in the second quarter of 2021. The milestone was achieved in the third quarter of 2021 upon submission of a variation application to the European Medicines Agency for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i303d549538f2427bba2cce5280974392_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMjk4Ng_992491c4-1dc5-4f8d-b536-54d323d1dabd">44.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="icb94b087da574d359c026c6f4dc7c12e" continuedAt="i032082e8268742d084c7878038159285"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59abfa55299448e3a17334e501e602fd_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi0xLTEtMS0w_4a25f817-dae7-45b7-b873-f1d33082fc16">20,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ef9a35f9714d0baf8ee7a1bf5fa4f9_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi0zLTEtMS0w_59e30426-bee8-4601-80e4-ebd84b107e85">9,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46630f5e17e048d6958cfa0d603db35f_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi01LTEtMS0w_50b2788d-aabc-49ce-b8ea-0b7c92d71aae">23,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf65eae8d34c44368baa6edb4df56a64_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi03LTEtMS0w_92872e8d-6828-45ff-8877-d10409263b41">32,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id970f743dae1483e88e2ddd200c78c24_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy0xLTEtMS0w_7f5b3ed7-85c1-4bd9-a272-eee929b1a0c8">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d005b00a57d4883b8ae4d21dc6bde0b_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy0zLTEtMS0w_9a821d4f-3014-4b20-bab7-190f8b208faa">13,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5db0c4605f84fbdb15d0ac333e9c674_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy01LTEtMS0w_6dd846cb-2027-4882-9f09-8898b3735f56">10,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5376f2dae7f547e9b48251e30c8efb87_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy03LTEtMS0w_494a6f76-bcb2-4a8c-8681-cb45d02b1661">16,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e1880501a749b483269275293c21a5_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC0xLTEtMS0w_bf897e3d-7344-4fa3-88bd-a6dd5d7ca2d1">22,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227171c03dd7470ab777a1c62dda82f1_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC0zLTEtMS0w_5b719c48-73f8-4197-8de4-37a4ce80a715">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC01LTEtMS0w_bc391bd2-3a89-48ce-b3de-ba8694780dcd">34,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3992056ab144b1b9917c48ab7ac95cf_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC03LTEtMS0w_de4106d4-0c03-48b9-af7d-b1d050280d65">49,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the three and nine months ended September&#160;30, 2021 included $<ix:nonFraction unitRef="usd" contextRef="id1e1880501a749b483269275293c21a5_D20210703-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYyOTI5MjE_2ff0f5f3-d01c-418a-bfad-15e1569bc253"><ix:nonFraction unitRef="usd" contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYyOTI5MjE_969dc30a-6596-4759-98d3-f81ff3703dbc">18.8</ix:nonFraction></ix:nonFraction>&#160;million recognized in connection with a $<ix:nonFraction unitRef="usd" contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjQyNQ_40a317b2-71ca-4345-8506-86830d680772">20.0</ix:nonFraction>&#160;million milestone we achieved upon Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i893a51123e7c4016962a39929c139bff_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMzgyMA_3fd993fe-e072-4a17-b23c-c30bad1bfd1c">41.7</ix:nonFraction> million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a <ix:nonFraction unitRef="number" contextRef="i180e76bcc0744dceb497bede8877d6bc_D20210102-20211001" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDEyMA_50aa1c13-2a65-4a9f-9bf0-c76702dcaeae">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="if33937ce988840acb055192972fe7d0e_D20210703-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg0Mg_fd9396d3-3e8d-44bc-b232-c87daace7590">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb3f26725f7e469ab88cddcff11f5119_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg0OQ_9e248f10-c617-484e-bbfe-9adedb895bc7">33.7</ix:nonFraction> million during the three and nine months ended September&#160;30, 2021, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="i19bb8d1b724e4bd8a470e35512bff9e4_D20200704-20201002" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg5OQ_b433434d-a9d0-435d-89a9-7f9c470d3526">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0eb6246a347b47a29f0ec6969990a643_D20200104-20201002" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDkwNg_49d722f8-d4ea-42e1-8a24-fd0f2a90a3b0">23.7</ix:nonFraction> million in the corresponding periods in 2020. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i358db05e547d43858e732933cb764b66"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. <ix:continuation id="i032082e8268742d084c7878038159285" continuedAt="i5c5f92c346e44c3fb8120595d2c20fcd">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i5c5f92c346e44c3fb8120595d2c20fcd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi0xLTEtMS0w_238086f3-dc83-421a-a80d-48c68a2ac904">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi0zLTEtMS0w_05eadb95-bb82-4dbd-9cde-b86a6c859fd3">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi01LTEtMS0w_cad71e2d-5bfb-4251-b811-8ed70d9277df">5,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi03LTEtMS0w_4193db9d-38ec-41cf-94e4-591011e00fa4">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy0xLTEtMS0w_04b97478-169e-4538-8659-a7efd4fe8ec5">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy0zLTEtMS0w_f0df1ce6-613b-4299-9bd7-a642e958ada5">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy01LTEtMS0w_b2b50850-8ebe-43cb-9bed-dd60f728a4fb">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy03LTEtMS0w_4818202f-dd4d-4afc-879d-8f4babf33204">3,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, in support of our development pipeline, we entered into collaboration and in-licensing arrangements with Adagene Inc. (Adagene), WuXi Biologics Ireland Limited (WuXi Bio), expanded our collaboration with Invenra, Inc. (Invenra), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjMzNg_487eeeba-7d8d-4724-b991-3c9b084a8e52">28.0</ix:nonFraction>&#160;million and will make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQxNQ_17064ff6-d795-4512-aa1a-6552dc758e17">98.0</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQ1MA_019a8be5-a302-4bdd-810c-6805a6e9dd00">229.0</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQ4OA_15236423-95fb-4518-9a21-85d8a13f4ae3">802.5</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In addition to the upfront and future milestone payments, we will also pay Invenra, in three equal annual installments, an exclusivity payment of up to $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjIxMQ_0d50def3-0a0c-4dde-830b-ec69b9c9689d">15.0</ix:nonFraction>&#160;million to nominate up to <ix:nonFraction unitRef="target" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="INF" name="exel:CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA0NDUzNjA0ODAyODk_b7fdcbc0-a9af-462d-8aa5-fd2622866884">20</ix:nonFraction> additional oncology targets and up to $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjIyNg_51d1e3e1-e4b0-47ce-af1d-72f3b6c5f2ae">30.0</ix:nonFraction>&#160;million in research program funding in equal quarterly payments over a <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" format="ixt-sec:durwordsen" name="exel:CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTI2NDQzODM3MzU4Mzk_5ee5ef12-90b4-4f9a-8c23-2a111555948c">three-year</ix:nonNumeric> period, as well as additional fees. As of September 30, 2021, we have paid the first exclusivity installment of $<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTY0OTI2NzQ0MzE3NTU_b13c360b-8778-4f89-9ab9-3246dd21ed25">5.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTY0OTI2NzQ0MzE3Njk_b6ff9ef6-f4d2-4de1-b527-8ca203c6ea00">2.5</ix:nonFraction>&#160;million for the first quarterly research and development funding installment. We have the ability to opt in to certain of Invenra&#8217;s other internal research programs in exchange for an option exercise payment of $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="exel:CollaborativeArrangementRightsAndObligationsOptionExercisePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjI0MQ_c34f0479-cd45-4f91-99c8-ead3971319e8">3.0</ix:nonFraction>&#160;million per program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in May 2021, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i42c64fd2685d49a09c1aaa714e8a71b5_D20210501-20210531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjcxOQ_6fe8c200-485c-40aa-878d-ef47f9c8c318">5.0</ix:nonFraction>&#160;million for the initial technology transfer, and subject to certain conditions, will make a $<ix:nonFraction unitRef="usd" contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531" decimals="-5" format="ixt:num-dot-decimal" name="exel:AssetAcquisitionPaymentUponClosingOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjgwNg_30451814-5f19-4f7e-8581-2efb9b4c52fc">9.0</ix:nonFraction>&#160;million payment upon the completion of an initial technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531" decimals="-5" format="ixt:num-dot-decimal" name="exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjkzMA_c6c0900f-cd9a-4bbc-87be-f7060f1b78a4">42.0</ix:nonFraction>&#160;million and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531" decimals="-5" format="ixt:num-dot-decimal" name="exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjk2OA_a91f39c5-ba73-481e-9e8a-e7bd63007601">22.5</ix:nonFraction>&#160;million, per product.</span></div></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjczNg_3b37b717-65e2-40a1-ad8b-adf7aa5d28b8" continuedAt="if4a60682f82d4abcab5e437b3499ba9c" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="if4a60682f82d4abcab5e437b3499ba9c" continuedAt="i1ab12b21fef74559be4dec54fd2ad4b9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjczOQ_5301930d-c9b9-4a05-835d-7723b60ab878" continuedAt="ibd2b37dceb314f399a6a94643da0b82a" escape="true"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc1MQ_81242d84-a5c8-467e-bd01-f1d0ade1987c" continuedAt="ie6e627d07fa147d4be6ada6f09017292" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ibd2b37dceb314f399a6a94643da0b82a"><ix:continuation id="ie6e627d07fa147d4be6ada6f09017292"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMS0xLTEtMS0w_5d8f92c7-594b-40ac-a242-33b57d90abe0">567,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMS0zLTEtMS0w_d55ec1c9-ca63-44ae-8d5c-15bcfc215c99">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMy0xLTEtMS0w_e3b89531-04e2-4a69-a9eb-3dd5b41959eb">31,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMy0zLTEtMS0w_30c01059-a3af-468e-815f-a21b13e8351d">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfNC0xLTEtMS0w_c2ac607b-7b10-459d-b278-8f478330d7d0">598,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfNC0zLTEtMS0w_d43c1215-6d48-43f6-9e5d-0220efe7595d">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of September&#160;30, 2021, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTA5OTUxMTYzMTA5Ng_d6f9cf5a-69a4-4c23-bc22-1566d42f20c8">29.6</ix:nonFraction>&#160;million of short-term investments, which is collateral under our January 2021 standby letter of </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i1ab12b21fef74559be4dec54fd2ad4b9" continuedAt="i41808678ee7a41cf836477f1c7cfe27f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc2Mw_59c41fb8-e280-4dde-a8cb-a3d2a380f1ac" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e81c19802d8419abd05b32afb361529_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy0xLTEtMS0w_5258f157-ceaa-4b61-94cf-f5218a696596">886,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e81c19802d8419abd05b32afb361529_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy0zLTEtMS0w_f8beff7a-e1e5-4c3e-ba32-b4cdcd6fec2d">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e81c19802d8419abd05b32afb361529_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy01LTEtMS0w_68f769ed-acf5-4656-8c03-777bb720493a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e81c19802d8419abd05b32afb361529_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy03LTEtMS0w_1c49ddaf-fb36-43bb-b9b1-acf9758515a5">886,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC0xLTEtMS0w_99c5f2ef-2a96-4093-954b-53c8c80cb2ce">503,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC0zLTEtMS0w_f0df31fd-2157-441d-aad3-32ed7cb28296">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC01LTEtMS0w_46566594-a142-47cc-aafb-022051e53c78">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC03LTEtMS0w_a8d21bd6-2283-46f3-a1a3-8e476af3d853">505,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS0xLTEtMS0w_48bc8856-7742-4b5e-ac6c-d811f256af0f">58,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS0zLTEtMS0w_e85e760f-31f2-4a1e-a399-eb4208accc70">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS01LTEtMS0w_d8acc0de-2d93-4c42-840c-fea726734e80">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS03LTEtMS0w_a5d711c8-ef34-4acf-842c-a8e33100c4bb">58,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi0xLTEtMS0w_b98ca716-a921-4b27-aafe-2178ab70d943">10,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi0zLTEtMS0w_56731770-364d-4b9b-b3a8-fe53ac0729bf">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi01LTEtMS0w_174235d9-c56e-4944-8077-87a276abed36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi03LTEtMS0w_a1832aa6-3cc9-4536-81fc-e5ed99aa3b81">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy0xLTEtMS0w_7043202b-f772-4f37-8638-5c15fc28b6ae">1,459,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy0zLTEtMS0w_b2bd52fc-92b8-4f84-8029-f825d25b4739">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy01LTEtMS0w_3e437967-2a34-4e44-be5c-9b12d43f7420">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy03LTEtMS0w_2fc72013-d3dc-4a52-bdf9-2bb3388efb50">1,461,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC0xLTEtMS0w_c45dc559-ef9d-414f-8063-d08b954e7934">80,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC0zLTEtMS0w_ba2a69de-3d66-46ec-b28e-2cccb8af208c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC01LTEtMS0w_575cb848-2f97-4897-bd3a-a593fb2c9390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC03LTEtMS0w_4561c20a-1203-496b-b175-55734d9fd069">80,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1603788af44df89cb2501d143c508e_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS0xLTEtMS0w_4c4b86e2-5089-40c6-b376-edebcc233669">119,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1603788af44df89cb2501d143c508e_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS0zLTEtMS0w_47c8d6af-ab18-4c9f-b4bd-df830d15d37a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1603788af44df89cb2501d143c508e_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS01LTEtMS0w_4735bd78-0372-4ab7-8552-95b5e332e636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1603788af44df89cb2501d143c508e_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS03LTEtMS0w_e5e0cf0d-47ce-4a14-ad40-5b89bc82e45b">119,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMS0xLTEtMA_185ac0bd-bc4d-423a-b7a2-8b38978a9ad2"><ix:nonFraction unitRef="usd" contextRef="ia937163ad2774ba59a4a97202dd4f1d3_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMS0xLTEtMA_72468528-233d-476c-8fd8-5661339ac2b0">134,106</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMy0xLTEtMA_80e3c689-c85e-478f-b1ef-fb6008a2ef12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtNS0xLTEtMA_2504e056-6eca-4e5c-904d-b16300e0e4f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtNy0xLTEtMA_7498871d-1797-4ede-b784-f936aff6d47b">134,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtMS0xLTEtMA_e18a75f7-66ec-4a03-a90a-399dc58cb758">1,794,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtMy0xLTEtMA_5d9818b2-451f-4014-8a06-e447118730d9">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtNS0xLTEtMA_439b1f3d-41ce-4608-b720-32a3eaeaf122">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtNy0xLTEtMA_516a9751-ff2c-49a5-aaa0-cb50f86acc34">1,796,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy0xLTEtMS0w_31178e7a-236b-46cf-adba-3888f311999a">569,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy0zLTEtMS0w_f1eef2dd-0e29-406b-bc2d-cac40b35385f">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy01LTEtMS0w_53cbb0c2-e133-4027-923e-40473701d562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy03LTEtMS0w_1a73d1bd-18e7-445c-9b6b-7635d6b68fae">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC0xLTEtMS0w_faef1c2e-602f-41e9-bdbd-e72ec31f2b52">543,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC0zLTEtMS0w_f125662d-1330-4db7-9604-d7497e986b8f">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC01LTEtMS0w_2088ebad-cbd6-4893-b6a2-278edfb482da">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC03LTEtMS0w_c9c50e66-d9b4-49a0-98f1-35eb47022565">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS0xLTEtMS0w_c4229c4b-0640-4f01-b6b2-61cdcba94808">208,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS0zLTEtMS0w_0e542cac-7140-4abe-b83b-1baf6b9b77f3">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS01LTEtMS0w_04eed4dd-9793-4546-83ac-474dad0e3cce">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS03LTEtMS0w_dfe6672e-9e46-4685-9ade-1b937f69e417">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi0xLTEtMS0w_10d18e4c-eaa3-456f-aca8-1d49ff6f26b5">28,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi0zLTEtMS0w_52168c0d-716c-4b98-8ffd-c5904d670695">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi01LTEtMS0w_94369058-8219-48bb-984d-b3e7bd935d1e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi03LTEtMS0w_599345e2-1162-4018-bce6-a7fdf443777f">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy0xLTEtMS0w_952eb233-efeb-4624-b97a-34a4750f7760">1,349,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy0zLTEtMS0w_f593dc75-d6f0-4a81-9fe9-da877fb82a61">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy01LTEtMS0w_eb3ef31a-5870-4b76-a9f5-bb87453925b9">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy03LTEtMS0w_24c6d3d7-59ca-4f7a-84f6-93dceff6fa30">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC0xLTEtMS0w_d28be6a6-068a-45fb-83f1-86134d19cabd">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC0zLTEtMS0w_627e42a2-9030-449b-9474-18576ababdcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC01LTEtMS0w_73e17b40-4e70-4e74-9186-47d6c694a81d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC03LTEtMS0w_e91975d0-1341-4483-84c1-6bcb87be6125">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS0xLTEtMS0w_eff4d68a-cf85-4035-88aa-ebcccae400eb">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS0zLTEtMS0w_bfc29160-8753-4073-bd3d-8c1fbdadefcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS01LTEtMS0w_100948c2-2387-45d2-b144-41394e69f105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS03LTEtMS0w_ecc97589-c4ce-4f8b-b3f4-2d0b1a8b0a9f">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtMS0xLTEtMA_fa59a91d-9dbc-41cf-9fae-837926e2f8ac">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtMy0xLTEtMA_fb7be8f9-c970-4fcc-a43f-644bf8694fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101" decimals="-3" format="ixt:fixed-zero" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtNS0xLTEtMA_ffc3cb19-73c7-41b1-8e8d-0ffcf7131f5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtNy0xLTEtMA_8927f37c-9f6e-4069-9e74-eb6a491dcf80">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtMS0xLTEtMA_f5e52180-e3a5-4947-a138-b4e09a5f5c8c">1,532,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtMy0xLTEtMA_e7666da8-c024-4465-81b3-05184955c585">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtNS0xLTEtMA_44abd114-9fef-47ff-ad51-b5b76df22fb3">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtNy0xLTEtMA_4849b79a-abad-424d-9cc7-61e5d9f122b1">1,538,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTI1OA_cafd4d09-a554-4ad4-880f-32d56cd05462">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTI2NQ_629d6e0e-275e-4450-9032-8ad91e8b802e">4.5</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2021 and 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i41808678ee7a41cf836477f1c7cfe27f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc0MQ_17daf5b0-541f-472b-b146-ea28ab8fcf7b" continuedAt="if1b3a2848238413abbd09b43ac4f49f0" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="if1b3a2848238413abbd09b43ac4f49f0"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfMy05LTEtMS0w_a14eca3f-96de-4e35-8feb-a89288f209c7">136,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfMy0xMS0xLTEtMA_62db7552-28e5-47cd-bd44-c75f47d1ee7f">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNC05LTEtMS0w_c3f06b3e-10b5-414e-b702-b1c2778c7d0f">10,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNC0xMS0xLTEtMA_6d9ed9f7-58aa-413d-a66e-a2c6356dcf90">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNi05LTEtMS0w_3f46b4e0-455a-4cb1-a457-281fd12a01b6">146,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNi0xMS0xLTEtMA_5d083d2f-6353-40c6-806a-53becc3421f5">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMi05LTEtMS0w_3273728e-e869-4b53-bd7e-dc7a0ce3403e">28,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMi0xMS0xLTEtMA_b1ae62bf-b646-45be-8efc-b286c93365b9">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMy05LTEtMS0w_0623e4bd-f6c7-46b7-a0e8-104e70ecd96e">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMy0xMS0xLTEtMA_03eebd9f-c26b-4eac-994e-555b60287972">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNC05LTEtMS0w_5e0b8ff7-b6f1-4aa7-bacc-74a0e13ba1ac">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNC0xMS0xLTEtMA_1c52db8f-45ff-465d-9730-14813010a4db">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNS05LTEtMS0w_1f51e13c-7f42-4f9f-aa51-bc5b044240d5">56,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNS0xMS0xLTEtMA_d1fe88c4-f60f-4a81-b77a-865cdba0f8ad">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTk4Nw_987464f0-53ca-4a39-a5a5-c2bd4ced40d3">41</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTk5NA_249cc8c6-5ca9-4382-b773-e42892b206d3">14</ix:nonFraction> investments in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the nine months ended September&#160;30, 2021 and 2020, we did <ix:nonFraction unitRef="usd" contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjEwMw_7271f294-3229-4559-ab3b-dcfe828f891f"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjEwMw_8d53fe86-5b70-4b7b-92ca-e45f267c2193">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjcyMA_b097c642-9eda-463b-9e6c-b8d3a15daa57" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMS0xLTEtMS0w_75b25c55-1729-48c6-8b4d-75edcf88b78e">1,103,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMS0zLTEtMS0w_438b5a17-a297-418a-b84b-ae7b531a0144">1,034,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMi0xLTEtMS0w_bb1ded5a-9171-4f81-b09d-10d908cba6f0">358,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMi0zLTEtMS0w_7b6277f2-9cce-4dce-baad-a4c5ce8b9fd7">321,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMy0xLTEtMS0w_b44ca5fe-cce6-49a3-ab35-9f3f9d0ff2c2">1,461,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMy0zLTEtMS0w_635bd25b-931b-45df-bac5-def99192ee99">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjUwMw_98abff44-4d3e-4272-a0fc-a6f95759c4ce" continuedAt="i053dbff6032b42c398a023dbb97f324f" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i053dbff6032b42c398a023dbb97f324f" continuedAt="i89675481f8d1494684e73cdcae5ef25a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i89675481f8d1494684e73cdcae5ef25a"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjQ5Nw_3bf2c57e-1c5a-4e4f-99d3-c4b4ff2fa19b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f02cd5c10e458e843d55805a3431fd_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi0xLTEtMS0w_aefd6523-d1d3-4f1d-828f-93eb8e6232fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba2574066cf4ff6a9f6e4150f0d9a59_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi0zLTEtMS0w_e553edf1-ac89-428e-913d-f97664db5e4a">886,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbe7cfb8d5147028098fffe5f993314_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi01LTEtMS0w_08c33c28-8595-468a-b60e-73a1690b1d50">886,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0747067a48245fc8dc26066c743c9d3_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy0xLTEtMS0w_aca4b986-4cac-4a5b-802f-65be643dc091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262de96d6b8744ae924a3782d09bacc8_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy0zLTEtMS0w_f4d64f03-e0b6-4f14-9db0-660f42f26450">505,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia884675fcb614de78f41b988cfa85253_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy01LTEtMS0w_03cf9de0-ca12-4443-90e1-7dcb0a3ec78f">505,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i788e7100b3c44fc79ba7388a22d4be54_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC0xLTEtMS0w_d4c30d46-d49d-4452-a371-2b419eb30738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f49a14a38b4618a641e7062e9a8119_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC0zLTEtMS0w_ab0e68d7-d701-49e5-9362-fbb700dcb867">58,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib852bbac7c2b4dae935d9ace85587f2b_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC01LTEtMS0w_111b8648-fe76-4ca9-8eda-398c1f2aa9f4">58,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2116aaf10cba486e9ea0a92a908bcf3f_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS0xLTEtMS0w_c1cbdfba-9d52-4dbd-a286-fe0abaa62435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac31bdedd8347f4a54d5329d8341508_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS0zLTEtMS0w_56e4608f-23f6-4f86-9387-dd3528280d4b">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6aee20093514a7c908b61d8a427f82f_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS01LTEtMS0w_69cbe701-d72e-426f-8b0a-5da148c21cf9">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85113d3b2cbb42bea2638a8879a3bc44_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi0xLTEtMS0w_eee00c2b-7dd2-4bba-bd0d-098faeeb111f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f7ba7484824fdfb1bf032ab871ce77_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi0zLTEtMS0w_b3c74a76-5b26-468a-a2a8-1a7f85faeb5c">1,461,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1060b811968c481ebf2bbc36128837fb_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi01LTEtMS0w_699e3c94-851b-4c44-93a1-f0b3ac19c627">1,461,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b53fa939094dbc9d03652f7ae327cd_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy0xLTEtMS0w_fa69c5df-6b18-4f0b-bf70-7115387dd5ac">119,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice95d1289bb548b3a198fedcadd68f9c_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy0zLTEtMS0w_38ff8e04-7008-4bfa-8cff-2943cc2db65e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0713852efdf4c9b8596061c2371f8c5_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy01LTEtMS0w_4a308603-7447-4ded-85e7-bdfc16bfaac7">119,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2720023a476a45c4ad1b14dea520df26_I20211001" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC0xLTEtMS0w_f10cf27d-ff53-460e-a3d8-f4305e42bd2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia937163ad2774ba59a4a97202dd4f1d3_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC0zLTEtMS0w_18ef1f0e-5966-45c5-81b4-086a22a72fe1">134,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f50cbeebde04173b4d76512c9e37178_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC01LTEtMS0w_d3c2b0b9-158a-4006-99ce-c22e40a314f2">134,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85113d3b2cbb42bea2638a8879a3bc44_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS0xLTEtMS0w_f41132ab-35bc-46e6-81c9-3fb13b10da1f">119,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f7ba7484824fdfb1bf032ab871ce77_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS0zLTEtMS0w_e3cd2e59-ba7e-4fc8-9916-101f59562820">1,595,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1060b811968c481ebf2bbc36128837fb_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS01LTEtMS0w_a17ff686-cea6-4b4e-bcb9-2dfddcad2f76">1,715,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce21a7f43c44e3f961a96a70156939e_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi0xLTEtMS0w_5827b002-c664-4a45-adf0-22fda39e56a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358c92e2bfaf46b3bda44418ad4ddff9_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi0zLTEtMS0w_49b44a91-2d67-44ef-8dc0-c6b37f54280c">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eee75baece241f6bc83d598c6a8dce5_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi01LTEtMS0w_d537f990-6ac3-4317-832b-d082ca3a97ec">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b60ddc46614de198e0d20fcc2e0d40_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy0xLTEtMS0w_6f32b8b2-f338-4134-a396-781589875a8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice80f13753ab4747b55be1f290360a38_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy0zLTEtMS0w_e70237f9-784e-4f0f-82cf-a5de04cb9fe5">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a068b43a44e4e71aed4fab765a9a10d_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy01LTEtMS0w_e3c5626b-0b57-447c-bf6d-4ecd53a15dba">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4197a386017d4ce4b80b50397cde9f66_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC0xLTEtMS0w_a5e4b1a3-284f-4229-9b98-60b12e2eeece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74bd879c428e43e38d7c190fb00c13bd_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC0zLTEtMS0w_3278ad02-7f15-4513-8186-e9f39c7f9049">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b26d8ad0e0c4ab9b2ddc26c19baf207_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC01LTEtMS0w_e1f646f1-11b0-4d28-89b1-b5f51e14d730">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06308a04850340b581f089fa2d42d8ab_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS0xLTEtMS0w_47553ae7-d9d3-4879-bc98-3a665591256d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a9bdf6dc464c5f9f939b05d8db8a62_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS0zLTEtMS0w_9edbbc9a-5636-48c9-b258-bcf2121bd19e">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3bb879c1144c2b8f21d8d76daa2611_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS01LTEtMS0w_efea0dba-ff90-4387-80d4-415c63f919c1">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi0xLTEtMS0w_9d6e816f-f621-4704-997c-11ae229312c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9dabe918ed4a75984789a54fabbc52_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi0zLTEtMS0w_479801b0-7060-40df-a6e2-d76d5debb2fa">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi01LTEtMS0w_38991be5-f747-40a6-a126-feaf090b8664">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576f4d76f4844ef59140fad75b749351_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy0xLTEtMS0w_5925ff6d-ae47-43a6-bf6b-f027a585ea70">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f14e7d83ac24bc0934f3ce817815377_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy0zLTEtMS0w_395f9feb-6e17-4ac1-97e3-1f6a8ba80628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie604d7023f6448e9bfdea6430b029c7d_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy01LTEtMS0w_25427fea-6158-4333-a61a-697da6f2e87a">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e3d41a820d64c68a08dc8510596f5bc_I20210101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC0xLTEtMS0w_3d397aa8-e343-49e7-aa2b-f8f935010464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc806a4586494bdea73d4d8ca8067226_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC0zLTEtMS0w_08ce1388-bcb6-4a5e-b269-2e79a9fd4acc">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5366d5070d44918ed8a0165ebd5ab0_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC01LTEtMS0w_487cf2ce-78f8-4a13-befa-ff9078b00dfa">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS0xLTEtMS0w_279a1725-e1f7-4914-8eea-daf5d8eeefbf">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9dabe918ed4a75984789a54fabbc52_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS0zLTEtMS0w_b79e466c-77a9-40e5-9c5f-e2fc26c5ef83">1,415,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS01LTEtMS0w_1722a292-593e-46f9-9e12-803d2cf9a0e7">1,456,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had <ix:nonFraction unitRef="forward_contract" contextRef="i68ac30fd607b41bc80b50c13706647e4_I20211001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTg2OA_1527f1d8-db48-4ba3-8b23-28d7ce092802">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i68ac30fd607b41bc80b50c13706647e4_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTkwOA_1aed45a2-e216-497e-9e75-592402b16bc2">9.8</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTk1MQ_e17300aa-447f-4b13-a605-49380e89916f">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of September&#160;30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months ended September&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainOnDerivativeInstrumentsPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjM0MA_b9d6db5c-30fe-4a0a-8c97-2e7cd6beac10">0.5</ix:nonFraction>&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income (Loss).</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RleHRyZWdpb246NWMyOTdmZGM4MWE0NGU4YmI4MzFhYWZmY2JkNGI0MTZfMTgw_26e62eed-c353-4031-9f1c-5a2acdeb9d4c" continuedAt="i4767d027ee8844ddb9120f28b8ca52df" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i4767d027ee8844ddb9120f28b8ca52df"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RleHRyZWdpb246NWMyOTdmZGM4MWE0NGU4YmI4MzFhYWZmY2JkNGI0MTZfMTgy_c4cda8e0-7e74-46a4-81cf-dd6ceef8bb24" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMS0xLTEtMS0w_f269009a-5623-418a-b3be-4ea1009b0614">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMS0zLTEtMS0w_648266ce-785b-4366-8e2f-d06c0aa36f43">7,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMi0xLTEtMS0w_928483be-aeb1-44cc-bed4-cd46ffb97d80">28,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMi0zLTEtMS0w_c1a6566c-e708-43bf-96f0-30add9383272">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMy0xLTEtMS0w_3450344f-cf3a-45fa-93b1-0a92b814f7f1">11,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMy0zLTEtMS0w_30736fd7-ef36-4789-a336-087f2ee0ed8b">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNC0xLTEtMS0w_fd2239a4-f952-4a9c-9e89-d5b20292dc3b">50,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNC0zLTEtMS0w_307500cd-3bfd-4bac-9f10-7c72133f26d7">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0936cbe6a0f84d479d483892d24f6d55_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNy0xLTEtMS0w_82e96343-d0db-4a64-a64a-01d9bb40eb93">28,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib720450b2a1a4fc8a2cdcdb63baed576_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNy0zLTEtMS0w_b4ee9c4e-21fe-453c-b8fe-e0450f2c58eb">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db00f27c60d4842a7a2bce3d6d547e1_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOC0xLTEtMS0w_8a2d391c-ce82-4c12-918f-1e97c9864536">21,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41fd2edf3a14dd7bf6bb33de4813ccc_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOC0zLTEtMS0w_aac6a72e-aa83-461d-a05e-b25defb897ec">14,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOS0xLTEtMS0w_c5d7bf28-de89-4fec-93c6-160b961299ae">50,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOS0zLTEtMS0w_bdb4c701-d14f-40d2-bcb2-40f4b3fd5f4f">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM5Nw_dcd68c7c-2943-41ee-a4ee-2449154ffae2" continuedAt="i7ef33bec3912499a8f563a6c5ae76b14" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i7ef33bec3912499a8f563a6c5ae76b14" continuedAt="i772437cc95a8445c8fcbc7f8c3e63286"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM3Nw_08a0d34a-325a-44a3-9f21-55748457d158" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafa823dcfbd4c2a9d8b8df5d69e150d_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi0xLTEtMS0w_405d3115-0144-46ca-a3f3-72b9d7acd2c6">11,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdb2309e0e5446b87b31a0eb6c99f2c_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi0zLTEtMS0w_dcf19138-4114-4034-bd8b-584743649e52">18,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67eaaa8ffdc4407780e4e29e54ed4917_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi01LTEtMS0w_94f2c06e-11c6-4bd2-935d-8486816051ef">37,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8058d357f34b1db293a0ba18c7b0e4_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi03LTEtMS0w_c5b76669-17a2-480d-926e-adae14139439">30,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff8c10e09a74083a913c8dd829db3e3_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy0xLTEtMS0w_768f8a27-bb2e-4c64-b596-2b2304ea957e">22,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133709ff0a1b4c138d61663fd033397e_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy0zLTEtMS0w_70335dc1-e150-489b-a688-14a25e65eb62">36,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b5f2d2f5d3425586df0611b0cd3dbb_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy01LTEtMS0w_2629d511-d04b-460d-919a-6c25cfda90c1">59,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4accc8a979184a968b8b082d620fbf50_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy03LTEtMS0w_c7caae55-f480-4d84-b07a-36fa0ec6b8f9">55,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC0xLTEtMS0w_72a4ff1a-650f-49f0-b25b-66eb7ab8e485">33,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC0zLTEtMS0w_81b6667a-d820-4c13-a39e-bdfa21b25358">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC01LTEtMS0w_8187512b-a0d0-4c31-8ff0-bea37149cc3f">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC03LTEtMS0w_b971d43c-a85a-43f4-89aa-194272427ddd">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e09d7534be4b2999db1628207e2de6_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi0xLTEtMS0w_6eb7282f-1c1d-47c0-9cb3-e8b0ffbe6403">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7299aa4e8d1145f896fecef97ca01e59_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi0zLTEtMS0w_a07e10ae-4154-4c7b-8e2c-5522200c938a">5,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi01LTEtMS0w_301e263e-50b2-4646-9d15-6567aa4ce9d4">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08eb8dd6d816445da416b2e82bf72356_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi03LTEtMS0w_ba7e03f3-e35a-418f-bd7e-cf6b642310ca">15,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0381b7e4bd74829a0a31d3bf8871cf0_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy0xLTEtMS0w_bf5df273-3e18-4d74-9618-dddc2070977f">13,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bef1feb8ca440608a019e77cde78bae_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy0zLTEtMS0w_77b224c9-f304-4be1-9ad7-38881f6fea0b">8,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy01LTEtMS0w_849d7bad-13a3-4419-a3b1-f72929c483aa">40,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808843dbbc3c44908e48a431eb1f24d0_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy03LTEtMS0w_b63535bd-222f-4ddd-9d1b-a5a2f32622c3">25,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2d7629149a482f9cc826940879689f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC0xLTEtMS0w_b9d86f35-e872-4744-848a-e50aad31c07e">14,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1460d3b96640419a83156ab690e99fb1_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC0zLTEtMS0w_7d36db7b-9600-4507-a189-ffcddb14f2de">41,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC01LTEtMS0w_b0c83bfd-1e38-4d7f-aed5-0c14f906fe40">37,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50addfcd8acf48179fe0db096adfbc86_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC03LTEtMS0w_1be3f2da-54a4-4aa5-a184-e4df5b94e9da">43,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838699b122594d4f9e99ff8f3d9dbddd_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS0xLTEtMS0w_1751d286-a006-4970-a573-3d4049515c5a">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a6530ae4124dd299a7574226b98393_D20200704-20201002" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS0zLTEtMS0w_2d02cde0-0493-49a1-b836-b7b8eed6adb4">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fce6ed1b2045eb851578aba3348c9a_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS01LTEtMS0w_54ce86c9-2012-4558-8454-e02434c0d6c1">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a75f9432ff64e73a1ac73574ddcfa54_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS03LTEtMS0w_bddbccc0-a187-4b1d-9d66-a7e8b0cf2410">2,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi0xLTEtMS0w_a3eb00a1-0f1c-477b-a1a9-16ddb57ea79d">33,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi0zLTEtMS0w_3ecfddb8-0e50-44b3-a212-e7678d77091e">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi01LTEtMS0w_d69c7126-2b8d-44d2-b476-de9a6afa82f3">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi03LTEtMS0w_dea79f03-69ec-493f-bd44-e6c303b04979">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzI2_9e028f2d-9545-4bb4-be8e-9b375b04819c">9,248,609</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNDg3_f9a1b5b8-d052-4e92-83d6-e6e3b003bbeb">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNTQ5_57c6bbab-fa6b-4189-8211-2e60bc21452a">1.5</ix:nonFraction> shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNjY1_6a874093-d299-457f-aceb-1e5b89b27419">2,032,884</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNzI0_0fcc37b8-7738-4935-b513-6239e8bd9249">21.81</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNzg1_01fa3523-ea9e-4a7e-aad2-e1536dd11c53">9.30</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="if1dc7061a4104e0b8aeb478b3078f095_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfODIw_aa01e6d4-adf7-424f-9e49-ed8b68a7382d">14,357,896</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="if1dc7061a4104e0b8aeb478b3078f095_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfODUz_f7d7a32b-a999-4307-9381-77a26943e3f9">28.6</ix:nonFraction> million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfOTMy_6132b71a-553f-4daf-a339-b8a0772dc468">3,947,355</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTAwMw_3af1c448-41ed-49c9-a264-81b84ac6e94a">21.50</ix:nonFraction> per share. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTAzOA_112b90cd-cf47-4d8b-a03a-6f7508d77975">8,218,085</ix:nonFraction> RSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTA2Mg_1254ceee-36a6-4213-a25f-4eced1ab11f6">136.3</ix:nonFraction> million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i772437cc95a8445c8fcbc7f8c3e63286"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded <ix:nonFraction unitRef="shares" contextRef="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTQ0Mg_f53bbe13-9b8b-4ac0-b205-5a5c3acbd6ea">1,027,650</ix:nonFraction> (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to <ix:nonFraction unitRef="number" contextRef="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTYzMw_04be0bdd-eff5-4a08-912f-9a22d38ab987">200</ix:nonFraction>% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. <ix:nonFraction unitRef="number" contextRef="iaf64fa313b794183bf4faf469cfd0c06_D20210301-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjAzOQ_48ed799f-02f2-471c-8b21-106711a5e98b">Fifty</ix:nonFraction> percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately <ix:nonNumeric contextRef="i7aaa7d8a46a34b038a5d053b7701b533_D20210301-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjIwOQ_b327c6a9-f4b9-48fb-aa1f-2f30687e06ba">one year</ix:nonNumeric> later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM2NQ_d504c105-2cb2-4e21-aaf5-da308fef1e4d" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjQ3MQ_03e3785b-778a-4ab0-87ef-54be8420ba93">24.54</ix:nonFraction> for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:90.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMC0xLTEtMS0w_133e0981-f0f5-42e6-8b77-1ca3bb390a6c">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMS0xLTEtMS0w_fc9ebe1b-5f05-40c3-b29c-22589a1a83ae">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMi0xLTEtMS0w_244bb486-f353-49d0-9564-7fcf2526100b">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMy0xLTEtMS0w_995d1291-f6a1-4dd2-b864-f4585c092554">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2021, there were&#160;<ix:nonFraction unitRef="shares" contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjk3OA_2f446379-9eee-438b-b8f9-b39c190754d1">7,768,188</ix:nonFraction> PSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzAwMg_dd14001b-9b5b-4417-9b85-681f65bb7c59">128.6</ix:nonFraction> million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2021, we achieved an additional performance target for <ix:nonFraction unitRef="shares" contextRef="i535221d9dcc64cd9a6a8c6fdc118809a_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTY0OTI2NzQ0MjI4MDE_7b685a42-e1ca-4f4a-b982-99bde31834f6">524,307</ix:nonFraction> PSUs granted during 2020 (the 2020 PSUs) and determined that it had become probable that we would achieve an additional performance target for <ix:nonFraction unitRef="shares" contextRef="i165ca677164a4242b9e75babf9daaee0_I20211001" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzg0ODI5MDcwMjg5NQ_33ca3915-28f2-4210-949f-5dae1e9c11b4">167,726</ix:nonFraction> PSUs granted during 2018 (the 2018 PSUs) and have recognized $<ix:nonFraction unitRef="usd" contextRef="i06b3a70674fc4636bc068b030241f7ab_D20210703-20211001" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTY0OTI2NzQ0MjI3ODY_7978834e-8c23-4111-b892-7441e9563a22">11.4</ix:nonFraction>&#160;million of stock-based compensation expense related to the 2020 PSUs and 2018 PSUs during the three months ended September&#160;30, 2021. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfNDUx_da90be60-ff39-4632-ab54-b34703888cd9" continuedAt="i323655388f734b6cb650f0922ee4ca81" escape="true">PROVISION FOR (BENEFIT FROM) INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i323655388f734b6cb650f0922ee4ca81">The effective tax rate for the three and nine months ended September&#160;30, 2021 was <ix:nonFraction unitRef="number" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfODE_62942aa9-72df-4c91-ae6e-a0f920bcb9a7">28.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfODg_06b2d663-4e23-4122-a52d-ad7d6e958aa1">22.8</ix:nonFraction>%, respectively, as compared to <ix:nonFraction unitRef="number" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfMTIx_4f236cec-1d4d-4815-8289-f9e4d596538b">15.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfMTI4_cf6fa8c0-635a-4110-9567-0e6decf5587c">18.8</ix:nonFraction>% for the corresponding periods in 2020. The effective tax rate for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits. The effective tax rate for the three and nine months ended September&#160;30, 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, the generation of federal tax credits, partially offset by non-deductible executive compensation during the periods.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzU1_5986805b-16fc-4456-a38f-27a0ba6d0c8e" continuedAt="i754480925da443ea9d2bcecde09549ab" escape="true">NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i754480925da443ea9d2bcecde09549ab"><ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzY0_2e38d258-489b-4c9a-91fa-4a6627781427" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy0xLTEtMS0w_eec64939-0628-4e1c-bef4-c7b332cf51c0">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy0zLTEtMS0w_5d74a91b-5ae2-4e97-840e-aa9fcb148c02">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy01LTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy03LTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS0xLTEtMS0w_f6a3bb63-8a07-4e3d-bd06-dd3045edbc4a">315,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS0zLTEtMS0w_c35715b6-078b-4c39-8cfa-7297534d1b34">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS01LTEtMS0w_68c773f3-238e-40db-af17-a503d176dd9c">313,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS03LTEtMS0w_bdfd78bb-b9ed-4a2e-a3d9-6a4692a22022">307,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi0xLTEtMS0w_7e3a87c4-bd16-423c-b78a-61b19533b5da">6,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi0zLTEtMS0w_0900f94b-5248-4938-a5b6-1c9fb2b4e22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi01LTEtMS0w_a9d843df-d74c-449a-af68-62b56a68f109">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi03LTEtMS0w_2b3402cf-8d44-41da-aa04-562d6c18102f">10,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy0xLTEtMS0w_6154e258-bd9f-4ee9-b75c-ca6f000c931e">322,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy0zLTEtMS0w_7e05f567-3376-4fe4-92b6-59389d789320">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy01LTEtMS0w_b1f70ec6-755a-4fa9-9218-a6c06a8e9fd4">322,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy03LTEtMS0w_63584e35-fade-48e8-b420-c51d55aec803">317,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS0xLTEtMS0w_38da336a-0b48-4091-9f1b-b15377dcee25">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS0zLTEtMS0w_8b8e09d1-d48a-4a50-aaf6-b8bf422d0d94">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS01LTEtMS0w_aedf411c-0d8e-4f3a-9f7f-1ddf85cea199">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS03LTEtMS0w_35726889-ce55-4d4b-bfd6-8861946f4c03">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtMS0xLTEtMA_dc73123c-dd75-4f8b-99d5-4ae2b7551ae2">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtMy0xLTEtMA_78fa6d13-2825-4eaf-81b3-644fc6613684">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtNS0xLTEtMA_26e7c67d-b597-44ff-be84-100e1db36ea8">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtNy0xLTEtMA_aff28865-8246-4a52-9a73-333948fa63c7">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, Performance Stock Options, unvested RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzUx_513b74a7-d8be-4ce0-b2e0-f99147790360" continuedAt="i941aa12809924687b25990b1256360d6" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i941aa12809924687b25990b1256360d6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi0xLTEtMS0w_debf13ae-5477-4758-b518-a48f28217480">20,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7e23ec3c3e84835ad5b3e3b31152b22_D20200704-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi0zLTEtMS0w_2bb5acd2-68a7-4c7a-891e-e3cd6f5f63a6">27,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2972daa1c2964506955e6854b99b0bd8_D20210102-20211001" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi01LTEtMS0w_3ada6a1a-546b-4a4c-86ee-2a5c1b7d227f">14,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic74264c148104da28095c53746f7d4fe_D20200104-20201002" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi03LTEtMS0w_8c8ae140-4d99-4007-8316-d4fe902e79ce">10,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y182MS9mcmFnOjExZjVmN2QyMDBiMzQ2ZjU5ZjEzMzUxZTJkOTQ3ZmYxL3RleHRyZWdpb246MTFmNWY3ZDIwMGIzNDZmNTlmMTMzNTFlMmQ5NDdmZjFfNTA1MA_37a66459-d307-4520-a400-27b4b71f026f" continuedAt="i1076d0565463482daae5e69cc4e09062" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1076d0565463482daae5e69cc4e09062" continuedAt="i6102c5f3ff2b4072ab10ecae723d018a">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent, each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><ix:continuation id="i6102c5f3ff2b4072ab10ecae723d018a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that all of U.S. Patent Nos. 9,724,324, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. A bench trial has been scheduled for June 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="i7e2d69fbadd646bd8aed87fedd3d018c_64"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 submitted to the Securities and Exchange Commission (SEC) on February&#160;10, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 1994, four products resulting from our discovery efforts have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, in the U.S. only, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC. This regulatory milestone expands upon the FDA&#8217;s prior approvals of CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016 and for previously untreated patients with advanced RCC in December 2017. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib, and most recently, on September 17, 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the European Commission (EC) for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. Ipsen also submitted a variation application to the European Medicines Agency (EMA) to approve CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC, with the EMA validating the variation and beginning its centralized review process in August 2021. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. Most recently, in August 2021, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partner in Japan, received Manufacturing and Marketing Approval from the Japanese MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine. We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator-sponsored trial (IST) program. Informed by the available data from these clinical trials, we advanced the development program for the cabozantinib franchise with potentially label-enabling trials. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pivotal trial that has resulted from this effort is COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. In December 2020, we announced that COSMIC-311 had met the primary endpoint of demonstrating significant improvement in progression-free survival (PFS), which served as the basis for the FDA&#8217;s September 2021 DTC approval for CABOMETYX. Study results from COSMIC-311 were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and at the European Society of Medical Oncology (ESMO) 2021 Congress, as well as published in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Oncology</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with immune checkpoint inhibitors (ICIs) may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC. We, along with our collaboration partner, BMS, announced in April 2020 that the trial met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis and objective response rate (ORR), and showed that the combination of cabozantinib with nivolumab significantly improved the three key efficacy outcomes as compared with sunitinib, doubling PFS and ORR and reducing the risk of disease progression or death by 40% compared with sunitinib. Data from CheckMate -9ER served as the basis for the FDA&#8217;s and EC&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021 and March 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Enrollment for COSMIC-313 was completed in March 2021, and we expect to report top-line results of the event-driven analyses from the trial in the late 2021 or early 2022 timeframe.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. Based on encouraging efficacy and safety data that has emerged from the trial, certain cohorts have been or may be further expanded, including the cohorts of patients with non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue (Cohort 6). Data from Cohort 6, announced in May 2021, resulted in an investigator assessed ORR of 27% and a blinded independent radiology committee (BIRC) assessed ORR of 18%. Detailed results from Cohort 6, including PFS data in the high-risk patient population, were presented at the ESMO 2021 Congress.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although, following our discussions with the FDA, we will not pursue a regulatory submission for the combination regimen based on Cohort 6, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic NSCLC, mCRPC and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us; CONTACT-02 is sponsored by us and co-funded by Roche. In June 2021, we announced results from COSMIC-312. The trial met one of the primary endpoints, demonstrating significant improvement in PFS at the planned primary analysis, reducing the risk of disease progression or death by 37% compared with sorafenib (hazard ratio: 0.63; 99% confidence internal: 0.44-0.91; P=0.0012). A prespecified interim analysis for the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second primary endpoint of OS, conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab but did not reach statistical significance. Safety for the combination appeared to be consistent with the known safety profiles of the individual medicines, and no new safety signals were identified. Based on the preliminary OS data, we anticipate that the probability of reaching statistical significance at the time of the final analysis is low, but the trial will continue as planned to the final analysis of OS, with results anticipated in early 2022. We plan to present the detailed trial results at a future medical meeting, and following discussions with the FDA, we intend to submit a supplemental New Drug Application (sNDA) for the combination regimen for patients with previously untreated advanced HCC in early 2022 when the final OS data are available. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to advance from our recent drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining the target profile of cabozantinib while improving key characteristics, including the pharmacokinetic half-life. To date, we have announced two large phase 1b clinical trials studying XL092, STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with either atezolizumab or avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany and Pfizer Inc., which is currently enrolling patients with advanced solid tumors. We expect the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, colorectal cancer (CRC), hormone-receptor positive breast cancer, mCRPC and urothelial carcinoma (UC) in the fourth quarter of 2021. STELLAR-002 is a phase 1b clinical trial that will evaluate XL092 in combination with either nivolumab, nivolumab and ipilimumab, or nivolumab and bempegaldesleukin, an investigational CD122-preferential IL-2&#8211;pathway agonist developed by Nektar Therapeutics (Nektar). We expect to initiate dose-escalation cohorts for STELLAR-002 in the fourth quarter of 2021, and depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and UC. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent, XL092 in combination with nivolumab, XL092 in combination with nivolumab and ipilimumab, and XL092 in combination with nivolumab and bempegaldesleukin.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compound to emerge from these arrangements is XL102 (formerly AUR102), the lead program targeting cyclin-dependent kinase 7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene). Based on encouraging preclinical data, we exercised our exclusive option to license XL102 from Aurigene, and subsequently initiated a phase 1 clinical trial evaluating the compound in January 2021. In addition, we exercised our exclusive option to in-license XL114 (formerly AUR104), Aurigene&#8217;s novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) signaling pathway, which promotes lymphocyte survival and proliferation. Following the FDA&#8217;s acceptance of our Investigational New Drug (IND) application for the small molecule in October 2021, we plan to initiate a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with non-Hodgkin&#8217;s lymphoma (NHL). In furtherance of efforts to expand our portfolio of differentiated small molecule therapies, in October 2021, we entered into an exclusive collaboration and license agreement with STORM Therapeutics LTD (STORM), focused on the discovery and development of inhibitors of novel RNA modifying enzymes, including ADAR1.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance biologic drug candidates, such as bispecific antibodies, antibody drug conjugates (ADCs) and other innovative biologics that have the potential to become anti-cancer therapies. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and have been validated by the multiple regulatory approvals for the commercial sale of ADCs. To facilitate the growth of these biologics programs, we have established multiple research collaborations and in-licensing arrangements, expanding our access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or bispecific antibodies. We have made significant progress under these arrangements and believe we will continue to do so. For example, based on promising preclinical data for XB002 (formerly known as ICON-2), the lead Tissue Factor ADC program under our research collaboration with Iconic Therapeutics, Inc. (Iconic), we exercised our exclusive option to license XB002 in December 2020. Following the FDA&#8217;s acceptance of our IND for XB002 in April 2021, we initiated a phase 1 clinical trial in June 2021. We have expanded our access to antibodies through arrangements with WuXi Biologics Ireland Limited (WuXi Bio), focused on leveraging WuXi Bio&#8217;s panel of monoclonal antibodies against an undisclosed target for the development of ADC, bispecific and certain other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">novel tumor-targeting biologics, and through the execution of an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), under which we will, upon the closing of the asset purchase and subject to certain conditions, acquire all rights, title and interest in GamaMabs&#8217; antibody program directed at anti-M&#252;llerian hormone receptor 2 (AMHR2), a novel oncology target with relevance in multiple forms of cancer. These antibodies, as well as those originating from collaboration with Invenra, Inc. (Invenra), which was expanded in August 2021 to include an additional 20 oncology targets, provide starting points for the construction of ADCs through our collaborations with NBE-Therapeutics AG and Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., utilizing their site-specific conjugation technologies and payloads. In addition, our collaboration with Adagene Inc. (Adagene), focused on using Adagene&#8217;s SAFEbody</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to develop novel masked ADCs or other innovative biologics, provides potential for developing ADCs or other biologics with improved therapeutic index.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. In total, we are advancing drug candidates across approximately 25 ongoing discovery programs toward and through preclinical development.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular with respect to our clinical trial and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To varying degrees and at different rates across our global clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. Beginning during the second quarter of 2020 and since that time, however, that trend reversed, and screening and enrollment activity began to increase. As a result, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful overall in preventing material delays to our ongoing and planned clinical trials due to the COVID-19 pandemic. We have done this through ongoing assessment of the COVID-19 pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may again be slowed due to recurring COVID-19 outbreaks and potential reintroduction of certain restrictions intended to mitigate the spread of COVID-19.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have fully resumed drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension combined with interruptions in the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19 caused us to experience modest delays in the advancement of certain of our early-stage programs, we continued to substantially progress our product pipeline despite the COVID-19 pandemic, including the submission of INDs for XL102, XB002 and XL114.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Despite the challenges posed by the COVID-19 pandemic, including requiring us to temporarily shift to telephonic and virtual interactions with healthcare professionals, we believe our commercial business was only modestly impacted. Our field employees have now partially resumed their in-person promotional activities while supplementing these activities with telephonic and virtual interactions and we believe they are well-positioned to execute on our commercial objectives. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not experienced production delays or seen any significant impairment to our supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain sufficient safety stock inventories for our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, distributors, suppliers, comparator drug sourcing vendors and collaboration partners to safeguard both the timely production and delivery of our products. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business Operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken numerous precautions, some temporary and others still in place, to help mitigate the risk of transmission of the virus in the workplace, including: initially reducing the number of our employees working on-site at our Alameda headquarters; implementing a vaccination mandate and maintaining </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhanced safety and social distancing protocols for those employees who have returned to working on-site, as well as initiating an on-site COVID-19 testing program and limiting certain non-essential business travel for our employees. While most of our employees worked remotely during much of 2020 and early 2021, our Alameda-based workforce has largely returned to working on-site at our headquarters consistent with the policies in place prior to the COVID-19 pandemic. As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances and public health requirements surrounding the COVID-19 pandemic continue to be subject to rapid change, and we will continue to monitor new developments that could pose additional risks for us, including the spread of the Delta variant in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout the remainder of 2021, and potentially into 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2021 Business Updates and Financial Highlights </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2021, we announced the expansion of our collaboration with Invenra to include an additional 20 targets for multi-specific antibody, ADC and other biologic candidate discovery and development.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2021, Takeda and Ono received regulatory approval from the Japanese MHLW to manufacture and market CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible, and we commenced the commercial launch of CABOMETYX in this indication upon such approval. The approval was based on positive results from the phase 3 pivotal trial, COSMIC-311, in which CABOMETYX met is primary endpoint of demonstrating significant improvement in PFS.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2021, cabozantinib was the subject of multiple data presentations at the ESMO 2021 Congress, which included: (i) a post-hoc exploratory analysis of CheckMate -9ER demonstrating that efficacy benefits of the combination compared with sunitinib were observed in patients regardless of their prior nephrectomy status; (ii) detailed results from the expanded Cohort 6 of COSMIC-021, demonstrating a median PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 of 5.6 months and 6.8 months for high-risk mCRPC patients per investigator assessment and BIRC assessment, respectively; and (iii) detailed results from COSMIC-311 evaluating cabozantinib in patients with RAI-refractory DTC. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2021, we announced an exclusive collaboration and license agreement with STORM to discover and develop inhibitors of novel RNA modifying enzymes, including ADAR1. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2021, we and Aurigene announced that we exercised our exclusive option for XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM signaling pathway, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL114. Following the FDA&#8217;s acceptance of the IND for XL114 in October 2021, we plan to initiate a phase 1 clinical trial evaluating XL114 as a monotherapy in patients with NHL. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the third quarter of 2021 were $263.1 million, compared to $168.6 million for the third quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the third quarter of 2021 were $328.4 million, compared to $231.1 million for the third quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the third quarter of 2021 were $163.4 million, compared to $176.8 million for the third quarter of 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the third quarter of 2021 were $101.6 million, compared to $88.2 million for the third quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for (benefit from) income taxes for the third quarter of 2021 was $15.1 million, compared to $(6.0) million for the third quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the third quarter of 2021 was $38.2 million, or $0.12 per share, basic and diluted, compared to net loss of $(32.0) million, or $(0.10) per share, basic and diluted share, for the third quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Cash, cash equivalents, restricted cash equivalents and investments were $1.8 billion as of September&#160;30, 2021, compared to $1.5 billion as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Challenges and Risks </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our 2021 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our remaining 2021 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the expanding role of therapies that combine targeted agents with ICIs and/or with other mechanisms of action, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations. Moreover, the complexities of this development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of Abbreviated New Drug Applications (ANDAs) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN) and by Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), and the approval of either MSN&#8217;s or Teva&#8217;s ANDA could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. As described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2021, which is a 52-week fiscal year, will end on December 31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021 are indicated as being as of and for the fiscal periods ended September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:23.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:22.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.963%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:23.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.884%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.879%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in net product revenues for CABOMETYX for the three and nine months ended September&#160;30, 2021, relative to the corresponding prior year periods, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to the increases in the number of units sold that was driven by the strong uptake for the combination therapy of CABOMETYX and OPDIVO following approval by the FDA in January 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in net product revenues for COMETRIQ for the three and nine months ended September&#160;30, 2021, relative to the corresponding prior year periods, were due to the decreases in the number of COMETRIQ units sold.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our net product revenues for the remainder of 2021 may increase relative to the corresponding prior year period, primarily as a result of the increase in demand for CABOMETYX following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, and to a lesser extent, an increase in selling price for CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. The increase in discounts and allowances for the three months </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended September&#160;30, 2021, relative to the corresponding prior year period, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks. The increase in discounts and allowances for the nine months ended September 30, 2021, relative to the corresponding prior year period, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks and, to a lesser extent, an increase in Medicaid utilization and the dollar amount of related Medicaid rebates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2021 relative to the corresponding prior year period as the number of patients participating in government programs continues to increase and as the discounts given and rebates paid to government payers also increase.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $19.7 million and $33.1 million for the three and nine months ended September&#160;30, 2021, respectively, as compared to $13.5 million and $57.1 million for the corresponding prior year periods. Milestone revenues by period included the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and nine months ended September&#160;30, 2021 included $18.8 million in connection with a $20.0 million milestone we achieved following Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable or metastatic RCC. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the nine months ended September 30, 2021 also included $11.9 million in connection with a $12.5 million regulatory milestone we determined, in the second quarter of 2021, was probable of achievement. The milestone was achieved in the third quarter of 2021 upon Ipsen&#8217;s submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and nine months ended September&#160;30, 2020 included $9.2 million in connection with a $10.0 million milestone related to Takeda&#8217;s and Ono&#8217;s submission of a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the nine months ended September&#160;30, 2020 also included $25.3 million in connection with $31.0 million in milestones we achieved following Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan and $18.9 million in revenues recognized in connection with a $20.0 million development milestone from Ipsen upon the initiation of a phase 3 pivotal trial.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $25.1 million and $70.4 million for the three and nine months ended September&#160;30, 2021, respectively, as compared to $19.9 million and $54.1 million for the corresponding prior year periods. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of September&#160;30, 2021, is approved in 61 countries outside of the U.S. Royalty revenues for the three and nine months ended September&#160;30, 2021 also included $2.0 million and $5.4 million, respectively, as compared to $0.7 million and $1.0 million for the corresponding prior year periods, related to Takeda&#8217;s net sales of CABOMETYX following approval in Japan during the second quarter of 2020 for the treatment of patients with curatively unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $1.7 million and $5.7 million for the three and nine months ended September&#160;30, 2021, respectively, as compared to $1.6 million and $4.4 million for the corresponding prior year periods. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $1.6 million and $3.3 million for the three and nine months ended September&#160;30, 2021, respectively, as compared to $1.4 million and $3.8 million for the corresponding prior year periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib. We received notification that, effective January 1, 2021, Royalty Pharma plc acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $17.5 million and $98.4 million for the three and nine months ended September&#160;30, 2021, respectively, as compared to $26.3 million and $60.3 million for the corresponding prior year periods. The decrease in development cost reimbursements for the three months ended September 30, 2021 relative to the corresponding prior year period is primarily attributable to a decrease in spending on the COSMIC-312, CONTACT-02 and COSMIC-021 studies, as well as the impact of Takeda&#8217;s decision to opt in and co-fund CONTACT-02 development costs and additional cohorts of COSMIC-021 studies in the third quarter of 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in development cost reimbursement for the nine months ended September 30, 2021 relative to the corresponding prior year period was</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily attributable to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of 2021. Ipsen is now responsible for 35% of the global development costs of COSMIC-311 and is obligated to reimburse us for these costs, as well as an additional payment calculated as a percentage of COSMIC-311 development costs, triggered by the timing of the exercise of its option. Accordingly, collaboration services revenues for the nine months ended September 30, 2021, includes a cumulative catch-up recognized in the second quarter of 2021 for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period. The increase in development cost reimbursements for the nine months ended September&#160;30, 2021 was partially offset by a decrease in total spending on the COSMIC-312 and COSMIC-021 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $3.7 million and $10.5 million for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the three and nine months ended September&#160;30, 2021, respectively, as compared to $2.9 million and $7.6 million for the corresponding prior year periods. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may increase for the remainder of 2021, relative to the corresponding prior year period, primarily as a result of increased development cost reimbursements related to Ipsen&#8217;s opt in and co-funding of COSMIC-311 as well as projections related to our other collaboration arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. The increases in cost of goods sold for the three and nine months ended September&#160;30, 2021, relative to the corresponding prior year peri</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ods, were primarily the result of increases in r</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oyalties as a result of increased U.S. CABOMETYX sales and certain other period costs. We do not project our gross margin to change significantly during the remainder of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biologics such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Primarily includes development milestone expense related to our in-licensing collaboration agreements as well as other miscellaneous development costs. During the three and nine months ended September 30, 2021, we recognized a $12.5 million development milestone we deemed probable of achievement under certain of our in-licensing collaboration arrangements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes stock-based compensation, the allocation of general corporate costs to research and development, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he decrease in research </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expenses for the three months ended September&#160;30, 2021, relative to the corresponding prior year period, was primarily related to decreases in clinical trial costs, license and other collaboration costs and stock-based compensation, partially offset by an increase in personnel expenses and other development costs. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, decreased relative to the corresponding prior year period primarily due to lower costs associated with the COSMIC-312, CONTACT-02 and COSMIC-021 studies. License and other collaboration costs decreased relative to the corresponding prior year period primarily due to decreases in upfront license fees and program initiation fees related to business development activities. Other development costs increased relative to the corresponding prior year period primarily related to a development milestone we deemed probable of achievement under certain of our in-licensing collaboration arrangements. Stock-based compensation expense decreased relative to the corresponding prior year period due to higher expense related to performance-based restricted stock units (PSUs) granted in 2019 that became probable of achievement in the third quarter of 2020, compared to the PSUs granted in 2020 that were either achieved or became probable of achievement in the third quarter of 2021. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the nine months ended September 30, 2021, relative to the corresponding prior year period, was primarily related to increases in personnel expenses, license and other collaboration costs, other development costs, and stock-based compensation, partially offset by a decrease in clinical trial costs. Personnel expenses increased relative to the corresponding prior year period primarily due to an increase in headcount to support our expanding discovery and development organization. License and other collaboration costs increased relative to the corresponding prior year period primarily due to increases in upfront license fees, program initiation fees, development milestones and research funding commitments related to business development activities. Other development costs increased relative to the corresponding prior year period primarily related to a development </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone we deemed probable of achievement under certain of our in-licensing collaboration arrangements. Stock-based compensation expense increased relative to the corresponding prior year period primarily due to an increase in stock-based compensation expense for service-based RSUs associated with higher headcount, partially offset by a lower stock-based compensation expense associated with PSUs. Clinical trial costs decreased relative to the corresponding prior year period primarily due to lower costs associated with the COSMIC-312 and COSMIC-021 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge and CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase for the remainder of 2021, relative to the corresponding prior year period, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including current early-stage trials evaluating XL092, XL102, XB002 and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in selling, general and administrative expenses for the three and nine months ended September&#160;30, 2021, relative to the corresponding prior year periods, were primarily related to increases in personnel expenses, corporate giving and marketing costs. In the three months ended September 30, 2021, the increase in selling, general and administrative expenses was partially offset by a decrease in stock-based compensation expense. Personnel expenses increased relative to the corresponding prior year periods primarily due to increases in administrative headcount to support our commercial and research and development organizations. Marketing costs increased relative to the corresponding prior year period primarily due to increased marketing activities in support of the launch of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC following approval by the FDA in January 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in stock-based compensation expense for the three months ended September 30, 2021 relative to the corresponding prior year period was primarily due to higher compensation expense associated with the PSUs granted in 2019 that became probable of achievement in the third quarter of 2020 compared to the PSUs granted in 2020 that were either achieved or became probable of achievement in the third quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may continue to increase for the remainder of 2021 relative to the corresponding prior year period in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.814%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in non-operating income for the three and nine months ended September&#160;30, 2021, relative to the corresponding prior year periods, were primarily the result of the decreases in interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit From) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes and effective income tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.814%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax provision for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 as a result of our current period reported pre-tax income, as compared to the corresponding prior year period, in which we recorded a benefit from income taxes as a result of a reported pre-tax loss.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in provision for income taxes for the nine months ended September 30, 2021, as compared to the corresponding prior year period, was due to the increase in pre-tax income. The effective tax rate for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory rate of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits. The effective tax rate for the three and nine months ended September&#160;30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, the generation of federal tax credits, partially offset by non-deductible executive compensation during the periods.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $1.8 billion in cash, cash equivalents, restricted cash equivalents and investments, compared to $1.5 billion as of December&#160;31, 2020. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $31.2 million and $1.6 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in other long-term assets in our Condensed Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of September&#160;30, 2021, restricted cash equivalents included $29.6&#160;million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income (Loss). </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for the nine months ended September&#160;30, 2021 increased relative to the corresponding prior year period, primarily due to an increase in cash received on sales of our products, an increase in cash received from our commercial collaboration arrangements and net favorable changes in operating assets and liabilities, partially offset by an increase in cash paid for operating expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2021 consisted of cash used in investment purchases of $1,077.4 million and purchases of property, equipment and other of $48.3 million, partially offset by proceeds from the maturities and sales of investments of $1,095.8 million.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2020 consisted of cash used in investment purchases of $867.0 million and purchases of property, equipment and other of $16.1 million, partially offset by proceeds from the maturities and sales of investments of $781.3 million.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2021 consisted of $18.2 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans, partially offset by $15.0 million of withholding taxes paid related to net share settlements of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the nine months ended September&#160;30, 2020 included $26.1 million of withholding taxes paid related to net share settlements of equity awards, partially offset by $19.7 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of September&#160;30, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the nine months ended September&#160;30, 2021, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 submitted to the SEC on February&#160;10, 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_79"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of September&#160;30, 2021 have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_88"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent, each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that all of U.S. Patent Nos. 9,724,324, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. A bench trial has been scheduled for June 2023.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_91"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for the cabozantinib franchise to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products, combination therapies and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Given the shifting landscape of therapeutic strategy following the advent of ICIs, we believe our future success will depend upon our ability to achieve positive clinical trial results for therapies combining cabozantinib with ICIs across multiple indications, and if approved, successfully commercialize such combination therapies. While we have had success in adapting our development strategy for the cabozantinib franchise to address the expanding role of therapies that combine ICIs with other targeted agents, including the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations. Moreover, the complexities of this development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to revert back to primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, it is possible that the PPACA will be subject to judicial or legislative challenges in the future, which may have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future healthcare reform measures of the Biden administration and federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Discount Program through the PPACA (the 340B Program) has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues, including the implementation of the program&#8217;s Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that manufacturers have overcharged them for covered outpatient drugs. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; implement data collection and reporting under Section 204 of Title II of Division BB of the Consolidated Appropriations Act, 2021, which requires, among other things, health plans and issuers to disclose rebates, fees and other remuneration provided by drug manufacturers related to certain pharmaceutical products; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid, which affect the amount of rebates that we pay on prescription drugs under Medicaid and to covered entities under the 340B Program; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and facilitate the importation of certain lower-cost drugs from other countries. For instance, President Biden issued an executive order in July 2021 supporting legislation to enact some of these drug pricing reforms, and in response, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices in September 2021 with specific legislative and administrative policies that Congress could enact to help improve affordability of and access to prescription drugs. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking, such as those incorporating International Pricing Index or Most-Favored-Nation models, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Upcoming legislative and policy changes in the EU, some of which may materialize during 2022, are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the Regulation on Health Technology Assessment, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug, and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. For instance, the FDA Reauthorization Act of 2017 includes, inter alia, measures to expedite the development and approval of generic products, where generic competition is lacking </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even in the absence of exclusivities or listed patents. In addition, the Ensuring Innovation Act, enacted on April 23, 2021, amended the FDA&#8217;s statutory authority for granting new chemical entity (NCE) exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken and continues to take steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, was signed into law as part of the 2019 year-end federal spending package. The legislation purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by California Privacy Rights Act of 2020 (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is also considering federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of new product candidates, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such events to occur. These events may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed, including in response to the COVID-19 pandemic could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $38.2 million and $135.9 million for the three and nine months ended September&#160;30, 2021 and $111.8 million for the year ended December&#160;31, 2020, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates. For example, we reported a net loss for the quarter ended September 30, 2020, primarily due to substantial increases in clinical trial costs, license and other collaboration costs, and personnel expenses relative to the prior fiscal quarters, and it is possible that we may experience net losses in future fiscal quarters or fiscal years, whether due to increases in costs and expenses or otherwise. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. Disruptions in the U.S. and global financial markets, including disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related volatility in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, inflation rates, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business. In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger-scale strategic transactions or investments. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial (including as a result of the COVID-19 pandemic), or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic, which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although we have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. The level of vulnerabilities that exist under normal conditions may have been exacerbated by the fact that, during the COVID-19 pandemic, the portion of our workforce operating remotely has increased, at least temporarily, and some phishing attacks are specifically designed to target remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any data breach and/or unauthorized access or disclosure of our information or intellectual property could </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, particularly with the emergence of the Delta variant and other SARS-CoV-2 variants, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation of crisis management initiatives have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial execution, and ultimately results. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intravenous infusion, such as COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02, CONTACT-03, our early-stage trials evaluating XL092, XL102 and other product candidates to the extent they may incorporate additional therapies that must be administered via professional intravenous infusion, or our early-stage trial evaluating XB002 that must be administered via professional intravenous infusion, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances, and may continue to delay or prevent, on-site infusion of XB002 or therapies being evaluated in combination with cabozantinib or our other product candidates. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, it could cause those studies to be delayed, suspended or prevented from producing statistically significant results.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to obtain regulatory approval for clinical protocols and increase the operating expenses associated with these new clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic caused us to suspend drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both drug discovery work in our laboratories and outsourced drug discovery activities have since fully resumed, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the COVID-19 pandemic grow in severity, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. With respect to the preclinical development work and drug discovery activities outsourced to third-party contractors, the COVID-19 pandemic could again impede these third parties from providing timely deliverables to us in the future. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including any shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Quarterly Report on Form 10-Q, we continue to maintain sufficient safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have taken numerous precautions, some temporary and others still in place, to help mitigate the risk of transmission of the virus in the workplace, including: initially reducing the number of our employees working on-site at our Alameda headquarters; implementing a vaccination mandate and maintaining enhanced safety and social distancing protocols for those employees who have returned to working on-site, as well as initiating an on-site COVID-19 testing program; limiting certain non-essential business travel for our employees; and partially limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, these measures could delay our research and development programs, reduce engagements with potential prescribers for our products, and impede our ability to execute on our long-term business plans. Further, even though our Alameda-based workforce has largely returned to working on-site at our headquarters consistent with the policies in place prior to the COVID-19 pandemic, future periods of primarily remote work, if necessitated by the circumstances surrounding the COVID-19 pandemic, could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of broad economic shifts during and as a consequence of efforts to address unemployment and other negative economic effects of the COVID-19 pandemic, we may experience reductions in the net price of our products. For example, there may be a substantial shift from private health insurance coverage to government insurance coverage, or additional downward pressure on the prices government purchasers will pay for our products due to significant increases in government debt incurred in connection with relief efforts, as well as significant increases in demand for our patient assistance and/or free drug program or other impacts that may not be foreseeable, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Such developments include continued spread of the Delta variant in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent, the ultimate duration of the pandemic and resulting disruptions to normal business and personal activities in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the rate at which vaccinations are made available and are administered, the percentage of the population that becomes fully vaccinated and the effectiveness of the vaccines against Delta or other SARS-CoV-2 variants. These continuing or future effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. For example, in September 2021, we announced the passing of Dr. Gisela Schwab, our President, Product Development and Medical Affairs and Chief Medical Officer, and Jon Berndt, our Senior Vice President, Sales. While we have continued to execute on our clinical development and commercial strategies, have filled the sales leadership position and are conducting a search to fill the Chief Medical Officer position, we cannot ensure that the losses of Dr. Schwab and Mr. Berndt will not negatively impact our business and operations. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other business development activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_94"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_100"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_106"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210930exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210930exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210930exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i7e2d69fbadd646bd8aed87fedd3d018c_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e2d69fbadd646bd8aed87fedd3d018c_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exel20210930exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifa55762187584bc68b3403e4d441dc7e_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;2, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exel20210930exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i00c53d3249844e32862e9aa6b3470d15_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;2, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exel20210930exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id8aa740e18fa461e94bb0f62c933056c_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1.&#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended October&#160;1, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the 2nd day of November 2021.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>exel-20211001.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20211001" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20211001">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211001_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211001_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211001_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20211001_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities">
        <link:definition>2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2128105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2329304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2430420 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2132106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2333305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2434422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2135107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2336306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails">
        <link:definition>2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes">
        <link:definition>2141108 - Disclosure - Provision For (Benefit From) Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>2442427 - Disclosure - Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2143109 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2344307 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2445428 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
        <link:definition>2446429 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2147110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" abstract="true" name="CollaborativeAgreementWithGamaMabsPharmaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" abstract="false" name="CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetAcquisitionPaymentUponClosingOfTransaction" abstract="false" name="AssetAcquisitionPaymentUponClosingOfTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AchievedMember" abstract="true" name="AchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsOptionExercisePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" abstract="false" name="RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" abstract="false" name="CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_AchievedAndProbableMember" abstract="true" name="AchievedAndProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>exel-20211001_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8706aa27-9d60-44dd-8eba-c2e113c72adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a728d8d4-b6c9-47de-9668-fe1eea2f9987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8706aa27-9d60-44dd-8eba-c2e113c72adf" xlink:to="loc_us-gaap_LiabilitiesCurrent_a728d8d4-b6c9-47de-9668-fe1eea2f9987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d0dcc907-6292-4d8a-b796-cc5e19b65f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8706aa27-9d60-44dd-8eba-c2e113c72adf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d0dcc907-6292-4d8a-b796-cc5e19b65f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f69a1735-a44d-4e70-a8e6-158d64ed99d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8706aa27-9d60-44dd-8eba-c2e113c72adf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f69a1735-a44d-4e70-a8e6-158d64ed99d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_51845bc0-3a10-458b-9cf4-3bc4cfabfac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8706aa27-9d60-44dd-8eba-c2e113c72adf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_51845bc0-3a10-458b-9cf4-3bc4cfabfac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_39b1c12f-41fa-4eab-accc-52aa577ed703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:to="loc_us-gaap_ShortTermInvestments_39b1c12f-41fa-4eab-accc-52aa577ed703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_b7d9e8d5-509f-4340-8981-e620c1dc44e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_b7d9e8d5-509f-4340-8981-e620c1dc44e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_68133413-6857-49c4-8b89-1a8614d62b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:to="loc_us-gaap_InventoryNet_68133413-6857-49c4-8b89-1a8614d62b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7cdb37e-0b7c-4607-bd77-14b5f7a98b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7cdb37e-0b7c-4607-bd77-14b5f7a98b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb0b3043-7bb1-48a8-8ecd-d7a2dc411f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9f2d1231-ae7b-4eb4-8a88-7f0014efa59b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb0b3043-7bb1-48a8-8ecd-d7a2dc411f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_39282e25-e08b-4b00-970b-f465955f1cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_us-gaap_AccountsPayableCurrent_39282e25-e08b-4b00-970b-f465955f1cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_20e6e019-ca72-4e32-b725-2d33e58595f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_20e6e019-ca72-4e32-b725-2d33e58595f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_65c114b4-251c-4b98-b497-9a347ba3422b" xlink:href="exel-20211001.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_65c114b4-251c-4b98-b497-9a347ba3422b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_c1b7e74f-6dc2-49b3-b5b8-f3cb36872d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_c1b7e74f-6dc2-49b3-b5b8-f3cb36872d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_97f8b223-8847-432e-a84b-f61516a351b8" xlink:href="exel-20211001.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_97f8b223-8847-432e-a84b-f61516a351b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63e3052d-869e-4239-a9a5-3ed40c1ebdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_26ba6513-478e-4fb8-bce6-e43957ce398d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63e3052d-869e-4239-a9a5-3ed40c1ebdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1261e182-ff28-4caa-a0fa-5f0e5c1a1e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_AssetsCurrent_1261e182-ff28-4caa-a0fa-5f0e5c1a1e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f07cb378-1817-49a7-9142-3b4201db8833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_LongTermInvestments_f07cb378-1817-49a7-9142-3b4201db8833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_980625a2-af2a-48e0-b214-d69a3e0fd048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_980625a2-af2a-48e0-b214-d69a3e0fd048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e4762588-a319-4abb-a824-3768d6befa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e4762588-a319-4abb-a824-3768d6befa6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_788ae7f1-3ff1-43a0-8557-f6c0030b921f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_Goodwill_788ae7f1-3ff1-43a0-8557-f6c0030b921f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_af7c9c05-ea0d-4bc1-9199-b108d7df1d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8f5b1cdc-86e5-4570-911f-d25f0334daf0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_af7c9c05-ea0d-4bc1-9199-b108d7df1d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b56743e7-7563-432c-9287-0ea5c9189c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4d411723-4432-4dc5-b7fb-33a307c45453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b56743e7-7563-432c-9287-0ea5c9189c7a" xlink:to="loc_us-gaap_Liabilities_4d411723-4432-4dc5-b7fb-33a307c45453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f1b8792f-da8c-447c-81f8-c0b9fe4a347a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b56743e7-7563-432c-9287-0ea5c9189c7a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f1b8792f-da8c-447c-81f8-c0b9fe4a347a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27597ac3-df9d-4313-983e-156ecd767e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b56743e7-7563-432c-9287-0ea5c9189c7a" xlink:to="loc_us-gaap_StockholdersEquity_27597ac3-df9d-4313-983e-156ecd767e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f3d0ee77-3ee2-49ee-9f40-326191fa4f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:to="loc_us-gaap_PreferredStockValue_f3d0ee77-3ee2-49ee-9f40-326191fa4f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ac7faa95-0f8f-4f07-a21a-753fe4eb65fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:to="loc_us-gaap_CommonStockValue_ac7faa95-0f8f-4f07-a21a-753fe4eb65fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55dea659-b16b-465c-a2e6-84f4e021ffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55dea659-b16b-465c-a2e6-84f4e021ffcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e2e9e9f-93fd-4c57-8ac2-b55a5ae3c304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e2e9e9f-93fd-4c57-8ac2-b55a5ae3c304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f3acb9f-83f2-4de7-941a-15158c976ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d6f9d57-d997-4389-9493-d8e5ad97cc77" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f3acb9f-83f2-4de7-941a-15158c976ed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1cbd8c47-b95c-40dc-a03b-e3748814dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f41b8ae6-36f3-4c8c-9bbb-23056a5d71f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1cbd8c47-b95c-40dc-a03b-e3748814dcda" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f41b8ae6-36f3-4c8c-9bbb-23056a5d71f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4116c8b5-6b02-4122-a469-d72b839d480a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1cbd8c47-b95c-40dc-a03b-e3748814dcda" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4116c8b5-6b02-4122-a469-d72b839d480a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886e42f3-8d48-41be-8d10-2b58c7ddf7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1cbd8c47-b95c-40dc-a03b-e3748814dcda" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886e42f3-8d48-41be-8d10-2b58c7ddf7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e06d152-12da-4edc-9c3e-bbbbe13b605d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d916a8aa-121c-4d24-9d0a-e672f7b8c175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e06d152-12da-4edc-9c3e-bbbbe13b605d" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d916a8aa-121c-4d24-9d0a-e672f7b8c175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759b0fc2-71cd-47a1-af04-4d531b50461f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e06d152-12da-4edc-9c3e-bbbbe13b605d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759b0fc2-71cd-47a1-af04-4d531b50461f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_3f0b8bec-cec5-4b0d-870d-f5d86d7d4ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_14b63620-8b21-41b2-84f7-3cce26b6cff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_3f0b8bec-cec5-4b0d-870d-f5d86d7d4ce2" xlink:to="loc_us-gaap_OperatingIncomeLoss_14b63620-8b21-41b2-84f7-3cce26b6cff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_6a6abcaa-0a81-4c93-a714-7baf863b5a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_3f0b8bec-cec5-4b0d-870d-f5d86d7d4ce2" xlink:to="loc_us-gaap_InterestIncomeOther_6a6abcaa-0a81-4c93-a714-7baf863b5a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a132d93-1e8e-4d1d-a16f-2175b8dbd913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_3f0b8bec-cec5-4b0d-870d-f5d86d7d4ce2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a132d93-1e8e-4d1d-a16f-2175b8dbd913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6ba31737-4248-4a2f-997c-4e18e6147805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_695401da-b310-470e-a498-95f6c2d9cc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6ba31737-4248-4a2f-997c-4e18e6147805" xlink:to="loc_us-gaap_CostsAndExpenses_695401da-b310-470e-a498-95f6c2d9cc0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_801083f9-fc2e-44c1-bc9b-17a47d63fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6ba31737-4248-4a2f-997c-4e18e6147805" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_801083f9-fc2e-44c1-bc9b-17a47d63fa1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0426871-ff5a-455b-a500-0c648a185ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb23e26e-035f-46a1-bbdb-9aa8049d0c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0426871-ff5a-455b-a500-0c648a185ab7" xlink:to="loc_us-gaap_NetIncomeLoss_bb23e26e-035f-46a1-bbdb-9aa8049d0c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67d60720-80fc-4e12-b882-ab7738299d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0426871-ff5a-455b-a500-0c648a185ab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_67d60720-80fc-4e12-b882-ab7738299d54" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb1bc0bf-cf0d-49f6-9f68-63569abf3b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8220001-8f1c-4908-b69c-803e2529e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb1bc0bf-cf0d-49f6-9f68-63569abf3b59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8220001-8f1c-4908-b69c-803e2529e73b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a122b938-a14d-4bef-83b3-98f27cac0d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb1bc0bf-cf0d-49f6-9f68-63569abf3b59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a122b938-a14d-4bef-83b3-98f27cac0d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d8ff289-217f-4c8b-81be-d6a72a04f3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb1bc0bf-cf0d-49f6-9f68-63569abf3b59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d8ff289-217f-4c8b-81be-d6a72a04f3d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_699105ab-1be1-437b-9881-38404205a8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d52a6e57-72c1-4a06-97d8-0975d1bde4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_699105ab-1be1-437b-9881-38404205a8b9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d52a6e57-72c1-4a06-97d8-0975d1bde4f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cf9c5217-f9ff-4eca-99b4-a632c3f83dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_699105ab-1be1-437b-9881-38404205a8b9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cf9c5217-f9ff-4eca-99b4-a632c3f83dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b258b407-fc6d-4de8-a2ca-f82888f3c44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c81561f8-27af-43a3-a516-83181ab99b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b258b407-fc6d-4de8-a2ca-f82888f3c44c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c81561f8-27af-43a3-a516-83181ab99b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e216cb24-17e1-474f-b282-3ab653ea62cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b258b407-fc6d-4de8-a2ca-f82888f3c44c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e216cb24-17e1-474f-b282-3ab653ea62cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4410675a-4b7c-42e2-bf07-dc5e6257f1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b258b407-fc6d-4de8-a2ca-f82888f3c44c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4410675a-4b7c-42e2-bf07-dc5e6257f1e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_449e8c0b-f399-494b-bdfd-d34bdc5584a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_NetIncomeLoss_449e8c0b-f399-494b-bdfd-d34bdc5584a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a8307109-fb99-4217-93f0-229e2d2e4a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a8307109-fb99-4217-93f0-229e2d2e4a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_35de50a6-47bf-4a3a-8f47-28f3dfd86523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_ShareBasedCompensation_35de50a6-47bf-4a3a-8f47-28f3dfd86523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_97d1b1e9-1ee9-46b5-8d3a-1a0fa532a428" xlink:href="exel-20211001.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_exel_NoncashLeaseExpense_97d1b1e9-1ee9-46b5-8d3a-1a0fa532a428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a4849c1a-a321-4a28-8371-f3cef61c835a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a4849c1a-a321-4a28-8371-f3cef61c835a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2297ffa-bf1b-48cd-9d25-5a8b0c672c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2297ffa-bf1b-48cd-9d25-5a8b0c672c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2f6e9bbd-c9d9-4cec-8f3e-2b80362e1b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2f6e9bbd-c9d9-4cec-8f3e-2b80362e1b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_003423cd-3d94-4257-be37-f412a421c952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_003423cd-3d94-4257-be37-f412a421c952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c7e3aa43-e97b-495a-aa1b-025de827f1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c7e3aa43-e97b-495a-aa1b-025de827f1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_065cea35-55c2-4eb9-a1b6-1c153fc01f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_065cea35-55c2-4eb9-a1b6-1c153fc01f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_40c05125-8431-4a2b-9b9f-1fbdf4e78ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_38aa8c4f-cade-4574-a83d-9a5c1fd8c34c" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_40c05125-8431-4a2b-9b9f-1fbdf4e78ee2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ad55c380-28bf-4c85-929f-eb39bf47e0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_82ef65cf-9f35-4d32-a9a3-80d80d04c3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_ad55c380-28bf-4c85-929f-eb39bf47e0b5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_82ef65cf-9f35-4d32-a9a3-80d80d04c3c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_09ed2a55-bad0-419b-9f26-5ff7875d79a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_ad55c380-28bf-4c85-929f-eb39bf47e0b5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_09ed2a55-bad0-419b-9f26-5ff7875d79a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_836ae595-aa3e-4467-a923-54241f9110ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64b957c3-2c93-4178-9245-ffbc3e4596ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_836ae595-aa3e-4467-a923-54241f9110ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64b957c3-2c93-4178-9245-ffbc3e4596ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_229c99ec-584f-4989-b456-bd45b72d3071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_836ae595-aa3e-4467-a923-54241f9110ab" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_229c99ec-584f-4989-b456-bd45b72d3071" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8437c37e-c9ff-49db-b533-744196f1b050" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_79d3f424-c954-4ffe-a168-c97fa6bfd9b1" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8437c37e-c9ff-49db-b533-744196f1b050" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_79d3f424-c954-4ffe-a168-c97fa6bfd9b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_bf58721b-e470-4ee0-a536-73fd6512a682" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8437c37e-c9ff-49db-b533-744196f1b050" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_bf58721b-e470-4ee0-a536-73fd6512a682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_360ef7e5-c951-4c44-a2df-e7efb1da3077" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8437c37e-c9ff-49db-b533-744196f1b050" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_360ef7e5-c951-4c44-a2df-e7efb1da3077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1efebbbb-b135-4a48-bdf1-228519b61775" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a62e3fcc-e803-4ca7-9b2f-0b9c8582fd0b" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1efebbbb-b135-4a48-bdf1-228519b61775" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a62e3fcc-e803-4ca7-9b2f-0b9c8582fd0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0447479d-8d5e-4f5c-8a59-165b1b764703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1efebbbb-b135-4a48-bdf1-228519b61775" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0447479d-8d5e-4f5c-8a59-165b1b764703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a03e552a-1da7-4e35-b9ba-67d0c32a3920" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_cf767cb7-b9ef-4f7a-afd2-1639bf222813" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a03e552a-1da7-4e35-b9ba-67d0c32a3920" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_cf767cb7-b9ef-4f7a-afd2-1639bf222813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_999d4134-c704-4cc7-8222-2cc1aa4e6c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a03e552a-1da7-4e35-b9ba-67d0c32a3920" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_999d4134-c704-4cc7-8222-2cc1aa4e6c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c57e50ee-ba15-459e-afcb-1aa9d5acb355" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_ae9bc68e-2c50-4b7a-ba35-3c92a51d9da6" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c57e50ee-ba15-459e-afcb-1aa9d5acb355" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_ae9bc68e-2c50-4b7a-ba35-3c92a51d9da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_504b874d-2642-4abb-8b31-a473df4b834f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c57e50ee-ba15-459e-afcb-1aa9d5acb355" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_504b874d-2642-4abb-8b31-a473df4b834f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a38bd38c-fd71-44a7-ac2c-458cf6b59fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cacb6bb1-d923-452d-bc75-967c2086f490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a38bd38c-fd71-44a7-ac2c-458cf6b59fa8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cacb6bb1-d923-452d-bc75-967c2086f490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20e47606-bd0d-47fe-a4ce-98dca2387921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a38bd38c-fd71-44a7-ac2c-458cf6b59fa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20e47606-bd0d-47fe-a4ce-98dca2387921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_90e31c2a-449f-4265-b01a-223259173710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a38bd38c-fd71-44a7-ac2c-458cf6b59fa8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_90e31c2a-449f-4265-b01a-223259173710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_65b0768e-46cf-4d2a-89e2-2f07880a2736" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_669f007d-c8e2-4763-a1e9-2a9528344429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_65b0768e-46cf-4d2a-89e2-2f07880a2736" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_669f007d-c8e2-4763-a1e9-2a9528344429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_fe726d6d-6066-4fed-9271-f7e3440a545e" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_65b0768e-46cf-4d2a-89e2-2f07880a2736" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_fe726d6d-6066-4fed-9271-f7e3440a545e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f29f1f58-a1a3-4dc3-99b2-ef478cdc960c" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6503dc8d-2722-46b7-a678-141add999cf1" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f29f1f58-a1a3-4dc3-99b2-ef478cdc960c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6503dc8d-2722-46b7-a678-141add999cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4be9956-48aa-4c47-b01a-00241439e234" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f29f1f58-a1a3-4dc3-99b2-ef478cdc960c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4be9956-48aa-4c47-b01a-00241439e234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e83cdce2-1010-4ea8-8c0e-fce98f420c09" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f29f1f58-a1a3-4dc3-99b2-ef478cdc960c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e83cdce2-1010-4ea8-8c0e-fce98f420c09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67f55ae1-8083-4970-a331-03e025cc36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fc268294-d74d-49c9-8ef8-2c39b60405b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67f55ae1-8083-4970-a331-03e025cc36eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fc268294-d74d-49c9-8ef8-2c39b60405b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d24a4a4-f7bf-48cf-8983-eef9d7d39062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67f55ae1-8083-4970-a331-03e025cc36eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d24a4a4-f7bf-48cf-8983-eef9d7d39062" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cb5a70b1-d061-4481-80dd-1226fe1ad044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45a2502c-0a13-4ef4-bc28-e4fa83f53ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_cb5a70b1-d061-4481-80dd-1226fe1ad044" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45a2502c-0a13-4ef4-bc28-e4fa83f53ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d867dc3c-85f4-401d-aae4-30a9b65f80f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_cb5a70b1-d061-4481-80dd-1226fe1ad044" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d867dc3c-85f4-401d-aae4-30a9b65f80f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_db3c5f7d-a17e-459f-9571-de47a8e10498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2b039e70-6b93-415c-8b8d-b9327935d0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_db3c5f7d-a17e-459f-9571-de47a8e10498" xlink:to="loc_us-gaap_InventoryRawMaterials_2b039e70-6b93-415c-8b8d-b9327935d0d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5c5c5c11-1c9b-4ad7-8dc0-6c1b9acb51be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_db3c5f7d-a17e-459f-9571-de47a8e10498" xlink:to="loc_us-gaap_InventoryWorkInProcess_5c5c5c11-1c9b-4ad7-8dc0-6c1b9acb51be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b638b387-6ae5-4405-ad1a-43a0c3574dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_db3c5f7d-a17e-459f-9571-de47a8e10498" xlink:to="loc_us-gaap_InventoryFinishedGoods_b638b387-6ae5-4405-ad1a-43a0c3574dbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e9230fc-9ee2-45cd-aa13-76149d9db592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b8a3e9b-6678-456c-b009-4b1b5bef1ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e9230fc-9ee2-45cd-aa13-76149d9db592" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7b8a3e9b-6678-456c-b009-4b1b5bef1ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_52bd71ce-441f-4a7f-a74c-9736094bacb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6e9230fc-9ee2-45cd-aa13-76149d9db592" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_52bd71ce-441f-4a7f-a74c-9736094bacb2" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>exel-20211001_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended" id="iffe59ca462174ebc9a548799dd0010f4_CondensedConsolidatedStatementsofIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce66722c-8e49-4e0d-a32e-6f8c254745db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce66722c-8e49-4e0d-a32e-6f8c254745db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_33a25fda-75ab-4171-a7e6-cfc0df6f7da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_33a25fda-75ab-4171-a7e6-cfc0df6f7da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_56e0e82b-eed4-440f-9136-6949a9ab4b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_56e0e82b-eed4-440f-9136-6949a9ab4b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_265e386f-9f8f-48ea-b18c-05e9467a656d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_265e386f-9f8f-48ea-b18c-05e9467a656d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0bc016a4-2e1c-47b2-8d69-5cb6db8d645b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_CostsAndExpenses_0bc016a4-2e1c-47b2-8d69-5cb6db8d645b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f8cfc2a7-e793-4c49-a90b-de5d0aa5db12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OperatingIncomeLoss_f8cfc2a7-e793-4c49-a90b-de5d0aa5db12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_9e30a8d9-ee4b-443e-89a1-ed0731329140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_InterestIncomeOther_9e30a8d9-ee4b-443e-89a1-ed0731329140" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3931-b07e-4389-87d9-d0db922391e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3931-b07e-4389-87d9-d0db922391e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_1f173076-aac3-4db2-848c-262fe3cd6101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_1f173076-aac3-4db2-848c-262fe3cd6101" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0b552f44-7c65-4992-9131-8859c3814cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0b552f44-7c65-4992-9131-8859c3814cb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e1b410a-e05e-4ab4-97cb-cd9ddbe1f208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_NetIncomeLoss_9e1b410a-e05e-4ab4-97cb-cd9ddbe1f208" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e5b53d89-e4e7-487b-9cb7-0d7eda910481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:to="loc_us-gaap_EarningsPerShareBasic_e5b53d89-e4e7-487b-9cb7-0d7eda910481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2944ea55-06d9-450d-b1a6-5cd1f516785f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2944ea55-06d9-450d-b1a6-5cd1f516785f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6d3158d-a9ad-4eac-8491-96790c61caed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6d3158d-a9ad-4eac-8491-96790c61caed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8784d9b5-1a28-4345-af96-9f862835f7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8784d9b5-1a28-4345-af96-9f862835f7b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:to="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:to="loc_srt_ProductsAndServicesDomain_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:to="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c740d670-7e2f-4293-a9dc-c94c8d37099a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_ProductMember_c740d670-7e2f-4293-a9dc-c94c8d37099a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1af35cb5-cab4-400c-9139-4c497f601e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_LicenseMember_1af35cb5-cab4-400c-9139-4c497f601e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f36c8103-6856-4c99-a26c-39ffac0acfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_ServiceMember_f36c8103-6856-4c99-a26c-39ffac0acfc2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i67ccc8f6557541f5b69766990abb301e_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_101bb5b6-40cb-4989-a735-0ae46577213b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_101bb5b6-40cb-4989-a735-0ae46577213b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c4ddb5e-d78d-4db7-bd43-7443744bd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockholdersEquity_2c4ddb5e-d78d-4db7-bd43-7443744bd9d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc1f0e9a-1026-4431-a925-c40e389523f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_NetIncomeLoss_dc1f0e9a-1026-4431-a925-c40e389523f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0484227c-c32f-4af6-b627-87d3635544c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0484227c-c32f-4af6-b627-87d3635544c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_31b35d4a-ce2f-40e2-ae67-2d68307009bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_31b35d4a-ce2f-40e2-ae67-2d68307009bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f37ce15-8d21-41ac-bdac-310de6475bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f37ce15-8d21-41ac-bdac-310de6475bb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3141483d-18be-4713-ab33-6c6dbb6cba35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3141483d-18be-4713-ab33-6c6dbb6cba35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5d42173-9f9d-4a20-a850-bce434330213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5d42173-9f9d-4a20-a850-bce434330213" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b90c810e-304f-49b0-8081-3de3d4c19f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d247127e-8674-42b8-9e35-851397c5ea33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:to="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f202c860-2586-4b24-967a-ee0e12a75727_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:to="loc_us-gaap_EquityComponentDomain_f202c860-2586-4b24-967a-ee0e12a75727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:to="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_39f64618-6d02-474a-9396-a4aaefa093b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_CommonStockMember_39f64618-6d02-474a-9396-a4aaefa093b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29f2cd7c-10a9-456a-9282-c9153ff3b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29f2cd7c-10a9-456a-9282-c9153ff3b6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9a5677b3-90b7-4581-adc0-212983f73cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9a5677b3-90b7-4581-adc0-212983f73cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5e284048-787e-4b34-a68a-05a94212cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_RetainedEarningsMember_5e284048-787e-4b34-a68a-05a94212cb56" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="if0fd57d2bcd144dba0592efa5beae44f_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_8f69568e-2e5c-4604-a86c-32157292290a" xlink:href="exel-20211001.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:to="loc_exel_NumberofProductsinCommercialMarket_8f69568e-2e5c-4604-a86c-32157292290a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6fa57626-b450-4a19-83ad-dbcca43ba443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6fa57626-b450-4a19-83ad-dbcca43ba443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:to="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:to="loc_srt_ProductsAndServicesDomain_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:to="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_5e95d67d-ce66-4eb8-b80e-1b9cb6df2d6f" xlink:href="exel-20211001.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_5e95d67d-ce66-4eb8-b80e-1b9cb6df2d6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_95d97933-cad5-4ac5-b387-af44637b6cec" xlink:href="exel-20211001.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_95d97933-cad5-4ac5-b387-af44637b6cec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i46ecb85571bf4b77ba8537736ee258e0_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_097f4d44-76e7-4cbc-a410-a4434fdd2914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_097f4d44-76e7-4cbc-a410-a4434fdd2914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:to="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16b4ddcd-b950-4aae-9e0b-205d6d2d761f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:to="loc_srt_ProductsAndServicesDomain_16b4ddcd-b950-4aae-9e0b-205d6d2d761f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:to="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_c971e4eb-fea5-4293-a367-163e2ea43cd1" xlink:href="exel-20211001.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_ProductGrossMember_c971e4eb-fea5-4293-a367-163e2ea43cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_0ddf5ce1-61e0-4568-ac84-3f8b97bf8974" xlink:href="exel-20211001.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_0ddf5ce1-61e0-4568-ac84-3f8b97bf8974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_72ade67b-be3c-48ae-aa92-911aa8e4d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_ProductMember_72ade67b-be3c-48ae-aa92-911aa8e4d2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8bede2ce-a207-442e-898e-8ed6ddfb4861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_LicenseMember_8bede2ce-a207-442e-898e-8ed6ddfb4861" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2873dfca-ac6d-4316-8380-801622703f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_ServiceMember_2873dfca-ac6d-4316-8380-801622703f58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_3592049e-f08b-445d-8742-32f4de6f78d0" xlink:href="exel-20211001.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_CollaborationMember_3592049e-f08b-445d-8742-32f4de6f78d0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="i364d8ea1b50647bb8f46930e5b261bea_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_89e7da8d-ebb8-41f4-9a40-df8c56df453f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_89e7da8d-ebb8-41f4-9a40-df8c56df453f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_04bce3d8-9245-42c5-b80c-323504d6c884_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:to="loc_srt_NameOfMajorCustomerDomain_04bce3d8-9245-42c5-b80c-323504d6c884_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:to="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_29f8854b-4a2a-4e79-8516-2e3a9d6530e7" xlink:href="exel-20211001.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_IpsenMember_29f8854b-4a2a-4e79-8516-2e3a9d6530e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_4df793a3-ef30-4c89-8d7e-9e3d85f4637f" xlink:href="exel-20211001.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_4df793a3-ef30-4c89-8d7e-9e3d85f4637f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_b8de2f9f-404c-4a10-9baf-a4b8c1ebf6d8" xlink:href="exel-20211001.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_b8de2f9f-404c-4a10-9baf-a4b8c1ebf6d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_de0a210f-8ce5-468f-acfe-7490d7661a91" xlink:href="exel-20211001.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_de0a210f-8ce5-468f-acfe-7490d7661a91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_33dc12a6-b6c3-470e-8d4f-08223ea88f29" xlink:href="exel-20211001.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_33dc12a6-b6c3-470e-8d4f-08223ea88f29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_3b04c3bb-812e-497b-9054-48632fa9ad8b" xlink:href="exel-20211001.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_TakedaMember_3b04c3bb-812e-497b-9054-48632fa9ad8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a6e17c16-e354-4e56-a074-9f388357f8f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a6e17c16-e354-4e56-a074-9f388357f8f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a406e497-ef32-448a-829e-b886daa318e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a406e497-ef32-448a-829e-b886daa318e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_129dd6f6-c880-4c74-b5aa-cadfa0f16dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:to="loc_us-gaap_AccountsReceivableMember_129dd6f6-c880-4c74-b5aa-cadfa0f16dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d7bb7ce2-c18e-4293-b8af-1827a0e7314e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d7bb7ce2-c18e-4293-b8af-1827a0e7314e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c8df44e8-a61b-4900-b0b4-f1ed11c78095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c8df44e8-a61b-4900-b0b4-f1ed11c78095" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="iad6f314e8f3b4655894d9b2fe3612ddb_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_642c3ec7-8c34-4aef-a416-b74a9742a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_642c3ec7-8c34-4aef-a416-b74a9742a687" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:to="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:to="loc_srt_SegmentGeographicalDomain_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:to="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_009e4a90-4de7-47f5-9f02-95749c7d92bf" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_country_US_009e4a90-4de7-47f5-9f02-95749c7d92bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6d7b295e-d2fb-40d9-a057-e0a3e8133d5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_srt_EuropeMember_6d7b295e-d2fb-40d9-a057-e0a3e8133d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2b491889-4713-4df0-a7cf-428ddabd0d7d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_country_JP_2b491889-4713-4df0-a7cf-428ddabd0d7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i1dda6cfbe17346f19f60580111e84861_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0a1f5a7-b237-4e70-9cae-d43b9a04d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0a1f5a7-b237-4e70-9cae-d43b9a04d5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:to="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:to="loc_srt_ProductsAndServicesDomain_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:to="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_2ebac036-0caa-4392-a5b7-4d8cbcc9dfbf" xlink:href="exel-20211001.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_exel_CabometyxMember_2ebac036-0caa-4392-a5b7-4d8cbcc9dfbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_6be29ad7-014e-4e33-bcf3-39fc2e5aaa46" xlink:href="exel-20211001.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_exel_CometriqMember_6be29ad7-014e-4e33-bcf3-39fc2e5aaa46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_82c97987-fa51-4e41-9fd6-8c459107561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_us-gaap_ProductMember_82c97987-fa51-4e41-9fd6-8c459107561e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="ib2ec42fa0b124459873617a381942faf_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2b4a2965-f318-409c-b1a5-e0417ecad191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2b4a2965-f318-409c-b1a5-e0417ecad191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_d1e786e0-cb4b-4d17-bdc3-28bfe03d69eb" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_d1e786e0-cb4b-4d17-bdc3-28bfe03d69eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_447b8380-559e-49cb-a331-eff26d745b0c" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_447b8380-559e-49cb-a331-eff26d745b0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b718fdd-cdfe-4288-bfd0-40ce7246ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b718fdd-cdfe-4288-bfd0-40ce7246ac98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4271708e-1909-4f28-8155-f4643faf60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_411167d4-ac7a-413c-9beb-719c025eb265" xlink:href="exel-20211001.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_411167d4-ac7a-413c-9beb-719c025eb265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_54946f48-6383-4e06-8c04-219e5c22c1c9" xlink:href="exel-20211001.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_54946f48-6383-4e06-8c04-219e5c22c1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_f04ffb41-4a7e-47a4-87a2-c54bb846cca9" xlink:href="exel-20211001.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_AllowanceForProductRebatesMember_f04ffb41-4a7e-47a4-87a2-c54bb846cca9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i1bb27292d1764cabb4089c8637e99441_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bdd752c-8043-41e0-8fea-e6899b67e890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bdd752c-8043-41e0-8fea-e6899b67e890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:to="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_180b0a5a-6d39-41b3-9139-3e026e1ce507_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:to="loc_srt_ProductsAndServicesDomain_180b0a5a-6d39-41b3-9139-3e026e1ce507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:to="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4e0344a0-7c42-42d9-896a-ef66f42b25af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:to="loc_us-gaap_LicenseMember_4e0344a0-7c42-42d9-896a-ef66f42b25af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7791b3fb-6e7f-4245-bf9b-b10c7d11f342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:to="loc_us-gaap_ServiceMember_7791b3fb-6e7f-4245-bf9b-b10c7d11f342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9756a661-480d-4f00-a85c-d3516c108523_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9756a661-480d-4f00-a85c-d3516c108523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_e83426e9-fb95-4dd2-a05d-73e3d64224ba" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_e83426e9-fb95-4dd2-a05d-73e3d64224ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i3a7a8f9c9c1f44f9a1e79d49a4f4ea11_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_110d85bd-a102-4a5b-9b76-909589548623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_110d85bd-a102-4a5b-9b76-909589548623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_a2bc97ea-9d94-43e6-86cb-f7f64dc9890c" xlink:href="exel-20211001.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_a2bc97ea-9d94-43e6-86cb-f7f64dc9890c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_891e8dd7-7c34-4c3a-9371-c34a8ddffa36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_891e8dd7-7c34-4c3a-9371-c34a8ddffa36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78adcc48-21a2-4f23-bbae-dae3b005aec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78adcc48-21a2-4f23-bbae-dae3b005aec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_735c40f6-2ffa-4913-b3cf-6da02216e2d7" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_735c40f6-2ffa-4913-b3cf-6da02216e2d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i3f345bfa7c17445dab726644c2154d80_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87dda19-8fc2-4650-a3c0-bfefa15068d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87dda19-8fc2-4650-a3c0-bfefa15068d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:to="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:to="loc_srt_ProductsAndServicesDomain_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:to="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_70a5d2a2-c369-4848-b3ce-c3e8c43678fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:to="loc_us-gaap_LicenseMember_70a5d2a2-c369-4848-b3ce-c3e8c43678fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_606d2178-fc3c-4955-8d13-5d6302b0fe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:to="loc_us-gaap_ServiceMember_606d2178-fc3c-4955-8d13-5d6302b0fe49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f87427a-c472-4dc9-929b-f6a7ef99d81f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f87427a-c472-4dc9-929b-f6a7ef99d81f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_b48d30c1-6098-44ae-a174-5735f8962ae3" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_b48d30c1-6098-44ae-a174-5735f8962ae3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="ifa6eb79cf9d44d2eb86fa6ae0216b2f0_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_160b4900-ea0d-4133-b154-2a64dd8b7111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_160b4900-ea0d-4133-b154-2a64dd8b7111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_5c295bc2-81ff-4106-82bf-69f54091cc5c" xlink:href="exel-20211001.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_5c295bc2-81ff-4106-82bf-69f54091cc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4a510676-7bfa-4178-bf27-e857b42eb944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4a510676-7bfa-4178-bf27-e857b42eb944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec7b474a-a9bd-416a-a6d8-9169d4deb963_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec7b474a-a9bd-416a-a6d8-9169d4deb963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_d91e51a6-b841-497c-a530-62876e254bc4" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_d91e51a6-b841-497c-a530-62876e254bc4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended" id="i028284bea98040fc995447b368215618_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_94b58ace-8dde-462f-b933-ddd8aa1591b0" xlink:href="exel-20211001.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_94b58ace-8dde-462f-b933-ddd8aa1591b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_3d749e1f-a3c5-41fc-9365-72feabfb2873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:to="loc_us-gaap_RoyaltyExpense_3d749e1f-a3c5-41fc-9365-72feabfb2873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:to="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_550d42b0-93e6-4027-b8d1-f8496b20ed7b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_550d42b0-93e6-4027-b8d1-f8496b20ed7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_03add398-d750-4a59-a948-f0b55756b7d4" xlink:href="exel-20211001.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:to="loc_exel_GlaxoSmithKlineMember_03add398-d750-4a59-a948-f0b55756b7d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e713e669-2a3c-4592-aa76-9a31823f6336_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e713e669-2a3c-4592-aa76-9a31823f6336_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_f0b6182c-7a54-4e5e-ad10-54d99657b59c" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_f0b6182c-7a54-4e5e-ad10-54d99657b59c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i1794405e6cdf4efcab6eb29cf5f528c5_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_7569ad4f-fbe1-48b8-b684-b478af70190a" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_7569ad4f-fbe1-48b8-b684-b478af70190a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b62d0b81-35f5-4eae-8aac-bf14084cc91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b62d0b81-35f5-4eae-8aac-bf14084cc91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a0e9172-0728-4f2e-aac7-c45a03234ad7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a0e9172-0728-4f2e-aac7-c45a03234ad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_8bb144f7-558a-46e8-b11a-601f77f0ee75" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_8bb144f7-558a-46e8-b11a-601f77f0ee75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:to="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d1044aac-b6c0-46bb-8b46-137deb6315f2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:to="loc_srt_ProductsAndServicesDomain_d1044aac-b6c0-46bb-8b46-137deb6315f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:to="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_62ddbbd4-4f5e-4a44-a008-67114a7f2343" xlink:href="exel-20211001.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:to="loc_exel_CotellicMember_62ddbbd4-4f5e-4a44-a008-67114a7f2343" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="extended" id="i2198c8a11b3f458d9d846c2801e79250_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4a0e8f81-d881-4a49-b9d0-79214e6886a6" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4a0e8f81-d881-4a49-b9d0-79214e6886a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_74b817e6-8e54-405f-aef1-f7c7d70de54f" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_74b817e6-8e54-405f-aef1-f7c7d70de54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_45025c33-aca6-4b22-9f37-ddf675129a4e" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_45025c33-aca6-4b22-9f37-ddf675129a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_59be3a95-2990-4456-af25-8a4996177fb5" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_59be3a95-2990-4456-af25-8a4996177fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_b1fe8b8e-899e-44c8-9cf7-6b524c1d62e8" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_b1fe8b8e-899e-44c8-9cf7-6b524c1d62e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_ab8bfb64-ef25-4e9c-ac07-62696236fe11" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_ab8bfb64-ef25-4e9c-ac07-62696236fe11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_c6570363-397c-4b3e-9c94-7db2fdec8746" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_c6570363-397c-4b3e-9c94-7db2fdec8746" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_32cc78be-ca8e-4751-8c1e-0ad64bac2c20" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_32cc78be-ca8e-4751-8c1e-0ad64bac2c20" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_7450784d-ea3d-4a97-af67-13784a3e25a7" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_7450784d-ea3d-4a97-af67-13784a3e25a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_0efaeef0-5f66-45dc-a6ea-b26520c16074" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_0efaeef0-5f66-45dc-a6ea-b26520c16074" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_a5769474-657e-4c45-81f0-4df7cb07fc82" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_a5769474-657e-4c45-81f0-4df7cb07fc82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff02d23b-2533-4904-9fb1-cc0a1d4dc5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff02d23b-2533-4904-9fb1-cc0a1d4dc5e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_d17101e8-455a-4645-a713-8a3ec83ced6c" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_d17101e8-455a-4645-a713-8a3ec83ced6c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_0bacaacc-0706-4c4b-ba91-705060961559" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_0bacaacc-0706-4c4b-ba91-705060961559" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_7a13253a-731e-40a9-a7c9-5e9a287277d8" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_7a13253a-731e-40a9-a7c9-5e9a287277d8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c8c36d64-1021-4def-8064-ca0132b9a371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c8c36d64-1021-4def-8064-ca0132b9a371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:to="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_6d3a1bc9-4d5c-4619-bb10-a2a756426c86" xlink:href="exel-20211001.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_6d3a1bc9-4d5c-4619-bb10-a2a756426c86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i027af4982f35451580052c07ca284d61_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3de1f27c-d248-4f9a-bac4-aafad389d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3de1f27c-d248-4f9a-bac4-aafad389d8ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73400a08-702a-4bbd-872c-e86045692a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73400a08-702a-4bbd-872c-e86045692a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4eb0fb17-5b93-45eb-ba38-0adde11bfbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4eb0fb17-5b93-45eb-ba38-0adde11bfbe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7bceba3-00bb-4e95-8f5d-d56da6ce10ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7bceba3-00bb-4e95-8f5d-d56da6ce10ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1988dd92-237d-4cf5-a6e0-151900acd5d0" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1988dd92-237d-4cf5-a6e0-151900acd5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_584f9d87-ea4e-463e-88c9-606c4ae42e57" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_584f9d87-ea4e-463e-88c9-606c4ae42e57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4d6bfb36-01c4-42cd-ac54-8c9ffea395a1" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4d6bfb36-01c4-42cd-ac54-8c9ffea395a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d60dcea3-fede-40d9-8e33-34d38ec6ebc7" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d60dcea3-fede-40d9-8e33-34d38ec6ebc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3c436022-3cdc-44d3-a474-1d8fb4831758" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3c436022-3cdc-44d3-a474-1d8fb4831758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c954cb0-5b6a-4db3-90b5-b88bb993fd7c" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c954cb0-5b6a-4db3-90b5-b88bb993fd7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7657fce3-3138-4f2d-b06d-bef5016c66dc" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7657fce3-3138-4f2d-b06d-bef5016c66dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_f5899872-ceb4-4ea3-815c-94547f004466" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_f5899872-ceb4-4ea3-815c-94547f004466" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c7b58f19-a739-4be1-a48b-5248abb15193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CommercialPaperMember_c7b58f19-a739-4be1-a48b-5248abb15193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_14d6926b-ff6f-435e-902f-fc85a99c380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_14d6926b-ff6f-435e-902f-fc85a99c380b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_fdef20a8-864c-44a5-abb1-f4e7f80a3256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_fdef20a8-864c-44a5-abb1-f4e7f80a3256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_701d49ec-0d8d-44a8-a17b-dcd03f567837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_MunicipalBondsMember_701d49ec-0d8d-44a8-a17b-dcd03f567837" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_98b4dc59-7ddf-4d74-86b8-c92049c72b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CashMember_98b4dc59-7ddf-4d74-86b8-c92049c72b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a202197-8cc3-4479-bef9-80e459fb9212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a202197-8cc3-4479-bef9-80e459fb9212" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_00d15193-b2e9-4028-8afb-4482615f923d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CertificatesOfDepositMember_00d15193-b2e9-4028-8afb-4482615f923d" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i3be161f5c2164dd69158ab66df10bfa0_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c1fed901-afb8-429c-a9ce-3a34bb65578e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c1fed901-afb8-429c-a9ce-3a34bb65578e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7e159683-06cd-424d-96de-5791b4ad9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7e159683-06cd-424d-96de-5791b4ad9bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d6381ea0-93e2-4ef4-bfd7-e1f39a400635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_CommercialPaperMember_d6381ea0-93e2-4ef4-bfd7-e1f39a400635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8d9ddb4a-5329-45a4-ab5c-481259f51609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8d9ddb4a-5329-45a4-ab5c-481259f51609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3c089cb5-cae1-4c59-8349-727504ef7653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3c089cb5-cae1-4c59-8349-727504ef7653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_9da6dc51-6f0d-4786-b10a-0c9b702645ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_MunicipalBondsMember_9da6dc51-6f0d-4786-b10a-0c9b702645ff" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="if808c6daf76b4242afd285f4719af3bc_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_678fd585-2caf-4727-b261-0a76362f6512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_678fd585-2caf-4727-b261-0a76362f6512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_974a68d3-869b-4a1c-a432-f641cd4842b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_974a68d3-869b-4a1c-a432-f641cd4842b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bfc25e10-c6d2-45d7-9415-a3b0800fcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bfc25e10-c6d2-45d7-9415-a3b0800fcb90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f88820cc-26a6-43c0-b92e-4bb13ae939e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f88820cc-26a6-43c0-b92e-4bb13ae939e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c9a94109-4d99-4168-95c8-ef98c6677c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CommercialPaperMember_c9a94109-4d99-4168-95c8-ef98c6677c30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_63a52db9-2d79-47e8-80b1-1fa60612e052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_63a52db9-2d79-47e8-80b1-1fa60612e052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f874003b-a1ac-40d9-bf48-472e47a23682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f874003b-a1ac-40d9-bf48-472e47a23682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_16f1ba81-bf82-4d76-90b7-43f378677079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_MunicipalBondsMember_16f1ba81-bf82-4d76-90b7-43f378677079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_842caab8-9c2e-4958-9b9b-34ce365e3937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_MoneyMarketFundsMember_842caab8-9c2e-4958-9b9b-34ce365e3937" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_fd930319-4c36-4a3b-ae9d-a364f78b121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CertificatesOfDepositMember_fd930319-4c36-4a3b-ae9d-a364f78b121e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2768bca7-f813-49a8-a832-51a499b3a76f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2768bca7-f813-49a8-a832-51a499b3a76f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05253d1a-ce95-4460-8160-41d7a11f6179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05253d1a-ce95-4460-8160-41d7a11f6179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8edfe879-1799-4db9-9096-faa309f1a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8edfe879-1799-4db9-9096-faa309f1a7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f23828fc-24b4-4f4b-8aae-8fd764717338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f23828fc-24b4-4f4b-8aae-8fd764717338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fde17965-fb8c-40f2-89b2-4f7b5a0e4df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fde17965-fb8c-40f2-89b2-4f7b5a0e4df2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i1ac26edc430e4ace8b1bae5c203c30dd_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_09726286-22a3-421c-802b-c5952fe55060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_09726286-22a3-421c-802b-c5952fe55060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_432d2f96-cc81-4327-87c4-062e5ed8512a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeNotionalAmount_432d2f96-cc81-4327-87c4-062e5ed8512a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_91564457-e95e-48a7-8f89-e1bf5deb4996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeTermOfContract_91564457-e95e-48a7-8f89-e1bf5deb4996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d6e00b40-98ad-4a73-993a-a48331f5862b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d6e00b40-98ad-4a73-993a-a48331f5862b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_4a13cda0-6361-47a8-9a85-694af6c2d858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_4a13cda0-6361-47a8-9a85-694af6c2d858" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i04df56c3e20246f0a7007ab96befaf44_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2801d118-69b8-40b7-b5fd-39c9c9d76f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryRawMaterials_2801d118-69b8-40b7-b5fd-39c9c9d76f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_30b2dc1c-10c9-4b86-a2d3-d4b90a5856ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryWorkInProcess_30b2dc1c-10c9-4b86-a2d3-d4b90a5856ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_63ca4dba-f3d4-49ab-b954-b348201d3382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryFinishedGoods_63ca4dba-f3d4-49ab-b954-b348201d3382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ede9a70a-93a5-4140-9532-9b9753c8a727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryGross_ede9a70a-93a5-4140-9532-9b9753c8a727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_52f85994-4289-47b6-b46b-f557f986a192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_52f85994-4289-47b6-b46b-f557f986a192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_098206d6-9148-4179-b46d-5398ba44d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:to="loc_us-gaap_InventoriesMember_098206d6-9148-4179-b46d-5398ba44d4b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_18f2f6c0-5ced-4b73-9460-6f3531d960a3" xlink:href="exel-20211001.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:to="loc_exel_OtherLongtermAssetsMember_18f2f6c0-5ced-4b73-9460-6f3531d960a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="ie187cfe4ed9f4c6c861e2a3c0364c183_StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e12bd786-9d46-4843-b566-7277dfc21101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e12bd786-9d46-4843-b566-7277dfc21101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b0516043-c391-43c5-b989-e74c090a5817_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b0516043-c391-43c5-b989-e74c090a5817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2db4aab-866e-4d0b-9f88-5fd09656521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2db4aab-866e-4d0b-9f88-5fd09656521b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_930c2484-6713-46e9-9e29-f791a7766076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_930c2484-6713-46e9-9e29-f791a7766076" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended" id="i71eff6a89d1c4a3d88da8923d7a1e394_StockBasedCompensationBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f5a7d41-90a5-4584-8c21-4138a1600d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f5a7d41-90a5-4584-8c21-4138a1600d94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:to="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1892d701-7939-4dc4-a608-54b6c2242fc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1892d701-7939-4dc4-a608-54b6c2242fc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eba8e878-c32a-43cc-a789-1f4773ee46bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eba8e878-c32a-43cc-a789-1f4773ee46bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_96ad7ced-c455-4d59-981b-a4e5c5fde6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_96ad7ced-c455-4d59-981b-a4e5c5fde6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c995f85c-9e64-4f96-8936-4cf39a4ad139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_PerformanceSharesMember_c995f85c-9e64-4f96-8936-4cf39a4ad139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2f846c2c-fd82-4664-9d1c-dcbf8c034071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_EmployeeStockMember_2f846c2c-fd82-4664-9d1c-dcbf8c034071" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="id4e9ded63b9644ea949b0c7ae86c79de_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7d69bd0d-9b6c-4440-a28c-85cf4862c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7d69bd0d-9b6c-4440-a28c-85cf4862c5df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_33b14fcd-9994-42e4-8202-4fb6c23602fa" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_33b14fcd-9994-42e4-8202-4fb6c23602fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_510b24cc-5e8d-461d-b90c-5dcfa3d4fcbe" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_510b24cc-5e8d-461d-b90c-5dcfa3d4fcbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_07aeffaa-e781-4a94-9c44-f3089556551c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_07aeffaa-e781-4a94-9c44-f3089556551c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862cf231-b2f3-45b0-a2b6-7836b690f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862cf231-b2f3-45b0-a2b6-7836b690f016" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a7da83e-4a69-4331-8e99-178b0f0e22a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a7da83e-4a69-4331-8e99-178b0f0e22a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec586965-da6d-4c5a-9482-ddb4fc082cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec586965-da6d-4c5a-9482-ddb4fc082cba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75f3f60b-2bc4-4b4a-8dec-45ee99ce62fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75f3f60b-2bc4-4b4a-8dec-45ee99ce62fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c427f972-1c67-4bd5-90e1-c24e3e7bc74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c427f972-1c67-4bd5-90e1-c24e3e7bc74d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e004e483-76c2-4b1f-9838-75c980f0274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e004e483-76c2-4b1f-9838-75c980f0274f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_48609c9c-831b-4298-94d6-bd66accaa6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_48609c9c-831b-4298-94d6-bd66accaa6b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_1b827fe8-50bb-45ce-9c36-404b4ecfd76a" xlink:href="exel-20211001.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_1b827fe8-50bb-45ce-9c36-404b4ecfd76a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0668650f-aa36-409a-9fc9-e9c924a80343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0668650f-aa36-409a-9fc9-e9c924a80343" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_404e4b5a-a682-4427-b3c1-f7452f2e8793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_404e4b5a-a682-4427-b3c1-f7452f2e8793" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a388e428-a889-4aec-95eb-3b6eb6c45a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a388e428-a889-4aec-95eb-3b6eb6c45a1b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51e683fd-7218-4671-977c-c7de9d282218_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51e683fd-7218-4671-977c-c7de9d282218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecf1f2ec-a4e2-43e5-8c20-4b92e6c39099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecf1f2ec-a4e2-43e5-8c20-4b92e6c39099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_89b2b96a-46dd-4f46-bad8-bfc74fd95f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_89b2b96a-46dd-4f46-bad8-bfc74fd95f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_48e4b467-89ce-47e2-a81d-2c00b32722cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_PerformanceSharesMember_48e4b467-89ce-47e2-a81d-2c00b32722cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:href="exel-20211001.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_7c36c6ed-e6bf-4260-bd66-f310b0a820a7_default" xlink:href="exel-20211001.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:to="loc_exel_StatusDomain_7c36c6ed-e6bf-4260-bd66-f310b0a820a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:href="exel-20211001.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:to="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_7a071356-d4fe-4410-8b7d-b84ffc6be059" xlink:href="exel-20211001.xsd#exel_AchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_AchievedMember_7a071356-d4fe-4410-8b7d-b84ffc6be059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_c0901ff1-2ea8-43fd-b457-1a2cd8243ae4" xlink:href="exel-20211001.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_ProbableMember_c0901ff1-2ea8-43fd-b457-1a2cd8243ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedAndProbableMember_5753eabc-b327-406a-b616-bf3984619ca5" xlink:href="exel-20211001.xsd#exel_AchievedAndProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_AchievedAndProbableMember_5753eabc-b327-406a-b616-bf3984619ca5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_005fce61-e01a-47db-8d5c-37970d872f5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:to="loc_us-gaap_VestingDomain_005fce61-e01a-47db-8d5c-37970d872f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:to="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_288fe787-4336-4160-b0fa-5b9a7407f99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_288fe787-4336-4160-b0fa-5b9a7407f99a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7310bd1-9f41-4909-ac8e-38fa2d6405c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7310bd1-9f41-4909-ac8e-38fa2d6405c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="id3fb8ca9bcbb440cbd106e02fd984fb5_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_663100f3-cfa0-4bfd-8348-7d39fb8f79a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_663100f3-cfa0-4bfd-8348-7d39fb8f79a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0b687fc9-551f-4d31-bf08-ef7372f879fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_SharePrice_0b687fc9-551f-4d31-bf08-ef7372f879fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ad1f08ac-2a23-4f4f-920f-b6a5b9f33fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ad1f08ac-2a23-4f4f-920f-b6a5b9f33fa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_de6a3528-d47a-428d-87f9-0f092ff3290f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_de6a3528-d47a-428d-87f9-0f092ff3290f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c0ef57d7-02d3-4a4d-afc7-56bec0f0de0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c0ef57d7-02d3-4a4d-afc7-56bec0f0de0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:to="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0719c9c-576e-4f62-92da-1feed392d1e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0719c9c-576e-4f62-92da-1feed392d1e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7f7b1242-d2b2-4d5d-a0dc-fadffda6b1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:to="loc_us-gaap_PerformanceSharesMember_7f7b1242-d2b2-4d5d-a0dc-fadffda6b1f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended" id="i02ffeb8f56a44700af4848e61658f4df_NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_029b1ad1-d136-4bbb-8c3a-3f55f0ad56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_029b1ad1-d136-4bbb-8c3a-3f55f0ad56cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_37a7485b-d682-44cf-88e2-6ac8801d7ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_37a7485b-d682-44cf-88e2-6ac8801d7ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_ee43df9c-9fc0-4353-a9b5-1e501d7c9750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:to="loc_us-gaap_StockCompensationPlanMember_ee43df9c-9fc0-4353-a9b5-1e501d7c9750" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>exel-20211001_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_489498e1-da9b-4a6b-ab89-cf4f3695d084_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_e3468b4a-780f-4b00-a5d5-d30a806632ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_67f3b63c-fff9-45d1-a284-4f8631f519be_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_52426173-73f4-4cd8-8317-cc59075135c5_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20211001.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_53bacec6-c71a-4177-a83a-ce781ff97be8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_ccddaa59-b28f-4f59-b2a2-a3a3a7480649_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f4b90f0-4ffe-46d1-9513-fe19345adf40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dba51c97-e36b-45d0-909f-ee15416b074c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e52154ad-436f-4d47-948e-8d3893c98270_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9b97a081-d848-421a-bf3c-04a04ce3922e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_03f114f3-50c6-425d-b26d-0a9abcf3fabc_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3bad36bf-7975-4bd9-bcb5-6d21b229118c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_7fbc8377-bc30-4fae-a780-2f0744571599_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_58389f0a-8f97-45c2-be81-76cd2f63abe2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3eecc7e3-5095-4508-a0ee-4fc42957752a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d081fbfb-dd0c-4819-9de4-cc7469d6048a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f54577d7-a180-4188-b817-ca04e79fd277_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_0c8a048b-a66c-4bfb-8915-4ffcbbd00f12_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20211001.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_984c86fb-dab9-4db3-8d2a-0c9502714639_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20211001.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_21971619-7551-4825-8a65-045c980d848e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4f0f6b08-0eba-42cc-982d-83925d643991_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_35704028-4690-41e6-99f6-1e1094cf7d35_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_66547c70-443c-4601-8bb6-3f171cf6feb5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3bdf8333-cb02-431e-85d7-09b4fb0b4491_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_92b113c7-4cf5-4a9b-96cb-20c4d3f96371_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_ddd5c6bb-08b5-449c-8c3b-9c033194d97b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Contracts for Non-Designated Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5865f163-407e-4edc-bb84-c9a81a31e0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a67b1005-9c08-427d-a02c-43274ec10fff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e6ffc389-3342-45bd-ad5c-acf8c4c3447c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_874d5194-c9c4-4ed0-a6fd-433838961301_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_4bb389a1-0aa5-431c-9ea5-bfd508b65ad9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_503a8e8d-bad5-4588-acca-ca0bbf9b2b66_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f884fd07-3854-40d5-bdf8-3ef434c80d79_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_58d0926d-add0-4d56-a688-d58f1e632085_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_67382ed2-467e-4c21-acb4-797a05a82962_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_eed7adc8-4f4b-4a25-87cd-1aa759a04a7b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_49e1d5a1-273b-4913-8fe8-425adb8f1b44_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_421fe00d-3e23-4cef-889b-e472f14643b7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_c2402cdf-f463-4c13-8454-8422b6591ce9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96103015-1a6e-45da-af51-0b8df58ff948_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_1e539b61-e0bf-4789-b9bc-d41b7a88bd8f_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20211001.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74617fe6-96ac-4c24-830e-48f8b175ea79_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_35dde3bd-7c8c-47e0-b732-1e75fa1fe9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_6642640a-37c2-4775-a4e0-c77ed4866e2f_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20211001.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_99f62766-2d96-423b-996a-10de61029dae_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8b416942-1578-468d-ada1-754453ac5d95_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_b56af844-0322-4430-ab66-22d13af1783a_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20211001.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2817f0ee-17c3-4fdd-a698-bf957a74ed63_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_01800330-3e66-4d8b-98ac-2d9d926300f5_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_86c2231d-066b-4c1e-b122-9db807cbcd3b_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ff590076-b8fc-4ec1-af06-0bb997137752_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $193, $453, $949 and $(893), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4b909f8-6427-4f48-a16f-e6b5de4e3435_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6f480c0f-cd0f-4f8c-a521-309617fe1f9f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_35cd1919-77b7-47e2-87fd-f3746d2b9c34_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8eb13d73-4dd5-4488-bead-6ffb2b3b607a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_8b6e186a-278d-4fef-96a9-a19482595432_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_6a44c767-976c-48a1-b261-4e2fc86aceea_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional oncology targets</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Number Of Additional Oncology Targets</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Number Of Additional Oncology Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_88e6a75e-e630-43f8-85aa-202f86dc6add_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c8f3f22-2535-44f6-bf33-4fd71d571085_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_42a1d3c2-3878-425d-8d23-4a695d766712_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e605f1f0-7921-4f36-91c6-9addf4f9112e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_cda22203-bf5e-4332-a4e7-cc779f4bb0de_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5e6efcf-4c5e-4990-9c5f-67f0a911a15d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a08fc7d9-0f51-4d94-9b59-14af79ccf56b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3aad26b1-27f9-468a-8ff5-44d1c21c3093_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0b39041e-428d-4b19-a6b7-df2ca4f66058_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_56f7cc50-da46-454d-be19-9d3515d4c1e9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_09f8fc09-72b5-416a-8a42-80ed2db87eff_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements, rights and obligations, option exercise payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Option Exercise Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Option Exercise Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f5528c17-3c4c-43f8-b029-6a5d2440b65f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_b15de2d2-786a-4552-8a61-ed0d5ea03ab8_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20211001.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cdc28128-1a63-4a3e-a413-235b78ece1c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_fb90d5c8-1799-4cbb-92eb-b31ffabfb0a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_74c71529-2984-4b23-9292-ebc9ef84213e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ef3e4c54-558c-4fdc-b1b2-f1e30ad1bb3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_61dd1b30-e328-4f71-8492-e53bef301166_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1d84a02f-52f7-454a-8df6-575dd316e640_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1404296d-cdbf-4f4f-bac7-43d5c07fe22d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b5e000a4-b9c7-4311-94cf-a407039d2982_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_6a2ad1c0-e1ea-4bd5-93d3-aff61c23fa21_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment upon closing of transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_label_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:to="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b0be4309-2129-497e-a82c-5dab54c7b84f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_27831bb8-59c4-413d-a94f-3d3996fa9a57_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_1e1b134f-1ae5-46be-b311-826bcfeefbd0_terseLabel_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, regulatory milestone probable of achievement</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_label_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement</link:label>
    <link:label id="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_documentation_en-US" xlink:label="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:href="exel-20211001.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:to="lab_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_376db28e-455a-4fb1-8b88-fd09872ad3d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3a7afa33-003f-4f66-a50b-4b4484d0ee13_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_e088344b-487c-4387-8f82-ec9080704a9e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_0b3352a6-40fb-47b1-b41b-61399b6f1302_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5baca38b-6f1c-483d-b136-2cde29053e0b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_ec27f435-530e-4025-b3a7-86d38567af9e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_777f9590-8442-44ff-916d-ee65bffebd64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9234be59-1a97-421e-afb3-6639f602fb6b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_d42bdb00-23fc-45f7-b305-d2d4013286be_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_429b522e-e91a-4c29-8c9c-5f4b19ec8662_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">collaborative arrangement, rights and obligations, aggregate research program funding payments, second installment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Research Program Funding Payments, First Installment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Aggregate Research Program Funding Payments, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8e9362fc-79cd-42a8-9834-7cd122e8498e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_4260bda7-853b-41fe-b205-413310658bed_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a52dcdd4-c6fb-46c6-800f-e9c6caa67586_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_33bba015-d5f3-4b99-9473-ceb1d8ae7c94_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_99ff2e3a-3ca4-4b1e-adc4-db477d1dac68_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f704d605-0152-4f63-bdee-86d1863c6c67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_bedabd82-d753-4b6f-971d-a33d317cb9af_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_0fad0c77-5647-4f78-bd66-3c497d9585a4_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_f8666b00-60c0-48eb-91cf-47ab59e11b40_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_42c47889-244e-4536-b770-8deb59c1118a_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20211001.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_f174099e-599c-41e0-af33-2b546ae04ed7_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20211001.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_fe3858c9-0c62-4fad-b217-c37ab57a753a_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20211001.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_09983900-4531-4985-94f0-c1a861019aa7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_87b4deba-43ce-4e12-9e7f-08afe9841f06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b94b970b-f72a-44c2-be0e-bda0997f28ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_538b93e3-4323-41e8-ad9d-f0008d046aeb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e9eb8ff9-cb49-4a54-b390-c9476e96e7f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_03bb671b-ac94-4fc5-a878-c5288092c05d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c7a48e21-277a-449d-aaec-005a66c83629_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1b7333b7-950a-4399-9744-b1befc871a5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6ae37646-b6e5-475d-b516-48e14a7a2fa5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b75d4c30-31a8-46a6-b020-1d326dd7b50e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_cf53d5e0-5cc1-4a9c-aa8b-2535a6d51479_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f7e8d470-a1f8-4c75-bf54-a3740ba0bbc3_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_de83ced4-ac9a-408b-88c4-383527058c1c_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_e91354b2-a841-4cc5-bfd3-11f9b3612fcf_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_de2ec6aa-5e30-4011-9b9a-7defacda445e_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d1607956-d141-4088-b1f0-eaaeec061078_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_120a12be-94c7-4b5e-8d65-b5970de63a3c_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20211001.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45f88eff-06a9-450f-9e67-a2ca7ab73cab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5b8ce27f-f897-440e-a721-d83a1fb6cfb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_5a55d4aa-2514-45c3-853c-e05efd70f131_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_35e19e4b-2384-4da9-9e24-7f580f227a85_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_20c091b0-8910-4c55-9d05-0f3a2556d1a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_7e1e9f00-330e-411f-addd-a0da1471ae61_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20211001.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_de239084-a5ea-4b65-be37-8e3066dd5fc8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c6a5bd0b-439b-4da6-9167-afe50305355b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9d67236d-6e5b-4087-bc29-54fc08ce2409_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_399c7017-b96f-4c08-837f-75f5e8444eb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e21377d7-d255-4f10-aa3b-76d553763c45_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cad7447c-4b50-44a7-b781-c3be10edb5e0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a2eff711-8212-4c27-86e0-3a2841ced6ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c868c43d-db4e-4646-80cf-e4ef3ba57296_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_7ce163ba-68c8-4553-a371-d64a76805adb_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20211001.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_539de4d8-4f5a-404e-b4dd-26cadbb9e99c_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0c762c96-6f69-4b26-bbfc-20301fa954ba_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_b3148149-4762-47d3-83f7-23f59aa76295_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_24b9a877-fb51-474e-b138-d215e8ba8c18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c784afad-5bd5-41bc-972a-0cc12ed2a5d4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_71132cdf-fcd1-4ccd-aaa4-d9fd07af9a5c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a852883a-fe47-4944-8ce7-08a379517c83_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_9a8fb0af-71b8-494f-8c1a-e5106bc4c6b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_88bf7b60-3fe8-4981-83a2-c590d2d9a4c9_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ae325d4f-9c5e-42b2-8e5b-1215c6123dd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 316,305 and 311,627 at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_fd62bcb5-f613-49e8-9a13-d9d1bb7e3b3b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_839540b1-31a8-4ec7-846c-dac25a9c0b27_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28e15e24-2587-410c-a5e3-4d11299d34f4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b203bdcd-95f4-491e-a280-0bfaffd26079_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0989b3da-47ac-41fc-8f0b-852e720fa377_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_6052bed1-737d-416c-a64c-66b599cfb321_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, research program funding payments, term</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Program Funding Payments Term</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Research Program Funding Payments Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c413a47d-de82-430b-a7f5-6f33574ba421_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_80d260b6-7402-4ff7-b284-bad8fc25bef9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash short-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9f9d257a-efb6-4e55-b287-af55d44d82ec_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5156ece6-909d-4aa0-b7c3-bd070d7a3c3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4a884214-c522-4363-b5ae-6a40e07e6867_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_966ccf49-0493-4625-b2a3-4cde3574b128_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_d7a7731b-beec-4be3-8a6a-00e634de494e_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f15065b7-a4d8-4ce0-bb33-cfba9bc4d8b6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5d575c32-434e-46e7-9b97-a2ec76cbc777_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_24090739-d384-467c-810a-7676d160719f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_eec34647-d746-4469-b4ae-e6a2bbff2ff9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ec613d70-4806-4c1b-9675-1a5aabfab57e_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4f7ef479-a189-43c5-ba99-7b7d0348b19a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_934a4f1d-85d9-4d78-b7cd-b385df9d7adc_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a96de970-f5f1-45fd-9bff-3fc55a20e84f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2efadfcb-fb0e-4a4a-86ee-2e1c7914d980_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6071a2b7-b2ad-4453-ab21-9fb470a8d612_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_e6cbd489-36e3-4f92-b77e-4a60f8a26f98_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:href="exel-20211001.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_438662ae-7d2d-4804-b121-4792eddfb7d8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f7452ff2-8c30-4078-a638-575f8cc5ac82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_9f87b783-5232-4075-90ba-7ccd5f1dd937_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_15d4764d-794b-49e4-9aff-52901cddb720_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_71de8368-07fb-4a2c-a811-9c5b1411a490_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_857a87f1-0712-4d96-8baf-efd31493e875_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ed5a5960-56d2-4ce1-b4ad-461c656c0f44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d304b3ce-cfbe-40aa-a695-d813d716398c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbf8ad7-de5e-49c9-9609-04ac886d703d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_80897471-02f2-483e-a296-043741c2ff05_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_84a2a4e5-42e8-4857-abf2-14fd08d7791e_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7224e315-9057-4165-a488-a1bf31d169b1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ee7a6802-c1a1-464c-9f86-c21aead1dff3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f849422a-53c4-4f5c-a5b8-13d154169976_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_c285948a-78e9-42c9-9898-bc4bf4e957c5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e3981a3e-e13d-4d9c-8d31-ac7a9df8d56f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab37ec68-e237-4ba1-b1d2-d543d3a734cb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_99b7a3d5-e269-4529-bcf6-dc22d28f4d38_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_4f609e76-fc4a-4873-9436-519118b298d5_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_46df81b9-6ece-4ef9-9be6-501cdb311d14_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_b6646228-9731-4078-9fcd-46f7072cd676_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20211001.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ec1ee3b0-6f17-436c-a0be-48cdb26fda7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a3b36f9a-c16a-4fb3-84c2-5974a1eade71_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da11cb-9174-4081-8697-16a5c335e895_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_62a4616b-f610-43ec-8649-23d8d6e0433c_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20211001.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_96b9bc7e-1867-484a-8778-46065448ddbe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_84e44d73-9ad3-4795-aaa8-d6d083504bd3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8ba066dd-648a-43ae-a518-ef077bef39be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0cdf13fd-da8f-4339-88ca-11dead8370a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_17dfac03-c4ac-4be6-9cfc-1f40b6d3fc6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c57deca3-ec05-4469-b4dd-14ee1beb13d7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_61008990-fd50-4fe2-bfed-145dc6b39ac4_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_27178487-884c-4736-a9bc-12036e5a01c2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a1da0ac9-7e2b-4687-973c-1711dcb7feb9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_012a0369-c592-4229-8c0c-ae70fbd21091_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20211001.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e155a62d-eb58-40f2-9d38-7409b79926b3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a5c26d64-e212-4d35-9fc2-028dbe8d075b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_97028a6b-411c-4ebc-b7f1-9b7262a31d43_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_941282fe-6ea9-41bf-9c9c-9e363238475f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a8c493cd-d3f5-470a-ad5d-deab6cc9f03a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_690a1f7f-8ec6-4d68-ab34-5a6b71583750_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_55656e55-e811-45db-b612-72c82e9e7c92_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5d3e9bf0-4960-4e84-862b-e5df95f3133d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7f2e14ed-b214-456c-9ed1-e56050f59a2d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9aebc675-ae50-426f-a786-d1b7e5e7645d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1dba8c4a-814c-433f-8a0c-5f91b6383dfe_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_dd236e86-284c-4cb8-bc81-21983cc95f00_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_30693578-f039-430a-95a5-6f9c38d0dd1c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_40a43792-88c3-408d-a131-2077c99b3b53_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_710bd87a-26c1-418c-bb95-534cefaee5b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_d5773c82-daea-4145-b690-f62062d87c55_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20211001.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0819b61f-54a5-41fb-9e68-3b696541095f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_aa0897eb-2eb9-470e-b8ac-400d95921ccc_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6e59117c-862e-4c62-ade7-79494b86daeb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_b1a62baf-7138-43f3-958b-2fe9c30bacd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_74b34fe0-b905-4e9c-927a-465ee2296103_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_061eadc9-ffd1-46d5-9957-801c845c5dd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_9a75ecec-160a-4b45-9ecf-3586ebc0f5c6_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_label_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA [Member]</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:href="exel-20211001.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:to="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d769a5a6-7862-4853-aa3a-a186c94076ab_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20211001.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9d821e8e-563d-48fd-a04e-8fe54cc09270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3222c2cc-260f-4915-8ad5-ae85b35a6231_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_ce0d5bed-45d6-4feb-9c63-3bed40f0251a_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20211001.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_42637702-f4a3-422d-bcd8-23be6c12821b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c89f5856-dd24-4e73-a911-9c4a2957edd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_21579344-f895-420f-8cee-7be2fcaa505b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_88b2830a-1ff9-489b-b536-f6f24a0bdbbb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_ec199e35-885d-4c2a-a72e-9e6305509912_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_f9422ed9-de77-43cb-9379-4108934c7f2f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_e7231458-76b4-469f-81d9-e6775fc53d4c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_0d70eff2-f044-4632-a63b-24c1e6231cb3_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedMember_3fdf80dd-f08a-48e5-b666-5ec678f90fba_terseLabel_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_label_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_documentation_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember" xlink:href="exel-20211001.xsd#exel_AchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember" xlink:to="lab_exel_AchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_83d4da77-e478-4474-8470-d7d72e6be1da_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_af4a6585-d532-489c-aea9-4e67e24a24b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_4e151e7b-6c79-473a-94ab-d130d8d53eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_5e07bbdd-48ad-4b3f-a9b0-c97726354501_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_a394a5c3-a976-42aa-9c0a-21ecb0377ace_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0985a350-48c6-4d48-9f02-3e952c31daa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c879ef8b-567d-43fe-a06d-0766cdf0ea74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b28cda51-b550-4e40-9188-3bfa7309185b_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_910ab131-1e17-4936-a3c3-2dcf9cae871d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f3c82-cb42-452c-a208-8c4dbf83a383_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d88a3c22-2ddf-442e-b17d-e30b1102bb2f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d9e8b9b1-2108-4a02-938b-206f483fca88_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_770dde16-f583-48ce-bb42-c3c01d9c20ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c4a26e4b-1297-4877-a97b-691e0b15c506_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d386a8f7-36fe-487d-8e38-0793841d415a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f3751891-95df-47cb-ad48-97fb4ef42824_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_492bb72e-fc29-4f02-89ab-dbd5a5040eb7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_981c51df-397a-43b7-a49a-654ecd21a34d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_35d76e01-9d01-4b53-bc89-5b125acc68dd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96238e34-2256-4010-a6ca-26d94facca6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e902ced9-b415-498d-ab0e-8c7a273ed398_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5470e769-9fc5-475c-9d4d-89b8c289d442_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_07a2d630-e6ab-4d49-9d4d-7782af79c393_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_960649bc-4cb3-4f8b-8a37-5cc90741d4d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_09e8c0ab-8b7a-4d3c-9376-db72f94e8072_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8240b29d-8d3a-4bf6-9865-96d57946f08e_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e06e958-0963-428c-a957-d10962f88a05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1aef3999-bd48-4f98-8f9d-58832d92757f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_85f502d3-2d94-441e-8d17-beda953f8642_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_5ca4c195-00c0-4473-a5b6-80745efe550a_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, aggregate research program funding payments, first installment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments, First Installment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2e77109a-024b-4653-9785-2c56e0903e15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_a511be49-f7a2-4f33-bec4-ca8a65d157de_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_62b9fc20-0bd7-41e3-af96-588558d3ae57_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_f25b27b0-c231-4f38-b8b1-37414e6d2779_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_9224f5c2-1321-48bd-bab5-a107b1a400d9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_43fe025d-1434-4f3d-837f-04f2cc798a91_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_30f0aace-2bfb-43e9-924b-80e22ba2c76d_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_GlaxoSmithKlineMember_de2ff536-6bdb-4204-b2ad-9f36ac17eb70_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember" xlink:href="exel-20211001.xsd#exel_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember" xlink:to="lab_exel_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1c5e0e6-3997-4896-bfba-bd27720bbdf7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_de8a0962-fc38-4121-9366-581234239381_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f713876-ff40-44e6-99f9-ce3cb4bc1fb1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4ca6b1f4-17ce-43cc-a052-ec2a8315162b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_68e605b1-2e2e-4e4a-83d1-5b429262cdfc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fbf83e70-654b-49df-b2dd-abf6a64cf581_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7b911d21-eab9-45d2-973e-f76bfaa5c84a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ade713ae-7161-44fa-bbcc-0cd36f19e144_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7c5b71ce-3abd-4edc-ba64-801b4538846c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f51eef23-61ec-4871-b4ac-9a75f44042ec_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_7d84d59b-7a81-4ff8-8e48-ed6a4681e071_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20211001.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_46d8f237-4db6-442f-9ac9-d0589bb407a8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8115049a-c819-44dc-a66d-110d082d7069_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5258e3fb-e230-474c-9276-b9d85a6a7f12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1b49a768-cca4-4b51-846a-b05a20e335f1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2d348604-01ef-4392-ba08-dcaf8a81da8d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9b0cbf42-6a25-4eee-8bb7-8ff3e9881fb1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a67a1bf0-96c2-4e42-93b3-85d5291cdbe6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b3c92bea-c5ef-44dd-9b70-e79813f7c9c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_b4396183-aac3-4d42-85fd-39dc70fe36c3_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2c1bf799-5d1d-45a6-ab65-b6d133e204f2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ce4e71be-0e48-4a65-9b5e-03883ae06b41_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_fe157fe8-e97a-4ab0-b464-b5795a5d6639_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_0bae9d99-7d11-4b39-b4db-e036992de0b0_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20211001.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_58592f49-bbc3-4f3f-97fd-8f61b4cefcc7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a94d550b-db9e-4de9-9282-5963d45b3094_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0b3797fb-53c6-4c0d-8e0e-9ba2666081ca_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e3307d29-906c-4b80-b81c-1bc4c04a75fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8dfb7ecd-824e-4f01-aa6b-c38b58e30f68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_069f1cdc-cf5d-4411-a3b7-4158ecbe2543_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_411de90b-3633-4a27-ad2b-62160d5a1a8c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate exclusivity payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ee7620a6-b041-49ea-adbc-801fcc7dc2dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_613c18e6-6055-45bb-a400-6913ec7ae6e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e3c724c-2bf8-43ac-9aee-4bcad555454a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_6cf40ca0-d6bf-463a-aac2-ef3b2080fbcf_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20211001.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c93d54d6-dcec-4dc7-b348-59e943ca4db7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_f631b69d-4c6a-4d51-bfc5-6e759c90a546_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_7041690d-0c37-478b-a2a7-2680396feaee_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_665c189f-92ce-4b18-b648-71d07315f01f_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20211001.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6f25739b-34fa-4d96-9cca-4592105c1432_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_f214661d-151f-405c-bf95-4ef4e54852d8_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20211001.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_972978bc-1b71-422a-9903-e1bf541bd533_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_340c7ed2-02d7-482a-8344-64e876d3a0ec_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_73ce9d53-b139-44e6-8c9b-a77390fb3c74_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_568f51ba-4c66-4631-b886-9eb8027778ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_201b2a70-eb85-4f41-9639-ba40abd655f3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_54330efa-8bf8-47e9-8170-71b124b16b12_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7b14b495-18da-495f-89ae-dd1d14d7d97b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_3d3df701-e7b8-445a-a4e8-3bfe76a9c6ac_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_9cc166c0-01b3-4d4b-8612-a6a7ea7de636_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_0953a721-ef2d-4d0c-a53f-0298c30ed426_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate research program funding</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Research Program Funding Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Research Program Funding Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dfb72b88-1981-46d5-8d8c-54ec65918668_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_008d866b-fea3-4e08-ba42-31ae1eb679a5_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_38aa8046-af69-4cd0-985a-6dac745460ad_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20211001.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_48a9e2a6-8d47-4a84-902d-244a4a2c2070_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f24458b5-f464-4d87-b3de-299fbe5c6660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_a0639cec-5b3b-4096-980a-84045d44600b_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20211001.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_63dbe667-5968-441f-b9e8-f5f265d42144_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77559958-7a0c-4fbc-b5c8-9227731f8227_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_c166482d-3f4b-41d8-bdd7-450a5df9ee1d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7c449825-5f2e-49b1-8037-104ae83e1169_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b3f8403b-62da-4ff3-bef2-520214177d52_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9833223d-5269-4b38-a75c-0ad1790744f2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_39fe4048-cb50-402f-b275-e4d351588567_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_3ae3084c-8ba4-4404-9e06-7a11cc925cda_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20211001.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed16d32c-d5b4-41f5-b4cd-da7143135d96_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_008262aa-b6f9-41fd-9f07-dedf58b2ca6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_fce8191d-d144-44bf-b85a-4544b9075e0a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_24c0233e-8ae4-4cc7-ab77-50d3abb24ae4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ebce14a1-c419-4f9e-8913-ef312e3f8755_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cea63558-83a8-47fa-8ae2-7ea6dae55804_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e08ad6dc-10ba-4c0d-980b-c218fc985c15_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_84802e01-82d2-4334-984b-286a219fdd2d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80b89ea3-6e28-4fe4-9493-af7f55614f80_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_1f8955b5-6cdc-4848-a48f-ecc6e9a3c0f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred in asset acquisition</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1b72b579-bee8-46b3-b41e-82fb3c7de439_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_133eb803-c43b-456d-9cb4-135fd7998c40_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_ee4d56ed-911c-457d-a9e5-af101bb36c6a_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_af7cd38f-50f3-4a48-bed6-5a0a84741a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3625411c-94b6-4dc3-b157-ad4d62c507c0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_62d3c517-5be0-432e-8b1b-2aaf54f82ff3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_610460bf-2deb-40d1-89aa-3703c5ba5168_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_5ba61a97-2805-45d9-b6bb-df412e6d504b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_72d8f707-db37-40ba-aee7-bb7c9e4a54d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ef7c4697-0ca8-419d-b2b8-f4c3ee907df1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4680d78d-c101-4f79-8ee9-b14d82b8bcad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_77155f24-1b69-4fe9-bb38-5853ea75ddaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3319f805-99de-4686-beea-de027f87e8bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0dad43d3-9ba4-4550-bf20-d5d70d98b860_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_fc882628-9da2-4031-8a36-4d3c64e51c97_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_722ba146-e062-4a39-8e35-f6b667436cdd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_04c75d95-1e4d-4ac7-ae53-0e0030a4f3de_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20211001.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_169089ae-7729-4b92-a9d3-2196d4886425_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f512f9f6-3b4b-4c88-972a-fa488006c849_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_10d37717-32e4-4231-9948-28dd674d54d2_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20211001.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_468d9e8e-69f1-457e-b05e-5ba432a92167_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4b5fd6af-8fde-45ee-bc5c-bfc1b0064e06_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6c0a06e0-3ea0-4415-a96c-f6134f319f6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21000803-589f-4e78-a2c4-de4fb09ae909_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_313f865f-bfec-4002-b51f-12e564e7967b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8abb1612-7524-486f-9175-f4c3248c0117_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6f5b9e06-aa05-4b03-867e-fed68fdf3043_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_069e4e90-cecf-499b-8fc6-92edd41fdf21_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_1d081c9e-ca24-4773-a5ee-db598c28f790_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_b7fc6637-5107-4cb1-8f2a-5f476ce2a970_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_52f3e3e2-2a9c-4cd4-8784-a604abefca8f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_257ee8a8-869c-40c5-8247-8266c8588ddf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b31698dc-632c-4bf9-9cb0-75a85053c54b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96465cda-f1f6-4d18-87f8-3cd4627f6ec1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0f98e0a-3403-46fa-b54b-42fc8f40d31e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cbc444e9-2008-4cc0-bab1-0189ae662c8e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_72bb8e6b-a49b-41a6-bdd1-dfd1d3cc7355_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f9d9420a-6abd-4ad4-8762-556c7c748d7c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_37303140-223c-4e98-8830-11ed1f02e9db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f36551c7-c9bd-44f3-aa6d-2e3705dc5be3_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_99149651-7977-4857-9c84-ccc151a6bdc6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4efabfa6-500c-4003-b6f0-43737adb1e00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eae642df-481a-423b-8bfc-87995d96ea6d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_28f88cfc-d4f5-47ac-9ffe-a0f9fa51b945_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d2e7f10f-b076-4e80-9fce-add18b147651_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_8303dd00-e2c0-41ba-a5c1-a77cc7084e9a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bbc09ca4-366d-4b8f-8604-dbeb336b3968_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d8697f3a-0f07-4f6f-9580-74851471ec5a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a47efeb1-eecf-458e-8d1e-8d32c57b0336_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedAndProbableMember_fa727833-3591-471b-b62d-b0540588f911_terseLabel_en-US" xlink:label="lab_exel_AchievedAndProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved And Probable</link:label>
    <link:label id="lab_exel_AchievedAndProbableMember_label_en-US" xlink:label="lab_exel_AchievedAndProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved And Probable [Member]</link:label>
    <link:label id="lab_exel_AchievedAndProbableMember_documentation_en-US" xlink:label="lab_exel_AchievedAndProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved And Probable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedAndProbableMember" xlink:href="exel-20211001.xsd#exel_AchievedAndProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedAndProbableMember" xlink:to="lab_exel_AchievedAndProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ee8826b8-4566-4c47-b983-864a2695198f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d7c7b85a-c5bb-4db9-a246-7c9686f9e7fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR (BENEFIT FROM) INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ae5fa7ae-8b74-4257-bbf6-ca9b060c145e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_f57ba911-a0df-4e45-aec0-572ee2754443_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_75cc96e1-3c50-45ea-9bba-07f61157497d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_60d297d5-6dbf-47f2-bc4d-8642141a51e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_87e54fda-d9f8-4281-92d7-38b40ebae538_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a7f8019-1863-4a57-a034-1994bad25194_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c0960b17-a189-4fb3-a59c-6ecd5aaf4499_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_042f0442-de56-44f5-b123-2392259091d4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a6617125-4cec-4230-9eee-a43468b2503d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0a67353f-a0f0-4a1b-b7b9-b01043bca47c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_aeed06ab-a40c-48e0-a588-61e1f992f962_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1be4c479-f1ab-4b75-a442-055aa1b60d22_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9e8c2d2a-bec1-4a5e-ba44-06f8dabbc01f_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_40c2a755-aac8-4e58-b418-c71fb766b972_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20211001.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c420ea3d-c706-4672-8db9-125bf94dbca8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b607cb07-35b2-48d0-860f-971cb2859b14_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4c9d97b9-94db-42c5-90f6-38832cb93100_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_998a75e9-1139-4b91-96b4-924bf1b971e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_983d475f-1598-4f50-b8c1-c4853e37a582_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7741199c-73aa-467a-b834-092505051e4f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b63203d0-488e-4d37-a82d-41a8df29baa1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d56b1801-a49e-4093-9a8d-f5a0ab2d108e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_14ff4257-6628-4333-bf19-658d870e558a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b608383d-bc0c-41f1-bfb2-8015a3c9df81_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_0d326801-7b05-4cc8-9bbd-f3c30994591a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_68c4e733-cce0-4d15-ba79-4d0d29280293_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_5e8e84d4-be83-456c-9a4d-9bc72373d221_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1a369c2d-f466-40ca-a1e1-dd49cdbaa8e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46d79097-65f8-4601-a04c-a1b3618b1a87_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_259f3cdc-8587-4013-be1b-819bc6961025_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_1abd552d-65f7-4969-81a6-509a4c598297_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22e3d211-d99b-4f52-b763-5299d51e3f67_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>exel-20211001_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0e725e96-6688-4692-b1d1-3eb2243a0886,g:c6400d91-38e8-47b8-8b68-7f9741afcf52-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20211001.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1d24ba3c-10f5-4f4a-b039-3727c078e364" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentType_1d24ba3c-10f5-4f4a-b039-3727c078e364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_08e4788e-2ece-4fcd-9c71-8b20569550ab" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentQuarterlyReport_08e4788e-2ece-4fcd-9c71-8b20569550ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_18696fe7-d858-4bd5-9955-700de9a82e79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentPeriodEndDate_18696fe7-d858-4bd5-9955-700de9a82e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e9929766-80bf-433b-a1a9-3131658f241b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentTransitionReport_e9929766-80bf-433b-a1a9-3131658f241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_75163d39-d824-44b2-b2b3-7b41d8945627" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityFileNumber_75163d39-d824-44b2-b2b3-7b41d8945627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9cec8e1d-3b81-4c58-95e8-f93182310b41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityRegistrantName_9cec8e1d-3b81-4c58-95e8-f93182310b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8eec78c6-4cae-4761-8fd6-9fed8c66e4fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8eec78c6-4cae-4761-8fd6-9fed8c66e4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3b48535c-f7cf-49c0-8eb4-84a0f8a9f7ba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityTaxIdentificationNumber_3b48535c-f7cf-49c0-8eb4-84a0f8a9f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8bf3ac08-e7d7-45e1-8af0-46c443e67a89" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityAddressAddressLine1_8bf3ac08-e7d7-45e1-8af0-46c443e67a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_48a6066c-5755-47c8-8bb1-7b859208d03d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityAddressCityOrTown_48a6066c-5755-47c8-8bb1-7b859208d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_baccd7aa-fc01-40f1-8f21-12b306af4313" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityAddressStateOrProvince_baccd7aa-fc01-40f1-8f21-12b306af4313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b5325a8-d15e-4ec8-8ba7-6d9f487654a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityAddressPostalZipCode_3b5325a8-d15e-4ec8-8ba7-6d9f487654a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3bc68afb-46c8-4034-8094-de677dba57e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_CityAreaCode_3bc68afb-46c8-4034-8094-de677dba57e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0b03b617-c1c1-43fb-9c70-78e6d9493720" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_LocalPhoneNumber_0b03b617-c1c1-43fb-9c70-78e6d9493720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4e4dedf7-8a9e-41df-afbe-eace246d6072" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_Security12bTitle_4e4dedf7-8a9e-41df-afbe-eace246d6072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c7a54871-d4db-44cf-baaa-be707adeaaf2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_TradingSymbol_c7a54871-d4db-44cf-baaa-be707adeaaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f1b65feb-2ee9-4265-92ba-b76a865aa7cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_SecurityExchangeName_f1b65feb-2ee9-4265-92ba-b76a865aa7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a4a4e5cc-fb06-45e2-85c3-cad6a2bb51ca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityCurrentReportingStatus_a4a4e5cc-fb06-45e2-85c3-cad6a2bb51ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_317ea4f2-9d5e-446a-89a0-ca503af87525" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityInteractiveDataCurrent_317ea4f2-9d5e-446a-89a0-ca503af87525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_20f4f443-4d65-46dc-a8b7-581771cdc52a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityFilerCategory_20f4f443-4d65-46dc-a8b7-581771cdc52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_72487019-002b-4437-8252-2dc5fc1cafca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntitySmallBusiness_72487019-002b-4437-8252-2dc5fc1cafca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_346e8fe5-d120-4034-aa78-03864afb5413" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityEmergingGrowthCompany_346e8fe5-d120-4034-aa78-03864afb5413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_370fb9b9-e0e1-4eba-9555-872424225d8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityShellCompany_370fb9b9-e0e1-4eba-9555-872424225d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_52c978a5-0ea0-460f-b270-97447ef4f713" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_52c978a5-0ea0-460f-b270-97447ef4f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3e5df20f-274e-437e-a6fb-2cbc8b3d7a83" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_AmendmentFlag_3e5df20f-274e-437e-a6fb-2cbc8b3d7a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1416c6c7-895b-41b2-9e3c-cd2f07bbf0d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentFiscalYearFocus_1416c6c7-895b-41b2-9e3c-cd2f07bbf0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e6aa1d62-9566-4eaa-b0e4-de88b2f52073" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e6aa1d62-9566-4eaa-b0e4-de88b2f52073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c022bef9-739a-4ce1-8074-10aebe1e21e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_EntityCentralIndexKey_c022bef9-739a-4ce1-8074-10aebe1e21e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5463f40c-068f-4617-9792-8edef6b0aafb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47dc667e-45d4-4329-8983-f5120fcbbb43" xlink:to="loc_dei_CurrentFiscalYearEndDate_5463f40c-068f-4617-9792-8edef6b0aafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9309beb0-472c-47c1-ae2e-054388756820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9309beb0-472c-47c1-ae2e-054388756820" xlink:to="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1605b063-35d2-4559-857d-921e3aa63c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1605b063-35d2-4559-857d-921e3aa63c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_db23f13b-ff5d-4e1e-b676-97f9c4332c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_ShortTermInvestments_db23f13b-ff5d-4e1e-b676-97f9c4332c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_2e696c02-9abd-4d5b-8eb6-4b5fa48c6a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_ReceivablesNetCurrent_2e696c02-9abd-4d5b-8eb6-4b5fa48c6a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f4112a3e-dc7c-4b94-b020-3da135604ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_InventoryNet_f4112a3e-dc7c-4b94-b020-3da135604ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a85f3f3b-bc48-43e4-9640-df738d3f6c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a85f3f3b-bc48-43e4-9640-df738d3f6c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8525c3e0-0d30-4c2b-814b-03198c90838f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4717925-1729-406b-a2bc-f6ed1198ed67" xlink:to="loc_us-gaap_AssetsCurrent_8525c3e0-0d30-4c2b-814b-03198c90838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a25ccd1f-e748-454d-b45c-c2594faaf071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_LongTermInvestments_a25ccd1f-e748-454d-b45c-c2594faaf071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34e88d3c-cbf1-4df6-bf78-b8f179c72d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34e88d3c-cbf1-4df6-bf78-b8f179c72d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_44cc9648-12ee-47eb-9a1f-bdc9a9a6d3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_44cc9648-12ee-47eb-9a1f-bdc9a9a6d3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f0535e91-7823-4dae-b864-96bc6ce9d94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_Goodwill_f0535e91-7823-4dae-b864-96bc6ce9d94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bb8e2323-ae65-4542-b605-f967ad447198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bb8e2323-ae65-4542-b605-f967ad447198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_74b81e3a-67c5-46b8-9d09-7d008858e7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8b05b44f-e522-4ff5-a308-f3935a1eda5e" xlink:to="loc_us-gaap_Assets_74b81e3a-67c5-46b8-9d09-7d008858e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9309beb0-472c-47c1-ae2e-054388756820" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4fe7c938-4e41-4aa2-83ad-6e6b04156e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_4fe7c938-4e41-4aa2-83ad-6e6b04156e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1764bcde-dc4e-43c3-81ce-25714896cca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1764bcde-dc4e-43c3-81ce-25714896cca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_ea1b6500-78b9-42ca-acc4-956794ed16d5" xlink:href="exel-20211001.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_ea1b6500-78b9-42ca-acc4-956794ed16d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_0aa097af-18b0-46b4-b3b9-1d8095c86072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_0aa097af-18b0-46b4-b3b9-1d8095c86072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_186c67e3-d059-4d9a-893b-2b640ecf445d" xlink:href="exel-20211001.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_186c67e3-d059-4d9a-893b-2b640ecf445d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a361d912-a2fe-45c6-afaa-bdeba1620ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a361d912-a2fe-45c6-afaa-bdeba1620ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_edbdf5a8-6833-47f4-b86f-5c53c5e031cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37b2984d-6c04-4114-b36b-37d86e30f4bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_edbdf5a8-6833-47f4-b86f-5c53c5e031cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_68a1edfc-686e-4024-a5f9-0bff0ecf9395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_68a1edfc-686e-4024-a5f9-0bff0ecf9395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_176e0ef2-834f-49ee-ba9c-541397c40247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_176e0ef2-834f-49ee-ba9c-541397c40247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c2a620b0-e6fd-4b31-9927-9b2a059838e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c2a620b0-e6fd-4b31-9927-9b2a059838e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4f587cb5-d414-49f9-87bf-76d21951005e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_Liabilities_4f587cb5-d414-49f9-87bf-76d21951005e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b66b2805-f4d3-4b72-bcbd-2781f82621ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b66b2805-f4d3-4b72-bcbd-2781f82621ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1cd61112-51e7-4ab2-a321-77100a11602a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_PreferredStockValue_1cd61112-51e7-4ab2-a321-77100a11602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a33aaaf2-5d05-4946-987b-9be15c06d99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_CommonStockValue_a33aaaf2-5d05-4946-987b-9be15c06d99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_28160093-0a22-4007-b408-0344ff6e59f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_28160093-0a22-4007-b408-0344ff6e59f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_91ab1583-cad7-4cf9-9d62-3bca7c776631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_91ab1583-cad7-4cf9-9d62-3bca7c776631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57c8cd9a-8dcf-45e4-9fb5-2e25c261f0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57c8cd9a-8dcf-45e4-9fb5-2e25c261f0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c6e7a699-be84-4e4b-9525-e94e4e957b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_daf65e7b-762e-4b92-b6de-2e6b4453defc" xlink:to="loc_us-gaap_StockholdersEquity_c6e7a699-be84-4e4b-9525-e94e4e957b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb69e4b2-a59a-4828-abec-26f40738ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7db6870-e3e0-4a7e-a05f-d59a8b79d441" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb69e4b2-a59a-4828-abec-26f40738ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_861ab94c-2e21-4669-bfd2-4b76572482b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9309beb0-472c-47c1-ae2e-054388756820" xlink:to="loc_us-gaap_CommonStockSharesIssued_861ab94c-2e21-4669-bfd2-4b76572482b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c51c4684-323c-4063-ac2c-f30c74095d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ce3bca1-0260-4262-8784-70c7cffb68ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c51c4684-323c-4063-ac2c-f30c74095d4e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ce3bca1-0260-4262-8784-70c7cffb68ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_04f1dcb0-bb88-494b-840c-4a9538e1e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6ce3bca1-0260-4262-8784-70c7cffb68ca" xlink:to="loc_us-gaap_StockholdersEquityAbstract_04f1dcb0-bb88-494b-840c-4a9538e1e8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_53b7b11e-8682-4a8b-967b-c35a9b7a36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_04f1dcb0-bb88-494b-840c-4a9538e1e8d9" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_53b7b11e-8682-4a8b-967b-c35a9b7a36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c284744-d45b-4575-84ba-28324c99c88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_53b7b11e-8682-4a8b-967b-c35a9b7a36d7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0c284744-d45b-4575-84ba-28324c99c88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_31c04d0c-bb54-4888-9761-ca3b72f9a187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_53b7b11e-8682-4a8b-967b-c35a9b7a36d7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_31c04d0c-bb54-4888-9761-ca3b72f9a187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_11a138c0-7ae0-4fbd-8222-bc7fd07853d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_53b7b11e-8682-4a8b-967b-c35a9b7a36d7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_11a138c0-7ae0-4fbd-8222-bc7fd07853d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_04f1dcb0-bb88-494b-840c-4a9538e1e8d9" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9e07da9-c392-44a1-924a-b2e5d5b17810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9e07da9-c392-44a1-924a-b2e5d5b17810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80df7637-4203-480d-9611-f8cc97ee1f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80df7637-4203-480d-9611-f8cc97ee1f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0a773007-88f6-45c4-8bf1-f47362437ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:to="loc_us-gaap_CommonStockSharesIssued_0a773007-88f6-45c4-8bf1-f47362437ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1f8c3208-642d-4610-b74c-bebf21f03c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0e9276ab-3e8d-4b33-bc08-725aca1dbb54" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1f8c3208-642d-4610-b74c-bebf21f03c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a49df48-eb40-431e-ad5b-32ea54db8552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a49df48-eb40-431e-ad5b-32ea54db8552" xlink:to="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:to="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_47ddbb7a-88f3-42bf-b7fe-6d89e1f467db" xlink:to="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c740d670-7e2f-4293-a9dc-c94c8d37099a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_ProductMember_c740d670-7e2f-4293-a9dc-c94c8d37099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1af35cb5-cab4-400c-9139-4c497f601e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_LicenseMember_1af35cb5-cab4-400c-9139-4c497f601e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f36c8103-6856-4c99-a26c-39ffac0acfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef04c0d-e527-48a8-bd32-8b9e1d808057" xlink:to="loc_us-gaap_ServiceMember_f36c8103-6856-4c99-a26c-39ffac0acfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9b9de92b-20e8-466e-8ba4-df3e8dc03fd1" xlink:to="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce66722c-8e49-4e0d-a32e-6f8c254745db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7efeca42-cf77-4a11-a336-b32eda5e8812" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce66722c-8e49-4e0d-a32e-6f8c254745db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_33a25fda-75ab-4171-a7e6-cfc0df6f7da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_33a25fda-75ab-4171-a7e6-cfc0df6f7da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_56e0e82b-eed4-440f-9136-6949a9ab4b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_56e0e82b-eed4-440f-9136-6949a9ab4b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_265e386f-9f8f-48ea-b18c-05e9467a656d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_265e386f-9f8f-48ea-b18c-05e9467a656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0bc016a4-2e1c-47b2-8d69-5cb6db8d645b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b6c12b83-fb13-4f0f-9e1b-d54fa7b82309" xlink:to="loc_us-gaap_CostsAndExpenses_0bc016a4-2e1c-47b2-8d69-5cb6db8d645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f8cfc2a7-e793-4c49-a90b-de5d0aa5db12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OperatingIncomeLoss_f8cfc2a7-e793-4c49-a90b-de5d0aa5db12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_9e30a8d9-ee4b-443e-89a1-ed0731329140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_InterestIncomeOther_9e30a8d9-ee4b-443e-89a1-ed0731329140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3931-b07e-4389-87d9-d0db922391e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3931-b07e-4389-87d9-d0db922391e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_1f173076-aac3-4db2-848c-262fe3cd6101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_1f173076-aac3-4db2-848c-262fe3cd6101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0b552f44-7c65-4992-9131-8859c3814cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0b552f44-7c65-4992-9131-8859c3814cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e1b410a-e05e-4ab4-97cb-cd9ddbe1f208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_NetIncomeLoss_9e1b410a-e05e-4ab4-97cb-cd9ddbe1f208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e5b53d89-e4e7-487b-9cb7-0d7eda910481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:to="loc_us-gaap_EarningsPerShareBasic_e5b53d89-e4e7-487b-9cb7-0d7eda910481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2944ea55-06d9-450d-b1a6-5cd1f516785f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_533bca9f-e8cf-449f-ae9c-a2be89cf7277" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2944ea55-06d9-450d-b1a6-5cd1f516785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1d7d4537-139d-4719-b1a6-c57abf0dcde8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6d3158d-a9ad-4eac-8491-96790c61caed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6d3158d-a9ad-4eac-8491-96790c61caed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8784d9b5-1a28-4345-af96-9f862835f7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_24aa1a14-eae1-4907-abf7-b73bd34f7607" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8784d9b5-1a28-4345-af96-9f862835f7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7b832ca0-7271-4f07-84ea-4689f3f166ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_706b85d3-3f44-48d1-a67e-dfc6f555e500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7b832ca0-7271-4f07-84ea-4689f3f166ed" xlink:to="loc_us-gaap_NetIncomeLoss_706b85d3-3f44-48d1-a67e-dfc6f555e500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8a0206cf-b3b4-457e-91c0-6a16bb493491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7b832ca0-7271-4f07-84ea-4689f3f166ed" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8a0206cf-b3b4-457e-91c0-6a16bb493491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9669ab6-f050-4848-8056-9bb013f765ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8a0206cf-b3b4-457e-91c0-6a16bb493491" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9669ab6-f050-4848-8056-9bb013f765ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4d70eb53-8ed8-4743-ac3f-19f79d44d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7b832ca0-7271-4f07-84ea-4689f3f166ed" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4d70eb53-8ed8-4743-ac3f-19f79d44d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f48da5eb-e8ff-40d0-a5f6-13daa4ddee9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_eec9ce3f-c7a6-4941-b07b-2efd743beb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f48da5eb-e8ff-40d0-a5f6-13daa4ddee9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_eec9ce3f-c7a6-4941-b07b-2efd743beb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_658ba179-39a5-4dbb-b22f-567f4284ed65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_658ba179-39a5-4dbb-b22f-567f4284ed65" xlink:to="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f202c860-2586-4b24-967a-ee0e12a75727" xlink:to="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_39f64618-6d02-474a-9396-a4aaefa093b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_CommonStockMember_39f64618-6d02-474a-9396-a4aaefa093b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29f2cd7c-10a9-456a-9282-c9153ff3b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29f2cd7c-10a9-456a-9282-c9153ff3b6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9a5677b3-90b7-4581-adc0-212983f73cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9a5677b3-90b7-4581-adc0-212983f73cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5e284048-787e-4b34-a68a-05a94212cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fbf5469b-d41e-45c2-b67e-89439bd5a918" xlink:to="loc_us-gaap_RetainedEarningsMember_5e284048-787e-4b34-a68a-05a94212cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_081241b6-8808-453e-9da1-5d69c42b7fe1" xlink:to="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_68b12be2-33a7-4e9f-be1f-ca1b66bb7c30" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_101bb5b6-40cb-4989-a735-0ae46577213b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_101bb5b6-40cb-4989-a735-0ae46577213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c4ddb5e-d78d-4db7-bd43-7443744bd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockholdersEquity_2c4ddb5e-d78d-4db7-bd43-7443744bd9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc1f0e9a-1026-4431-a925-c40e389523f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_NetIncomeLoss_dc1f0e9a-1026-4431-a925-c40e389523f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0484227c-c32f-4af6-b627-87d3635544c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0484227c-c32f-4af6-b627-87d3635544c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_31b35d4a-ce2f-40e2-ae67-2d68307009bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_31b35d4a-ce2f-40e2-ae67-2d68307009bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f37ce15-8d21-41ac-bdac-310de6475bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0f37ce15-8d21-41ac-bdac-310de6475bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3141483d-18be-4713-ab33-6c6dbb6cba35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3141483d-18be-4713-ab33-6c6dbb6cba35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5d42173-9f9d-4a20-a850-bce434330213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5d42173-9f9d-4a20-a850-bce434330213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b90c810e-304f-49b0-8081-3de3d4c19f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b90c810e-304f-49b0-8081-3de3d4c19f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d247127e-8674-42b8-9e35-851397c5ea33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a817689d-ddf9-49c9-aa5f-b3af98d7d36c" xlink:to="loc_us-gaap_StockholdersEquity_d247127e-8674-42b8-9e35-851397c5ea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20211001.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06996ac4-2e3f-4d13-9eec-6e099cb9c5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_NetIncomeLoss_06996ac4-2e3f-4d13-9eec-6e099cb9c5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e74c5bec-d3ac-42b8-8991-51582be5b1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e74c5bec-d3ac-42b8-8991-51582be5b1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a577e27b-6ef0-4525-a485-06c474581476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_us-gaap_ShareBasedCompensation_a577e27b-6ef0-4525-a485-06c474581476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_c3462b5e-41b5-46b6-a4fb-299f9e724adb" xlink:href="exel-20211001.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_exel_NoncashLeaseExpense_c3462b5e-41b5-46b6-a4fb-299f9e724adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4cdf4d7f-a979-4478-a94f-b55581b756f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4cdf4d7f-a979-4478-a94f-b55581b756f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bc5c0b97-9b0a-4b59-a18a-9a36b9be77db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bc5c0b97-9b0a-4b59-a18a-9a36b9be77db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f457f83f-d489-40ee-8ae5-3ff972955289" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bf891913-baf0-48b4-a43a-c812fea9a649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bf891913-baf0-48b4-a43a-c812fea9a649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e195000a-6044-414b-ae72-0f9479559d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e195000a-6044-414b-ae72-0f9479559d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8edfb343-11a0-4a2c-b45f-cbf90c75f667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8edfb343-11a0-4a2c-b45f-cbf90c75f667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_650f1e44-c505-4fc5-ab88-751b4591f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_650f1e44-c505-4fc5-ab88-751b4591f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4dfb0728-ed7d-46fc-8e24-9faa40d460a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8c121b8-dc48-4017-a53b-8f11cf7ea192" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4dfb0728-ed7d-46fc-8e24-9faa40d460a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b90ea774-ecf9-49c7-a3fa-f9b66fb678fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b90ea774-ecf9-49c7-a3fa-f9b66fb678fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7efbf18b-49ba-4738-8360-8a54c0ff631d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7efbf18b-49ba-4738-8360-8a54c0ff631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_03230780-e1e8-49a0-bf3e-e3d3d222c78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_03230780-e1e8-49a0-bf3e-e3d3d222c78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_91cc77b0-f04f-4bd3-9009-931dc3ea24f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_91cc77b0-f04f-4bd3-9009-931dc3ea24f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b40d0b02-a466-488f-873c-8232d601640f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c2c81a67-04b7-4286-9ebf-f2690bc9a4cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b40d0b02-a466-488f-873c-8232d601640f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47ce95d2-9139-4e7c-8c6b-b19945e95131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47ce95d2-9139-4e7c-8c6b-b19945e95131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4512b593-b07b-4608-bb57-321c28d474c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47ce95d2-9139-4e7c-8c6b-b19945e95131" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4512b593-b07b-4608-bb57-321c28d474c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7a06b928-09ec-418f-a834-c30c4e4c82e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47ce95d2-9139-4e7c-8c6b-b19945e95131" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7a06b928-09ec-418f-a834-c30c4e4c82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_980498a4-9428-40a5-9754-a7760b44855a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_47ce95d2-9139-4e7c-8c6b-b19945e95131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_980498a4-9428-40a5-9754-a7760b44855a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_696579a7-ecd9-45fa-ba27-14ee060d36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_696579a7-ecd9-45fa-ba27-14ee060d36a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce35296-0f91-457c-88bd-ea1243beaf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce35296-0f91-457c-88bd-ea1243beaf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc510210-6b95-4aa8-9f60-e4621354d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc510210-6b95-4aa8-9f60-e4621354d9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e16f51d6-433d-4319-aff3-a5c9e1cdc7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e22a4f7f-7242-41bd-a2f8-91e07310c399" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e16f51d6-433d-4319-aff3-a5c9e1cdc7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_2ea3279a-4c51-4064-bd0f-50bd5062cad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e16f51d6-433d-4319-aff3-a5c9e1cdc7f5" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_2ea3279a-4c51-4064-bd0f-50bd5062cad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_63a3625f-60a4-40ba-9b78-b03d7b337a9d" xlink:href="exel-20211001.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_2ea3279a-4c51-4064-bd0f-50bd5062cad1" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_63a3625f-60a4-40ba-9b78-b03d7b337a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_e1b8f030-daeb-4ac1-b2cc-62d63668de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e16f51d6-433d-4319-aff3-a5c9e1cdc7f5" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_e1b8f030-daeb-4ac1-b2cc-62d63668de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ae4f8e76-9ebb-40e2-b1cc-dd8a298a26df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_e1b8f030-daeb-4ac1-b2cc-62d63668de0b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ae4f8e76-9ebb-40e2-b1cc-dd8a298a26df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_6f3bd588-6188-45aa-b186-6c7589c6630b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_e1b8f030-daeb-4ac1-b2cc-62d63668de0b" xlink:to="loc_us-gaap_LiabilitiesAssumed1_6f3bd588-6188-45aa-b186-6c7589c6630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20211001.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7f4c574-b6cd-4d49-92af-36f13ff59320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c5323157-11e4-4754-9ab7-ec2ac1702f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7f4c574-b6cd-4d49-92af-36f13ff59320" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c5323157-11e4-4754-9ab7-ec2ac1702f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20211001.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_25982eea-6106-4a9a-b21f-6f2e5ec63b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_25982eea-6106-4a9a-b21f-6f2e5ec63b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18e0f303-5793-40d1-9d13-db22911ddebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18e0f303-5793-40d1-9d13-db22911ddebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_11a5ec4a-e278-40fe-8050-fae0dff36c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_FiscalPeriod_11a5ec4a-e278-40fe-8050-fae0dff36c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1356e16c-b564-4de8-a95b-4643559de9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1356e16c-b564-4de8-a95b-4643559de9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6547038a-b2f7-4bc3-87f0-762d7d89e6da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_UseOfEstimates_6547038a-b2f7-4bc3-87f0-762d7d89e6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e8535169-4d8e-4345-b437-57203b46ca51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e8535169-4d8e-4345-b437-57203b46ca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_bdcae859-3b54-4426-97f0-73c4a1d2068c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_bdcae859-3b54-4426-97f0-73c4a1d2068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c346218f-8f9e-4471-b154-9ab04864883c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c346218f-8f9e-4471-b154-9ab04864883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c136b67f-a36c-4fe6-819e-753c9dc41bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e290e6-52d3-43e2-9572-cc01d7111f00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c136b67f-a36c-4fe6-819e-753c9dc41bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51e923e4-4068-4b50-9e19-c29dabd226c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51e923e4-4068-4b50-9e19-c29dabd226c8" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:to="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7fa340c-ee30-4e90-ac84-8e2d4fe9a7c6" xlink:to="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_5e95d67d-ce66-4eb8-b80e-1b9cb6df2d6f" xlink:href="exel-20211001.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_5e95d67d-ce66-4eb8-b80e-1b9cb6df2d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_95d97933-cad5-4ac5-b387-af44637b6cec" xlink:href="exel-20211001.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_035f0946-d2fd-47ec-9c65-ada9df61eab8" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_95d97933-cad5-4ac5-b387-af44637b6cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:href="exel-20211001.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_1a25ad9f-816e-4c8c-b699-746815da4dfb" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_8f69568e-2e5c-4604-a86c-32157292290a" xlink:href="exel-20211001.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:to="loc_exel_NumberofProductsinCommercialMarket_8f69568e-2e5c-4604-a86c-32157292290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6fa57626-b450-4a19-83ad-dbcca43ba443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_614682db-2d7c-4910-8470-07c76d4c0345" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6fa57626-b450-4a19-83ad-dbcca43ba443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20211001.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51d44cdf-37fd-4174-92a3-c357646ae0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b13e75a7-eabb-4028-be31-5e38dfa8179a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51d44cdf-37fd-4174-92a3-c357646ae0c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b13e75a7-eabb-4028-be31-5e38dfa8179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_109e0fb8-dcc0-4cb4-b0b5-3fceaa98cdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_109e0fb8-dcc0-4cb4-b0b5-3fceaa98cdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_881329c6-439e-4088-8724-e1cf9889356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_881329c6-439e-4088-8724-e1cf9889356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2d3f9b41-484f-449e-be1d-9dfbfc5c9d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2d3f9b41-484f-449e-be1d-9dfbfc5c9d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_eb802eb8-94c2-4f86-82da-ef94f5d7a1fb" xlink:href="exel-20211001.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_eb802eb8-94c2-4f86-82da-ef94f5d7a1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_729ce48f-5dc6-4b25-9580-77f4321653e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3444d53-c999-4bb1-b226-a147457562af" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_729ce48f-5dc6-4b25-9580-77f4321653e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d07f55d8-8987-4bcc-bd1a-8f185b17cf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d07f55d8-8987-4bcc-bd1a-8f185b17cf3e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:to="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_16b4ddcd-b950-4aae-9e0b-205d6d2d761f" xlink:to="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_c971e4eb-fea5-4293-a367-163e2ea43cd1" xlink:href="exel-20211001.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_ProductGrossMember_c971e4eb-fea5-4293-a367-163e2ea43cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_0ddf5ce1-61e0-4568-ac84-3f8b97bf8974" xlink:href="exel-20211001.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_0ddf5ce1-61e0-4568-ac84-3f8b97bf8974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_72ade67b-be3c-48ae-aa92-911aa8e4d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_ProductMember_72ade67b-be3c-48ae-aa92-911aa8e4d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8bede2ce-a207-442e-898e-8ed6ddfb4861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_LicenseMember_8bede2ce-a207-442e-898e-8ed6ddfb4861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2873dfca-ac6d-4316-8380-801622703f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_us-gaap_ServiceMember_2873dfca-ac6d-4316-8380-801622703f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_3592049e-f08b-445d-8742-32f4de6f78d0" xlink:href="exel-20211001.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_683bd4bf-d691-4901-9356-98491d1ddf6a" xlink:to="loc_exel_CollaborationMember_3592049e-f08b-445d-8742-32f4de6f78d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b6836b44-03ef-40d8-bde5-033037981902" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_097f4d44-76e7-4cbc-a410-a4434fdd2914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_83a6981e-4b11-47af-b821-b34ec1b7266e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_097f4d44-76e7-4cbc-a410-a4434fdd2914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0595ce13-aad3-4594-9576-040fde1ae18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0595ce13-aad3-4594-9576-040fde1ae18b" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_04bce3d8-9245-42c5-b80c-323504d6c884" xlink:to="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_29f8854b-4a2a-4e79-8516-2e3a9d6530e7" xlink:href="exel-20211001.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_IpsenMember_29f8854b-4a2a-4e79-8516-2e3a9d6530e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_4df793a3-ef30-4c89-8d7e-9e3d85f4637f" xlink:href="exel-20211001.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_4df793a3-ef30-4c89-8d7e-9e3d85f4637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_b8de2f9f-404c-4a10-9baf-a4b8c1ebf6d8" xlink:href="exel-20211001.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_b8de2f9f-404c-4a10-9baf-a4b8c1ebf6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_de0a210f-8ce5-468f-acfe-7490d7661a91" xlink:href="exel-20211001.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_de0a210f-8ce5-468f-acfe-7490d7661a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_33dc12a6-b6c3-470e-8d4f-08223ea88f29" xlink:href="exel-20211001.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_33dc12a6-b6c3-470e-8d4f-08223ea88f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_3b04c3bb-812e-497b-9054-48632fa9ad8b" xlink:href="exel-20211001.xsd#exel_TakedaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_80020752-fa7d-4a52-ace5-c89ffedac44d" xlink:to="loc_exel_TakedaMember_3b04c3bb-812e-497b-9054-48632fa9ad8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6e17c16-e354-4e56-a074-9f388357f8f0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a406e497-ef32-448a-829e-b886daa318e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a406e497-ef32-448a-829e-b886daa318e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_129dd6f6-c880-4c74-b5aa-cadfa0f16dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_304c3a78-d002-4577-a3bd-08dfcc289963" xlink:to="loc_us-gaap_AccountsReceivableMember_129dd6f6-c880-4c74-b5aa-cadfa0f16dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d7bb7ce2-c18e-4293-b8af-1827a0e7314e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c8df44e8-a61b-4900-b0b4-f1ed11c78095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_24308e89-92fd-4436-96a1-668ba601f9a5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c8df44e8-a61b-4900-b0b4-f1ed11c78095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_361c3c4d-6792-456b-97a3-6b7795459b86" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_89e7da8d-ebb8-41f4-9a40-df8c56df453f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_b24fa52b-df66-4c11-a563-bd83ee90ed62" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_89e7da8d-ebb8-41f4-9a40-df8c56df453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_033cddac-e40d-4f66-a855-0dfbd1846f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_033cddac-e40d-4f66-a855-0dfbd1846f46" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:to="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3b9eb21d-18a8-45fa-9feb-a8103d29f9d2" xlink:to="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_009e4a90-4de7-47f5-9f02-95749c7d92bf" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_country_US_009e4a90-4de7-47f5-9f02-95749c7d92bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6d7b295e-d2fb-40d9-a057-e0a3e8133d5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_srt_EuropeMember_6d7b295e-d2fb-40d9-a057-e0a3e8133d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_2b491889-4713-4df0-a7cf-428ddabd0d7d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c21b5c81-0802-4ce8-9e9e-62f149a0942d" xlink:to="loc_country_JP_2b491889-4713-4df0-a7cf-428ddabd0d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1e124e46-381a-46e9-9d18-14b0e42e2c31" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_642c3ec7-8c34-4aef-a416-b74a9742a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cc38fe3c-b7d8-4239-88d7-5b4206c93ecd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_642c3ec7-8c34-4aef-a416-b74a9742a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bc5b84ec-1c81-42b7-880b-81c555a54dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bc5b84ec-1c81-42b7-880b-81c555a54dea" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:to="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f44b78e8-31d3-4b4a-bf6c-d08bb304b4d3" xlink:to="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_2ebac036-0caa-4392-a5b7-4d8cbcc9dfbf" xlink:href="exel-20211001.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_exel_CabometyxMember_2ebac036-0caa-4392-a5b7-4d8cbcc9dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_6be29ad7-014e-4e33-bcf3-39fc2e5aaa46" xlink:href="exel-20211001.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_exel_CometriqMember_6be29ad7-014e-4e33-bcf3-39fc2e5aaa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_82c97987-fa51-4e41-9fd6-8c459107561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05ca07db-0c47-4a21-8d59-60cb27773143" xlink:to="loc_us-gaap_ProductMember_82c97987-fa51-4e41-9fd6-8c459107561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b3924b6-6279-4ae4-95ae-88555feb297d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0a1f5a7-b237-4e70-9cae-d43b9a04d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6c3f8d92-bb1a-4284-bb1a-2972b792fd61" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0a1f5a7-b237-4e70-9cae-d43b9a04d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed595796-c23e-45f6-89ed-89cbd6f2af5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed595796-c23e-45f6-89ed-89cbd6f2af5e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7befd5a-5fff-4def-8e95-a4b7ca2e8b79" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_411167d4-ac7a-413c-9beb-719c025eb265" xlink:href="exel-20211001.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_411167d4-ac7a-413c-9beb-719c025eb265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_54946f48-6383-4e06-8c04-219e5c22c1c9" xlink:href="exel-20211001.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_54946f48-6383-4e06-8c04-219e5c22c1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_f04ffb41-4a7e-47a4-87a2-c54bb846cca9" xlink:href="exel-20211001.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_dcf6100f-8d3e-4dd1-bf7f-73ab0f6b48ad" xlink:to="loc_exel_AllowanceForProductRebatesMember_f04ffb41-4a7e-47a4-87a2-c54bb846cca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b43b1231-c742-4f72-87e4-9a01f24f92cd" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5ffe8a04-dec7-4e3c-9b28-bd50e9f3ac94" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2b4a2965-f318-409c-b1a5-e0417ecad191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2b4a2965-f318-409c-b1a5-e0417ecad191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_d1e786e0-cb4b-4d17-bdc3-28bfe03d69eb" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_d1e786e0-cb4b-4d17-bdc3-28bfe03d69eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_447b8380-559e-49cb-a331-eff26d745b0c" xlink:href="exel-20211001.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_241945aa-0878-41ee-88ae-87408e3aacff" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_447b8380-559e-49cb-a331-eff26d745b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b718fdd-cdfe-4288-bfd0-40ce7246ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b718fdd-cdfe-4288-bfd0-40ce7246ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4271708e-1909-4f28-8155-f4643faf60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a0c78f9-51dc-4819-bc45-f4c62b1424d3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4271708e-1909-4f28-8155-f4643faf60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_30e4cc92-a7b6-4bb2-9ee5-fa6c74c3dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_30e4cc92-a7b6-4bb2-9ee5-fa6c74c3dd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_165eb7db-555c-4ef9-893a-53856012f811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_165eb7db-555c-4ef9-893a-53856012f811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b4868826-bbc7-42b0-857a-4a1a3bd7859e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_165eb7db-555c-4ef9-893a-53856012f811" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b4868826-bbc7-42b0-857a-4a1a3bd7859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_abe12427-c1b1-4090-9ec3-cefd29c7d3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_165eb7db-555c-4ef9-893a-53856012f811" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_abe12427-c1b1-4090-9ec3-cefd29c7d3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_40eeaa39-d455-4ed8-838b-70bedabe657f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_165eb7db-555c-4ef9-893a-53856012f811" xlink:to="loc_us-gaap_ContractWithCustomerLiability_40eeaa39-d455-4ed8-838b-70bedabe657f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_e862410d-ac2c-4732-b5b5-d25271e34d66" xlink:href="exel-20211001.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_e862410d-ac2c-4732-b5b5-d25271e34d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_91916e26-3a34-45d4-8865-4c537b26d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_91916e26-3a34-45d4-8865-4c537b26d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b865d0bc-66c8-415e-8c23-e05268802624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b675396b-df5d-40bd-8197-ff5c32785f61" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b865d0bc-66c8-415e-8c23-e05268802624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47a88363-4a50-4446-8718-0280b2e258e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e6f8bdee-2449-4218-a516-b08509424a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47a88363-4a50-4446-8718-0280b2e258e3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e6f8bdee-2449-4218-a516-b08509424a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64a97c63-646e-47e3-87fa-9cf2b5f70524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_bc02ac5f-9c78-4aaa-b883-77079b226eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64a97c63-646e-47e3-87fa-9cf2b5f70524" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_bc02ac5f-9c78-4aaa-b883-77079b226eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f48a026c-3612-4450-b9d6-3f0c18a09b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f48a026c-3612-4450-b9d6-3f0c18a09b50" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:to="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_180b0a5a-6d39-41b3-9139-3e026e1ce507" xlink:to="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4e0344a0-7c42-42d9-896a-ef66f42b25af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:to="loc_us-gaap_LicenseMember_4e0344a0-7c42-42d9-896a-ef66f42b25af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7791b3fb-6e7f-4245-bf9b-b10c7d11f342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7b191f86-edec-4171-9d06-7dde7cead05b" xlink:to="loc_us-gaap_ServiceMember_7791b3fb-6e7f-4245-bf9b-b10c7d11f342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9756a661-480d-4f00-a85c-d3516c108523" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_e83426e9-fb95-4dd2-a05d-73e3d64224ba" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_56c433d7-9d64-44ac-8e3a-6377b53e3372" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_e83426e9-fb95-4dd2-a05d-73e3d64224ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0326cf54-0b48-40da-8828-2a8b78dd7028" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bdd752c-8043-41e0-8fea-e6899b67e890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5593a71b-757b-4c47-b553-9430d83250c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bdd752c-8043-41e0-8fea-e6899b67e890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb1b813d-5e52-4190-93a5-177bc30cf3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb1b813d-5e52-4190-93a5-177bc30cf3ef" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78adcc48-21a2-4f23-bbae-dae3b005aec0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_735c40f6-2ffa-4913-b3cf-6da02216e2d7" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a55d1f10-518d-47ce-82c7-82a7335a7cdd" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_735c40f6-2ffa-4913-b3cf-6da02216e2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_91027559-9f98-4807-8179-714fc7429c54" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_110d85bd-a102-4a5b-9b76-909589548623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_110d85bd-a102-4a5b-9b76-909589548623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_a2bc97ea-9d94-43e6-86cb-f7f64dc9890c" xlink:href="exel-20211001.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_a2bc97ea-9d94-43e6-86cb-f7f64dc9890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_891e8dd7-7c34-4c3a-9371-c34a8ddffa36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68964118-56ff-4b51-b13d-e69dac2a1304" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_891e8dd7-7c34-4c3a-9371-c34a8ddffa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d27fdb8-3134-4a8e-a211-744471a50978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d27fdb8-3134-4a8e-a211-744471a50978" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:to="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7a0dbb5-a01c-45a7-ba3c-e5cbe91fe240" xlink:to="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_70a5d2a2-c369-4848-b3ce-c3e8c43678fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:to="loc_us-gaap_LicenseMember_70a5d2a2-c369-4848-b3ce-c3e8c43678fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_606d2178-fc3c-4955-8d13-5d6302b0fe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_604df2c2-8721-4e32-a8b5-ce676d459221" xlink:to="loc_us-gaap_ServiceMember_606d2178-fc3c-4955-8d13-5d6302b0fe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f87427a-c472-4dc9-929b-f6a7ef99d81f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_b48d30c1-6098-44ae-a174-5735f8962ae3" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf813f6f-f6a5-4af8-afd0-ffcda0f1820d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_b48d30c1-6098-44ae-a174-5735f8962ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90c3bf89-fdb7-4883-b8b7-59ef92d77c4d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87dda19-8fc2-4650-a3c0-bfefa15068d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c3d017f-1979-4a6b-bd4a-cde58482e46c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87dda19-8fc2-4650-a3c0-bfefa15068d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1995f90-ff9e-456f-8829-5b28f7b69ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1995f90-ff9e-456f-8829-5b28f7b69ca8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec7b474a-a9bd-416a-a6d8-9169d4deb963" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_d91e51a6-b841-497c-a530-62876e254bc4" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b71774ad-31d2-4635-a53b-00b14461a209" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_d91e51a6-b841-497c-a530-62876e254bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00848e14-ad1b-483a-93d0-188f4619d897" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_160b4900-ea0d-4133-b154-2a64dd8b7111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_160b4900-ea0d-4133-b154-2a64dd8b7111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_5c295bc2-81ff-4106-82bf-69f54091cc5c" xlink:href="exel-20211001.xsd#exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement_5c295bc2-81ff-4106-82bf-69f54091cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4a510676-7bfa-4178-bf27-e857b42eb944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5147d390-8c30-4142-9cf4-fc5daea5d114" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4a510676-7bfa-4178-bf27-e857b42eb944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3e6ca796-7df4-4be7-9c09-91bc1382e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3e6ca796-7df4-4be7-9c09-91bc1382e8fc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:to="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_550d42b0-93e6-4027-b8d1-f8496b20ed7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_03add398-d750-4a59-a948-f0b55756b7d4" xlink:href="exel-20211001.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_16f872e8-7ae3-4515-a4fe-04caaef4f9a7" xlink:to="loc_exel_GlaxoSmithKlineMember_03add398-d750-4a59-a948-f0b55756b7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e713e669-2a3c-4592-aa76-9a31823f6336" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_f0b6182c-7a54-4e5e-ad10-54d99657b59c" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a558060-1383-4fe7-b930-bf4126c46669" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_f0b6182c-7a54-4e5e-ad10-54d99657b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a53b21a-d35e-4328-9a8e-b81fc4205ef4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_94b58ace-8dde-462f-b933-ddd8aa1591b0" xlink:href="exel-20211001.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_94b58ace-8dde-462f-b933-ddd8aa1591b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_3d749e1f-a3c5-41fc-9365-72feabfb2873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86f69f9b-a31d-4756-869f-479e7bf264d7" xlink:to="loc_us-gaap_RoyaltyExpense_3d749e1f-a3c5-41fc-9365-72feabfb2873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2506d89c-473f-4960-bde0-c6efb28ea4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2506d89c-473f-4960-bde0-c6efb28ea4b6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a0e9172-0728-4f2e-aac7-c45a03234ad7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_8bb144f7-558a-46e8-b11a-601f77f0ee75" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6af7e3f1-04bf-475f-a89f-db2e8d351686" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_8bb144f7-558a-46e8-b11a-601f77f0ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:to="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d1044aac-b6c0-46bb-8b46-137deb6315f2" xlink:to="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_62ddbbd4-4f5e-4a44-a008-67114a7f2343" xlink:href="exel-20211001.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_600bf245-dac0-4b29-925c-1b9a04294eed" xlink:to="loc_exel_CotellicMember_62ddbbd4-4f5e-4a44-a008-67114a7f2343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_64db3a0b-2896-4b94-a6c5-15a5c505d45a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_7569ad4f-fbe1-48b8-b684-b478af70190a" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_7569ad4f-fbe1-48b8-b684-b478af70190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b62d0b81-35f5-4eae-8aac-bf14084cc91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3269dc7-8225-4e50-9273-9839e0de0661" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b62d0b81-35f5-4eae-8aac-bf14084cc91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce4d8efa-2f63-4e88-90c3-bd4eb2dbcbce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce4d8efa-2f63-4e88-90c3-bd4eb2dbcbce" xlink:to="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c8c36d64-1021-4def-8064-ca0132b9a371" xlink:to="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_6d3a1bc9-4d5c-4619-bb10-a2a756426c86" xlink:href="exel-20211001.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_05a336db-7e32-4159-8a11-8036193ac409" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_6d3a1bc9-4d5c-4619-bb10-a2a756426c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_8dfd6ff9-4857-4a5c-ad05-d26900351df3" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4a0e8f81-d881-4a49-b9d0-79214e6886a6" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_4a0e8f81-d881-4a49-b9d0-79214e6886a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_74b817e6-8e54-405f-aef1-f7c7d70de54f" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_74b817e6-8e54-405f-aef1-f7c7d70de54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_45025c33-aca6-4b22-9f37-ddf675129a4e" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_45025c33-aca6-4b22-9f37-ddf675129a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_59be3a95-2990-4456-af25-8a4996177fb5" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_59be3a95-2990-4456-af25-8a4996177fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_b1fe8b8e-899e-44c8-9cf7-6b524c1d62e8" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments_b1fe8b8e-899e-44c8-9cf7-6b524c1d62e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_ab8bfb64-ef25-4e9c-ac07-62696236fe11" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets_ab8bfb64-ef25-4e9c-ac07-62696236fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_c6570363-397c-4b3e-9c94-7db2fdec8746" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments_c6570363-397c-4b3e-9c94-7db2fdec8746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_32cc78be-ca8e-4751-8c1e-0ad64bac2c20" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm_32cc78be-ca8e-4751-8c1e-0ad64bac2c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_7450784d-ea3d-4a97-af67-13784a3e25a7" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment_7450784d-ea3d-4a97-af67-13784a3e25a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_0efaeef0-5f66-45dc-a6ea-b26520c16074" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment_0efaeef0-5f66-45dc-a6ea-b26520c16074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_a5769474-657e-4c45-81f0-4df7cb07fc82" xlink:href="exel-20211001.xsd#exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment_a5769474-657e-4c45-81f0-4df7cb07fc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff02d23b-2533-4904-9fb1-cc0a1d4dc5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_ff02d23b-2533-4904-9fb1-cc0a1d4dc5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_d17101e8-455a-4645-a713-8a3ec83ced6c" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_d17101e8-455a-4645-a713-8a3ec83ced6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_0bacaacc-0706-4c4b-ba91-705060961559" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_0bacaacc-0706-4c4b-ba91-705060961559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_7a13253a-731e-40a9-a7c9-5e9a287277d8" xlink:href="exel-20211001.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_28e02aaa-4efc-4e9b-9749-624f6738098e" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_7a13253a-731e-40a9-a7c9-5e9a287277d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25676e2d-d204-4879-8f4c-9f0d89d0424d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_404c3ac4-c7bc-430c-a1fb-13a3ab8368d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25676e2d-d204-4879-8f4c-9f0d89d0424d" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_404c3ac4-c7bc-430c-a1fb-13a3ab8368d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9af7456f-05c1-4d69-a6b1-840b87cab2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9af7456f-05c1-4d69-a6b1-840b87cab2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_9e76cef3-65ce-4288-ae36-87f3af537194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_9e76cef3-65ce-4288-ae36-87f3af537194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_b5f54b68-0e70-4f94-bd5d-9094e9119886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_b5f54b68-0e70-4f94-bd5d-9094e9119886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1e779ca4-606f-49f2-966e-8f052eff4e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1e779ca4-606f-49f2-966e-8f052eff4e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c60217fc-6db5-4b63-973b-5898c4208975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b25f508-ae5f-45fd-80cd-2859d143f878" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c60217fc-6db5-4b63-973b-5898c4208975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc583d6-d299-4de5-b3cb-c0f59bfc24b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_640cccba-7900-4971-9122-50f2212c90c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc583d6-d299-4de5-b3cb-c0f59bfc24b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_640cccba-7900-4971-9122-50f2212c90c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d2e0f75f-7e09-4ea8-aefd-2d0c8da83255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_640cccba-7900-4971-9122-50f2212c90c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d2e0f75f-7e09-4ea8-aefd-2d0c8da83255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_e5fe6eef-303d-4539-9222-a67fe2624f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_640cccba-7900-4971-9122-50f2212c90c9" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_e5fe6eef-303d-4539-9222-a67fe2624f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3ac1877-cd5c-46ee-9fd5-061718f17864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_640cccba-7900-4971-9122-50f2212c90c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3ac1877-cd5c-46ee-9fd5-061718f17864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38ff083d-5fe7-4686-bd7b-0de0e0aa7adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_3daf27e7-2c32-4f96-802e-468309238af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38ff083d-5fe7-4686-bd7b-0de0e0aa7adc" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_3daf27e7-2c32-4f96-802e-468309238af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_8ac060c3-3997-40ae-b250-738a2747b7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38ff083d-5fe7-4686-bd7b-0de0e0aa7adc" xlink:to="loc_us-gaap_InterestReceivable_8ac060c3-3997-40ae-b250-738a2747b7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1d26b2a4-32d3-4010-ad22-b68ffd02ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38ff083d-5fe7-4686-bd7b-0de0e0aa7adc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1d26b2a4-32d3-4010-ad22-b68ffd02ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d23a2188-8441-4905-a6e3-0ad556f01103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38ff083d-5fe7-4686-bd7b-0de0e0aa7adc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d23a2188-8441-4905-a6e3-0ad556f01103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e28a9411-d6c4-41ea-a315-784a5e34f313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e28a9411-d6c4-41ea-a315-784a5e34f313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7615dcf5-5d23-4aa1-9d2d-9f28d46f0596" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c7b58f19-a739-4be1-a48b-5248abb15193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CommercialPaperMember_c7b58f19-a739-4be1-a48b-5248abb15193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_14d6926b-ff6f-435e-902f-fc85a99c380b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_14d6926b-ff6f-435e-902f-fc85a99c380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_fdef20a8-864c-44a5-abb1-f4e7f80a3256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_fdef20a8-864c-44a5-abb1-f4e7f80a3256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_701d49ec-0d8d-44a8-a17b-dcd03f567837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_MunicipalBondsMember_701d49ec-0d8d-44a8-a17b-dcd03f567837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_98b4dc59-7ddf-4d74-86b8-c92049c72b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CashMember_98b4dc59-7ddf-4d74-86b8-c92049c72b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2a202197-8cc3-4479-bef9-80e459fb9212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2a202197-8cc3-4479-bef9-80e459fb9212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_00d15193-b2e9-4028-8afb-4482615f923d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81be6309-637a-4727-9a49-601056218617" xlink:to="loc_us-gaap_CertificatesOfDepositMember_00d15193-b2e9-4028-8afb-4482615f923d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d9fe99f6-2ee4-4879-814d-adef39e4a1e9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3de1f27c-d248-4f9a-bac4-aafad389d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3de1f27c-d248-4f9a-bac4-aafad389d8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73400a08-702a-4bbd-872c-e86045692a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_73400a08-702a-4bbd-872c-e86045692a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4eb0fb17-5b93-45eb-ba38-0adde11bfbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4eb0fb17-5b93-45eb-ba38-0adde11bfbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7bceba3-00bb-4e95-8f5d-d56da6ce10ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0946edd0-b5f3-48ad-948b-5fc0c3c5f47f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7bceba3-00bb-4e95-8f5d-d56da6ce10ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1988dd92-237d-4cf5-a6e0-151900acd5d0" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1988dd92-237d-4cf5-a6e0-151900acd5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_584f9d87-ea4e-463e-88c9-606c4ae42e57" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_584f9d87-ea4e-463e-88c9-606c4ae42e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4d6bfb36-01c4-42cd-ac54-8c9ffea395a1" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4d6bfb36-01c4-42cd-ac54-8c9ffea395a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d60dcea3-fede-40d9-8e33-34d38ec6ebc7" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_73ffb806-4444-4200-a9df-8e49a31045b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_d60dcea3-fede-40d9-8e33-34d38ec6ebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3c436022-3cdc-44d3-a474-1d8fb4831758" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3c436022-3cdc-44d3-a474-1d8fb4831758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c954cb0-5b6a-4db3-90b5-b88bb993fd7c" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c954cb0-5b6a-4db3-90b5-b88bb993fd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7657fce3-3138-4f2d-b06d-bef5016c66dc" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7657fce3-3138-4f2d-b06d-bef5016c66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_f5899872-ceb4-4ea3-815c-94547f004466" xlink:href="exel-20211001.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ae214e4c-af9a-447d-9bd1-52ae6615f8a5" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_f5899872-ceb4-4ea3-815c-94547f004466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3da98a9-a0dd-45ab-aa60-119193983d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e3da98a9-a0dd-45ab-aa60-119193983d0e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_74f7cebd-d542-4d6e-b4d8-5e2f73eff09d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d6381ea0-93e2-4ef4-bfd7-e1f39a400635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_CommercialPaperMember_d6381ea0-93e2-4ef4-bfd7-e1f39a400635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8d9ddb4a-5329-45a4-ab5c-481259f51609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8d9ddb4a-5329-45a4-ab5c-481259f51609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3c089cb5-cae1-4c59-8349-727504ef7653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3c089cb5-cae1-4c59-8349-727504ef7653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_9da6dc51-6f0d-4786-b10a-0c9b702645ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92e60c83-4cf8-4c25-abc3-79d042af95a0" xlink:to="loc_us-gaap_MunicipalBondsMember_9da6dc51-6f0d-4786-b10a-0c9b702645ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5b030daa-f466-4e28-9fcb-bcf856603be6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08ea0da0-a162-4d83-ade5-80d84e416b7e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c1fed901-afb8-429c-a9ce-3a34bb65578e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c1fed901-afb8-429c-a9ce-3a34bb65578e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7e159683-06cd-424d-96de-5791b4ad9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_fc53ad02-595f-494b-9931-1dbf91f2b8d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7e159683-06cd-424d-96de-5791b4ad9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205550a6-b6a3-40d6-be61-9d1c74d9a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e85ec8da-8d32-44c2-bb59-b8edc2ecbf0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205550a6-b6a3-40d6-be61-9d1c74d9a6e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e85ec8da-8d32-44c2-bb59-b8edc2ecbf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1cb43557-fe97-4a81-aee8-01f193f04e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205550a6-b6a3-40d6-be61-9d1c74d9a6e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1cb43557-fe97-4a81-aee8-01f193f04e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0afd1d76-8624-44a8-8815-e282be602aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_205550a6-b6a3-40d6-be61-9d1c74d9a6e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0afd1d76-8624-44a8-8815-e282be602aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a4dcc277-99b2-490d-92e5-bae8db8c25ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2d855606-e58e-4dc5-a80e-0705d0ce5ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a4dcc277-99b2-490d-92e5-bae8db8c25ec" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2d855606-e58e-4dc5-a80e-0705d0ce5ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0431e00b-7b67-439b-aede-c0ed707fdd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9252f415-ee6a-4b5d-a6b4-b9eb2ab234d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0431e00b-7b67-439b-aede-c0ed707fdd00" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9252f415-ee6a-4b5d-a6b4-b9eb2ab234d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_53e1f80a-c1c2-49bf-963b-faa6092b0c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_53e1f80a-c1c2-49bf-963b-faa6092b0c26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f88820cc-26a6-43c0-b92e-4bb13ae939e6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c9a94109-4d99-4168-95c8-ef98c6677c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CommercialPaperMember_c9a94109-4d99-4168-95c8-ef98c6677c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_63a52db9-2d79-47e8-80b1-1fa60612e052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_63a52db9-2d79-47e8-80b1-1fa60612e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f874003b-a1ac-40d9-bf48-472e47a23682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f874003b-a1ac-40d9-bf48-472e47a23682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_16f1ba81-bf82-4d76-90b7-43f378677079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_MunicipalBondsMember_16f1ba81-bf82-4d76-90b7-43f378677079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_842caab8-9c2e-4958-9b9b-34ce365e3937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_MoneyMarketFundsMember_842caab8-9c2e-4958-9b9b-34ce365e3937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_fd930319-4c36-4a3b-ae9d-a364f78b121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77752673-9469-4316-bc10-cd2225449a77" xlink:to="loc_us-gaap_CertificatesOfDepositMember_fd930319-4c36-4a3b-ae9d-a364f78b121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2768bca7-f813-49a8-a832-51a499b3a76f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05253d1a-ce95-4460-8160-41d7a11f6179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05253d1a-ce95-4460-8160-41d7a11f6179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8edfe879-1799-4db9-9096-faa309f1a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d6e9111-4965-4183-9888-c5269a0a1c6c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8edfe879-1799-4db9-9096-faa309f1a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f23828fc-24b4-4f4b-8aae-8fd764717338" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fde17965-fb8c-40f2-89b2-4f7b5a0e4df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7de677f6-b213-4276-b3e4-5624e5d2f36b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fde17965-fb8c-40f2-89b2-4f7b5a0e4df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_be3319eb-3e0c-43e4-98ee-71de8ab2df56" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_678fd585-2caf-4727-b261-0a76362f6512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_678fd585-2caf-4727-b261-0a76362f6512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_974a68d3-869b-4a1c-a432-f641cd4842b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_974a68d3-869b-4a1c-a432-f641cd4842b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bfc25e10-c6d2-45d7-9415-a3b0800fcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_77d5e4a5-e25f-4439-9350-e98833e43538" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bfc25e10-c6d2-45d7-9415-a3b0800fcb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_735eacd9-78b9-49af-b74f-b2a7e39384ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_735eacd9-78b9-49af-b74f-b2a7e39384ce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4f6f8fcd-ebc9-4295-bdde-37b12dfbc799" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_4a13cda0-6361-47a8-9a85-694af6c2d858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_43fb2293-63f4-4ecf-821e-f51b1e2ae1f8" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_4a13cda0-6361-47a8-9a85-694af6c2d858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc6dc84-b414-435f-887d-3dcc2ba8c002" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_09726286-22a3-421c-802b-c5952fe55060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_09726286-22a3-421c-802b-c5952fe55060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_432d2f96-cc81-4327-87c4-062e5ed8512a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeNotionalAmount_432d2f96-cc81-4327-87c4-062e5ed8512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_91564457-e95e-48a7-8f89-e1bf5deb4996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_DerivativeTermOfContract_91564457-e95e-48a7-8f89-e1bf5deb4996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d6e00b40-98ad-4a73-993a-a48331f5862b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc7431-4712-4818-ad06-f38139658598" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_d6e00b40-98ad-4a73-993a-a48331f5862b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20211001.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_946c5e80-610a-4ed4-8c36-49e02a9b2590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3d0fc7d5-c3f2-48ce-bd7b-2917e54ecdff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_946c5e80-610a-4ed4-8c36-49e02a9b2590" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_3d0fc7d5-c3f2-48ce-bd7b-2917e54ecdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20211001.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_295fb2a9-d862-4974-850a-2ee133be6db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0cd4ea2b-a3ca-4d6b-9e19-13428d08d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_295fb2a9-d862-4974-850a-2ee133be6db0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0cd4ea2b-a3ca-4d6b-9e19-13428d08d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_961bd7c8-fe4f-45fc-a023-989cbac9e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_961bd7c8-fe4f-45fc-a023-989cbac9e1ee" xlink:to="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_52f85994-4289-47b6-b46b-f557f986a192" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_098206d6-9148-4179-b46d-5398ba44d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:to="loc_us-gaap_InventoriesMember_098206d6-9148-4179-b46d-5398ba44d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_18f2f6c0-5ced-4b73-9460-6f3531d960a3" xlink:href="exel-20211001.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bd702e57-9ddc-4ff8-ad9c-bb67a1a763d4" xlink:to="loc_exel_OtherLongtermAssetsMember_18f2f6c0-5ced-4b73-9460-6f3531d960a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_3d4e76d0-ee2e-48c5-8ad7-df5b84aafa0c" xlink:to="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2801d118-69b8-40b7-b5fd-39c9c9d76f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryRawMaterials_2801d118-69b8-40b7-b5fd-39c9c9d76f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_30b2dc1c-10c9-4b86-a2d3-d4b90a5856ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryWorkInProcess_30b2dc1c-10c9-4b86-a2d3-d4b90a5856ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_63ca4dba-f3d4-49ab-b954-b348201d3382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryFinishedGoods_63ca4dba-f3d4-49ab-b954-b348201d3382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ede9a70a-93a5-4140-9532-9b9753c8a727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_374e7a09-8975-4fe9-8b4d-84051c9ce822" xlink:to="loc_us-gaap_InventoryGross_ede9a70a-93a5-4140-9532-9b9753c8a727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5fefd96-a05f-4021-87ea-d8d37c910750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a203a0f8-be88-4733-95e9-3db9e4df3bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5fefd96-a05f-4021-87ea-d8d37c910750" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a203a0f8-be88-4733-95e9-3db9e4df3bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a62e3672-d652-455c-b8e6-12300700ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_457d2fab-55ad-4fb6-8d39-5498ca9b4d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a62e3672-d652-455c-b8e6-12300700ad6c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_457d2fab-55ad-4fb6-8d39-5498ca9b4d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_4d21c2be-72da-43de-9972-1d16e0f91c89" xlink:href="exel-20211001.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a62e3672-d652-455c-b8e6-12300700ad6c" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_4d21c2be-72da-43de-9972-1d16e0f91c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba73ea68-fe32-481c-8ecf-e9ee7d6aae90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba73ea68-fe32-481c-8ecf-e9ee7d6aae90" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b0516043-c391-43c5-b989-e74c090a5817" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2db4aab-866e-4d0b-9f88-5fd09656521b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2db4aab-866e-4d0b-9f88-5fd09656521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_930c2484-6713-46e9-9e29-f791a7766076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79e5d00f-dcc5-45f8-a09a-da1f20830ed4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_930c2484-6713-46e9-9e29-f791a7766076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c69b90ef-9c66-4c4f-b674-c782d2175c6b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e12bd786-9d46-4843-b566-7277dfc21101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c49d9ae3-62eb-450b-8664-1175ec6f9af8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e12bd786-9d46-4843-b566-7277dfc21101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1f759fa-6e24-4015-bdff-1fae3ce82f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1f759fa-6e24-4015-bdff-1fae3ce82f4f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:to="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1892d701-7939-4dc4-a608-54b6c2242fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eba8e878-c32a-43cc-a789-1f4773ee46bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eba8e878-c32a-43cc-a789-1f4773ee46bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_96ad7ced-c455-4d59-981b-a4e5c5fde6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_96ad7ced-c455-4d59-981b-a4e5c5fde6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c995f85c-9e64-4f96-8936-4cf39a4ad139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_PerformanceSharesMember_c995f85c-9e64-4f96-8936-4cf39a4ad139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2f846c2c-fd82-4664-9d1c-dcbf8c034071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56c79fdd-ed21-48a3-bbbe-b6852df0ebaf" xlink:to="loc_us-gaap_EmployeeStockMember_2f846c2c-fd82-4664-9d1c-dcbf8c034071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d29b05d-3949-47cc-82fe-133bd13e0760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f5a7d41-90a5-4584-8c21-4138a1600d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_44a60eac-c8d5-4665-a9b6-5f6f2754901a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f5a7d41-90a5-4584-8c21-4138a1600d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5eea16ea-846b-4627-86de-388faabe04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5eea16ea-846b-4627-86de-388faabe04b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_51e683fd-7218-4671-977c-c7de9d282218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecf1f2ec-a4e2-43e5-8c20-4b92e6c39099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecf1f2ec-a4e2-43e5-8c20-4b92e6c39099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_89b2b96a-46dd-4f46-bad8-bfc74fd95f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_89b2b96a-46dd-4f46-bad8-bfc74fd95f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_48e4b467-89ce-47e2-a81d-2c00b32722cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c55d617f-2571-4d68-8720-8629ca75d16e" xlink:to="loc_us-gaap_PerformanceSharesMember_48e4b467-89ce-47e2-a81d-2c00b32722cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:href="exel-20211001.xsd#exel_StatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:href="exel-20211001.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_7c36c6ed-e6bf-4260-bd66-f310b0a820a7" xlink:to="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_7a071356-d4fe-4410-8b7d-b84ffc6be059" xlink:href="exel-20211001.xsd#exel_AchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_AchievedMember_7a071356-d4fe-4410-8b7d-b84ffc6be059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_c0901ff1-2ea8-43fd-b457-1a2cd8243ae4" xlink:href="exel-20211001.xsd#exel_ProbableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_ProbableMember_c0901ff1-2ea8-43fd-b457-1a2cd8243ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedAndProbableMember_5753eabc-b327-406a-b616-bf3984619ca5" xlink:href="exel-20211001.xsd#exel_AchievedAndProbableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6fc61c92-1bc8-4347-bc29-fc93570ef03c" xlink:to="loc_exel_AchievedAndProbableMember_5753eabc-b327-406a-b616-bf3984619ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_005fce61-e01a-47db-8d5c-37970d872f5e" xlink:to="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_288fe787-4336-4160-b0fa-5b9a7407f99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_288fe787-4336-4160-b0fa-5b9a7407f99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7310bd1-9f41-4909-ac8e-38fa2d6405c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_dcb5721e-443c-491f-ae92-6e600e47ddf6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c7310bd1-9f41-4909-ac8e-38fa2d6405c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf88ff-8d1e-42d2-9097-e84eaba1b45d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7d69bd0d-9b6c-4440-a28c-85cf4862c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7d69bd0d-9b6c-4440-a28c-85cf4862c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_33b14fcd-9994-42e4-8202-4fb6c23602fa" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_33b14fcd-9994-42e4-8202-4fb6c23602fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_510b24cc-5e8d-461d-b90c-5dcfa3d4fcbe" xlink:href="exel-20211001.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_510b24cc-5e8d-461d-b90c-5dcfa3d4fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_07aeffaa-e781-4a94-9c44-f3089556551c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_07aeffaa-e781-4a94-9c44-f3089556551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862cf231-b2f3-45b0-a2b6-7836b690f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862cf231-b2f3-45b0-a2b6-7836b690f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a7da83e-4a69-4331-8e99-178b0f0e22a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a7da83e-4a69-4331-8e99-178b0f0e22a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec586965-da6d-4c5a-9482-ddb4fc082cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec586965-da6d-4c5a-9482-ddb4fc082cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75f3f60b-2bc4-4b4a-8dec-45ee99ce62fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_75f3f60b-2bc4-4b4a-8dec-45ee99ce62fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c427f972-1c67-4bd5-90e1-c24e3e7bc74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c427f972-1c67-4bd5-90e1-c24e3e7bc74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e004e483-76c2-4b1f-9838-75c980f0274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e004e483-76c2-4b1f-9838-75c980f0274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_48609c9c-831b-4298-94d6-bd66accaa6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_48609c9c-831b-4298-94d6-bd66accaa6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_1b827fe8-50bb-45ce-9c36-404b4ecfd76a" xlink:href="exel-20211001.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_1b827fe8-50bb-45ce-9c36-404b4ecfd76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0668650f-aa36-409a-9fc9-e9c924a80343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0668650f-aa36-409a-9fc9-e9c924a80343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_404e4b5a-a682-4427-b3c1-f7452f2e8793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_404e4b5a-a682-4427-b3c1-f7452f2e8793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a388e428-a889-4aec-95eb-3b6eb6c45a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_793e891d-5f32-410b-b7e4-500a8f3f6356" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a388e428-a889-4aec-95eb-3b6eb6c45a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd807963-afd8-49f2-8829-d9ee33707e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd807963-afd8-49f2-8829-d9ee33707e47" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:to="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b0719c9c-576e-4f62-92da-1feed392d1e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7f7b1242-d2b2-4d5d-a0dc-fadffda6b1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bcc1ada-87cc-4c15-b79d-16b30d26ba4d" xlink:to="loc_us-gaap_PerformanceSharesMember_7f7b1242-d2b2-4d5d-a0dc-fadffda6b1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca3f1246-9e7e-4113-8241-729b3c041c66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_663100f3-cfa0-4bfd-8348-7d39fb8f79a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_663100f3-cfa0-4bfd-8348-7d39fb8f79a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0b687fc9-551f-4d31-bf08-ef7372f879fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_SharePrice_0b687fc9-551f-4d31-bf08-ef7372f879fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ad1f08ac-2a23-4f4f-920f-b6a5b9f33fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_ad1f08ac-2a23-4f4f-920f-b6a5b9f33fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_de6a3528-d47a-428d-87f9-0f092ff3290f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_de6a3528-d47a-428d-87f9-0f092ff3290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c0ef57d7-02d3-4a4d-afc7-56bec0f0de0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1793a962-40d3-4a52-ab8f-f1ab445203e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c0ef57d7-02d3-4a4d-afc7-56bec0f0de0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20211001.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1cb1a0-b923-42a1-b532-b8e5bd98966d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99128abf-1552-4e32-b341-67da2184b4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1cb1a0-b923-42a1-b532-b8e5bd98966d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_99128abf-1552-4e32-b341-67da2184b4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#ProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87d2c945-8852-4b09-bbe4-34fc8d880e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a1c45178-bb28-4d06-a8cd-d55e62513613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87d2c945-8852-4b09-bbe4-34fc8d880e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a1c45178-bb28-4d06-a8cd-d55e62513613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d24fb5d1-96b1-4e31-9658-0f69c923f7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7f6f55c9-bdad-438e-8ad3-3056a4311391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d24fb5d1-96b1-4e31-9658-0f69c923f7f3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7f6f55c9-bdad-438e-8ad3-3056a4311391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_99a3759f-13c8-47b6-b38b-9c0fe5e397e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7eab2d48-2c24-4b47-8705-f4380d446cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99a3759f-13c8-47b6-b38b-9c0fe5e397e4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7eab2d48-2c24-4b47-8705-f4380d446cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d3ca10e-762f-4856-a445-76886f5d89b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99a3759f-13c8-47b6-b38b-9c0fe5e397e4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d3ca10e-762f-4856-a445-76886f5d89b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57633e58-45ea-4726-90ae-2fc2fafef4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_aaae3768-e2fc-4acd-a5c5-70a49120f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57633e58-45ea-4726-90ae-2fc2fafef4a5" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_aaae3768-e2fc-4acd-a5c5-70a49120f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dd055629-6393-41e3-9ee6-a88ba82c4d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_aaae3768-e2fc-4acd-a5c5-70a49120f27a" xlink:to="loc_us-gaap_NetIncomeLoss_dd055629-6393-41e3-9ee6-a88ba82c4d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e7191555-59eb-4f22-9323-c64827019e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57633e58-45ea-4726-90ae-2fc2fafef4a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e7191555-59eb-4f22-9323-c64827019e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_034892c8-a129-4dbd-a3c1-99b92a4f13c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e7191555-59eb-4f22-9323-c64827019e47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_034892c8-a129-4dbd-a3c1-99b92a4f13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_939b772f-af8d-4904-8417-0172e0732a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e7191555-59eb-4f22-9323-c64827019e47" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_939b772f-af8d-4904-8417-0172e0732a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19b6a346-b31e-4122-bdcb-8f9046145a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e7191555-59eb-4f22-9323-c64827019e47" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19b6a346-b31e-4122-bdcb-8f9046145a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_83dc78cc-9cd1-4fe9-baec-eac9d168f238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57633e58-45ea-4726-90ae-2fc2fafef4a5" xlink:to="loc_us-gaap_EarningsPerShareBasic_83dc78cc-9cd1-4fe9-baec-eac9d168f238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4bbf8164-3c3e-4c12-860d-c8b849ef7bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57633e58-45ea-4726-90ae-2fc2fafef4a5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4bbf8164-3c3e-4c12-860d-c8b849ef7bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20211001.xsd#NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89cc5633-7a07-4c3e-9962-b53d5162a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89cc5633-7a07-4c3e-9962-b53d5162a14e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_37a7485b-d682-44cf-88e2-6ac8801d7ceb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_ee43df9c-9fc0-4353-a9b5-1e501d7c9750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa690866-afaa-43cf-8bfa-8f8b9fba600c" xlink:to="loc_us-gaap_StockCompensationPlanMember_ee43df9c-9fc0-4353-a9b5-1e501d7c9750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_055b32ee-3f53-453b-830d-602aafa6c9ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_029b1ad1-d136-4bbb-8c3a-3f55f0ad56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eebbcd58-49d0-428d-b487-c6bc3a050c17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_029b1ad1-d136-4bbb-8c3a-3f55f0ad56cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20211001.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ee5f481-109c-4fa5-bd81-83e7e2ac97df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c79de826-3507-4f0f-991c-b0e569a7ae8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ee5f481-109c-4fa5-bd81-83e7e2ac97df" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c79de826-3507-4f0f-991c-b0e569a7ae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>exel-20211001_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exel-20211001_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
M@JQ^WY_PM?6KCX;^#[[=X8TR;;J]Y"WRZI<(?]6I'WH8V'7H[C(R%4GY7B_B
MK#9#@'BZ^LGI"/64O\ENWT7G9/[KP]X$QO%6:QR_#>[!:U)VTA'J_5[175^2
M;7DW_!0;]MN^_:]^)NRRDFMO!>ANT>DVA!4SGHUS(/\ GHXZ _<7 X)8M\^4
M45_%N:YIB<QQ4\;BY<TYN[?Z+LDM$NB/]*,AR/!Y/@*66Y?#EI4U9+\VWU;>
MK?5ML****\\]8***^C/^"9G[*O\ PTS^T+;2ZC;^;X6\*;-1U3>N8[AMW[FW
M/_71E)([HC]\5Z64977S+&4\#AE>=1I+]6_)+5^2/'X@SS"Y-EM;-,8[4Z47
M)^?9+SD[)>;1]W?\$K/V5?\ AGO]G^+6=4M_+\4>-%CO[H.N'MK?!,$/J#M8
MNPZAG(/W17U%117]S9+E-#+,#3P&'^&"MZ]V_-N[?FS_ "[XDX@Q6=YG6S7&
M/WZLFWV2V45Y15DO)!1117J'AA1110 4444 %?,O_!8K_E''\1O^X;_Z<[2O
MIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/F]JZ?X*_
M\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "J^K:K:Z#I5S?7UQ#
M9V=G$T]Q/,X2."-069V8\!0 22> !5BOSE_X+G?MM2>%M#@^#OAV[\N]U:);
MOQ'+&?FBMR08K;/8R8WL.#M"#D.13BKNPF[(^4O^"FW_  4!OOVS_BJUEI,]
MQ;_#_P /3,FDVIRGVU_NM>2K_>;D*",HAQP6?/S#\WM1\WM1\WM72E96,-P^
M;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?
M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
M/F]J/F]J/F]J/F]J #YO:CYO:CYO:ON?_@GU_P $;=7_ &A=)L?&7Q$FO/#?
M@^Z"SV-A" NH:O'U#G(/DPL.C$%V'("@JY3E8:5SXG\,>%-5\;:U#INBZ;J&
MK:C<'$5K96[W$TI_V40%C^ KZ(^&/_!(;X]_$V*&8>"VT"TFQB;6KR*S*9_O
M1$F8?]\5^S7P5_9W\#_LZ^'1I?@KPSI/AZUVA9#;0_OKC'0RRG,DC>[L37:5
MDZG8OV?<_)#PW_P;[?$R\B#:IXR\#Z>2,[;=KJY*].#F)!ZYP3^.:U?^(>CQ
ME_T43PS_ . 4_P#C7ZM45/M&5R(_)?6/^#?#XBP*?[/\<>"KIMN0+A;F#YO3
MY8WX]_TKA?%W_!#+X[>&T8V=KX5\0%<X%AJX0M]/M"1=??%?M%13]HPY$?@!
M\0O^"=WQO^&0D;5OAEXJ,<9(>2QM?[0C3'4EK<R*![YQ7C^H:;<:/?26MY;S
M6MU"=LD4R&.1#Z%3R*_I?KFOB-\&_"7Q?T[[+XJ\,Z#XCM]I54U*PBN=@_V=
MZDJ>^1@@TU4[D^S/YO\ YO:CYO:OV9^.'_!#GX.?$V.6?PVNL> ]0;)5K"X-
MS:%CW:&8L<>R.@KXG_:)_P"")_Q>^#*W%[X?AL_B!I$.6#Z5F.^51W:V?YB?
M]F)I#S5JHF2XM'Q]\WM1\WM5G6M$O/#>JW%AJ%I=:??6CF.>WN8FBEA<=596
M ((]",U6^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU)_X(J_
M\$^!X:TJV^,?C"Q_XF%_&?\ A&+.=.;:%N#>D'^-QD1^B$MSO4KX;_P2T_X)
M?7W[27B2R\=>-K*:S^'NFS++;VTR%7\12*<A%!_Y=P?OO_%RJ_Q,G[%6]O'9
MP1PPQI%#$H1$1=JHHX  '0"LJDNB-(QZLDHHHK$T"BBB@#XK_P""Q?[!EQ^T
MQ\,H/&WA:R:Y\:>#X&#V\2YEU6QR6:)1WDC)9T Y;+J,EE%?&_\ P2O_ ."E
MDG[(WB%O!OB]YKCX?:Q<[_-P7DT&=L RJO5HFXWH.1C<O.Y7_9RO@G_@HS_P
M1TM?CKJFH>./AC]CTGQ;=%I]0TB5A#9ZN_4R1MTAF;OGY')R2AW,VD9+9DRC
MK='3?\%!_P#@GS<_\%'=5\&^+/"/C7P_:Z38Z;)%%,R-<Q7B2.'62-XS@CJ/
MP_+WS]BG]G>Y_92_9D\,> ;S4X=8N=!%SYEW#"8HY3-=37'"DDC;YNWD\[<\
M9P/QK^%G[2?QP_X)P^-KK0[>35_#;K+ONM!UFU,EE<$'!<1OQAL?ZR(J6 'S
M$8KZV^'G_!PVJV"1^+/AJ6NE4;KC2=4Q'(?:*1"5_P"_C=?;D<96LB5)7N?I
ME7YT_M3?\$+KGXM?'?7O%'@WQ5HOAS2-=G^W?V=<6DC?99WYEV%#C87RP&!M
MW;1P!3?%'_!PWX;M[*0Z+\-M<O+C'R"]U.*V3..I*)(>#V[CTKY9_:._X*S_
M !D_:G1M!L[I/"VCZ@Q@&F>'TD2>\#<"-Y<F5\YP50JK9Y4T1C)#E)'TE^W=
M_P %++[X"? :S^#WAWQA;^+_ (CP6 TOQ)XJL%,<5H%&QU0[FS=,O#NK?(VX
M_*_RIYW_ ,$5_P!@ZZ^*/Q&M?BMXEL9(_#'AF??HJ2I@:G?(>)%SUCA/.1P9
M H!.QQ1^P;_P17\2?%#5+'Q+\5K6Z\,^&(W65-%?,6I:F!SMD'6WC/0YQ(1D
M )D/7ZP>%?"NF^!_#=CH^CV-KINE:;"MO:VMO&(XK>-1A551P !1*22LA)-N
M[-"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
M8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4?-[4P#YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH _H%_X)^_\F0_"K_L6+'_T2M>P5X__ ,$_?^3(?A5_V+%C_P"B
M5KV"N0WCL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ H90ZX/(/4>M%% 'X[?\%?O^"=_P#PSGXWD^(/A&QV
M^!?$5Q_I=O"GR:)>.2=N!]V&0Y*=E;*<#8#\1_-[5_27\0_A]H_Q6\#ZIX;\
M06,.IZ+K-NUK=VTH^65&]^H(X((P00",$ U^$/[>G[%NL?L3_&NXT&Z\Z\\/
MZANN=#U)E^6\M\_=8CCS8\A7'KA@ K+6U.5]#.4>IXE\WM1\WM1\WM1\WM6I
MF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5[+^PK^V/K7[%7QNM?$EC
MYUWHMYMM=;TU6XO[;.3@'@2)RR-Q@Y&=K,#XU\WM1\WM2W _I)^&WQ'T7XN^
M ]*\3>';^'4M%UJW6YM+F(\2(?4=0P.5*G!5@0<$$5N5^-G_  2+_P""AQ_9
ME\>+X'\6WQ7P%XDN (IYG^31+ML 2Y/W87X#]E.'XPV?V35@ZY'(/0^M<\HV
M-HRN%%%%24%%%?'_ /P5C_X*$K^R9\-O^$7\,WB?\+"\3VY\AD8%M&MCE6NB
M/[YPRQ@_Q!FYV8+2N[!L?/7_  6E_P""A_\ ;U_>?!OP9??Z#:.%\47L#_Z^
M53G[$K#^%3@R8ZL G\+@_F_\WM2SSO<S222.TDDC%F9CEF)Y))]:3YO:NF,;
M*Q@W</F]J/F]J/F]J/F]J8@^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO
M:N__ &8_V</$/[5GQETKP9X;AW7>H-ON+EE)AT^W4CS+B3_94$>[$JHR6 /&
M>'O#M]XNU^RTK2[.XU#4M2G2VM;:!"\D\KD*J*HY))( 'O7[E_\ !-G]A&Q_
M8G^#:QWBP77C;Q J3ZY>)AA&1DK;1M_SSCR>?XF+-TP!$Y6148W/5/V<?V?/
M#W[+WP@TGP;X9MS'I^F1_O)G \Z]F;F2>0CJ['D]@, 8  '=445SFP4444 %
M%%% !1110 4444 %?F__ ,'$/_(F?"W_ *_-1_\ 0+>OT@K\W_\ @XA_Y$SX
M6_\ 7YJ/_H%O51W)EL?EU\WM1\WM1\WM1\WM728A\WM1\WM1\WM1\WM0 ?-[
M4?-[4?-[4?-[4 'S>U?IG_P;I]/C%_W!?_<A7YF?-[5^F?\ P;I]/C%_W!?_
M '(5%3X2H[GZ94445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O_266OYU/F]J_HK_ &H/
M^3:?B)_V+.I?^DLM?SJ?-[5M2,Z@?-[4?-[4?-[4?-[5J9A\WM1\WM1\WM1\
MWM0 ?-[4?-[4?-[4?-[4 >F_L4_\GD?"7_L<M'_]+H:_H8K^>?\ 8I_Y/(^$
MO_8Y:/\ ^ET-?T,5A4W-:>P4445F6%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\R_\%BO^4<?Q&_[AO\ Z<[2OIJOF7_@L5_RCC^(W_<-_P#3
MG:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-
M[4 'S>U=/\%?^2Q^$O\ L,V?_H]*YCYO:NG^"O\ R6/PE_V&;/\ ]'I2 _H^
MHHHKE.@**** "BBB@ HHHH **** /SO_ ."S7[(.QX?BUH-M\K>79^(HXUZ'
MA(;H\?2-B3_SR]6-?GG7]!7BWPKI_CGPSJ&C:M:Q7NF:I;O:W5O(,K-&X*LI
M^H)^E?B+^U_^S7J'[*GQTU;PK=&2:R0_:=+NV'_'Y:.3Y;_[PP5;L&1L<8)_
ME_Q@X/\ J>+6<86/[NJ_?MTGW]);_P"*_=']P?1W\0O[1P#X=QLOWM!7IM_:
MI]O6#T_PM6^%GE]%%%?B9_3 4444 %%%% !5[PUXDOO!WB*QU;2[J:QU+3)T
MNK6XB.'@E1@RL/<$ U1HJH2E&2E%V:)J0C.+A-73T:>S78_<7]C7]INP_:O^
M!6E^)K?R8=24?9=6M$/_ !Z7: ;P!_=;(=>?NN,\@UZO7XU?\$W/VNF_97^.
ML*ZE<,GA'Q,4LM74GY;?G]W<X_Z9LQR>?D9^IQ7[(PS+<0K)&RNCJ&1E.58'
MH0:_LSP[XM6>Y6IU'^^IVC-=WTEZ26OK==#_ #?\7_#^7"V>2IT5_L]6\J;[
M+K#U@W;ORN+>K)****^^/RD**** "BBB@ HHHH ***R?''C?2OAMX0U'7M<O
MH=-TC28&N;JYE/RQ(OMU)/0 9))  )(%14J1A%SF[):MO1)=V:4J4ZLU2IIR
ME)I)+5MO1)+JV<G^TS^T;H/[+GPGOO%.O2;E@'E6=HC 2W]P<[(D]SC)/\*@
MGM7XJ?'3XVZ]^T-\3=3\5^)+HW&H:C)E4!/E6L0^Y#&/X44< =3R3DDD]S^V
M_P#MAZM^V#\6)-4F\^S\.::6@T;3F;_CWBSS(X''FO@%CSCA02%!KQ>OY$\2
M..I9YBOJ^&;^KTW[O]Y_S/\ ]M71:[MG^@_@SX6PX7P'US&Q3QE9>]UY([J"
M??K)K=Z:I)LHHHK\Q/VT**** "M7P1X,U+XB^,=+T'1[9KS5-8N8[2UA7^.1
MV"CZ#GD] ,GM657Z#_\ !%G]E;[1=7WQ7UBW.V$R:=H =?O-@K/<#Z F($=S
M*.U?2<)\/U<ZS.G@*>B;O)]HK=_HO-I'QO'W%U#AK)*V:U;-Q5H1_FF](K[]
M7VBF^A]L_LT_ ?3?V:_@KH7@_3-LBZ7 /M-P%VF\N&^:64]_F<D@$G"[1T K
MO***_N#"X6EAJ,</17+"*2271)62/\P\=CJ^,Q-3%XF3E4J-RDWNVW=OYL**
M**Z#E"BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_].=I7TU7S+_P6*_Y1Q_$
M;_N&_P#ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F
M]J/F]J/F]J #YO:NG^"O_)8_"7_89L__ $>E<Q\WM73_  5_Y+'X2_[#-G_Z
M/2D!_1]1117*= 4444 %%%% !1110!^(_P#P6B^*;?$C]O#7[-9"]KX3L[71
MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
M!0__ (6'HEK\(O&5]NU[2X2OAV\G?YM0MT4DVS$]9(E!*^L:XZIEORF^;VJW
MX>\07WA+7K+5-,NI['4M-G2ZM;F!RDEO*C!D=2.0P8 @^HJ91NK%1E9G]+5%
M?-__  37_;QL?VU_@^K7LD%KXX\/HD.MVBX42DC"W4:_\\Y,'('W&RO3:3[M
M\1/B%H_PG\#:KXD\07T.FZ-HMNUU=W$A^6-%_F3P !R20!DD5SVL[&QY_P#M
MH_M;Z'^QI\$[[Q5JQCN;YLV^DZ=OVR:C=$':@[A1]YF[*#U) /X+_%_XM:]\
M=?B5K'BSQ-?/J&M:W<&XN)3]U>RH@_A15 55' 50.U>D?MX_MG:Q^VO\;KG7
M[SSK30=/W6NA::6^6RMMWWF'3S9,!G;G)PN=JJ!XI\WM6\(VU,92N'S>U'S>
MU'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[5]J
M_P#!(7_@GB?VE?'B^//%UCN\!^&[C]S!,F5UN\7!$>#UA3@N>C'"<Y?:G*VH
M+4^A_P#@C)_P3O/PWT2V^+GC2PV^(-4A)\/64Z?-IULZX^TL#TDE4D+W6,GN
MY"_H30JA%P. .@]**YI2;=V;I6"BBBD,**** "BBB@ HHHH **** "OS?_X.
M(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z_-1_] MZJ.Y,MC\NOF]J
M/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK],_P#@
MW3Z?&+_N"_\ N0K\S/F]J_3/_@W3Z?&+_N"_^Y"HJ?"5'<_3*BBBN<V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M%_:@_P"3:?B)_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4
M^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8
MK"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE
M_P""Q7_*./XC?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F
M]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*
M_P#)8_"7_89L_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444
M %%%% !1110 4444 %?-_P#P4Q_9$'[4'P*DN=+MA)XN\*A[W2]H^>Z3 \VV
M_P"!A05_VT49 +5](45YN<95A\RP=3 XI7A-6?EV:\T]5YH]GA[/L7DN94<T
MP3M4I2379]T_*2NFNJ;/YY71HW*LI5E."".0:;7V!_P5P_9!_P"%*?%@>.-%
MM?+\,^,IV:=47"6-^06=/99 #(ON)!@ "OC^OX=S[)<1E./J8#$_%![]&NC7
MDUJ?Z>\*<383/\JHYM@W[M17MUC+:47YQ=UY[K1A1117CGT04444 %%%% !7
MZH?\$A?VO_\ A;GPQ;X?ZY=>9XB\(P#[$\C9>\L 0J_5HB50_P"R8^O-?E?7
M5_!+XOZQ\!/BGHOBS0Y?+U'1[@3*I.$G0\/$W^RZ%E/L:^OX(XHJ9%FD,6OX
M;]V:[Q>_S6Z]+;-GY[XF\#4N*LCJ8!V56/O4Y=IK9>DOA?D[[I'[XT5RGP3^
M+VD?'KX6Z+XMT.7S-/UJW$RJ2"T#]'B;'\2,&4^X-=77]KT*].M3C6I.\9)-
M-;-/5/YG^:.*PM7#5IX>O%QG!N,D]TT[-/S3"BBBMCG"BBB@ HHHH 9)(L,;
M.[*JJ,LQ. !ZFOR@_P""H'[>C?M%^,7\'>%[MO\ A!]"G/F31M\NLW"\>83W
MB0Y"#H>7Y^7;[#_P5G_;[_L>UO/A3X-O?]+G4Q^([Z%O]0A_Y<T/]YA_K".@
M.SDEPOYR5_.'BQQ][64LCR^7NK2I)=7_ ")]E]KN].CO_9'@#X4>PC#BC-X>
M_)7HQ:V3_P"7C7=_8[+WMVK%%%%?@1_6 4444 %%%% '9?L_?!;4_P!H?XQ:
M#X/TD;;K6;D1O+C*VT0^:65O9$#-[XQU-?N=\-_A]I?PI\!:1X;T6W6VTO1+
M5+2W0==JC&3ZLQR2>Y)/>OD/_@C=^RK_ ,*W^&=S\1M8MMFL>+H_)TT./FM[
M ,#N]O-<!O\ =1"/O&OMBOZQ\(^%?[-RWZ_77[VO9^:A]E?/XG\NQ_ _T@>/
M/[9SK^RL+*]#"MK3:53[3_[=^%>:DUHPHHHK];/Y_"BBB@ HHHH **** "BB
MB@ KYE_X+%?\HX_B-_W#?_3G:5]-5\R_\%BO^4<?Q&_[AO\ Z<[2JCN@/PT^
M;VH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@
MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"_M0?\FT_$3_L6=2_
M])9:_G4^;VK^BO\ :@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\
MWM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_R>1\)?^QRT?_TN
MAK^ABOYY_P!BG_D\CX2_]CEH_P#Z70U_0Q6%3<UI[!1116984444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7S+_P6*_Y1Q_$;_N&_P#ISM*^FJ^9
M?^"Q7_*./XC?]PW_ -.=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'
MS>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_P"PS9_^CTKF/F]JZ?X*_P#)
M8_"7_89L_P#T>E(#^CZBBBN4Z HHHH **** "BBB@ HHHH **** .-^/?P6T
MC]H;X2:UX1UI?]"UB QK*JY>UE'S1S)_M(P##L<8/!(K\.?B]\*]8^"/Q+UC
MPKKT'V?5-%N&MY@/NR#JLBGNCJ593W# U^_%?$O_  6%_9!_X61\/E^)6AVN
M[6_"\.S54C3YKRQSG><#EH22<_W"V?N@5^/^+?"/]HX'^TL,OWM%:]Y0W:]8
M_$O*ZW:/Z&^C_P"(7]C9K_8N,E;#XEJU]HU-D_2>D7Y\KT29^7M%%%?RF?WD
M%%%% !1110 4444 ?9G_  2%_; _X5'\3&^'VNW>SP[XNF'V%Y&^2ROSA5')
MP%E&$/\ M"/IEC7ZH5_/-#,UO*LD;-')&0RLIP5(Y!![8K]D_P#@G!^UTO[5
M?P*A_M&X5_%WAH)9:PI/S3\'RKG'I(%.>GSJ_ &*_I#P;XO]I3>18J7O1NZ;
M?5;N/RW7E?HD?QM]([P]]C57%.!C[L[1K)=);1G_ -O?#+SY7O)GT-1117[X
M?R@%%%% !7R__P %*/V[(?V6/ 7]AZ#<(_CO7H3]D PW]F0G(-RXZ9X(13U8
M$\A2#Z5^V!^U;HO[(WPDN?$&I;;K4KC-OI.G!MKW]QC@>R+P7;L.F25!_%GX
MH_$[6OC)X^U3Q-XBO9-0UC5IC-<3-P/0*HZ*BC"JHX 4 =*_(?%#CU930_L[
M R_VB:U:^Q%]?\3^SV6O:_\ 0?@?X4O/\6LXS.'^R4GHG_R\FNGG"/VN[]W7
MWK8M[>S:E>37%Q-+<7%P[22RR,6>1B<EF)Y)))))Y)-0T45_*3;;NS^]4DE9
M!1112 **** "O7?V(_V9KC]JK]H#2?#FR3^QX6^VZQ,F1Y-HA!<9'1G)"*>S
M.#T!KR*OV _X)9_LJ_\ #.O[/L.J:E;>7XH\9!-0O=X^>V@Q^X@]L*Q=@>0T
MC _=%?>>'?"SSO-HTJB_=4_>GZ+:/_;ST]+OH?EGB_QTN&,@G7HNU>K[E/NF
MUK+_ +<6O;FY4]SZ4TS3;?1=.M[.TACMK6TB6&"&-0J1(H 55 Z    >@JQ1
M17]GQBDK(_S;E)R=WN%%%%,04444 %%%% !1110 4444 %?,O_!8K_E''\1O
M^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72
M<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/
M2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** /YR?
MVAO"K>!?C]XXT1E\MM'\07]D5';R[B1/4^GJ?QKD/F]J^F/^"O7PR?X:?M[^
M,CY?EVOB P:U;'&-XFB7S#_W^64>^*^9_F]JZH['.P^;VH^;VH^;VH^;VI@'
MS>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 L4K02JZ,R.C!E93AE(Z$'UK]#O
MV&O^"X6H> [*S\,?%Z*\US3(ML,'B*W'F7UNO0?:(_\ ELHX^=?WF <B0FOS
MP^;VH^;VI2BGN-.Q_1Y\)?C;X1^._AE=8\'>(M)\1:<<!I;*<2&$D9"R+]Z-
ML?PN P]*ZFOYL_ /Q(\0?"KQ'#K'AG6M4T'5(?N75A<O;R@9!QN4@E3@9!X/
M<&OL+X$?\%V/BM\.%@M?%UEH_CS3X\*TDR?8;XJ.,"6(;#QW:)B3WZYQ=-]#
M1374_8JBOC/X-_\ !<KX,_$18X?$#:[X'O6 #?;[0W-KN/998-YQ[NB"OJ#X
M:_';P5\9K3SO"?BSP[XB3;N(T_4(KAT'^TJL64^Q -0XM;EW1UE%%%( HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _GY_X*!_\GN?%7_L9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C
M6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:C
MYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;V
MH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;V
MH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK]4?^#>OX93:7\,O
MB%XNFC98]9U&VTNW9AC(MHWD<K[$W"C/3*>QK\P?!7@S5/B+XPTS0=%LYM0U
M;6+E+.SMHA\TTKL%4#L.3U/ ')Q7]!7[)7[/MG^RW^SQX8\$69CD;1[4?;)U
M'_'U=.2\TGK@R,V,]%"CL*RJ2TL7#<](HHHK$U"BBB@ JEXC\16/A#0+W5=4
MN[?3]-TV![FZN9W"16\2 LSL3P  "2?:KM?E'_P6>_X*'?\ "QM=NOA'X-OM
MV@Z3/CQ#>0O\NH7*-_Q[ CK'$P!;^](/1 6J,;NPF['@O_!2?]NZ^_;6^,;/
M927%MX(\/N\&B6;97S1G#74B_P#/23 X/W5PO7<3\X?-[4?-[4?-[5T15C /
MF]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?57_!
M+3_@G]/^V/\ %7^UM=MYH_A[X9F5]2?E?[3F&&6S1ASR,%R.53C(+*:\@_9*
M_9;\0?M??&G3?!^@+Y7GGSK^^9-T6FVJD>9,XXSC.%7(W,57(SD?O9\"_@EX
M>_9U^%FD>#_"]F+/2-'A$:9P9)W/+RR-_%([99CZGC P!G4E;1%QC<ZBPL(-
M*L8;6UAAM[6WC6*&&) D<2*,*JJ. H   ' %3445@:A1110 4444 %%%% !1
M110 4444 %%%% 'PK_P6*_X)X?\ "^O"$GQ*\(6._P 9^'[?&HVL"9?6K1!U
M 'WIHAG;W9,KR50#\A/F]J_IEK\C?^"R'_!.\?!;Q7-\4?!MCY?A'7KC_B;V
M<*?)I%VY_P!8H'W896/3HKDC@,BC6G+HS.<>I\&?-[4?-[4?-[4?-[5L9A\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U;/P]^(.L?"GQQI?B3P_?3:;K
M6C7"W5I<Q'YHG7]"#R"#D$$@Y!(K&^;VH^;VI ?OO^P7^VAH_P"VO\$K?7K7
MR;/Q!I^VUUW35;FRN,?>4'GRI,%D//&5R65L>W5_/G^QC^UKKG[&WQNL/%>C
M[KBS;%MJNGE]J:C:D@O&?1AC<C?PL!U&0?WG^$'Q;T'X[?#;1_%GAF^34-%U
MJW%Q;RCAE[,CC^%U8%64\AE([5SRC8VC*YTM%%%24%%%% !7YO\ _!Q#_P B
M9\+?^OS4?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\
MWM1\WM728A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'N__!,GX;3?%#]NSX;V<,32
M)INK)K$S#.(TM,W&2?\ >C4#U+ =Z_>ZOSQ_X(/?LCW'@GP7JWQ8UJU:&\\3
M1?V=HBR+AA9*X:6;'I)(J!>AQ$3R'%?H=7/4=V;1V"BBBH*"BBB@ HHHH X7
M]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U?T5_M0?\FT_$3_ +%G4O\ TEEK^=3Y
MO:MJ1G4#YO:CYO:CYO:CYO:M3,/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@
M ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;V
MH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH /F]J/F]J/F]JZ_X!_!/6OVB_C!H/@S0(3)J6NW0@5MI9;=.LDSX_@1 S'V
M4T@/UD_X(3?#27P9^Q;-K-Q'MD\6Z[<WT+$8+01JENO_ (_#*?QK[2KGOA1\
M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>exel-20211001_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exel="http://www.exelixis.com/20211001"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20211001.xsd" xlink:type="simple"/>
    <context id="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia9f82e383c694af98e6ab4c223730d0f_I20211025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-10-25</instant>
        </period>
    </context>
    <context id="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ide163890188b441d915e37fe3b4e3038_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i65446bf2aefe4b8b84374a8e8278071d_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ibd49a4943be041879f2e79978071f89b_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i518c57cfc2514e6599b766ac488ba69f_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i0a3cacefb1924a19b321562f6cc1c50f_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ie15e8da8abd24a81a7bb05a35813d724_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i5fe73b8c15e74b31812388266b3b6221_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i8e12bec23f4e45b9b13fab2a662de8d6_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaef3dfbd7d00493facc23c12218a5c77_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib93fec9e93714e5e8df46aa0e36139b7_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i4355be7a9b5344b3b5089274a3522b2c_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i3e1c3a859c9742a09f45706125e87b43_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i6a199c9648744541be4de3d34bb7e362_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="ide320c4815644a62a658d3862311595c_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i47efd87d077d432f81f34c8bf9b33d22_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i4646f21cac644933a185200c07101315_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i198373947b4145e597fec4495ee48f55_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ib44a54e568514d1cba61fe6a37c6f581_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i5aa21b82a225453a9b5b3197b7945bb2_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i1ddb6bce36184f08be45c8955d58a6fe_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ia5f35a35374542268bc2759496673a02_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="id6c9d55484894ea1b4af267e9c70eb4d_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4cdd133e47d04123866777ff9abd71d2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i15ab773d1d894523a26a2a3ceb10fe3e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i451f3b4d1aa14a1bbcb5d26014d13efc_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i62c8618c9439454b8cb846aaed306eaa_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i048c97d67ba14a7e9c9166ecce15a78f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="iccbb310782fb42fea3375eb6a1ccf6a8_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ib8ee09a03bec4322b0b7c0889fe08791_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i72d66ad81fc247a8856e28f96b5e71b4_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="icbe7efeffe4d4f2fa1c6ab83e7c2abd3_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ia0c0fbefe45c4bddad088d3948fec4d4_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ib422db6657d447b49fd7f409b08a14d0_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7652c419cd5e434ebdaf01060d9d1b55_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic5cb6b35aa834afe81197ed5f5a2983b_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9c1d06f401ca4330abe2df73ad44d932_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i300f361eb7ac41089fb4dcbbbaa0b22c_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9d98f6b265ec4941b70dd37ca3904b2d_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i399cf68a318047d4b6e4fe4633d1e94f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7bb3578547994d3fb6471e6ac46c8ae1_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i83bf53370dce463db3d2184cc9abeeed_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ife1a4766b133423c94f7ac43bee70be1_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic66848fd649d4aa3b3af5f75c759ed57_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i07c6d26551a848e69c150ea689520c0c_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iaf8e62d4ceae407da69dddd7a401315a_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i5701273b195d4b8fa25b28e5eaf36b88_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i84f8a9eb0dca41b09aaedd7f9d03c606_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie7eaebb9b56c4a4da079b1660c8ec3cb_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i2e11bac7372644709417934e0ca155a5_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i916390b099cf490a8faaf1f1536bb941_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i27140a762b04420283d20b05a3483f19_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ifdd6869dd7354422821f089dadf50b8c_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ib82fd13f9c484bcd90d7acca51198b90_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id19e6f8ceb3d4193a62ed61fe70f30d2_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i85d11b7619ee4ffdb9ca1f1ae9dcfcce_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i43aff9879b254a2bb8d73b57aaad937d_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i748062d52a79415b951264743fd8a262_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i333ba041ae564029967d730948f966a1_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i533ba6a6b82e4d4b9cb2b6bf9f6227d8_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icab832c59885481194024af60a61d1df_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i094984ccbfca4e3fac09b15012e1be74_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i237d077e560b4407af980d2b6dbb5351_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="icf27c022f00045578983d2cd05cefd50_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icfefd582d8584f539f09611fe980f68f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i96da6fb9308c4441a6c7e0e9966c1d83_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="idef660618700414f8dcbfb860da76a87_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaa1e2a62f0694219aade24fac80d1c5e_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i9326972b57124d95b7c72df93cabd3e1_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ie773f2a3a13f4701a26b5a39d5d1daee_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ia33755e44bf94f1da1da6239ce61afce_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic1034b890c344f2187aff9b841e56da4_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ie8b6af8835eb4a388447fefe69add707_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i8f554670ff6b4145bbceb659e8d31cee_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i362468d981744887840c7c13b4494a7b_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ife4a5f75f1f84d7cb2773b54773806d1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i1a51cab5342b4f589598449b9d53e45a_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9fe7a926c38a46a6a1270839bca439ab_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8e56e167d51d4361a27af591b87356ee_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaae0fe3ee92a4735919e62e7c773d8f8_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iac98a4d51cd54e6993377fc838bb765a_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i31062813c13140b7b457913dd4852e78_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5422d1856079466bbb9f65186f532193_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="id0cbb1bbb9c8465c8eaa7264a9c37ea6_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic620d2de433e40fca7e2944d830c2bda_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9b511d5be3cc42d6a46455b239456426_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i210d874da4ec4ad2b439ac379d882d7c_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7ebc613892384a1e81978aadc22bc1fd_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id076f77c6811421996bf94e07e9611b6_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibf26fde834484f20a6cb7803fb0e1cd7_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i94d721a4a024409b8e51b7763addb8a4_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic6cabd3bc8aa4381abca308dce1cb94b_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i3f2514fa13b9413db7b3f86827a216cc_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i52ed7af7a5b8432dad75ddaa4bc98d77_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i886d9164ed4647cf9aab2503a662e148_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if43ea83781f046ea919b9cbceae39832_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i44c6af5351c04591a3a684eaf231d711_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="idb1fd8c412d841c9b9361bc3a6ccd5d4_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic37bf6ef982543208fd55d26c3a8d017_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i2fb4d4519bbd45b58964c21b78d81e64_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="if92ef125dfb745409eb663f06a66015c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i347244ecea174e2b84d7115e9117517a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iecec3a46caf04b9bb463218152250078_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="idc219e31879f4e968543b9a4acc1c6bd_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i7f92052702c84e3da6d1adf2f5d4712a_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i299213a2fe8a44d19010980daaddadd2_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ia8e6809b452b4c0d91e76fccd77f2f8c_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i62c12de1d32146d68e9fb7edd1441d2d_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i92e4ab99fdb34795911040b0e2097e76_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3beaad32f58b469c90e2e895a020fed6_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i8050e574dc1c4db78e12b097abdec6dc_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="id4ebdacb1fea40dd827669ddd4d97f01_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ieabc23478b384ed9851e76ca8df34e39_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4c088daadd8a408f89a19ef83a3570ed_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i41488a2e36454734af6a6a327ecb17cf_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7f0256d26fd34b138fadf3cd0c240a78_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7c65d788a4d64260968ac3714dcfe64f_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ia7183ea49abb44619f51586094019e9f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i303d549538f2427bba2cce5280974392_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i59abfa55299448e3a17334e501e602fd_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if8ef9a35f9714d0baf8ee7a1bf5fa4f9_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i46630f5e17e048d6958cfa0d603db35f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="icf65eae8d34c44368baa6edb4df56a64_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id970f743dae1483e88e2ddd200c78c24_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3d005b00a57d4883b8ae4d21dc6bde0b_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="if5db0c4605f84fbdb15d0ac333e9c674_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i5376f2dae7f547e9b48251e30c8efb87_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id1e1880501a749b483269275293c21a5_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i227171c03dd7470ab777a1c62dda82f1_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if3992056ab144b1b9917c48ab7ac95cf_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i893a51123e7c4016962a39929c139bff_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i180e76bcc0744dceb497bede8877d6bc_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if33937ce988840acb055192972fe7d0e_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="idb3f26725f7e469ab88cddcff11f5119_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i19bb8d1b724e4bd8a470e35512bff9e4_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i0eb6246a347b47a29f0ec6969990a643_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i42c64fd2685d49a09c1aaa714e8a71b5_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="iab15a25bff164a59ba9db9bb00ba2c21_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i4e81c19802d8419abd05b32afb361529_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i4a8f21157bbf4e7a88b78baa89878020_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i5d54e684ac234965a52c3f8147a489f2_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i80f3b300dd384295b48111fb3de48dc8_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i7dce2e60a7dd497a8e784207c60eda67_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i4b1603788af44df89cb2501d143c508e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i6d33b9db55634d2f8dd4b55f547600b6_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ia937163ad2774ba59a4a97202dd4f1d3_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i72ba7cec3f784d029dbad83cfea8cad5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic704aa165c1c46d4ae28412336d3f23c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iac2eb9472f9747efb6644dfa8c514a6a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i522e306d776042df8fab951f97ebaf9e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3e0f0514bbc24b8596206e4a278f05c9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7942a0d26aa2410493571fbd1d1a1d40_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i57f02cd5c10e458e843d55805a3431fd_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="icba2574066cf4ff6a9f6e4150f0d9a59_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="icdbe7cfb8d5147028098fffe5f993314_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="if0747067a48245fc8dc26066c743c9d3_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i262de96d6b8744ae924a3782d09bacc8_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ia884675fcb614de78f41b988cfa85253_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i788e7100b3c44fc79ba7388a22d4be54_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib5f49a14a38b4618a641e7062e9a8119_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib852bbac7c2b4dae935d9ace85587f2b_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i2116aaf10cba486e9ea0a92a908bcf3f_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i2ac31bdedd8347f4a54d5329d8341508_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="if6aee20093514a7c908b61d8a427f82f_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i85113d3b2cbb42bea2638a8879a3bc44_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i47f7ba7484824fdfb1bf032ab871ce77_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i1060b811968c481ebf2bbc36128837fb_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i74b53fa939094dbc9d03652f7ae327cd_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ice95d1289bb548b3a198fedcadd68f9c_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ic0713852efdf4c9b8596061c2371f8c5_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i2720023a476a45c4ad1b14dea520df26_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i2f50cbeebde04173b4d76512c9e37178_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i8ce21a7f43c44e3f961a96a70156939e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i358c92e2bfaf46b3bda44418ad4ddff9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2eee75baece241f6bc83d598c6a8dce5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i12b60ddc46614de198e0d20fcc2e0d40_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ice80f13753ab4747b55be1f290360a38_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i5a068b43a44e4e71aed4fab765a9a10d_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4197a386017d4ce4b80b50397cde9f66_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i74bd879c428e43e38d7c190fb00c13bd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6b26d8ad0e0c4ab9b2ddc26c19baf207_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i06308a04850340b581f089fa2d42d8ab_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i81a9bdf6dc464c5f9f939b05d8db8a62_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="idd3bb879c1144c2b8f21d8d76daa2611_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3b9dabe918ed4a75984789a54fabbc52_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i576f4d76f4844ef59140fad75b749351_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9f14e7d83ac24bc0934f3ce817815377_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ie604d7023f6448e9bfdea6430b029c7d_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8e3d41a820d64c68a08dc8510596f5bc_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ifc806a4586494bdea73d4d8ca8067226_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="idb5366d5070d44918ed8a0165ebd5ab0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i68ac30fd607b41bc80b50c13706647e4_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i0936cbe6a0f84d479d483892d24f6d55_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib720450b2a1a4fc8a2cdcdb63baed576_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0db00f27c60d4842a7a2bce3d6d547e1_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ia41fd2edf3a14dd7bf6bb33de4813ccc_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icafa823dcfbd4c2a9d8b8df5d69e150d_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i6bdb2309e0e5446b87b31a0eb6c99f2c_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i67eaaa8ffdc4407780e4e29e54ed4917_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i8b8058d357f34b1db293a0ba18c7b0e4_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i9ff8c10e09a74083a913c8dd829db3e3_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i133709ff0a1b4c138d61663fd033397e_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ia4b5f2d2f5d3425586df0611b0cd3dbb_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4accc8a979184a968b8b082d620fbf50_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id9e09d7534be4b2999db1628207e2de6_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7299aa4e8d1145f896fecef97ca01e59_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i08eb8dd6d816445da416b2e82bf72356_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie0381b7e4bd74829a0a31d3bf8871cf0_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i5bef1feb8ca440608a019e77cde78bae_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5d30612661b1407c8474216f06f0d220_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i808843dbbc3c44908e48a431eb1f24d0_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ieb2d7629149a482f9cc826940879689f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i1460d3b96640419a83156ab690e99fb1_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ieec069f01d574d05981611f9a549d71e_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i50addfcd8acf48179fe0db096adfbc86_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i838699b122594d4f9e99ff8f3d9dbddd_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i68a6530ae4124dd299a7574226b98393_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i41fce6ed1b2045eb851578aba3348c9a_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7a75f9432ff64e73a1ac73574ddcfa54_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="if1dc7061a4104e0b8aeb478b3078f095_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf64fa313b794183bf4faf469cfd0c06_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7aaa7d8a46a34b038a5d053b7701b533_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id421b19fea1b414c8e38865109ab0e73_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i535221d9dcc64cd9a6a8c6fdc118809a_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i165ca677164a4242b9e75babf9daaee0_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i06b3a70674fc4636bc068b030241f7ab_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedAndProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if7e23ec3c3e84835ad5b3e3b31152b22_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2972daa1c2964506955e6854b99b0bd8_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic74264c148104da28095c53746f7d4fe_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="target">
        <measure>exel:target</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="forward_contract">
        <measure>exel:forward_contract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M18yLTEtMS0xLTA_6ae81369-d6cf-4ecb-88f8-8e8acd7e7c22">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M180LTEtMS0xLTA_78d11355-35b2-4c7a-a7f4-a33320b1df9b">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M181LTEtMS0xLTA_b8508a82-36f9-4144-8869-3a4c33e0c88c">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M182LTEtMS0xLTA_0573daf1-6541-4324-93de-6deef93998fb">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180L2ZyYWc6ZDJmYzc1NmM3MWJkNGNmYThmZWQzYjg1ZTUwZDA4ZmEvdGFibGU6NzUxNTFjN2Q0MDkzNDgyZWFhNDY2MTc1ODQzYzU5OTMvdGFibGVyYW5nZTo3NTE1MWM3ZDQwOTM0ODJlYWE0NjYxNzU4NDNjNTk5M183LTEtMS0xLTA_05dfb2f8-64e4-4391-92de-bdff1ca5e752">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6OTUxYjE2YTJlYTg3NDA3ZmIxYjY3MzIwYzcwNTYzZWIvdGFibGVyYW5nZTo5NTFiMTZhMmVhODc0MDdmYjFiNjczMjBjNzA1NjNlYl8wLTEtMS0xLTA_0ec99e8d-7110-4612-809b-f7c3ffe0d04c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ODRlNjc2M2Q0M2ZlNDNlY2E0MTc1NzBkOTgyYmNkYjMvdGFibGVyYW5nZTo4NGU2NzYzZDQzZmU0M2VjYTQxNzU3MGQ5ODJiY2RiM18wLTAtMS0xLTA_79a29efc-d2ce-4c28-b875-a69f312e4bb3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18zMjk4NTM0ODg1Mjg0_a49fed01-a2d9-4af7-be06-aa7533fe9e7e">2021-10-01</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6M2QyZmU4MzU0ZjljNGI4Yzg3OGE2OTcyNWQ2NTZkMDQvdGFibGVyYW5nZTozZDJmZTgzNTRmOWM0YjhjODc4YTY5NzI1ZDY1NmQwNF8wLTAtMS0xLTA_39f4197a-fba1-4e23-a90e-560b01a52c2a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODcy_bdbf2759-e470-408c-a074-608f94aeb4ef">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NDc4ZGViOGZiYWRmNDg3YjkxMmFlMWM2YjNjMDVkYzUvdGFibGVyYW5nZTo0NzhkZWI4ZmJhZGY0ODdiOTEyYWUxYzZiM2MwNWRjNV8xLTAtMS0xLTA_39ffb2d5-19d2-4370-92c0-45c7295cfb14">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NmExNzg0MmE4YjkxNDVkNDkzYjgzODhhNDFhZjc1NjUvdGFibGVyYW5nZTo2YTE3ODQyYThiOTE0NWQ0OTNiODM4OGE0MWFmNzU2NV8wLTAtMS0xLTA_e9bfcd9f-e078-48b4-bd1d-2e49f60bbf42">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6NmExNzg0MmE4YjkxNDVkNDkzYjgzODhhNDFhZjc1NjUvdGFibGVyYW5nZTo2YTE3ODQyYThiOTE0NWQ0OTNiODM4OGE0MWFmNzU2NV8wLTEtMS0xLTA_55e5ffbd-ea45-4796-9bf0-27350de8a2de">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODcz_fdbd1b8d-5c44-4c79-bff4-979c9a9bc6f8">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc5_ea0c287a-c546-4ff3-a72a-13b7b92a485a">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODgw_f8ae221d-406f-4afe-8833-dff178c902d3">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc0_5296291b-9cff-4e9f-9a2f-9aede2ebdf3b">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc1_9ea08894-52c3-47e7-b74a-9d71c11b1049">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc2_2b31e832-5fe0-4491-b750-c60270e28093">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTAtMS0xLTA_cfa8d593-7863-465a-862f-3931dc014404">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTEtMS0xLTA_d4cc3907-4b07-446c-9d95-ffd3d38d4f39">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjQ2MzBmNTcyMjgzNDQzNzk1OWIzOWMyOWFjNTM4ZTcvdGFibGVyYW5nZTpmNDYzMGY1NzIyODM0NDM3OTU5YjM5YzI5YWM1MzhlN18xLTItMS0xLTA_14086888-f8e0-4ff1-b428-9d60093c3a38">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODgx_22e20b35-9ecf-4bcc-ade6-8a1eba92c99b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc3_2535097c-c3f1-487e-805a-9a17e4a6ac43">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8wLTAtMS0xLTA_8f27ca95-0388-47fa-a027-ec6665272191">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8xLTQtMS0xLTA_e40d127b-2cc2-47d1-a2fa-4a971e431880">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGFibGU6ZjhjYTQzMjI2NDI4NDkxNGJkZjQxOTFiZGNmOWMwNjEvdGFibGVyYW5nZTpmOGNhNDMyMjY0Mjg0OTE0YmRmNDE5MWJkY2Y5YzA2MV8yLTEtMS0xLTA_ba4e9160-bba9-4584-94f7-187219614e4e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODc4_20572e20-1f84-4aa6-a055-cd99915aad36">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia9f82e383c694af98e6ab4c223730d0f_I20211025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xL2ZyYWc6NDc2MzNlNTJkODI4NGNkYmE2NGJlZWRiMTgxNGIxMDMvdGV4dHJlZ2lvbjo0NzYzM2U1MmQ4Mjg0Y2RiYTY0YmVlZGIxODE0YjEwM18xODE3_37f3346d-f93f-4ac4-a26f-bddf93ad8456"
      unitRef="shares">316397360</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNy0xLTEtMS0w_5d8f92c7-594b-40ac-a242-33b57d90abe0"
      unitRef="usd">567325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNy0zLTEtMS0w_d55ec1c9-ca63-44ae-8d5c-15bcfc215c99"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOC0xLTEtMS0w_63404abe-77ef-4b23-94e4-fd9debf3283b"
      unitRef="usd">835406000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOC0zLTEtMS0w_3575c0da-fcc3-49d3-a81d-29e9dfa1a17d"
      unitRef="usd">887319000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOS0xLTEtMS0w_2d6992d2-feaf-4084-95d8-8130cf6e7e77"
      unitRef="usd">179493000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfOS0zLTEtMS0w_9f1357ec-99d0-4810-9722-7741f9ac4584"
      unitRef="usd">160875000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTAtMS0xLTEtMA_7976117f-3aeb-4b32-8bd5-aa24c087b73e"
      unitRef="usd">28240000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTAtMy0xLTEtMA_ab2bf300-087e-410d-a7e8-f76d4fafcc6a"
      unitRef="usd">20973000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTItMS0xLTEtMA_fe12a199-abe3-4dde-9834-c82444e696ef"
      unitRef="usd">51564000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTItMy0xLTEtMA_0c048b74-da84-4593-8df1-f41dac430751"
      unitRef="usd">57011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTMtMS0xLTEtMA_2a500f5b-37e7-4bd5-b2be-9768c8080a1b"
      unitRef="usd">1662028000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTMtMy0xLTEtMA_a4684479-b93d-4749-8342-4405e5c73f39"
      unitRef="usd">1445395000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTQtMS0xLTEtMA_bc92c52b-a233-4081-bec9-3ce473d2586a"
      unitRef="usd">362218000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTQtMy0xLTEtMA_89ce001b-0f88-44b3-9ab1-71301070f9bb"
      unitRef="usd">330751000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTUtMS0xLTEtMA_e1fcba99-8c0a-4558-9da8-fe4869af47dc"
      unitRef="usd">99838000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTUtMy0xLTEtMA_fac8e37d-7c43-49aa-ad3d-b923f31cb859"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTYtMS0xLTEtMA_51bf3d5a-e7d2-41d9-bf0b-9e04f51e6c02"
      unitRef="usd">125295000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTYtMy0xLTEtMA_d4e7d35c-79c2-4933-b8cd-7bc515f387fa"
      unitRef="usd">156711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTctMS0xLTEtMA_0922e084-1c9a-45ca-ab7d-611eaa95ab9c"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTctMy0xLTEtMA_e1acb485-618b-4cb0-97b0-864144020ada"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTgtMS0xLTEtMA_f686649f-7243-4abf-b0a2-77a44fc4e368"
      unitRef="usd">134678000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTgtMy0xLTEtMA_ec6b0426-4165-458b-a502-6edd475dbbf5"
      unitRef="usd">73408000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTktMS0xLTEtMA_5b908855-cad6-477e-aa42-df989a120d12"
      unitRef="usd">2447741000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMTktMy0xLTEtMA_523da919-6d83-4a56-923d-6ca97fc0878b"
      unitRef="usd">2137333000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjItMS0xLTEtMA_6c73b39f-1af8-4018-9cea-ad0d0bcc1c7f"
      unitRef="usd">24314000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjItMy0xLTEtMA_d36e2b70-29ff-4d8b-9ff6-dc7fef65b5b4"
      unitRef="usd">23632000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjMtMS0xLTEtMA_04dde1e9-abbd-48b5-ad8f-e244782c9f92"
      unitRef="usd">53306000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjMtMy0xLTEtMA_be84b3c9-e344-462d-bee1-421d1668f2c0"
      unitRef="usd">51189000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjQtMS0xLTEtMA_15a511fc-3aa0-4e88-ba4f-fdb6c3d3a33d"
      unitRef="usd">70618000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjQtMy0xLTEtMA_14d0fef0-f25e-40a3-a04e-45c6bd06f474"
      unitRef="usd">52251000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjUtMS0xLTEtMA_aaea9336-e7e1-422a-a62f-bbad88805278"
      unitRef="usd">31120000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjUtMy0xLTEtMA_132d217b-55b7-4830-add4-c14cda1dc6e3"
      unitRef="usd">20683000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjYtMS0xLTEtMA_14bdf128-1f1b-4f1f-b938-53053d218ddc"
      unitRef="usd">35403000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjYtMy0xLTEtMA_8fe9e4cc-c645-42e3-9364-c99e1eec89c9"
      unitRef="usd">12456000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjgtMS0xLTEtMA_1631f0bb-6d7b-404c-96c2-f3f50fa447d1"
      unitRef="usd">54747000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjgtMy0xLTEtMA_91932d84-d81c-4607-9648-9e082797b8bc"
      unitRef="usd">44447000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjktMS0xLTEtMA_83393950-eea6-4710-a404-f3b7e397abab"
      unitRef="usd">269508000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMjktMy0xLTEtMA_58eaec3d-2f31-4f80-80ca-eeab07d8c577"
      unitRef="usd">204658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzAtMS0xLTEtMA_47b20cc8-b928-4cf1-82a5-6e2b32756279"
      unitRef="usd">9444000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzAtMy0xLTEtMA_8a4f8791-8ab7-4138-aa3f-6636426170e6"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzEtMS0xLTEtMA_d1c71c35-1302-4be4-9132-0fe34719d0b6"
      unitRef="usd">52252000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzEtMy0xLTEtMA_23d6d40b-b2ff-4337-bc6a-f2b21ea00050"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzItMS0xLTEtMA_3bf46fd3-64b8-41c2-8011-8c1ef84397b0"
      unitRef="usd">4090000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzItMy0xLTEtMA_c090237f-0981-4677-a5ae-3a4bde6fde73"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzMtMS0xLTEtMA_d273161d-6ed7-4d29-98a5-31b73c3b4741"
      unitRef="usd">335294000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzMtMy0xLTEtMA_99481dff-5031-4136-912e-fb8da22738d4"
      unitRef="usd">258220000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzQtMS0xLTEtMA_4e338356-8a53-473c-a670-db09d5b67b9c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzQtMy0xLTEtMA_376b1ddb-cf65-479d-bd12-f68ea1f6d8a0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzIx_2a071ec1-b0c4-4667-b768-a1f50723ba3b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzIx_37343c4a-f02b-47cd-9241-16411ddeb55e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzM1_191f9632-6b98-4d80-be67-5a4f8fed32ce"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzM1_f0f6c149-ea2e-48de-a10e-4b2493ac1b09"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzYw_1c297645-f262-424c-96a4-ccad78eb625d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjIwMDYwYmE1YjRkYTQ5NWViZjE3ZDY1M2U4MmI5NzFhXzYw_3e1445e6-ae1a-466b-bd69-a13fa450d62e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMS0xLTEtMA_adaf8321-9a86-4766-aee9-b3fd94652971"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzYtMy0xLTEtMA_67cf1537-8e93-41d3-a1c6-91a9f4254319"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzE4_1c29d531-b605-445f-96c6-c45d3ec04823"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzE4_22015caa-3c3f-4e16-b1bd-0df8d3b3a3ad"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMy_0a785c16-4bf4-4288-ac74-f0c4b4fefdc5"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMy_f3d30448-e064-421e-9ce6-d242315a378f"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMyOTg1MzQ4ODM0ODM_1f0840cf-b356-4567-a6b0-dc73f6f47476"
      unitRef="shares">316305000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzMyOTg1MzQ4ODM0ODM_8c6ae5ae-af28-4f01-af61-e6ec4130a6fc"
      unitRef="shares">316305000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzEwOTk1MTE2Mjc5MDA_0efd639a-093d-4986-9b55-a8b2f064c1c0"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjc4Yzg3MGVmMTVlMTRiNzM4NjhjMTVlMGQ0MTc2NWU4XzEwOTk1MTE2Mjc5MDA_68d08d64-bda5-47a2-8086-131b5a8940a4"
      unitRef="shares">311627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMS0xLTEtMA_019b8789-f285-4ee9-8c62-d202dffe8f5d"
      unitRef="usd">316000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzctMy0xLTEtMA_61caa702-2527-48fb-a7a4-a756bcdd6af6"
      unitRef="usd">312000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzgtMS0xLTEtMA_134bada4-2c4e-47a6-bb00-d19c19723dd4"
      unitRef="usd">2422323000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzgtMy0xLTEtMA_66556e0c-3988-4185-8fb3-5ca8c65db0e4"
      unitRef="usd">2321895000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzktMS0xLTEtMA_60701b39-5ffd-4529-9a2e-2f8bd3152fd1"
      unitRef="usd">1481000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfMzktMy0xLTEtMA_74d669b0-c5f4-4729-8c09-9d203a336107"
      unitRef="usd">4476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDAtMS0xLTEtMA_72c96fff-56b8-4782-aacb-e7f5e80271f2"
      unitRef="usd">-311673000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDAtMy0xLTEtMA_d2f1be3d-642b-40fe-9a17-253977f58ef4"
      unitRef="usd">-447570000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDEtMS0xLTEtMA_153d92fa-7cef-46ef-9aae-0cbda906f14a"
      unitRef="usd">2112447000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDEtMy0xLTEtMA_12f365d6-f06d-4619-b8f1-dad4c81868ec"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDItMS0xLTEtMA_88ceaf62-93d0-438f-b92c-6c99c0edc541"
      unitRef="usd">2447741000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xNi9mcmFnOmZiN2Q3OTFhYzFhODQyMGY5NmRhZjI3ZDM1YzFjODEwL3RhYmxlOmZkZTU0YTI3MTc2ZDQzMTA4OTM0ZGUzN2E5OGY2ZTI3L3RhYmxlcmFuZ2U6ZmRlNTRhMjcxNzZkNDMxMDg5MzRkZTM3YTk4ZjZlMjdfNDItMy0xLTEtMA_74582a24-b4b7-4636-b70b-0c8e4c04505d"
      unitRef="usd">2137333000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy0xLTEtMS0w_a31b5224-e4b9-43b1-8188-e8b6e91334fc"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy0zLTEtMS0w_c5f8b58d-8ce9-456c-add0-bfa3c1abae37"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy01LTEtMS0w_9f046351-9bbf-42bf-b528-68208008e6be"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMy03LTEtMS0w_9730b25e-7620-49a9-9cac-38419dfef73c"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC0xLTEtMS0w_3b1ef0c9-b136-4389-9a28-4a28eb73fde0"
      unitRef="usd">49694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC0zLTEtMS0w_d3b52731-7a23-4e93-91ce-5b423161b31f"
      unitRef="usd">33205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC01LTEtMS0w_f682ad28-82a5-40f5-9e2e-035914cf93d3"
      unitRef="usd">116862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNC03LTEtMS0w_585a4b31-d8ea-4eff-9835-45bcbb4edd97"
      unitRef="usd">113318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS0xLTEtMS0w_3db50703-463d-4a90-b331-d8e26f6120d6"
      unitRef="usd">15612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS0zLTEtMS0w_e165ab2a-f7bb-4c6a-b810-407080510a14"
      unitRef="usd">29300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS01LTEtMS0w_e070fe31-1520-45da-ba32-862b67817fc5"
      unitRef="usd">92391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNS03LTEtMS0w_1e23b9b5-5cf3-425f-a992-0d0c05d3007c"
      unitRef="usd">62971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi0xLTEtMS0w_a3542f78-9185-478e-8aca-c408fa0d776a"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi0zLTEtMS0w_98d2a79a-959f-4a9f-9b7e-22755b99438d"
      unitRef="usd">231092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi01LTEtMS0w_44b3934c-ab1d-4870-969d-4d0344153ea7"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfNi03LTEtMS0w_83941c97-30e8-4f23-b142-a666157d021f"
      unitRef="usd">717486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC0xLTEtMS0w_2f02bc13-8614-402a-a9d9-a15e9459e94a"
      unitRef="usd">11874000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC0zLTEtMS0w_5db81e3e-8768-425a-8685-fbc88ef9b164"
      unitRef="usd">8725000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC01LTEtMS0w_49f2dd26-c7a7-4282-9797-7442c47ce8ad"
      unitRef="usd">39956000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOC03LTEtMS0w_5aa88188-e74a-4e41-a646-d2df48b854e5"
      unitRef="usd">27235000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS0xLTEtMS0w_e6bb5d6b-d476-4d4f-b2d4-6c2c36c6e896"
      unitRef="usd">163370000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS0zLTEtMS0w_8a302c45-ed13-4b67-80d6-c48260526dfb"
      unitRef="usd">176762000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS01LTEtMS0w_84778e22-a86f-482c-a4e9-2c2949adeeff"
      unitRef="usd">471448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfOS03LTEtMS0w_f141793c-989a-4bb4-906f-740616015205"
      unitRef="usd">393572000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtMS0xLTEtMA_b9d3ecf0-e454-4173-a399-e4d750067d11"
      unitRef="usd">101558000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtMy0xLTEtMA_8cf6d2e6-cefa-4cf9-8be7-7340cb0d339f"
      unitRef="usd">88185000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtNS0xLTEtMA_b58ec43b-24d0-468a-b86d-fb2c1dab5e12"
      unitRef="usd">302404000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTAtNy0xLTEtMA_1c26a477-c09d-4916-a23d-3a5180a226d9"
      unitRef="usd">210916000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtMS0xLTEtMA_0789091c-d42c-4925-b635-1ac5fa99a42f"
      unitRef="usd">276802000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtMy0xLTEtMA_682eb8ba-a84a-4593-a9b7-3492fa022128"
      unitRef="usd">273672000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtNS0xLTEtMA_6ac20d0e-452d-483a-8f2c-8b910ba66530"
      unitRef="usd">813808000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTEtNy0xLTEtMA_7d37d2eb-701d-4c8b-9f58-76a1ffa3ba35"
      unitRef="usd">631723000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItMS0xLTEtMA_7a85ec2d-0363-4b07-a11f-87aee6e6a7a2"
      unitRef="usd">51621000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItMy0xLTEtMA_403fa1a0-d129-4c7b-a9f5-27d2cfb3b1cd"
      unitRef="usd">-42580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItNS0xLTEtMA_59ce7e52-153c-48f4-8e42-3e2ec78b180a"
      unitRef="usd">170022000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTItNy0xLTEtMA_a22b3022-c9f8-4e8a-bf26-8d8d57c1e083"
      unitRef="usd">85763000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtMS0xLTEtMA_43096d93-7225-47ea-8624-811f27eb49c7"
      unitRef="usd">1658000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtMy0xLTEtMA_07a16425-9d7c-4c3e-b8d5-3b1848f572a5"
      unitRef="usd">3994000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtNS0xLTEtMA_f4723d7b-fe30-4b7d-86c0-ebd67b49836d"
      unitRef="usd">6231000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTMtNy0xLTEtMA_0c7ca7fc-7539-4559-b2b6-88426edb80c9"
      unitRef="usd">16376000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtMS0xLTEtMA_8ef39262-ceac-4a44-adf8-ec9d3895b101"
      unitRef="usd">-19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtMy0xLTEtMA_94e9fafe-1a67-4ef1-810b-5b4c89f5d7a3"
      unitRef="usd">565000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtNS0xLTEtMA_e5db7f63-a8e2-422d-9ad2-34d63b0d8079"
      unitRef="usd">-120000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTQtNy0xLTEtMA_4f81ea16-07ba-4e92-9f63-14c144633207"
      unitRef="usd">571000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtMS0xLTEtMA_76ddbf98-8ea5-4ece-a87b-53f49918e890"
      unitRef="usd">53260000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtMy0xLTEtMA_bccd7d13-a13e-46ff-a750-9a1057081bb7"
      unitRef="usd">-38021000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtNS0xLTEtMA_2ae1b0af-8ef0-46ae-84ba-da577bc3921d"
      unitRef="usd">176133000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTUtNy0xLTEtMA_a9b5f637-7f65-41ed-8a64-8d2253d6a185"
      unitRef="usd">102710000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtMS0xLTEtMA_2813745d-caf6-444c-8161-fc12ff5d1f8c"
      unitRef="usd">15056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtMy0xLTEtMA_c060d4c6-a336-46b2-974c-dc750185c69f"
      unitRef="usd">-5981000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtNS0xLTEtMA_122353dc-9681-441a-8de2-d1f0a09fdf5a"
      unitRef="usd">40236000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTYtNy0xLTEtMA_4d3d5a63-4aec-43f4-a20b-42095533c49b"
      unitRef="usd">19317000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctMS0xLTEtMA_eec64939-0628-4e1c-bef4-c7b332cf51c0"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctMy0xLTEtMA_5d74a91b-5ae2-4e97-840e-aa9fcb148c02"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctNS0xLTEtMA_af656ecd-b39a-4c5e-9561-2871623aafe6"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTctNy0xLTEtMA_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktMS0xLTEtMA_38da336a-0b48-4091-9f1b-b15377dcee25"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktMy0xLTEtMA_8b8e09d1-d48a-4a50-aaf6-b8bf422d0d94"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktNS0xLTEtMA_aedf411c-0d8e-4f3a-9f7f-1ddf85cea199"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMTktNy0xLTEtMA_35726889-ce55-4d4b-bfd6-8861946f4c03"
      unitRef="usdPerShare">0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtMS0xLTEtMA_dc73123c-dd75-4f8b-99d5-4ae2b7551ae2"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtMy0xLTEtMA_78fa6d13-2825-4eaf-81b3-644fc6613684"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtNS0xLTEtMA_26e7c67d-b597-44ff-be84-100e1db36ea8"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjAtNy0xLTEtMA_aff28865-8246-4a52-9a73-333948fa63c7"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItMS0xLTEtMA_f6a3bb63-8a07-4e3d-bd06-dd3045edbc4a"
      unitRef="shares">315380000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItMy0xLTEtMA_c35715b6-078b-4c39-8cfa-7297534d1b34"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItNS0xLTEtMA_68c773f3-238e-40db-af17-a503d176dd9c"
      unitRef="shares">313990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjItNy0xLTEtMA_bdfd78bb-b9ed-4a2e-a3d9-6a4692a22022"
      unitRef="shares">307437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtMS0xLTEtMA_fd8c778b-b113-4c4a-baa1-499b24073763"
      unitRef="shares">322022000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtMy0xLTEtMA_bbb87449-9592-4f7a-9873-cea3f5a5a616"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtNS0xLTEtMA_6d8cb68d-a799-4b19-9b8b-f885f2dc8de9"
      unitRef="shares">322084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18xOS9mcmFnOjUzMTVjYjRiNDQxNjRkOTA5N2YzYTNlOWVhZDE4ZmY5L3RhYmxlOmRiMDNmZjI3YWYwNDQ2ZDM4MGRiNGJmNGFkZmY3ODBmL3RhYmxlcmFuZ2U6ZGIwM2ZmMjdhZjA0NDZkMzgwZGI0YmY0YWRmZjc4MGZfMjMtNy0xLTEtMA_98453d27-5604-456c-8efc-96eae6bdd965"
      unitRef="shares">317495000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi0xLTEtMS0w_eec64939-0628-4e1c-bef4-c7b332cf51c0"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi0zLTEtMS0w_5d74a91b-5ae2-4e97-840e-aa9fcb148c02"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi01LTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfMi03LTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfOTY_92dc79b0-cd21-45d0-8148-f3e5dd4763e0"
      unitRef="usd">-193000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTAx_aa0a952b-6532-43bf-a7a1-e6c9d340fae9"
      unitRef="usd">453000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTA2_d211cbd9-5fde-4691-8a46-aa03b2fb55e7"
      unitRef="usd">-949000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0wLTEtMS0wL3RleHRyZWdpb246ZDk1YzFhMzEzMjY0NDNkNzkwZjQ5ZDE4NjQyNTA2MmZfMTE0_ae5a243c-7670-4a23-88a9-8432a0c58689"
      unitRef="usd">-893000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0xLTEtMS0w_963078fa-6e35-4278-ab30-2453bfc43a43"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC0zLTEtMS0w_e2ffebfa-e929-4d02-8ae4-e29fca626df3"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC01LTEtMS0w_6a137331-c53e-45e2-abb0-86d8417f1a38"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNC03LTEtMS0w_38870f69-f5e6-4ff0-9685-87e79c2b991d"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi0xLTEtMS0w_8c5a5aa8-396c-4ecc-ad78-3af5faad074c"
      unitRef="usd">37700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi0zLTEtMS0w_d52325b9-a698-4945-a3c9-f341dc31f130"
      unitRef="usd">-33641000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi01LTEtMS0w_9f0cdf87-1834-4823-b12c-b3dc3710d258"
      unitRef="usd">132902000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yMi9mcmFnOjUzODQxMGZlZWNhYjQyZDk4MDQ1YzIyYzY2OGMyMDM3L3RhYmxlOmRhY2FhMDMxYWM4ODRmMTZiMDY5MmViZDY4NDE5MzMwL3RhYmxlcmFuZ2U6ZGFjYWEwMzFhYzg4NGYxNmIwNjkyZWJkNjg0MTkzMzBfNi03LTEtMS0w_f195f119-a241-414f-9d10-7759fca82809"
      unitRef="usd">86563000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i65446bf2aefe4b8b84374a8e8278071d_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMS0xLTEtMA_4cd249e3-7075-4d67-9fc9-eb1fd7283548"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i65446bf2aefe4b8b84374a8e8278071d_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMy0xLTEtMA_8e3216c0-a051-4f75-a55d-979173597fe5"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd49a4943be041879f2e79978071f89b_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtNS0xLTEtMA_56fbe028-5d9a-4b30-953b-17c2575522b4"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i518c57cfc2514e6599b766ac488ba69f_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtNy0xLTEtMA_16c05371-4267-46ea-99ee-03fb7d84e402"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a3cacefb1924a19b321562f6cc1c50f_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtOS0xLTEtMA_c1af744b-c065-427d-b795-c834ad44e741"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie15e8da8abd24a81a7bb05a35813d724_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjMtMTEtMS0xLTA_7c53826f-f0e5-4788-b4fa-6b2d1df62e49"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5fe73b8c15e74b31812388266b3b6221_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjQtOS0xLTEtMA_695a354d-dbdd-4a82-bf6d-0f7bbb7008c0"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjQtMTEtMS0xLTA_800ac956-088f-459a-b6c8-54242ee51e7c"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8e12bec23f4e45b9b13fab2a662de8d6_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjUtNy0xLTEtMA_ad98fc27-9368-47b2-8010-780b590751d4"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjUtMTEtMS0xLTA_3f2088a9-9b84-4f48-a4a2-bb63e62af074"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMS0xLTEtMA_8fa4aaae-7827-4838-9353-472b6dc5ac0b"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib46e92c6285b4e9dbd93c323e1f2918f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMy0xLTEtMA_45915857-ee1a-4b44-aae9-f4b45944d8cf"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtNS0xLTEtMA_9c0b541b-1b4c-49ed-a9ff-8929845a721b"
      unitRef="usd">3304000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjYtMTEtMS0xLTA_add759d4-0800-4ea7-9d21-7e983e56b80f"
      unitRef="usd">3305000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjctNS0xLTEtMA_1ac7afc7-69b3-411d-ba75-f4a43fc816ac"
      unitRef="usd">5958000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjctMTEtMS0xLTA_037e81c6-1f51-4033-ba32-2175d75785da"
      unitRef="usd">5958000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e013cb87aeb43098d4d666986bdb14f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjgtNS0xLTEtMA_ebd187a5-6229-4cb0-8f68-49df5cba2242"
      unitRef="usd">34323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjgtMTEtMS0xLTA_9061eb8b-8c93-4149-9dc9-1a7b9a235de9"
      unitRef="usd">34323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMS0xLTEtMA_5f43d558-da1e-4129-8d03-6475ae1418ac"
      unitRef="shares">316305000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMS0xLTEtMA_9d9ec062-c9e7-4be4-a6ae-5e03c4ac4fbb"
      unitRef="shares">316305000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMy0xLTEtMA_6cafb514-9742-42ee-a7df-f2c8d41a908e"
      unitRef="usd">316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib93fec9e93714e5e8df46aa0e36139b7_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktNS0xLTEtMA_099f1faf-8c71-4535-9e31-733718a444e1"
      unitRef="usd">2422323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktNy0xLTEtMA_aff693b5-38de-4b27-bfc0-4725de8c0924"
      unitRef="usd">1481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktOS0xLTEtMA_2ea2bae8-4970-414d-bf21-0e03eac5b49c"
      unitRef="usd">-311673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOmRiYmIwMjNhMDVlMDQxMjA4MTIzYWZhMTk3MTAxMjZlL3RhYmxlcmFuZ2U6ZGJiYjAyM2EwNWUwNDEyMDgxMjNhZmExOTcxMDEyNmVfMjktMTEtMS0xLTA_3aca33c4-eb9f-4d58-9092-3aa88509f955"
      unitRef="usd">2112447000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMS0xLTEtMA_7af61aa7-2c42-46e3-bab5-db2bf578e83e"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3dd48cc6d53e4d52ad212f0b6a9346f5_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMy0xLTEtMA_51364f83-93bf-40d5-817f-2268367ab27e"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4355be7a9b5344b3b5089274a3522b2c_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtNS0xLTEtMA_c7d45e1e-07fd-48a6-8309-1ca3d26e6f7e"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e1c3a859c9742a09f45706125e87b43_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtNy0xLTEtMA_9e01167f-479d-44c8-84b1-0ba89634b490"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a199c9648744541be4de3d34bb7e362_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtOS0xLTEtMA_a3d46e91-e8ff-4ae1-81c8-b64643320e21"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide320c4815644a62a658d3862311595c_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjQtMTEtMS0xLTA_01bbb9f8-6ca6-4230-8306-43eb2e1e61b3"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i47efd87d077d432f81f34c8bf9b33d22_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjUtOS0xLTEtMA_495328f5-6d4d-4dfb-86e6-e73543f59efa"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjUtMTEtMS0xLTA_29a06051-37c7-44b5-ae92-2560f4c45adf"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4646f21cac644933a185200c07101315_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjYtNy0xLTEtMA_79445059-f2fe-41ee-b8bf-64fe8e3f88bf"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjYtMTEtMS0xLTA_b5eee533-424d-469a-a954-c50869752959"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMS0xLTEtMA_d92df501-d70b-486f-86f1-0b45a4e25f01"
      unitRef="shares">516000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2ec00c24e2f74368aec0d0808e662ec9_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMy0xLTEtMA_522d31cb-edf4-41aa-8500-5243fdc4a543"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctNS0xLTEtMA_d3216b7b-ade3-408e-a653-307d0741b6e9"
      unitRef="usd">1872000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjctMTEtMS0xLTA_d3519021-5fb6-4730-887f-4bee649730c6"
      unitRef="usd">1872000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjgtNS0xLTEtMA_a0b37bda-4b74-4604-a4ec-34aed5743018"
      unitRef="usd">5179000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjgtMTEtMS0xLTA_716e7f0c-3af4-4410-adf2-aab73a29dd79"
      unitRef="usd">5179000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb20cf0b980e4254af4b90a047dda086_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjktNS0xLTEtMA_b1748ddf-dc5a-4586-bfcc-ce2ad8950a6e"
      unitRef="usd">55655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMjktMTEtMS0xLTA_0264b537-7ec3-4c82-840a-fcec5736b658"
      unitRef="usd">55655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i198373947b4145e597fec4495ee48f55_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMS0xLTEtMA_a45898cf-26a6-4d7e-8fc5-188941e8d2d7"
      unitRef="shares">309402000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i198373947b4145e597fec4495ee48f55_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMy0xLTEtMA_1787b8be-6dea-43df-8c6b-4fbc77c3c35d"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib44a54e568514d1cba61fe6a37c6f581_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtNS0xLTEtMA_88e2c08b-8fc2-40bd-a6bc-0b5f617d45e7"
      unitRef="usd">2321441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtNy0xLTEtMA_3672f4ac-9e17-4dc3-a0c1-cf93625a5ca5"
      unitRef="usd">6239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5aa21b82a225453a9b5b3197b7945bb2_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtOS0xLTEtMA_752a60b3-a8ef-4209-89da-21b388c2f81c"
      unitRef="usd">-475958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjc5MDBiMGFiOWE2OTQ0MDg5NDM1MzU2YzBjNjRmMGY1L3RhYmxlcmFuZ2U6NzkwMGIwYWI5YTY5NDQwODk0MzUzNTZjMGM2NGYwZjVfMzAtMTEtMS0xLTA_77dd8760-9601-4b7d-865f-91140bd1c45d"
      unitRef="usd">1852031000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia5f35a35374542268bc2759496673a02_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMS0xLTEtMA_404edfb1-ecce-4d53-9a80-05f01633ba29"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia5f35a35374542268bc2759496673a02_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMy0xLTEtMA_19d9850c-9a5b-44df-a702-9c0bce5a6f02"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6c9d55484894ea1b4af267e9c70eb4d_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtNS0xLTEtMA_66cb538c-699b-4484-a78f-1b9747af834b"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cdd133e47d04123866777ff9abd71d2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtNy0xLTEtMA_80c0d9fd-2801-4a7b-8607-e7dfbf4ea876"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15ab773d1d894523a26a2a3ceb10fe3e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtOS0xLTEtMA_068a0f32-948c-4615-85c6-846f3fff5c19"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjMtMTEtMS0xLTA_b2944140-0699-42e6-ab97-84ca1bba9520"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjQtOS0xLTEtMA_af656ecd-b39a-4c5e-9561-2871623aafe6"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjQtMTEtMS0xLTA_62ed2ce1-7d9c-40d4-b889-51cf27170dd3"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i451f3b4d1aa14a1bbcb5d26014d13efc_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjUtNy0xLTEtMA_012dfb7a-c905-404b-9d91-e7481689572b"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjUtMTEtMS0xLTA_8302e0e3-6e31-4073-9525-19a2654e8d5c"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMS0xLTEtMA_307acd8b-aa37-4058-ba85-80c721516f96"
      unitRef="shares">4678000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i76612b6f7a5a4874a76b2811ab6c9688_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMy0xLTEtMA_3ea38f70-b3f1-4de3-ae08-93f97a149923"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtNS0xLTEtMA_6ee1a5ca-319f-42ac-adde-8a37d8ebe9ff"
      unitRef="usd">18788000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjYtMTEtMS0xLTA_aa9e71e0-441e-40eb-b228-85bf59022b64"
      unitRef="usd">18792000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjctNS0xLTEtMA_645fd383-4960-4b87-b204-2992570d0e38"
      unitRef="usd">15371000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjctMTEtMS0xLTA_c72c89b4-9fdf-4ad7-a295-0ffac76a0d64"
      unitRef="usd">15371000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac8415c7a45f468c890b8bba5b865bd8_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjgtNS0xLTEtMA_9d928c07-c881-4f63-8b40-4dfd982da71a"
      unitRef="usd">97011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjgtMTEtMS0xLTA_513b3d9d-b8c6-41eb-846c-ca7ecd6ecdf9"
      unitRef="usd">97011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMS0xLTEtMA_5f43d558-da1e-4129-8d03-6475ae1418ac"
      unitRef="shares">316305000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMS0xLTEtMA_9d9ec062-c9e7-4be4-a6ae-5e03c4ac4fbb"
      unitRef="shares">316305000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaef3dfbd7d00493facc23c12218a5c77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMy0xLTEtMA_6cafb514-9742-42ee-a7df-f2c8d41a908e"
      unitRef="usd">316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib93fec9e93714e5e8df46aa0e36139b7_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktNS0xLTEtMA_dd702cf3-897a-477e-8b88-e05ff8bceb3a"
      unitRef="usd">2422323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fd8d37bb5df4a929fb5466e9a4f1ae2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktNy0xLTEtMA_aff693b5-38de-4b27-bfc0-4725de8c0924"
      unitRef="usd">1481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2236d6cb8dd4e79a44707dde39bc25e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktOS0xLTEtMA_2ea2bae8-4970-414d-bf21-0e03eac5b49c"
      unitRef="usd">-311673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjczOThmZTJjYTlmMDRlM2JhNzM5YzU3Yzk0Y2EwZjk4L3RhYmxlcmFuZ2U6NzM5OGZlMmNhOWYwNGUzYmE3MzljNTdjOTRjYTBmOThfMjktMTEtMS0xLTA_a3eb767e-9994-41d7-b43f-b32fd1549137"
      unitRef="usd">2112447000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62c8618c9439454b8cb846aaed306eaa_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMS0xLTEtMA_b0dfcd5a-23d8-47e5-a34f-a67ee2a1ba36"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i62c8618c9439454b8cb846aaed306eaa_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMy0xLTEtMA_0975785c-c51e-461e-924e-ff3dbae3110f"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i048c97d67ba14a7e9c9166ecce15a78f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtNS0xLTEtMA_b845800a-8a7c-4ab0-b30d-a5620b9aff4b"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccbb310782fb42fea3375eb6a1ccf6a8_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtNy0xLTEtMA_23930714-6148-450c-a741-10a28a8402ea"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8ee09a03bec4322b0b7c0889fe08791_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtOS0xLTEtMA_ccd22d99-e116-4440-aa56-547df39b8562"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72d66ad81fc247a8856e28f96b5e71b4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjMtMTEtMS0xLTA_a3c548bf-091d-41b0-9555-f0fffd6c6bd9"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icbe7efeffe4d4f2fa1c6ab83e7c2abd3_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjQtOS0xLTEtMA_42a3ba4b-0d88-4769-8c64-68ba25f9299f"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjQtMTEtMS0xLTA_e8e4102a-726e-4a1b-b09c-1e55366d525c"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia0c0fbefe45c4bddad088d3948fec4d4_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjUtNy0xLTEtMA_49429602-f338-45b4-ab2c-b07d3728f07b"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjUtMTEtMS0xLTA_a8f7fb3d-0c8b-482a-9934-f117da03e640"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMS0xLTEtMA_578014af-d639-4b10-ad28-b3629708fac9"
      unitRef="shares">4571000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i116e85ea64a54ea5b8026e37468579bc_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMy0xLTEtMA_eb5d524c-a2a1-4734-9af6-bcb3fa814aed"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtNS0xLTEtMA_326fdfb8-fb22-47c5-afbe-04900f60321d"
      unitRef="usd">19823000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjYtMTEtMS0xLTA_f12792c2-7dce-4e0c-8733-cd647390cad9"
      unitRef="usd">19827000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjctNS0xLTEtMA_83bb0933-1085-40f8-a4f2-502f789dc627"
      unitRef="usd">26120000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjctMTEtMS0xLTA_bf5cd2d6-8097-4372-be6d-5f8bc5e15a58"
      unitRef="usd">26120000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2103e36b9a7346a6b141cdc195459cbe_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjgtNS0xLTEtMA_e0208267-5df8-49d0-bf2d-fd24f3a06cb7"
      unitRef="usd">85791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjgtMTEtMS0xLTA_c20ebe55-d7da-4e73-bf5f-f8d618117601"
      unitRef="usd">85791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i198373947b4145e597fec4495ee48f55_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMS0xLTEtMA_a45898cf-26a6-4d7e-8fc5-188941e8d2d7"
      unitRef="shares">309402000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i198373947b4145e597fec4495ee48f55_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMy0xLTEtMA_1787b8be-6dea-43df-8c6b-4fbc77c3c35d"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib44a54e568514d1cba61fe6a37c6f581_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktNS0xLTEtMA_88e2c08b-8fc2-40bd-a6bc-0b5f617d45e7"
      unitRef="usd">2321441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaf90431ea6b48c3bf8c1f1a63111fc3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktNy0xLTEtMA_3672f4ac-9e17-4dc3-a0c1-cf93625a5ca5"
      unitRef="usd">6239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5aa21b82a225453a9b5b3197b7945bb2_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktOS0xLTEtMA_752a60b3-a8ef-4209-89da-21b388c2f81c"
      unitRef="usd">-475958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yNS9mcmFnOjBhNTAxMDgyMWE4MzQyNDlhNWNjMjgxZTYxNTVkMmVlL3RhYmxlOjY0MjQ3N2E4Y2Q5MDRjN2NhNzQ1NDg0OGI4MTMxZjNhL3RhYmxlcmFuZ2U6NjQyNDc3YThjZDkwNGM3Y2E3NDU0ODQ4YjgxMzFmM2FfMjktMTEtMS0xLTA_77dd8760-9601-4b7d-865f-91140bd1c45d"
      unitRef="usd">1852031000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMi0xLTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMi0zLTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNC0xLTEtMS0w_aaedc619-5cdf-4ef8-a0ae-429bcac9a1b7"
      unitRef="usd">11699000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNC0zLTEtMS0w_c9189f0e-1013-4e96-baf8-6f68074ed391"
      unitRef="usd">6731000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNS0xLTEtMS0w_737f832e-270f-47d6-959a-a50e653ba959"
      unitRef="usd">96654000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNS0zLTEtMS0w_8f189f15-2238-4258-b199-8cc07657aef8"
      unitRef="usd">85791000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNi0xLTEtMS0w_5c6ef68f-ed7e-4ad2-8d7f-e551bdefc19e"
      unitRef="usd">3952000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNi0zLTEtMS0w_19da72b0-d868-4e05-b64f-6ff510e1d839"
      unitRef="usd">3607000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNy0xLTEtMS0w_417ff460-ce9a-4df6-9e92-36aff2e1ef7c"
      unitRef="usd">-32365000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNy0zLTEtMS0w_7b90575b-223e-4746-a6ba-c113804d5e0b"
      unitRef="usd">-15803000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfOC0xLTEtMS0w_02b8ef9e-b9ff-4883-ac08-b5f9d37ff694"
      unitRef="usd">-35871000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfOC0zLTEtMS0w_8b0f8a33-b165-4c3f-a3b3-a7bc6cbba68f"
      unitRef="usd">-1609000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTAtMS0xLTEtMA_0646ac28-e20c-4deb-9402-be9fd29af82f"
      unitRef="usd">20124000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTAtMy0xLTEtMA_90e4677c-76f0-4185-a448-c2e03dde79ab"
      unitRef="usd">47074000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTEtMS0xLTEtMA_23400ba1-bf91-4f06-9ff7-1a236a7c7b70"
      unitRef="usd">26956000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTEtMy0xLTEtMA_1c4e86f5-f64f-48e1-8215-9fc19a7603e2"
      unitRef="usd">13466000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTMtMS0xLTEtMA_1c64cb45-7e15-4b15-9ab8-95df9c462ee2"
      unitRef="usd">24252000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTMtMy0xLTEtMA_079a087e-1c3f-47bd-9d0f-df9cbf5f5aa7"
      unitRef="usd">15868000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTUtMS0xLTEtMA_ca96c156-c144-4fdf-9f8d-4866c0bcc728"
      unitRef="usd">11434000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTUtMy0xLTEtMA_957d7e65-fdea-414b-a25a-1ef780503267"
      unitRef="usd">4012000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTYtMS0xLTEtMA_a9d09a44-6446-4bf8-9efb-face6049889c"
      unitRef="usd">47812000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTYtMy0xLTEtMA_cc368bba-cc2f-4c71-a67f-348d571819b4"
      unitRef="usd">51151000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTctMS0xLTEtMA_4ba5a6fb-4c2d-41f6-a483-1cde9bcaf61d"
      unitRef="usd">304352000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTctMy0xLTEtMA_9b15f680-9dd8-4ffe-9446-e3cd2274676d"
      unitRef="usd">175689000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTktMS0xLTEtMA_fd0347b4-fbbb-4b9b-97db-cc8ee7d789e5"
      unitRef="usd">48265000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMTktMy0xLTEtMA_402d4b28-597b-4355-aac6-fa6c152db194"
      unitRef="usd">16055000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjEtMS0xLTEtMA_e7a11f39-5e12-4d7c-9a54-b039dc57ef36"
      unitRef="usd">1077377000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjEtMy0xLTEtMA_e7266415-e51c-4c8d-9665-1f2c64bb0b1e"
      unitRef="usd">866975000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjItMS0xLTEtMA_86621ce4-5ad5-44d4-902e-a343532d610a"
      unitRef="usd">1095813000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjItMy0xLTEtMA_e337dc78-bef2-4335-bf78-46de393b8e89"
      unitRef="usd">781324000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjMtMS0xLTEtMA_daae5b61-5cc3-4ad4-a489-998013842e09"
      unitRef="usd">-29829000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjMtMy0xLTEtMA_193ab283-e609-4c34-87e3-01a10963c6f1"
      unitRef="usd">-101706000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjUtMS0xLTEtMA_69e41f7f-e56d-404a-aa00-26692454f0f5"
      unitRef="usd">18242000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjUtMy0xLTEtMA_6fc7a907-a433-4667-b024-4b6a80d38dc8"
      unitRef="usd">19682000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjYtMS0xLTEtMA_8e037889-9a7a-483c-b8ea-993f27cfe6e3"
      unitRef="usd">15049000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjYtMy0xLTEtMA_3dbb2809-3b6a-407b-b12d-658df1036e5c"
      unitRef="usd">26120000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjktMS0xLTEtMA_2a61ef8d-4b5f-4748-b7f9-3755cbedafa9"
      unitRef="usd">3193000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMjktMy0xLTEtMA_9526d8fb-e01d-4202-83ed-5c2a48e63abf"
      unitRef="usd">-6438000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzAtMS0xLTEtMA_28c6d279-005b-4c3f-ab17-deb2d6b19580"
      unitRef="usd">277716000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzAtMy0xLTEtMA_ca06ae5b-c938-4fc1-8161-4eb0d867cc3f"
      unitRef="usd">67545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzEtMS0xLTEtMA_ff386474-cc5a-402e-b03c-be5acda8da4b"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72d66ad81fc247a8856e28f96b5e71b4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzEtMy0xLTEtMA_691f427c-2d6a-49ae-ab90-d42cffe1af28"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzItMS0xLTEtMA_dac59af9-aaac-4255-ac22-92c39e2a8c8f"
      unitRef="usd">598488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzItMy0xLTEtMA_53b14c49-f613-40b1-8895-32457a2fd6c1"
      unitRef="usd">335682000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzctMS0xLTEtMA_d9c72316-8529-4241-9f31-e2f53f6cb969"
      unitRef="usd">4893000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzctMy0xLTEtMA_93944947-1c93-4a55-b038-fca13f019391"
      unitRef="usd">1824000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzktMS0xLTEtMA_0f50d609-ed52-439a-87dd-be005c43f470"
      unitRef="usd">5143000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfMzktMy0xLTEtMA_5d1f2a9d-764e-4abd-9c53-9bcabc470cdc"
      unitRef="usd">843000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNDAtMS0xLTEtMA_31029412-b01c-4a1f-bfd2-287528aa9d03"
      unitRef="usd">9000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18yOC9mcmFnOjlmNmViOGQxYWM2ZDQ0YzZiNmE1NGMwZmMyMmQzNzQ5L3RhYmxlOmIwODljMWU3MzI4OTQ4YzJhOTYxZmNlNTEyNGJmZTM0L3RhYmxlcmFuZ2U6YjA4OWMxZTczMjg5NDhjMmE5NjFmY2U1MTI0YmZlMzRfNDAtMy0xLTEtMA_63fa4c49-cf1f-4bcf-92da-530ef78061a0"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1MA_546cc494-4c1c-4641-90b8-9b538597f5fb">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since our founding in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#x2019;s OPDIVO&#xae; (nivolumab), and for previously treated hepatocellular carcinoma (HCC) and, in the U.S. only, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income (loss) from operations, net income (loss), total assets, total liabilities or total stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the nine months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as compared to the significant accounting policies disclosed in Note 1 &#x2013; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ib422db6657d447b49fd7f409b08a14d0_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfNjMw_d873235c-76c0-4524-9746-c1b30b044dff"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i7652c419cd5e434ebdaf01060d9d1b55_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfMTUxMg_098a6cae-2c1c-4d49-9028-3005ad3eafd1"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1MQ_4afb3437-4ba4-40ac-acd4-71644b09f022">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1Mg_cb79c548-bcfa-4260-ae5e-6b1426435def">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU0Nw_a4c46ecd-8a62-436b-9943-c35612b12819">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3NA_4c058857-219d-4945-891a-78df12221863">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfNDIwNw_5fee590f-cd3b-4796-a08c-1e87a57bc356"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3NQ_e8091265-00be-434b-800a-b33183f94e64">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3Nw_064eb144-9dae-4488-8846-bef8e2ddb74f">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income (loss) from operations, net income (loss), total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU1Mw_d1fd0267-5ac9-4733-bdd9-1835d9fd6b2b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNC9mcmFnOjMwMDcxNmY0Y2VlOTQwYzFhZmQ4ZjI0MWE1MDViYzRmL3RleHRyZWdpb246MzAwNzE2ZjRjZWU5NDBjMWFmZDhmMjQxYTUwNWJjNGZfODU3OQ_06f16e8b-db5d-4b6b-b790-8b16fef98af4">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI3OQ_875b35dd-5662-4d10-a278-e31f37dac66f">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets were zero as of September 30, 2021 and December 31, 2020. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities as of September 30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized $6.8 million in revenues in each of the nine months ended September&#160;30, 2021 and 2020, that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021, we recognized $48.4 million and $116.2 million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $33.1 million and $115.3 million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$86.5 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements&#x2014; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI4Mw_bfb0411a-1f72-40a2-85cb-4e55ecc85593">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5cb6b35aa834afe81197ed5f5a2983b_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy0xLTEtMS0w_173add81-4513-41d5-8e51-2971b874c7c7"
      unitRef="usd">357462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c1d06f401ca4330abe2df73ad44d932_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy0zLTEtMS0w_00e8983c-64c7-49dd-98ff-0845ce8e3602"
      unitRef="usd">220401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i300f361eb7ac41089fb4dcbbbaa0b22c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy01LTEtMS0w_b2499a3e-15f5-4bb4-8e28-da562e4befe5"
      unitRef="usd">1051871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d98f6b265ec4941b70dd37ca3904b2d_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMy03LTEtMS0w_66d23f3a-962a-4f2c-ba84-1e9722657011"
      unitRef="usd">702865000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i399cf68a318047d4b6e4fe4633d1e94f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC0xLTEtMS0w_436fde0b-ba48-4589-8acc-7789f6fd4d9f"
      unitRef="usd">-94345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bb3578547994d3fb6471e6ac46c8ae1_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC0zLTEtMS0w_838ffbfe-9f06-4e51-9599-e14cb8948e7f"
      unitRef="usd">-51814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83bf53370dce463db3d2184cc9abeeed_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC01LTEtMS0w_7f16a07f-c46c-4ef4-b292-7ae72a896db3"
      unitRef="usd">-277294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife1a4766b133423c94f7ac43bee70be1_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNC03LTEtMS0w_27a29d45-399c-423c-a347-1887be1816e3"
      unitRef="usd">-161668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS0xLTEtMS0w_a31b5224-e4b9-43b1-8188-e8b6e91334fc"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS0zLTEtMS0w_c5f8b58d-8ce9-456c-add0-bfa3c1abae37"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS01LTEtMS0w_9f046351-9bbf-42bf-b528-68208008e6be"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNS03LTEtMS0w_9730b25e-7620-49a9-9cac-38419dfef73c"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idab36e2bcd114d1aa611a0fd8b23c6b8_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy0xLTEtMS0w_3b1ef0c9-b136-4389-9a28-4a28eb73fde0"
      unitRef="usd">49694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cb38727c00646bc8e4403f441c1d3cb_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy0zLTEtMS0w_d3b52731-7a23-4e93-91ce-5b423161b31f"
      unitRef="usd">33205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i695c14681e4f4d5f87205f78f9fad87f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy01LTEtMS0w_f682ad28-82a5-40f5-9e2e-035914cf93d3"
      unitRef="usd">116862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27d09316772e48fc9b79753ef65c18b4_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfNy03LTEtMS0w_585a4b31-d8ea-4eff-9835-45bcbb4edd97"
      unitRef="usd">113318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5660f465a85747aa8a0de0eb64461b04_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC0xLTEtMS0w_3db50703-463d-4a90-b331-d8e26f6120d6"
      unitRef="usd">15612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2e4421f00894202ab2f02e776a6a38d_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC0zLTEtMS0w_e165ab2a-f7bb-4c6a-b810-407080510a14"
      unitRef="usd">29300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0abc96c63a314b6fa495822ac6ac6120_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC01LTEtMS0w_e070fe31-1520-45da-ba32-862b67817fc5"
      unitRef="usd">92391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia02fe1481f9d46d3bdf069159261aa7b_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOC03LTEtMS0w_1e23b9b5-5cf3-425f-a992-0d0c05d3007c"
      unitRef="usd">62971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic66848fd649d4aa3b3af5f75c759ed57_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS0xLTEtMS0w_ab4f63e5-5379-4071-accf-923cb0ab3d68"
      unitRef="usd">65306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07c6d26551a848e69c150ea689520c0c_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS0zLTEtMS0w_41fc3bf7-f5c5-4725-8514-343b52f61e92"
      unitRef="usd">62505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf8e62d4ceae407da69dddd7a401315a_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS01LTEtMS0w_c9cf5bae-bf24-4429-a48c-2b4b29cf7387"
      unitRef="usd">209253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5701273b195d4b8fa25b28e5eaf36b88_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfOS03LTEtMS0w_468e9f42-54d3-4981-afd9-d580bef22a95"
      unitRef="usd">176289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtMS0xLTEtMA_a3542f78-9185-478e-8aca-c408fa0d776a"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtMy0xLTEtMA_98d2a79a-959f-4a9f-9b7e-22755b99438d"
      unitRef="usd">231092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtNS0xLTEtMA_44b3934c-ab1d-4870-969d-4d0344153ea7"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmYwYTgwMmY3NTMxNjQ3YmZiZjQ4NDAzYjYwYjJlYzcyL3RhYmxlcmFuZ2U6ZjBhODAyZjc1MzE2NDdiZmJmNDg0MDNiNjBiMmVjNzJfMTAtNy0xLTEtMA_83941c97-30e8-4f23-b142-a666157d021f"
      unitRef="usd">717486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5NQ_9ef8b030-f2a8-46d4-818e-952dd52092b4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi0xLTEtMS0w_6cbc135a-baeb-4764-9867-e9e6654eaa0d"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84f8a9eb0dca41b09aaedd7f9d03c606_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi0zLTEtMS0w_a9160fdd-3a89-4fa8-937e-d091c8f8f0dd"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie7eaebb9b56c4a4da079b1660c8ec3cb_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi01LTEtMS0w_dccf70f7-dafc-4214-aa7a-a1ed433082de"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e11bac7372644709417934e0ca155a5_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMi03LTEtMS0w_7b32cc81-551d-4c9a-b276-7987c909f120"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i916390b099cf490a8faaf1f1536bb941_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy0xLTEtMS0w_c7d6593d-5883-4687-824d-a6465813692e"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i27140a762b04420283d20b05a3483f19_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy0zLTEtMS0w_7491d2c5-e4cb-4ba9-b2ca-6338cf5d13ed"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifdd6869dd7354422821f089dadf50b8c_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy01LTEtMS0w_c5972a48-fe20-4a11-afa7-3e55bb5f2993"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib82fd13f9c484bcd90d7acca51198b90_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfMy03LTEtMS0w_298ec37b-1452-4b05-b688-248ff0db0fe2"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id19e6f8ceb3d4193a62ed61fe70f30d2_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC0xLTEtMS0w_b0c54e6f-c9a0-4c1b-8a6f-4f142b922047"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85d11b7619ee4ffdb9ca1f1ae9dcfcce_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC0zLTEtMS0w_cbb0a9d4-6a45-4f7e-a670-c716e2231cdb"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i43aff9879b254a2bb8d73b57aaad937d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC01LTEtMS0w_5ca7da7b-7007-49a2-b0b6-5f04c8cbcf60"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i748062d52a79415b951264743fd8a262_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNC03LTEtMS0w_9bc488ee-e479-4ce9-9736-dac2451ea243"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i333ba041ae564029967d730948f966a1_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS0xLTEtMS0w_6e7f548d-eda0-4c8b-b4ff-2c8465a00c5d"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i533ba6a6b82e4d4b9cb2b6bf9f6227d8_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS0zLTEtMS0w_11d08a9a-0560-4714-a3ce-11d795117a23"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icab832c59885481194024af60a61d1df_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS01LTEtMS0w_08e27025-dbb7-4a86-ba04-fe9c32f15ab1"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i094984ccbfca4e3fac09b15012e1be74_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNS03LTEtMS0w_f0cbae35-a98e-432d-bb81-47c09c3305d7"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i237d077e560b4407af980d2b6dbb5351_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi0xLTEtMS0w_f93efa01-84c1-43cf-a2be-a5f02a2a2028"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf27c022f00045578983d2cd05cefd50_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi0zLTEtMS0w_f26c2ae9-c2a2-465d-9eb8-a2f00ae2db57"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icfefd582d8584f539f09611fe980f68f_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi01LTEtMS0w_f464bb80-9f60-446b-a8f4-8b4bedb5c955"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i96da6fb9308c4441a6c7e0e9966c1d83_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfNi03LTEtMS0w_67db7558-90ff-4aa0-85f3-906931a54b70"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idef660618700414f8dcbfb860da76a87_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC0xLTEtMS0w_7b397668-6776-4b72-b195-cdef22700e35"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa1e2a62f0694219aade24fac80d1c5e_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC0zLTEtMS0w_1147789a-f15f-446e-b719-8d16fe86834f"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9326972b57124d95b7c72df93cabd3e1_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC01LTEtMS0w_e0f94e77-fb17-407f-8e11-f858e62eca39"
      unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie773f2a3a13f4701a26b5a39d5d1daee_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmI1NjNhMjRhNDA3ODRkMGQ4NTY2YjEwNDZkYTM2NTJhL3RhYmxlcmFuZ2U6YjU2M2EyNGE0MDc4NGQwZDg1NjZiMTA0NmRhMzY1MmFfOC03LTEtMS0w_966c6ba7-953b-4ccf-b5d6-2714914e6fa4"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia33755e44bf94f1da1da6239ce61afce_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMS0xLTEtMS0w_4880df0e-3066-4b51-85a4-53dc80f56bc6"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic1034b890c344f2187aff9b841e56da4_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMS0zLTEtMS0w_e5fdb826-6908-46d5-8bba-4aecf57009f8"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie8b6af8835eb4a388447fefe69add707_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMi0xLTEtMS0w_85cb694c-2b0f-450f-9577-3d743d5a9ec8"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8f554670ff6b4145bbceb659e8d31cee_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMi0zLTEtMS0w_39568caa-bb5c-41c9-a715-80fef6e544b9"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i362468d981744887840c7c13b4494a7b_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMy0xLTEtMS0w_b87f2087-cce2-4bcf-8a2c-060badb51873"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ife4a5f75f1f84d7cb2773b54773806d1_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfMy0zLTEtMS0w_d800b7e1-2ac0-4c9f-b516-faa4ec522499"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a51cab5342b4f589598449b9d53e45a_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNC0xLTEtMS0w_b5d5527a-2478-4b09-9252-f6b45a560fea"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9fe7a926c38a46a6a1270839bca439ab_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNC0zLTEtMS0w_03ada757-bdfd-4011-965c-12eaa2776866"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8e56e167d51d4361a27af591b87356ee_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNS0xLTEtMS0w_6906ac86-0f3d-4d78-a614-fbaf45b6456a"
      unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaae0fe3ee92a4735919e62e7c773d8f8_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmFjZWI1YjJiM2E0ZTQ2OTVhNTMxMTc4MzU1YTAwMmFlL3RhYmxlcmFuZ2U6YWNlYjViMmIzYTRlNDY5NWE1MzExNzgzNTVhMDAyYWVfNS0zLTEtMS0w_b8ef8fb8-b6a2-46f2-b299-c80c79b9c744"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5MQ_ce8ad047-da59-43fc-b059-6e4691245cc3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac98a4d51cd54e6993377fc838bb765a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi0xLTEtMS0w_70e3f27d-12a3-487f-8565-43939e843af2"
      unitRef="usd">266436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31062813c13140b7b457913dd4852e78_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi0zLTEtMS0w_0ae7ec58-f612-4883-8de0-fe39068a30ca"
      unitRef="usd">171552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5422d1856079466bbb9f65186f532193_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi01LTEtMS0w_2bb1619f-0b75-4fc2-869e-75931ef24cce"
      unitRef="usd">783583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0cbb1bbb9c8465c8eaa7264a9c37ea6_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMi03LTEtMS0w_46f4a963-914d-4afa-a85e-f0dbcf474a07"
      unitRef="usd">549379000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic620d2de433e40fca7e2944d830c2bda_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy0xLTEtMS0w_dd65bfb8-b417-4152-b7ac-ab08c248b8a1"
      unitRef="usd">38095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b511d5be3cc42d6a46455b239456426_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy0zLTEtMS0w_f0542b6f-1fec-40b8-9c23-f76fc8f1ee48"
      unitRef="usd">36006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i210d874da4ec4ad2b439ac379d882d7c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy01LTEtMS0w_8b50088d-6f81-4f3d-b257-01284f95a684"
      unitRef="usd">162822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ebc613892384a1e81978aadc22bc1fd_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfMy03LTEtMS0w_74d8e3df-f33b-40e0-9b09-911d3b8cb544"
      unitRef="usd">117959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id076f77c6811421996bf94e07e9611b6_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC0xLTEtMS0w_dba68782-a68f-4452-9c73-51e0782d63fc"
      unitRef="usd">23892000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf26fde834484f20a6cb7803fb0e1cd7_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC0zLTEtMS0w_e6197e16-e564-4453-bcdc-9d38322ba45e"
      unitRef="usd">23534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d721a4a024409b8e51b7763addb8a4_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC01LTEtMS0w_b72a6cb1-cd92-43cb-868c-23b148413c72"
      unitRef="usd">37425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6cabd3bc8aa4381abca308dce1cb94b_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNC03LTEtMS0w_d2ad1f16-a73e-4e0f-8133-e473a61dd542"
      unitRef="usd">50148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS0xLTEtMS0w_529019e6-e35e-4d54-971b-589e21c93047"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS0zLTEtMS0w_ca79663f-6e73-4ccd-9e7e-da790d41e914"
      unitRef="usd">231092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS01LTEtMS0w_97af7416-3830-4653-83aa-fd43caa13c61"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjllZWY0ODU5YjE1YzRlMzI4ZDA5YWVhMTY1MjBjOThjL3RhYmxlcmFuZ2U6OWVlZjQ4NTliMTVjNGUzMjhkMDlhZWExNjUyMGM5OGNfNS03LTEtMS0w_32787fea-9872-4914-9c55-8cea9274aceb"
      unitRef="usd">717486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI4NQ_b46950c6-f64a-4467-8700-014a7c33b270">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets were zero as of September 30, 2021 and December 31, 2020. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities as of September 30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f2514fa13b9413db7b3f86827a216cc_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi0xLTEtMS0w_30ea9611-8061-40f2-9fce-4bf8d9e6152a"
      unitRef="usd">259791000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52ed7af7a5b8432dad75ddaa4bc98d77_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi0zLTEtMS0w_e9ce1009-7ca8-4fea-b3b5-a32a2274f03d"
      unitRef="usd">159555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i886d9164ed4647cf9aab2503a662e148_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi01LTEtMS0w_6d8f548c-cde8-4720-96e2-ca5ceed0f1a2"
      unitRef="usd">759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if43ea83781f046ea919b9cbceae39832_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMi03LTEtMS0w_24817ef6-e6c9-4548-b71d-df43fc0b0271"
      unitRef="usd">522381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44c6af5351c04591a3a684eaf231d711_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy0xLTEtMS0w_d58ef229-fa97-435c-b347-3c60c9c5c745"
      unitRef="usd">3326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb1fd8c412d841c9b9361bc3a6ccd5d4_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy0zLTEtMS0w_e2f0e254-76c9-46da-b1b9-6711e88438e7"
      unitRef="usd">9032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37bf6ef982543208fd55d26c3a8d017_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy01LTEtMS0w_5bf0a2b3-9125-4bfb-a3e1-a887fcfa0879"
      unitRef="usd">15577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fb4d4519bbd45b58964c21b78d81e64_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfMy03LTEtMS0w_87b2e9b9-e487-4cdc-af61-0c8e5d7bd2d9"
      unitRef="usd">18816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80c64cdb5d4b43caa67aaef3a98e7d3f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC0xLTEtMS0w_9b774a79-1f7f-4ea5-9455-043123aeb78f"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide163890188b441d915e37fe3b4e3038_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC0zLTEtMS0w_497fa6a5-17ed-446e-a189-13d88c90aab1"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f29cb9f08ee45a29dd136d558748075_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC01LTEtMS0w_5658e17a-d949-4e92-b9ea-3cdecaf0041f"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27e293917aa24f789ba66049fb463e9a_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjE2NmU4YjdkODU0ZTRlZjViZGE5M2U2NmMwNTE1YWI2L3RhYmxlcmFuZ2U6MTY2ZThiN2Q4NTRlNGVmNWJkYTkzZTY2YzA1MTVhYjZfNC03LTEtMS0w_8ebc4ca6-17cb-4129-becb-33e7727e1d7a"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5OA_c86bbeee-e402-4415-9b3d-0c8a4c14b498">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if92ef125dfb745409eb663f06a66015c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS0xLTEtMS0w_3f8c50e6-0127-40a7-9676-6b69a3d2ed21"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i347244ecea174e2b84d7115e9117517a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS0zLTEtMS0w_c574b52c-8c06-4d9a-bf83-abe158a7ab7d"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iecec3a46caf04b9bb463218152250078_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS01LTEtMS0w_99c469f4-ff36-476b-95d8-06046d1741f4"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMS05LTEtMS0w_fd36fff4-684a-4f59-98de-74a72397a8cd"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy0xLTEtMS0w_ef441f16-17ed-4584-b965-ca13a6d309bf"
      unitRef="usd">178083000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy0zLTEtMS0w_ea6f22f8-a25c-4ea8-a62b-f12975cd8761"
      unitRef="usd">22945000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy01LTEtMS0w_4bd43313-5ecf-468d-925c-8b65ead482be"
      unitRef="usd">74851000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfMy05LTEtMS0w_59787200-10fe-4b38-98f4-6ed0db6c86e8"
      unitRef="usd">275879000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC0xLTEtMS0w_b01296d8-d6ff-433c-a1b4-6181ffd6d929"
      unitRef="usd">-22000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC0zLTEtMS0w_2f8db0c0-2156-4bdf-9168-d6c6dfbbab5b"
      unitRef="usd">-225000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC01LTEtMS0w_5807bfe9-2a2a-4226-9bf8-879db3afcbae"
      unitRef="usd">1662000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNC05LTEtMS0w_b110690c-4d91-4f9e-b858-9b526c5b8505"
      unitRef="usd">1415000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iad4c2b3290de4474a262c04c938c86de_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS0xLTEtMS0w_786ff62e-5f59-489e-a8cb-dd13f9703238"
      unitRef="usd">171416000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iaf40ff7bc36a4345bac98a87498946c4_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS0zLTEtMS0w_6d18787c-fb2d-4a12-997f-ab6b1326c292"
      unitRef="usd">18789000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib1e4a9fd672f437fb8e0eb25faa88184_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS01LTEtMS0w_c5a3d412-9373-451e-960e-2f04dde2105b"
      unitRef="usd">70007000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNS05LTEtMS0w_97eba886-199a-4e31-a912-94df070df238"
      unitRef="usd">260212000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idc219e31879f4e968543b9a4acc1c6bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi0xLTEtMS0w_27139e91-111c-4095-8898-9be180ed094d"
      unitRef="usd">16498000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7f92052702c84e3da6d1adf2f5d4712a_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi0zLTEtMS0w_ab551e4d-29ba-4a73-8d01-b55191e36625"
      unitRef="usd">7210000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i299213a2fe8a44d19010980daaddadd2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi01LTEtMS0w_52d40783-a605-4638-810b-3d0e9124f31b"
      unitRef="usd">23910000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOjJkMTVhYWYzODY2YjQ1OTg4MWZmNDViMjk4NDE3ODFjL3RhYmxlcmFuZ2U6MmQxNWFhZjM4NjZiNDU5ODgxZmY0NWIyOTg0MTc4MWNfNi05LTEtMS0w_f2b8fd8a-4212-42b0-abc1-4ebe17cca377"
      unitRef="usd">47618000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNzE0NjgyNTU4Njk3Mw_4d662736-3da9-4c2c-ae24-bce92a607099"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNzE0NjgyNTU4Njk3Mw_d9edb405-899f-4141-b15e-067f8f4cc7ad"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNTI5Mw_5f2754bc-69e0-4d2e-9f40-8bd592fb4fa5">Contract liabilities were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfNy0xLTEtMS0w_4961e843-2d0a-41ef-944c-1cad7c1ae753"
      unitRef="usd">7535000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfNy0zLTEtMS0w_143b7f85-500b-463e-b2b4-df1c894b2bcd"
      unitRef="usd">1790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOC0xLTEtMS0w_e4c7e80e-c129-4b1d-861f-e94669e43810"
      unitRef="usd">9444000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOC0zLTEtMS0w_6895c262-6d90-4e31-b17b-cd36ae89fe6d"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOS0xLTEtMS0w_9d71572b-a22e-44c3-8a0b-3a203b1673f8"
      unitRef="usd">16979000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RhYmxlOmQ0NDZhY2VjYzY1ZDRmNjlhOGM1NzcxMWI5NTUwMDE3L3RhYmxlcmFuZ2U6ZDQ0NmFjZWNjNjVkNGY2OWE4YzU3NzExYjk1NTAwMTdfOS0zLTEtMS0w_9fe2733e-2e5e-4928-b0b1-e74b3dae373a"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDI1Ng_2d9082a9-cc21-4ada-9f61-9b00cc5982c5"
      unitRef="usd">6800000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDI1Ng_e0647e83-a1b8-45d7-a820-ebe87357d016"
      unitRef="usd">6800000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDQwNg_50ca8bac-407e-4ece-b374-3aba93e57e06"
      unitRef="usd">48400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDQxMw_9cdbfd03-dbd0-452e-99a7-c789c00f55f3"
      unitRef="usd">116200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDUxNw_b95abcba-1980-4a15-8f22-ace158305a75"
      unitRef="usd">33100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDUyNA_4b148db8-a688-4c21-ac75-0841802e90a9"
      unitRef="usd">115300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y18zNy9mcmFnOjZiZTQxZjJiZWI1NTRmZjQ4YzA0MjNjYzEzMGQ3OWJhL3RleHRyZWdpb246NmJlNDFmMmJlYjU1NGZmNDhjMDQyM2NjMTMwZDc5YmFfNDc3NA_a94755c3-0dd5-4fd1-b335-d2029d9946dd"
      unitRef="usd">86500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNzAwMw_bfd90d17-290b-46e5-8f63-440ae163e24e">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the collaboration agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;triggered by the timing of the exercise of its option. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, collaboration services revenues for the nine months ended September&#160;30, 2021, includes a cumulative catch up for Ipsen&#x2019;s share of global development costs incurred since the beginning of the study and through the end of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone revenues for the nine months ended September 30, 2021 included $11.9&#160;million recognized in connection with a $12.5&#160;million regulatory milestone we determined was probable of achievement in the second quarter of 2021. The milestone was achieved in the third quarter of 2021 upon submission of a variation application to the European Medicines Agency for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$44.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the tr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone revenues for the three and nine months ended September&#160;30, 2021 included $18.8&#160;million recognized in connection with a $20.0&#160;million milestone we achieved upon Takeda&#x2019;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, $41.7 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK and Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $11.5 million and $33.7 million during the three and nine months ended September&#160;30, 2021, respectively, as compared to $7.9 million and $23.7 million in the corresponding periods in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, in support of our development pipeline, we entered into collaboration and in-licensing arrangements with Adagene Inc. (Adagene), WuXi Biologics Ireland Limited (WuXi Bio), expanded our collaboration with Invenra, Inc. (Invenra), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $28.0&#160;million and will make payments for potential future development milestones of up to $98.0&#160;million, regulatory milestones of up to $229.0&#160;million and commercial milestones of up to $802.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In addition to the upfront and future milestone payments, we will also pay Invenra, in three equal annual installments, an exclusivity payment of up to $15.0&#160;million to nominate up to 20 additional oncology targets and up to $30.0&#160;million in research program funding in equal quarterly payments over a three-year period, as well as additional fees. As of September 30, 2021, we have paid the first exclusivity installment of $5.0&#160;million and $2.5&#160;million for the first quarterly research and development funding installment. We have the ability to opt in to certain of Invenra&#x2019;s other internal research programs in exchange for an option exercise payment of $3.0&#160;million per program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in May 2021, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $5.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $9.0&#160;million payment upon the completion of an initial technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNzAwNQ_b42a56cd-733e-4299-aab5-a6d590a99aa8">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8e6809b452b4c0d91e76fccd77f2f8c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi0xLTEtMS0w_4d44c815-e9ba-4255-9423-c505b5769399"
      unitRef="usd">25139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62c12de1d32146d68e9fb7edd1441d2d_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi0zLTEtMS0w_e7ff58b2-7f81-4a8e-81f3-96a5857bfb11"
      unitRef="usd">19910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92e4ab99fdb34795911040b0e2097e76_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi01LTEtMS0w_c83b5118-3cb7-400d-ba62-b83ed124fe95"
      unitRef="usd">81246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3beaad32f58b469c90e2e895a020fed6_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMi03LTEtMS0w_ea3368c7-a9b4-4a66-8a1b-d86aca996cc8"
      unitRef="usd">71456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8050e574dc1c4db78e12b097abdec6dc_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy0xLTEtMS0w_9655fa2d-89e6-4b32-a243-4ee399ea748b"
      unitRef="usd">12956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ebdacb1fea40dd827669ddd4d97f01_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy0zLTEtMS0w_c5b8e14c-cdb9-457d-930a-352ef3884324"
      unitRef="usd">16096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieabc23478b384ed9851e76ca8df34e39_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy01LTEtMS0w_f7da5fa0-6625-422f-a9a1-d1f9074eb738"
      unitRef="usd">81576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c088daadd8a408f89a19ef83a3570ed_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfMy03LTEtMS0w_6d27c294-6879-4b23-afad-d482ba9edcf7"
      unitRef="usd">46503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41488a2e36454734af6a6a327ecb17cf_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC0xLTEtMS0w_e60e3764-3db0-4f20-b851-c05a6fb671f2"
      unitRef="usd">38095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f0256d26fd34b138fadf3cd0c240a78_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC0zLTEtMS0w_08cb184e-f3da-492c-90b6-450acbb659e6"
      unitRef="usd">36006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC01LTEtMS0w_7148ffd8-313b-4a96-a6b3-c962f575e771"
      unitRef="usd">162822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c65d788a4d64260968ac3714dcfe64f_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmJlZDg2NjNiYWVmNDQyZmU5ODYyZmNjOWViNGMwYmJlL3RhYmxlcmFuZ2U6YmVkODY2M2JhZWY0NDJmZTk4NjJmY2M5ZWI0YzBiYmVfNC03LTEtMS0w_991a5492-633b-4507-b0ad-e987d0e2c7d7"
      unitRef="usd">117959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjM4MQ_641f434d-23c4-45c7-8d8e-0b3e72166750"
      unitRef="usd">11900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement
      contextRef="ia7183ea49abb44619f51586094019e9f_D20210403-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjM5Ng_a5cfac8d-708f-4588-adfc-55f02f29015c"
      unitRef="usd">12500000</exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i303d549538f2427bba2cce5280974392_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMjk4Ng_992491c4-1dc5-4f8d-b536-54d323d1dabd"
      unitRef="usd">44800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59abfa55299448e3a17334e501e602fd_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi0xLTEtMS0w_4a25f817-dae7-45b7-b873-f1d33082fc16"
      unitRef="usd">20078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8ef9a35f9714d0baf8ee7a1bf5fa4f9_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi0zLTEtMS0w_59e30426-bee8-4601-80e4-ebd84b107e85"
      unitRef="usd">9780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46630f5e17e048d6958cfa0d603db35f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi01LTEtMS0w_50b2788d-aabc-49ce-b8ea-0b7c92d71aae"
      unitRef="usd">23476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf65eae8d34c44368baa6edb4df56a64_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMi03LTEtMS0w_92872e8d-6828-45ff-8877-d10409263b41"
      unitRef="usd">32726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id970f743dae1483e88e2ddd200c78c24_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy0xLTEtMS0w_7f5b3ed7-85c1-4bd9-a272-eee929b1a0c8"
      unitRef="usd">2656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d005b00a57d4883b8ae4d21dc6bde0b_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy0zLTEtMS0w_9a821d4f-3014-4b20-bab7-190f8b208faa"
      unitRef="usd">13204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5db0c4605f84fbdb15d0ac333e9c674_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy01LTEtMS0w_6dd846cb-2027-4882-9f09-8898b3735f56"
      unitRef="usd">10815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5376f2dae7f547e9b48251e30c8efb87_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfMy03LTEtMS0w_494a6f76-bcb2-4a8c-8681-cb45d02b1661"
      unitRef="usd">16468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1e1880501a749b483269275293c21a5_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC0xLTEtMS0w_bf897e3d-7344-4fa3-88bd-a6dd5d7ca2d1"
      unitRef="usd">22734000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i227171c03dd7470ab777a1c62dda82f1_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC0zLTEtMS0w_5b719c48-73f8-4197-8de4-37a4ce80a715"
      unitRef="usd">22984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC01LTEtMS0w_bc391bd2-3a89-48ce-b3de-ba8694780dcd"
      unitRef="usd">34291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3992056ab144b1b9917c48ab7ac95cf_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOmM1MzIyMTAyNzY1ZjQyNmE5M2I0ZTg1NDA0NmMwNTEyL3RhYmxlcmFuZ2U6YzUzMjIxMDI3NjVmNDI2YTkzYjRlODU0MDQ2YzA1MTJfNC03LTEtMS0w_de4106d4-0c03-48b9-af7d-b1d050280d65"
      unitRef="usd">49194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id1e1880501a749b483269275293c21a5_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYyOTI5MjE_2ff0f5f3-d01c-418a-bfad-15e1569bc253"
      unitRef="usd">18800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYyOTI5MjE_969dc30a-6596-4759-98d3-f81ff3703dbc"
      unitRef="usd">18800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement
      contextRef="i5ef648d1ee19491fb976970fc7fce62b_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDk0NzgwMjMzNjQyNQ_40a317b2-71ca-4345-8506-86830d680772"
      unitRef="usd">20000000</exel:RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i893a51123e7c4016962a39929c139bff_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMzgyMA_3fd993fe-e072-4a17-b23c-c30bad1bfd1c"
      unitRef="usd">41700000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i180e76bcc0744dceb497bede8877d6bc_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDEyMA_50aa1c13-2a65-4a9f-9bf0-c76702dcaeae"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="if33937ce988840acb055192972fe7d0e_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg0Mg_fd9396d3-3e8d-44bc-b232-c87daace7590"
      unitRef="usd">11500000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="idb3f26725f7e469ab88cddcff11f5119_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg0OQ_9e248f10-c617-484e-bbfe-9adedb895bc7"
      unitRef="usd">33700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i19bb8d1b724e4bd8a470e35512bff9e4_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDg5OQ_b433434d-a9d0-435d-89a9-7f9c470d3526"
      unitRef="usd">7900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i0eb6246a347b47a29f0ec6969990a643_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNDkwNg_49d722f8-d4ea-42e1-8a24-fd0f2a90a3b0"
      unitRef="usd">23700000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi0xLTEtMS0w_238086f3-dc83-421a-a80d-48c68a2ac904"
      unitRef="usd">1743000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi0zLTEtMS0w_05eadb95-bb82-4dbd-9cde-b86a6c859fd3"
      unitRef="usd">1595000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi01LTEtMS0w_cad71e2d-5bfb-4251-b811-8ed70d9277df"
      unitRef="usd">5697000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMi03LTEtMS0w_4193db9d-38ec-41cf-94e4-591011e00fa4"
      unitRef="usd">4378000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy0xLTEtMS0w_04b97478-169e-4538-8659-a7efd4fe8ec5"
      unitRef="usd">1576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i906cf0b972234d0e8f7951b005f940ae_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy0zLTEtMS0w_f0df1ce6-613b-4299-9bd7-a642e958ada5"
      unitRef="usd">1370000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa915d8924f24f73b69b7ac81e7408ad_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy01LTEtMS0w_b2b50850-8ebe-43cb-9bed-dd60f728a4fb"
      unitRef="usd">3309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba781b6b360e4ed4aba39ac1313cfd1b_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RhYmxlOjY4NGQwNTIxNjljMDQxYjM5YWRlYmVjNmI2MWQ3MzNjL3RhYmxlcmFuZ2U6Njg0ZDA1MjE2OWMwNDFiMzlhZGViZWM2YjYxZDczM2NfMy03LTEtMS0w_4818202f-dd4d-4afc-879d-8f4babf33204"
      unitRef="usd">3804000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjMzNg_487eeeba-7d8d-4724-b991-3c9b084a8e52"
      unitRef="usd">28000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQxNQ_17064ff6-d795-4512-aa1a-6552dc758e17"
      unitRef="usd">98000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQ1MA_019a8be5-a302-4bdd-810c-6805a6e9dd00"
      unitRef="usd">229000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjQ4OA_15236423-95fb-4518-9a21-85d8a13f4ae3"
      unitRef="usd">802500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjIxMQ_0d50def3-0a0c-4dde-830b-ec69b9c9689d"
      unitRef="usd">15000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments>
    <exel:CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA0NDUzNjA0ODAyODk_b7fdcbc0-a9af-462d-8aa5-fd2622866884"
      unitRef="target">20</exel:CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjIyNg_51d1e3e1-e4b0-47ce-af1d-72f3b6c5f2ae"
      unitRef="usd">30000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments>
    <exel:CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTI2NDQzODM3MzU4Mzk_5ee5ef12-90b4-4f9a-8c23-2a111555948c">P3Y</exel:CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTY0OTI2NzQ0MzE3NTU_b13c360b-8778-4f89-9ab9-3246dd21ed25"
      unitRef="usd">5000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment>
    <exel:CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTY0OTI2NzQ0MzE3Njk_b6ff9ef6-f4d2-4de1-b527-8ca203c6ea00"
      unitRef="usd">2500000</exel:CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment>
    <exel:CollaborativeArrangementRightsAndObligationsOptionExercisePayment
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfMTA5OTUxMTYzNjI0MQ_c34f0479-cd45-4f91-99c8-ead3971319e8"
      unitRef="usd">3000000</exel:CollaborativeArrangementRightsAndObligationsOptionExercisePayment>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i42c64fd2685d49a09c1aaa714e8a71b5_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjcxOQ_6fe8c200-485c-40aa-878d-ef47f9c8c318"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <exel:AssetAcquisitionPaymentUponClosingOfTransaction
      contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjgwNg_30451814-5f19-4f7e-8581-2efb9b4c52fc"
      unitRef="usd">9000000</exel:AssetAcquisitionPaymentUponClosingOfTransaction>
    <exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments
      contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjkzMA_c6c0900f-cd9a-4bbc-87be-f7060f1b78a4"
      unitRef="usd">42000000</exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments>
    <exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments
      contextRef="iab15a25bff164a59ba9db9bb00ba2c21_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180MC9mcmFnOjUwODMyZjdiY2E3YTQ5YWM5YTFhOTViZTU2ZjhhMGIxL3RleHRyZWdpb246NTA4MzJmN2JjYTdhNDlhYzlhMWE5NWJlNTZmOGEwYjFfNjk2OA_a91f39c5-ba73-481e-9e8a-e7bd63007601"
      unitRef="usd">22500000</exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjczNg_3b37b717-65e2-40a1-ad8b-adf7aa5d28b8">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of September&#160;30, 2021, restricted cash equivalents included $29.6&#160;million of short-term investments, which is collateral under our January 2021 standby letter of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $2.6 million and $4.5 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position for less than 12 months. There were 41 and 14 investments in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the nine months ended September&#160;30, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjczOQ_5301930d-c9b9-4a05-835d-7723b60ab878">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc1MQ_81242d84-a5c8-467e-bd01-f1d0ade1987c">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMS0xLTEtMS0w_5d8f92c7-594b-40ac-a242-33b57d90abe0"
      unitRef="usd">567325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMS0zLTEtMS0w_d55ec1c9-ca63-44ae-8d5c-15bcfc215c99"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMy0xLTEtMS0w_e3b89531-04e2-4a69-a9eb-3dd5b41959eb"
      unitRef="usd">31163000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfMy0zLTEtMS0w_30c01059-a3af-468e-815f-a21b13e8351d"
      unitRef="usd">1555000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfNC0xLTEtMS0w_c2ac607b-7b10-459d-b278-8f478330d7d0"
      unitRef="usd">598488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOmEzNGFjMDZlODYwOTRiNWViNzAyMDViMmZhMzRlODVmL3RhYmxlcmFuZ2U6YTM0YWMwNmU4NjA5NGI1ZWI3MDIwNWIyZmEzNGU4NWZfNC0zLTEtMS0w_d43c1215-6d48-43f6-9e5d-0220efe7595d"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTA5OTUxMTYzMTA5Ng_d6f9cf5a-69a4-4c23-bc22-1566d42f20c8"
      unitRef="usd">29600000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc2Mw_59c41fb8-e280-4dde-a8cb-a3d2a380f1ac">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,796,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4e81c19802d8419abd05b32afb361529_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy0xLTEtMS0w_5258f157-ceaa-4b61-94cf-f5218a696596"
      unitRef="usd">886323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4e81c19802d8419abd05b32afb361529_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy0zLTEtMS0w_f8beff7a-e1e5-4c3e-ba32-b4cdcd6fec2d"
      unitRef="usd">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4e81c19802d8419abd05b32afb361529_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy01LTEtMS0w_68f769ed-acf5-4656-8c03-777bb720493a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e81c19802d8419abd05b32afb361529_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMy03LTEtMS0w_1c49ddaf-fb36-43bb-b9b1-acf9758515a5"
      unitRef="usd">886396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC0xLTEtMS0w_99c5f2ef-2a96-4093-954b-53c8c80cb2ce"
      unitRef="usd">503707000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC0zLTEtMS0w_f0df31fd-2157-441d-aad3-32ed7cb28296"
      unitRef="usd">1967000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC01LTEtMS0w_46566594-a142-47cc-aafb-022051e53c78"
      unitRef="usd">126000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNC03LTEtMS0w_a8d21bd6-2283-46f3-a1a3-8e476af3d853"
      unitRef="usd">505548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS0xLTEtMS0w_48bc8856-7742-4b5e-ac6c-d811f256af0f"
      unitRef="usd">58965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS0zLTEtMS0w_e85e760f-31f2-4a1e-a399-eb4208accc70"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS01LTEtMS0w_d8acc0de-2d93-4c42-840c-fea726734e80"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNS03LTEtMS0w_a5d711c8-ef34-4acf-842c-a8e33100c4bb"
      unitRef="usd">58985000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi0xLTEtMS0w_b98ca716-a921-4b27-aafe-2178ab70d943"
      unitRef="usd">10670000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi0zLTEtMS0w_56731770-364d-4b9b-b3a8-fe53ac0729bf"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi01LTEtMS0w_174235d9-c56e-4944-8077-87a276abed36"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80f3b300dd384295b48111fb3de48dc8_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNi03LTEtMS0w_a1832aa6-3cc9-4536-81fc-e5ed99aa3b81"
      unitRef="usd">10711000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy0xLTEtMS0w_7043202b-f772-4f37-8638-5c15fc28b6ae"
      unitRef="usd">1459665000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy0zLTEtMS0w_b2bd52fc-92b8-4f84-8029-f825d25b4739"
      unitRef="usd">2102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy01LTEtMS0w_3e437967-2a34-4e44-be5c-9b12d43f7420"
      unitRef="usd">127000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfNy03LTEtMS0w_2fc72013-d3dc-4a52-bdf9-2bb3388efb50"
      unitRef="usd">1461640000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC0xLTEtMS0w_c45dc559-ef9d-414f-8063-d08b954e7934"
      unitRef="usd">80828000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC0zLTEtMS0w_ba2a69de-3d66-46ec-b28e-2cccb8af208c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC01LTEtMS0w_575cb848-2f97-4897-bd3a-a593fb2c9390"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i7dce2e60a7dd497a8e784207c60eda67_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOC03LTEtMS0w_4561c20a-1203-496b-b175-55734d9fd069"
      unitRef="usd">80828000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i4b1603788af44df89cb2501d143c508e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS0xLTEtMS0w_4c4b86e2-5089-40c6-b376-edebcc233669"
      unitRef="usd">119538000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i4b1603788af44df89cb2501d143c508e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS0zLTEtMS0w_47c8d6af-ab18-4c9f-b4bd-df830d15d37a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i4b1603788af44df89cb2501d143c508e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS01LTEtMS0w_4735bd78-0372-4ab7-8552-95b5e332e636"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i4b1603788af44df89cb2501d143c508e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfOS03LTEtMS0w_e5e0cf0d-47ce-4a14-ad40-5b89bc82e45b"
      unitRef="usd">119538000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMS0xLTEtMA_185ac0bd-bc4d-423a-b7a2-8b38978a9ad2"
      unitRef="usd">134106000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia937163ad2774ba59a4a97202dd4f1d3_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMS0xLTEtMA_72468528-233d-476c-8fd8-5661339ac2b0"
      unitRef="usd">134106000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtMy0xLTEtMA_80e3c689-c85e-478f-b1ef-fb6008a2ef12"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtNS0xLTEtMA_2504e056-6eca-4e5c-904d-b16300e0e4f1"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i6d33b9db55634d2f8dd4b55f547600b6_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTAtNy0xLTEtMA_7498871d-1797-4ede-b784-f936aff6d47b"
      unitRef="usd">134106000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtMS0xLTEtMA_e18a75f7-66ec-4a03-a90a-399dc58cb758"
      unitRef="usd">1794137000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtMy0xLTEtMA_5d9818b2-451f-4014-8a06-e447118730d9"
      unitRef="usd">2102000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtNS0xLTEtMA_439b1f3d-41ce-4608-b720-32a3eaeaf122"
      unitRef="usd">127000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjdjMmJmODUyNGE4YzQ0MzA5ZmY4ZDI4NjA5MTNkYjI2L3RhYmxlcmFuZ2U6N2MyYmY4NTI0YThjNDQzMDlmZjhkMjg2MDkxM2RiMjZfMTEtNy0xLTEtMA_516a9751-ff2c-49a5-aaa0-cb50f86acc34"
      unitRef="usd">1796112000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy0xLTEtMS0w_31178e7a-236b-46cf-adba-3888f311999a"
      unitRef="usd">569456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy0zLTEtMS0w_f1eef2dd-0e29-406b-bc2d-cac40b35385f"
      unitRef="usd">372000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy01LTEtMS0w_53cbb0c2-e133-4027-923e-40473701d562"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c1e55582ef1405eb4b03f5847cfea9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMy03LTEtMS0w_1a73d1bd-18e7-445c-9b6b-7635d6b68fae"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC0xLTEtMS0w_faef1c2e-602f-41e9-bdbd-e72ec31f2b52"
      unitRef="usd">543520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC0zLTEtMS0w_f125662d-1330-4db7-9604-d7497e986b8f"
      unitRef="usd">5244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC01LTEtMS0w_2088ebad-cbd6-4893-b6a2-278edfb482da"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNC03LTEtMS0w_c9c50e66-d9b4-49a0-98f1-35eb47022565"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS0xLTEtMS0w_c4229c4b-0640-4f01-b6b2-61cdcba94808"
      unitRef="usd">208326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS0zLTEtMS0w_0e542cac-7140-4abe-b83b-1baf6b9b77f3"
      unitRef="usd">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS01LTEtMS0w_04eed4dd-9793-4546-83ac-474dad0e3cce"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNS03LTEtMS0w_dfe6672e-9e46-4685-9ade-1b937f69e417"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi0xLTEtMS0w_10d18e4c-eaa3-456f-aca8-1d49ff6f26b5"
      unitRef="usd">28680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi0zLTEtMS0w_52168c0d-716c-4b98-8ffd-c5904d670695"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi01LTEtMS0w_94369058-8219-48bb-984d-b3e7bd935d1e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNi03LTEtMS0w_599345e2-1162-4018-bce6-a7fdf443777f"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy0xLTEtMS0w_952eb233-efeb-4624-b97a-34a4750f7760"
      unitRef="usd">1349982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy0zLTEtMS0w_f593dc75-d6f0-4a81-9fe9-da877fb82a61"
      unitRef="usd">5931000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy01LTEtMS0w_eb3ef31a-5870-4b76-a9f5-bb87453925b9"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfNy03LTEtMS0w_24c6d3d7-59ca-4f7a-84f6-93dceff6fa30"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC0xLTEtMS0w_d28be6a6-068a-45fb-83f1-86134d19cabd"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC0zLTEtMS0w_627e42a2-9030-449b-9474-18576ababdcd"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC01LTEtMS0w_73e17b40-4e70-4e74-9186-47d6c694a81d"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i522e306d776042df8fab951f97ebaf9e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOC03LTEtMS0w_e91975d0-1341-4483-84c1-6bcb87be6125"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS0xLTEtMS0w_eff4d68a-cf85-4035-88aa-ebcccae400eb"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS0zLTEtMS0w_bfc29160-8753-4073-bd3d-8c1fbdadefcc"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS01LTEtMS0w_100948c2-2387-45d2-b144-41394e69f105"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i3e0f0514bbc24b8596206e4a278f05c9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfOS03LTEtMS0w_ecc97589-c4ce-4f8b-b3f4-2d0b1a8b0a9f"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtMS0xLTEtMA_fa59a91d-9dbc-41cf-9fae-837926e2f8ac"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtMy0xLTEtMA_fb7be8f9-c970-4fcc-a43f-644bf8694fc0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtNS0xLTEtMA_ffc3cb19-73c7-41b1-8e8d-0ffcf7131f5a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i7942a0d26aa2410493571fbd1d1a1d40_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTAtNy0xLTEtMA_8927f37c-9f6e-4069-9e74-eb6a491dcf80"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtMS0xLTEtMA_f5e52180-e3a5-4947-a138-b4e09a5f5c8c"
      unitRef="usd">1532923000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtMy0xLTEtMA_e7666da8-c024-4465-81b3-05184955c585"
      unitRef="usd">5931000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtNS0xLTEtMA_44abd114-9fef-47ff-ad51-b5b76df22fb3"
      unitRef="usd">12000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjA5NGU5ZTM5OWU2YzQ2YzBiOTU0NzE5M2M0NjgyOGY0L3RhYmxlcmFuZ2U6MDk0ZTllMzk5ZTZjNDZjMGI5NTQ3MTkzYzQ2ODI4ZjRfMTEtNy0xLTEtMA_4849b79a-abad-424d-9cc7-61e5d9f122b1"
      unitRef="usd">1538842000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTI1OA_cafd4d09-a554-4ad4-880f-32d56cd05462"
      unitRef="usd">2600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTI2NQ_629d6e0e-275e-4450-9032-8ad91e8b802e"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjc0MQ_17daf5b0-541f-472b-b146-ea28ab8fcf7b">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfMy05LTEtMS0w_a14eca3f-96de-4e35-8feb-a89288f209c7"
      unitRef="usd">136319000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4a8f21157bbf4e7a88b78baa89878020_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfMy0xMS0xLTEtMA_62db7552-28e5-47cd-bd44-c75f47d1ee7f"
      unitRef="usd">126000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNC05LTEtMS0w_c3f06b3e-10b5-414e-b702-b1c2778c7d0f"
      unitRef="usd">10007000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5d54e684ac234965a52c3f8147a489f2_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNC0xMS0xLTEtMA_6d9ed9f7-58aa-413d-a66e-a2c6356dcf90"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNi05LTEtMS0w_3f46b4e0-455a-4cb1-a457-281fd12a01b6"
      unitRef="usd">146326000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjYwNjc1YmIzOTZkNDRiY2U4ZjFkOTM0ZmFiNGVlYTQzL3RhYmxlcmFuZ2U6NjA2NzViYjM5NmQ0NGJjZThmMWQ5MzRmYWI0ZWVhNDNfNi0xMS0xLTEtMA_5d083d2f-6353-40c6-806a-53becc3421f5"
      unitRef="usd">127000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMi05LTEtMS0w_3273728e-e869-4b53-bd7e-dc7a0ce3403e"
      unitRef="usd">28445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i72ba7cec3f784d029dbad83cfea8cad5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMi0xMS0xLTEtMA_b1ae62bf-b646-45be-8efc-b286c93365b9"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMy05LTEtMS0w_0623e4bd-f6c7-46b7-a0e8-104e70ecd96e"
      unitRef="usd">21989000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic704aa165c1c46d4ae28412336d3f23c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfMy0xMS0xLTEtMA_03eebd9f-c26b-4eac-994e-555b60287972"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNC05LTEtMS0w_5e0b8ff7-b6f1-4aa7-bacc-74a0e13ba1ac"
      unitRef="usd">5865000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iac2eb9472f9747efb6644dfa8c514a6a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNC0xMS0xLTEtMA_1c52db8f-45ff-465d-9730-14813010a4db"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNS05LTEtMS0w_1f51e13c-7f42-4f9f-aa51-bc5b044240d5"
      unitRef="usd">56299000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjc1MTBhYTExNWUyYjRmYTNhMGQ0MWJlY2YwMGE3OWIxL3RhYmxlcmFuZ2U6NzUxMGFhMTE1ZTJiNGZhM2EwZDQxYmVjZjAwYTc5YjFfNS0xMS0xLTEtMA_d1fe88c4-f60f-4a81-b77a-865cdba0f8ad"
      unitRef="usd">12000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTk4Nw_987464f0-53ca-4a39-a5a5-c2bd4ced40d3"
      unitRef="investment">41</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMTk5NA_249cc8c6-5ca9-4382-b773-e42892b206d3"
      unitRef="investment">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i1ddb6bce36184f08be45c8955d58a6fe_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjEwMw_7271f294-3229-4559-ab3b-dcfe828f891f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjEwMw_8d53fe86-5b70-4b7b-92ca-e45f267c2193"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RleHRyZWdpb246ZjI1MjBiZjc0NTQzNDlmNWExZDVkZWEyM2RkZTU4N2VfMjcyMA_b097c642-9eda-463b-9e6c-b8d3a15daa57">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMS0xLTEtMS0w_75b25c55-1729-48c6-8b4d-75edcf88b78e"
      unitRef="usd">1103122000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMS0zLTEtMS0w_438b5a17-a297-418a-b84b-ae7b531a0144"
      unitRef="usd">1034150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMi0xLTEtMS0w_bb1ded5a-9171-4f81-b09d-10d908cba6f0"
      unitRef="usd">358518000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMi0zLTEtMS0w_7b6277f2-9cce-4dce-baad-a4c5ce8b9fd7"
      unitRef="usd">321751000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMy0xLTEtMS0w_b44ca5fe-cce6-49a3-ab35-9f3f9d0ff2c2"
      unitRef="usd">1461640000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180My9mcmFnOmYyNTIwYmY3NDU0MzQ5ZjVhMWQ1ZGVhMjNkZGU1ODdlL3RhYmxlOjAwNWVlMjQwZjA3NjRhYWQ5ZmM5ODFlMGE3MjNmZTRhL3RhYmxlcmFuZ2U6MDA1ZWUyNDBmMDc2NGFhZDlmYzk4MWUwYTcyM2ZlNGFfMy0zLTEtMS0w_635bd25b-931b-45df-bac5-def99192ee99"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjUwMw_98abff44-4d3e-4272-a0fc-a6f95759c4ce">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, we had one forward contract outstanding to sell &#x20ac;9.8&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of September&#160;30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months ended September&#160;30, 2021, we recognized $0.5&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjQ5Nw_3bf2c57e-1c5a-4e4f-99d3-c4b4ff2fa19b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57f02cd5c10e458e843d55805a3431fd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi0xLTEtMS0w_aefd6523-d1d3-4f1d-828f-93eb8e6232fa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icba2574066cf4ff6a9f6e4150f0d9a59_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi0zLTEtMS0w_e553edf1-ac89-428e-913d-f97664db5e4a"
      unitRef="usd">886396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdbe7cfb8d5147028098fffe5f993314_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMi01LTEtMS0w_08c33c28-8595-468a-b60e-73a1690b1d50"
      unitRef="usd">886396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0747067a48245fc8dc26066c743c9d3_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy0xLTEtMS0w_aca4b986-4cac-4a5b-802f-65be643dc091"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i262de96d6b8744ae924a3782d09bacc8_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy0zLTEtMS0w_f4d64f03-e0b6-4f14-9db0-660f42f26450"
      unitRef="usd">505548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia884675fcb614de78f41b988cfa85253_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfMy01LTEtMS0w_03cf9de0-ca12-4443-90e1-7dcb0a3ec78f"
      unitRef="usd">505548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i788e7100b3c44fc79ba7388a22d4be54_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC0xLTEtMS0w_d4c30d46-d49d-4452-a371-2b419eb30738"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5f49a14a38b4618a641e7062e9a8119_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC0zLTEtMS0w_ab0e68d7-d701-49e5-9362-fbb700dcb867"
      unitRef="usd">58985000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib852bbac7c2b4dae935d9ace85587f2b_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNC01LTEtMS0w_111b8648-fe76-4ca9-8eda-398c1f2aa9f4"
      unitRef="usd">58985000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2116aaf10cba486e9ea0a92a908bcf3f_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS0xLTEtMS0w_c1cbdfba-9d52-4dbd-a286-fe0abaa62435"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ac31bdedd8347f4a54d5329d8341508_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS0zLTEtMS0w_56e4608f-23f6-4f86-9387-dd3528280d4b"
      unitRef="usd">10711000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6aee20093514a7c908b61d8a427f82f_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNS01LTEtMS0w_69cbe701-d72e-426f-8b0a-5da148c21cf9"
      unitRef="usd">10711000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85113d3b2cbb42bea2638a8879a3bc44_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi0xLTEtMS0w_eee00c2b-7dd2-4bba-bd0d-098faeeb111f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47f7ba7484824fdfb1bf032ab871ce77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi0zLTEtMS0w_b3c74a76-5b26-468a-a2a8-1a7f85faeb5c"
      unitRef="usd">1461640000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1060b811968c481ebf2bbc36128837fb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNi01LTEtMS0w_699e3c94-851b-4c44-93a1-f0b3ac19c627"
      unitRef="usd">1461640000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74b53fa939094dbc9d03652f7ae327cd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy0xLTEtMS0w_fa69c5df-6b18-4f0b-bf70-7115387dd5ac"
      unitRef="usd">119538000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice95d1289bb548b3a198fedcadd68f9c_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy0zLTEtMS0w_38ff8e04-7008-4bfa-8cff-2943cc2db65e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0713852efdf4c9b8596061c2371f8c5_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfNy01LTEtMS0w_4a308603-7447-4ded-85e7-bdfc16bfaac7"
      unitRef="usd">119538000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2720023a476a45c4ad1b14dea520df26_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC0xLTEtMS0w_f10cf27d-ff53-460e-a3d8-f4305e42bd2a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia937163ad2774ba59a4a97202dd4f1d3_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC0zLTEtMS0w_18ef1f0e-5966-45c5-81b4-086a22a72fe1"
      unitRef="usd">134106000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f50cbeebde04173b4d76512c9e37178_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOC01LTEtMS0w_d3c2b0b9-158a-4006-99ce-c22e40a314f2"
      unitRef="usd">134106000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85113d3b2cbb42bea2638a8879a3bc44_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS0xLTEtMS0w_f41132ab-35bc-46e6-81c9-3fb13b10da1f"
      unitRef="usd">119538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i47f7ba7484824fdfb1bf032ab871ce77_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS0zLTEtMS0w_e3cd2e59-ba7e-4fc8-9916-101f59562820"
      unitRef="usd">1595746000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1060b811968c481ebf2bbc36128837fb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjY1MjI0YjIyYmQ1YjQyMGJhMjc3OTI0OGFlZGJiZDUzL3RhYmxlcmFuZ2U6NjUyMjRiMjJiZDViNDIwYmEyNzc5MjQ4YWVkYmJkNTNfOS01LTEtMS0w_a17ff686-cea6-4b4e-bcb9-2dfddcad2f76"
      unitRef="usd">1715284000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ce21a7f43c44e3f961a96a70156939e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi0xLTEtMS0w_5827b002-c664-4a45-adf0-22fda39e56a6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i358c92e2bfaf46b3bda44418ad4ddff9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi0zLTEtMS0w_49b44a91-2d67-44ef-8dc0-c6b37f54280c"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2eee75baece241f6bc83d598c6a8dce5_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMi01LTEtMS0w_d537f990-6ac3-4317-832b-d082ca3a97ec"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12b60ddc46614de198e0d20fcc2e0d40_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy0xLTEtMS0w_6f32b8b2-f338-4134-a396-781589875a8a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice80f13753ab4747b55be1f290360a38_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy0zLTEtMS0w_e70237f9-784e-4f0f-82cf-a5de04cb9fe5"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a068b43a44e4e71aed4fab765a9a10d_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfMy01LTEtMS0w_e3c5626b-0b57-447c-bf6d-4ecd53a15dba"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4197a386017d4ce4b80b50397cde9f66_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC0xLTEtMS0w_a5e4b1a3-284f-4229-9b98-60b12e2eeece"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74bd879c428e43e38d7c190fb00c13bd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC0zLTEtMS0w_3278ad02-7f15-4513-8186-e9f39c7f9049"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b26d8ad0e0c4ab9b2ddc26c19baf207_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNC01LTEtMS0w_e1f646f1-11b0-4d28-89b1-b5f51e14d730"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06308a04850340b581f089fa2d42d8ab_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS0xLTEtMS0w_47553ae7-d9d3-4879-bc98-3a665591256d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81a9bdf6dc464c5f9f939b05d8db8a62_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS0zLTEtMS0w_9edbbc9a-5636-48c9-b258-bcf2121bd19e"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd3bb879c1144c2b8f21d8d76daa2611_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNS01LTEtMS0w_efea0dba-ff90-4387-80d4-415c63f919c1"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi0xLTEtMS0w_9d6e816f-f621-4704-997c-11ae229312c6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b9dabe918ed4a75984789a54fabbc52_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi0zLTEtMS0w_479801b0-7060-40df-a6e2-d76d5debb2fa"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNi01LTEtMS0w_38991be5-f747-40a6-a126-feaf090b8664"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i576f4d76f4844ef59140fad75b749351_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy0xLTEtMS0w_5925ff6d-ae47-43a6-bf6b-f027a585ea70"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f14e7d83ac24bc0934f3ce817815377_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy0zLTEtMS0w_395f9feb-6e17-4ac1-97e3-1f6a8ba80628"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie604d7023f6448e9bfdea6430b029c7d_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfNy01LTEtMS0w_25427fea-6158-4333-a61a-697da6f2e87a"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8e3d41a820d64c68a08dc8510596f5bc_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC0xLTEtMS0w_3d397aa8-e343-49e7-aa2b-f8f935010464"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifc806a4586494bdea73d4d8ca8067226_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC0zLTEtMS0w_08ce1388-bcb6-4a5e-b269-2e79a9fd4acc"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idb5366d5070d44918ed8a0165ebd5ab0_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOC01LTEtMS0w_487cf2ce-78f8-4a13-befa-ff9078b00dfa"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if5ad5dfb4c3a4e98a8382e232c0b8843_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS0xLTEtMS0w_279a1725-e1f7-4914-8eea-daf5d8eeefbf"
      unitRef="usd">40761000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b9dabe918ed4a75984789a54fabbc52_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS0zLTEtMS0w_b79e466c-77a9-40e5-9c5f-e2fc26c5ef83"
      unitRef="usd">1415905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i862bbdfb2cb94b96a90d9fe26729fb4f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RhYmxlOjE4ZmVlZDc1MDA4ZjRhMmViNjEyMTI1ZGMwZDQ3NjQ5L3RhYmxlcmFuZ2U6MThmZWVkNzUwMDhmNGEyZWI2MTIxMjVkYzBkNDc2NDlfOS01LTEtMS0w_1722a292-593e-46f9-9e12-803d2cf9a0e7"
      unitRef="usd">1456666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i68ac30fd607b41bc80b50c13706647e4_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTg2OA_1527f1d8-db48-4ba3-8b23-28d7ce092802"
      unitRef="forward_contract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i68ac30fd607b41bc80b50c13706647e4_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTkwOA_1aed45a2-e216-497e-9e75-592402b16bc2"
      unitRef="eur">9800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMTk1MQ_e17300aa-447f-4b13-a605-49380e89916f">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i69591ba96b424b9584c7f124cef272e0_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180Ni9mcmFnOmYxMDFjMWIxY2UwYTQ5ZTRhNjA1MzI4ODZkY2FkMjQxL3RleHRyZWdpb246ZjEwMWMxYjFjZTBhNDllNGE2MDUzMjg4NmRjYWQyNDFfMjM0MA_b9d6db5c-30fe-4a0a-8c97-2e7cd6beac10"
      unitRef="usd">500000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RleHRyZWdpb246NWMyOTdmZGM4MWE0NGU4YmI4MzFhYWZmY2JkNGI0MTZfMTgw_26e62eed-c353-4031-9f1c-5a2acdeb9d4c">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RleHRyZWdpb246NWMyOTdmZGM4MWE0NGU4YmI4MzFhYWZmY2JkNGI0MTZfMTgy_c4cda8e0-7e74-46a4-81cf-dd6ceef8bb24">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMS0xLTEtMS0w_f269009a-5623-418a-b3be-4ea1009b0614"
      unitRef="usd">10317000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMS0zLTEtMS0w_648266ce-785b-4366-8e2f-d06c0aa36f43"
      unitRef="usd">7773000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMi0xLTEtMS0w_928483be-aeb1-44cc-bed4-cd46ffb97d80"
      unitRef="usd">28016000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMi0zLTEtMS0w_c1a6566c-e708-43bf-96f0-30add9383272"
      unitRef="usd">20610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMy0xLTEtMS0w_3450344f-cf3a-45fa-93b1-0a92b814f7f1"
      unitRef="usd">11707000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfMy0zLTEtMS0w_30736fd7-ef36-4789-a336-087f2ee0ed8b"
      unitRef="usd">7291000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNC0xLTEtMS0w_fd2239a4-f952-4a9c-9e89-d5b20292dc3b"
      unitRef="usd">50040000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNC0zLTEtMS0w_307500cd-3bfd-4bac-9f10-7c72133f26d7"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0936cbe6a0f84d479d483892d24f6d55_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNy0xLTEtMS0w_82e96343-d0db-4a64-a64a-01d9bb40eb93"
      unitRef="usd">28240000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib720450b2a1a4fc8a2cdcdb63baed576_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfNy0zLTEtMS0w_b4ee9c4e-21fe-453c-b8fe-e0450f2c58eb"
      unitRef="usd">20973000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0db00f27c60d4842a7a2bce3d6d547e1_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOC0xLTEtMS0w_8a2d391c-ce82-4c12-918f-1e97c9864536"
      unitRef="usd">21800000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ia41fd2edf3a14dd7bf6bb33de4813ccc_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOC0zLTEtMS0w_aac6a72e-aa83-461d-a05e-b25defb897ec"
      unitRef="usd">14701000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOS0xLTEtMS0w_c5d7bf28-de89-4fec-93c6-160b961299ae"
      unitRef="usd">50040000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y180OS9mcmFnOjVjMjk3ZmRjODFhNDRlOGJiODMxYWFmZmNiZDRiNDE2L3RhYmxlOmYxM2M3NGM1ZmNhNjQyNmY4OWViMTRkNzk0ODgwNzllL3RhYmxlcmFuZ2U6ZjEzYzc0YzVmY2E2NDI2Zjg5ZWIxNGQ3OTQ4ODA3OWVfOS0zLTEtMS0w_bdb4c701-d14f-40d2-bcb2-40f4b3fd5f4f"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM5Nw_dcd68c7c-2943-41ee-a4ee-2449154ffae2">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 9,248,609 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, we granted 2,032,884 stock options with a weighted average exercise price of $21.81 per share and a weighted average grant&#160;date fair&#160;value of $9.30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of September&#160;30, 2021, there were 14,357,896 stock options outstanding and $28.6 million of related unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, we granted 3,947,355 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $21.50 per share. As of September&#160;30, 2021, there were 8,218,085 RSUs outstanding and $136.3 million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we awarded 1,027,650 (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#x2019;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;September&#160;30, 2021, there were&#160;7,768,188 PSUs outstanding and $128.6 million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2021, we achieved an additional performance target for 524,307 PSUs granted during 2020 (the 2020 PSUs) and determined that it had become probable that we would achieve an additional performance target for 167,726 PSUs granted during 2018 (the 2018 PSUs) and have recognized $11.4&#160;million of stock-based compensation expense related to the 2020 PSUs and 2018 PSUs during the three months ended September&#160;30, 2021. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM3Nw_08a0d34a-325a-44a3-9f21-55748457d158">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icafa823dcfbd4c2a9d8b8df5d69e150d_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi0xLTEtMS0w_405d3115-0144-46ca-a3f3-72b9d7acd2c6"
      unitRef="usd">11487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6bdb2309e0e5446b87b31a0eb6c99f2c_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi0zLTEtMS0w_dcf19138-4114-4034-bd8b-584743649e52"
      unitRef="usd">18936000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67eaaa8ffdc4407780e4e29e54ed4917_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi01LTEtMS0w_94f2c06e-11c6-4bd2-935d-8486816051ef"
      unitRef="usd">37550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b8058d357f34b1db293a0ba18c7b0e4_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMi03LTEtMS0w_c5b76669-17a2-480d-926e-adae14139439"
      unitRef="usd">30134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ff8c10e09a74083a913c8dd829db3e3_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy0xLTEtMS0w_768f8a27-bb2e-4c64-b596-2b2304ea957e"
      unitRef="usd">22479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i133709ff0a1b4c138d61663fd033397e_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy0zLTEtMS0w_70335dc1-e150-489b-a688-14a25e65eb62"
      unitRef="usd">36719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4b5f2d2f5d3425586df0611b0cd3dbb_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy01LTEtMS0w_2629d511-d04b-460d-919a-6c25cfda90c1"
      unitRef="usd">59104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4accc8a979184a968b8b082d620fbf50_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfMy03LTEtMS0w_c7caae55-f480-4d84-b07a-36fa0ec6b8f9"
      unitRef="usd">55657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC0xLTEtMS0w_72a4ff1a-650f-49f0-b25b-66eb7ab8e485"
      unitRef="usd">33966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC0zLTEtMS0w_81b6667a-d820-4c13-a39e-bdfa21b25358"
      unitRef="usd">55655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC01LTEtMS0w_8187512b-a0d0-4c31-8ff0-bea37149cc3f"
      unitRef="usd">96654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjI0NzAxNDZiM2FhOTRlODc5NmY1ZTFiYjFhNGViMmM4L3RhYmxlcmFuZ2U6MjQ3MDE0NmIzYWE5NGU4Nzk2ZjVlMWJiMWE0ZWIyYzhfNC03LTEtMS0w_b971d43c-a85a-43f4-89aa-194272427ddd"
      unitRef="usd">85791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9e09d7534be4b2999db1628207e2de6_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi0xLTEtMS0w_6eb7282f-1c1d-47c0-9cb3-e8b0ffbe6403"
      unitRef="usd">4607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7299aa4e8d1145f896fecef97ca01e59_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi0zLTEtMS0w_a07e10ae-4154-4c7b-8e2c-5522200c938a"
      unitRef="usd">5021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi01LTEtMS0w_301e263e-50b2-4646-9d15-6567aa4ce9d4"
      unitRef="usd">15203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08eb8dd6d816445da416b2e82bf72356_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMi03LTEtMS0w_ba7e03f3-e35a-418f-bd7e-cf6b642310ca"
      unitRef="usd">15316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0381b7e4bd74829a0a31d3bf8871cf0_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy0xLTEtMS0w_bf5df273-3e18-4d74-9618-dddc2070977f"
      unitRef="usd">13721000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bef1feb8ca440608a019e77cde78bae_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy0zLTEtMS0w_77b224c9-f304-4be1-9ad7-38881f6fea0b"
      unitRef="usd">8816000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy01LTEtMS0w_849d7bad-13a3-4419-a3b1-f72929c483aa"
      unitRef="usd">40802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i808843dbbc3c44908e48a431eb1f24d0_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfMy03LTEtMS0w_b63535bd-222f-4ddd-9d1b-a5a2f32622c3"
      unitRef="usd">25212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb2d7629149a482f9cc826940879689f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC0xLTEtMS0w_b9d86f35-e872-4744-848a-e50aad31c07e"
      unitRef="usd">14971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1460d3b96640419a83156ab690e99fb1_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC0zLTEtMS0w_7d36db7b-9600-4507-a189-ffcddb14f2de"
      unitRef="usd">41226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC01LTEtMS0w_b0c83bfd-1e38-4d7f-aed5-0c14f906fe40"
      unitRef="usd">37616000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50addfcd8acf48179fe0db096adfbc86_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNC03LTEtMS0w_1be3f2da-54a4-4aa5-a184-e4df5b94e9da"
      unitRef="usd">43151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i838699b122594d4f9e99ff8f3d9dbddd_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS0xLTEtMS0w_1751d286-a006-4970-a573-3d4049515c5a"
      unitRef="usd">667000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68a6530ae4124dd299a7574226b98393_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS0zLTEtMS0w_2d02cde0-0493-49a1-b836-b7b8eed6adb4"
      unitRef="usd">592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41fce6ed1b2045eb851578aba3348c9a_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS01LTEtMS0w_54ce86c9-2012-4558-8454-e02434c0d6c1"
      unitRef="usd">3033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a75f9432ff64e73a1ac73574ddcfa54_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNS03LTEtMS0w_bddbccc0-a187-4b1d-9d66-a7e8b0cf2410"
      unitRef="usd">2112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi0xLTEtMS0w_a3eb00a1-0f1c-477b-a1a9-16ddb57ea79d"
      unitRef="usd">33966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi0zLTEtMS0w_3ecfddb8-0e50-44b3-a212-e7678d77091e"
      unitRef="usd">55655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi01LTEtMS0w_d69c7126-2b8d-44d2-b476-de9a6afa82f3"
      unitRef="usd">96654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjExZDNmNGVlM2JkYzQ5YzRhOGRmNGJmZjA1YzliMjdhL3RhYmxlcmFuZ2U6MTFkM2Y0ZWUzYmRjNDljNGE4ZGY0YmZmMDVjOWIyN2FfNi03LTEtMS0w_dea79f03-69ec-493f-bd44-e6c303b04979"
      unitRef="usd">85791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzI2_9e028f2d-9545-4bb4-be8e-9b375b04819c"
      unitRef="shares">9248609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNDg3_f9a1b5b8-d052-4e92-83d6-e6e3b003bbeb"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNTQ5_57c6bbab-fa6b-4189-8211-2e60bc21452a"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNjY1_6a874093-d299-457f-aceb-1e5b89b27419"
      unitRef="shares">2032884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNzI0_0fcc37b8-7738-4935-b513-6239e8bd9249"
      unitRef="usdPerShare">21.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i771c66c8a1e34ad49bfbf4cc3a76993f_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfNzg1_01fa3523-ea9e-4a7e-aad2-e1536dd11c53"
      unitRef="usdPerShare">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if1dc7061a4104e0b8aeb478b3078f095_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfODIw_aa01e6d4-adf7-424f-9e49-ed8b68a7382d"
      unitRef="shares">14357896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if1dc7061a4104e0b8aeb478b3078f095_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfODUz_f7d7a32b-a999-4307-9381-77a26943e3f9"
      unitRef="usd">28600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfOTMy_6132b71a-553f-4daf-a339-b8a0772dc468"
      unitRef="shares">3947355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d30612661b1407c8474216f06f0d220_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTAwMw_3af1c448-41ed-49c9-a264-81b84ac6e94a"
      unitRef="usdPerShare">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTAzOA_112b90cd-cf47-4d8b-a03a-6f7508d77975"
      unitRef="shares">8218085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i68143e0cb8e84c71b754bbeaaa3b0ba7_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTA2Mg_1254ceee-36a6-4213-a25f-4eced1ab11f6"
      unitRef="usd">136300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTQ0Mg_f53bbe13-9b8b-4ac0-b205-5a5c3acbd6ea"
      unitRef="shares">1027650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i9938695793df4dd0b636d555e96b3e8a_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTYzMw_04be0bdd-eff5-4a08-912f-9a22d38ab987"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iaf64fa313b794183bf4faf469cfd0c06_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjAzOQ_48ed799f-02f2-471c-8b21-106711a5e98b"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7aaa7d8a46a34b038a5d053b7701b533_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjIwOQ_b327c6a9-f4b9-48fb-aa1f-2f30687e06ba">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzM2NQ_d504c105-2cb2-4e21-aaf5-da308fef1e4d">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjQ3MQ_03e3785b-778a-4ab0-87ef-54be8420ba93"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMC0xLTEtMS0w_133e0981-f0f5-42e6-8b77-1ca3bb390a6c"
      unitRef="usdPerShare">21.31</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMS0xLTEtMS0w_fc9ebe1b-5f05-40c3-b29c-22589a1a83ae"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMi0xLTEtMS0w_244bb486-f353-49d0-9564-7fcf2526100b"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ieec069f01d574d05981611f9a549d71e_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RhYmxlOjY0ODE4Mjc2YmUwMDQwNjE4MGUyOTFhMmQzNTQ1N2RmL3RhYmxlcmFuZ2U6NjQ4MTgyNzZiZTAwNDA2MTgwZTI5MWEyZDM1NDU3ZGZfMy0xLTEtMS0w_995d1291-f6a1-4dd2-b864-f4585c092554"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMjk3OA_2f446379-9eee-438b-b8f9-b39c190754d1"
      unitRef="shares">7768188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id421b19fea1b414c8e38865109ab0e73_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzAwMg_dd14001b-9b5b-4417-9b85-681f65bb7c59"
      unitRef="usd">128600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i535221d9dcc64cd9a6a8c6fdc118809a_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTY0OTI2NzQ0MjI4MDE_7b685a42-e1ca-4f4a-b982-99bde31834f6"
      unitRef="shares">524307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i165ca677164a4242b9e75babf9daaee0_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMzg0ODI5MDcwMjg5NQ_33ca3915-28f2-4210-949f-5dae1e9c11b4"
      unitRef="shares">167726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06b3a70674fc4636bc068b030241f7ab_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181Mi9mcmFnOjhkYzM0ZWVmZDA0ZDQ0ZmNhNjQ0YjJmZTY3YWVmODkyL3RleHRyZWdpb246OGRjMzRlZWZkMDRkNDRmY2E2NDRiMmZlNjdhZWY4OTJfMTY0OTI2NzQ0MjI3ODY_7978834e-8c23-4111-b892-7441e9563a22"
      unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfNDUx_da90be60-ff39-4632-ab54-b34703888cd9">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three and nine months ended September&#160;30, 2021 was 28.3% and 22.8%, respectively, as compared to 15.7% and 18.8% for the corresponding periods in 2020. The effective tax rate for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits. The effective tax rate for the three and nine months ended September&#160;30, 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, the generation of federal tax credits, partially offset by non-deductible executive compensation during the periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfODE_62942aa9-72df-4c91-ae6e-a0f920bcb9a7"
      unitRef="number">0.283</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfODg_06b2d663-4e23-4122-a52d-ad7d6e958aa1"
      unitRef="number">0.228</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfMTIx_4f236cec-1d4d-4815-8289-f9e4d596538b"
      unitRef="number">0.157</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181NS9mcmFnOmNhYzk4OTM4OTQzMDQ3N2FiYzA5YjhmNDJhMTZlODEyL3RleHRyZWdpb246Y2FjOTg5Mzg5NDMwNDc3YWJjMDliOGY0MmExNmU4MTJfMTI4_cf6fa8c0-635a-4110-9567-0e6decf5587c"
      unitRef="number">0.188</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzU1_5986805b-16fc-4456-a38f-27a0ba6d0c8e">NET INCOME (LOSS) PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, Performance Stock Options, unvested RSUs, PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzY0_2e38d258-489b-4c9a-91fa-4a6627781427">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy0xLTEtMS0w_eec64939-0628-4e1c-bef4-c7b332cf51c0"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy0zLTEtMS0w_5d74a91b-5ae2-4e97-840e-aa9fcb148c02"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy01LTEtMS0w_af656ecd-b39a-4c5e-9561-2871623aafe6"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMy03LTEtMS0w_ce26ef26-86e3-4a00-9562-fc5b05ec7c3e"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS0xLTEtMS0w_f6a3bb63-8a07-4e3d-bd06-dd3045edbc4a"
      unitRef="shares">315380000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS0zLTEtMS0w_c35715b6-078b-4c39-8cfa-7297534d1b34"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS01LTEtMS0w_68c773f3-238e-40db-af17-a503d176dd9c"
      unitRef="shares">313990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNS03LTEtMS0w_bdfd78bb-b9ed-4a2e-a3d9-6a4692a22022"
      unitRef="shares">307437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi0xLTEtMS0w_7e3a87c4-bd16-423c-b78a-61b19533b5da"
      unitRef="shares">6642000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi0zLTEtMS0w_0900f94b-5248-4938-a5b6-1c9fb2b4e22c"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi01LTEtMS0w_a9d843df-d74c-449a-af68-62b56a68f109"
      unitRef="shares">8094000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNi03LTEtMS0w_2b3402cf-8d44-41da-aa04-562d6c18102f"
      unitRef="shares">10058000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy0xLTEtMS0w_6154e258-bd9f-4ee9-b75c-ca6f000c931e"
      unitRef="shares">322022000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy0zLTEtMS0w_7e05f567-3376-4fe4-92b6-59389d789320"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy01LTEtMS0w_b1f70ec6-755a-4fa9-9218-a6c06a8e9fd4"
      unitRef="shares">322084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfNy03LTEtMS0w_63584e35-fade-48e8-b420-c51d55aec803"
      unitRef="shares">317495000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS0xLTEtMS0w_38da336a-0b48-4091-9f1b-b15377dcee25"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS0zLTEtMS0w_8b8e09d1-d48a-4a50-aaf6-b8bf422d0d94"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS01LTEtMS0w_aedf411c-0d8e-4f3a-9f7f-1ddf85cea199"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfOS03LTEtMS0w_35726889-ce55-4d4b-bfd6-8861946f4c03"
      unitRef="usdPerShare">0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtMS0xLTEtMA_dc73123c-dd75-4f8b-99d5-4ae2b7551ae2"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id31540f0d48540a58fe6711bbcb2383f_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtMy0xLTEtMA_78fa6d13-2825-4eaf-81b3-644fc6613684"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtNS0xLTEtMA_26e7c67d-b597-44ff-be84-100e1db36ea8"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7f711048cd97485bbfbbaabdae084421_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmYyY2Q4MGIwYmExNTRhYjNhYjgxZjVlZTgyNzI4YTcwL3RhYmxlcmFuZ2U6ZjJjZDgwYjBiYTE1NGFiM2FiODFmNWVlODI3MjhhNzBfMTAtNy0xLTEtMA_aff28865-8246-4a52-9a73-333948fa63c7"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RleHRyZWdpb246NjEzZTcwMjZlYzE5NDUwOWIxYzhhOGE4ZGEwNzUwZjRfNzUx_513b74a7-d8be-4ce0-b2e0-f99147790360">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi0xLTEtMS0w_debf13ae-5477-4758-b518-a48f28217480"
      unitRef="shares">20346000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7e23ec3c3e84835ad5b3e3b31152b22_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi0zLTEtMS0w_2bb5acd2-68a7-4c7a-891e-e3cd6f5f63a6"
      unitRef="shares">27033000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2972daa1c2964506955e6854b99b0bd8_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi01LTEtMS0w_3ada6a1a-546b-4a4c-86ee-2a5c1b7d227f"
      unitRef="shares">14213000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic74264c148104da28095c53746f7d4fe_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y181OC9mcmFnOjYxM2U3MDI2ZWMxOTQ1MDliMWM4YThhOGRhMDc1MGY0L3RhYmxlOmRiY2VmYWNiMjk5YzQzYTE5MjllZjg4MDBlZTNjMTA0L3RhYmxlcmFuZ2U6ZGJjZWZhY2IyOTljNDNhMTkyOWVmODgwMGVlM2MxMDRfMi03LTEtMS0w_8c8ae140-4d99-4007-8316-d4fe902e79ce"
      unitRef="shares">10224000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMmQ2OWZiYWRkNjQ2YmQ4YWVkODdmZWRkM2QwMThjL3NlYzo3ZTJkNjlmYmFkZDY0NmJkOGFlZDg3ZmVkZDNkMDE4Y182MS9mcmFnOjExZjVmN2QyMDBiMzQ2ZjU5ZjEzMzUxZTJkOTQ3ZmYxL3RleHRyZWdpb246MTFmNWY3ZDIwMGIzNDZmNTlmMTMzNTFlMmQ5NDdmZjFfNTA1MA_37a66459-d307-4520-a400-27b4b71f026f">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent, each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that all of U.S. Patent Nos. 9,724,324, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. A bench trial has been scheduled for June 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397483304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,397,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594311367704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,325<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">835,406<span></span>
</td>
<td class="nump">887,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">179,493<span></span>
</td>
<td class="nump">160,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">28,240<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">51,564<span></span>
</td>
<td class="nump">57,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,662,028<span></span>
</td>
<td class="nump">1,445,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">362,218<span></span>
</td>
<td class="nump">330,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">99,838<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">125,295<span></span>
</td>
<td class="nump">156,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">134,678<span></span>
</td>
<td class="nump">73,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,447,741<span></span>
</td>
<td class="nump">2,137,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">24,314<span></span>
</td>
<td class="nump">23,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">53,306<span></span>
</td>
<td class="nump">51,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">70,618<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">31,120<span></span>
</td>
<td class="nump">20,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">35,403<span></span>
</td>
<td class="nump">12,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">54,747<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">269,508<span></span>
</td>
<td class="nump">204,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">9,444<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">52,252<span></span>
</td>
<td class="nump">49,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">335,294<span></span>
</td>
<td class="nump">258,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 316,305 and 311,627 at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,422,323<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(311,673)<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,112,447<span></span>
</td>
<td class="nump">1,879,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,447,741<span></span>
</td>
<td class="nump">$ 2,137,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">316,305<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594400459928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">316,305,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">316,305,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309925480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">11,874<span></span>
</td>
<td class="nump">8,725<span></span>
</td>
<td class="nump">39,956<span></span>
</td>
<td class="nump">27,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">163,370<span></span>
</td>
<td class="nump">176,762<span></span>
</td>
<td class="nump">471,448<span></span>
</td>
<td class="nump">393,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">101,558<span></span>
</td>
<td class="nump">88,185<span></span>
</td>
<td class="nump">302,404<span></span>
</td>
<td class="nump">210,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">276,802<span></span>
</td>
<td class="nump">273,672<span></span>
</td>
<td class="nump">813,808<span></span>
</td>
<td class="nump">631,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">51,621<span></span>
</td>
<td class="num">(42,580)<span></span>
</td>
<td class="nump">170,022<span></span>
</td>
<td class="nump">85,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">6,231<span></span>
</td>
<td class="nump">16,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income (loss) before income taxes</a></td>
<td class="nump">53,260<span></span>
</td>
<td class="num">(38,021)<span></span>
</td>
<td class="nump">176,133<span></span>
</td>
<td class="nump">102,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">15,056<span></span>
</td>
<td class="num">(5,981)<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
<td class="nump">19,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">315,380<span></span>
</td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">313,990<span></span>
</td>
<td class="nump">307,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">322,022<span></span>
</td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">322,084<span></span>
</td>
<td class="nump">317,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 263,117<span></span>
</td>
<td class="nump">$ 168,587<span></span>
</td>
<td class="nump">$ 774,577<span></span>
</td>
<td class="nump">$ 541,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 15,612<span></span>
</td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="nump">$ 92,391<span></span>
</td>
<td class="nump">$ 62,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314721496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $193, $453, $949 and $(893), respectively</a></td>
<td class="num">(504)<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="num">$ (33,641)<span></span>
</td>
<td class="nump">$ 132,902<span></span>
</td>
<td class="nump">$ 86,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307636504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="num">$ (193)<span></span>
</td>
<td class="nump">$ 453<span></span>
</td>
<td class="num">$ (949)<span></span>
</td>
<td class="num">$ (893)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314589048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 2,241,947<span></span>
</td>
<td class="nump">$ 3,069<span></span>
</td>
<td class="num">$ (559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">83,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">19,827<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">19,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(26,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">85,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 02, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 02, 2020</a></td>
<td class="nump">1,852,031<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,321,441<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="num">(475,958)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jul. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jul. 03, 2020</a></td>
<td class="nump">1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
<td class="num">(443,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(32,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(1,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">55,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 02, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 02, 2020</a></td>
<td class="nump">$ 1,852,031<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,321,441<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="num">(475,958)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">135,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">18,792<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">18,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(15,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 97,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 01, 2021</a></td>
<td class="nump">316,305<span></span>
</td>
<td class="nump">316,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 01, 2021</a></td>
<td class="nump">$ 2,112,447<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">2,422,323<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="num">(311,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jul. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jul. 02, 2021</a></td>
<td class="nump">2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(349,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">38,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(5,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 01, 2021</a></td>
<td class="nump">316,305<span></span>
</td>
<td class="nump">316,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 01, 2021</a></td>
<td class="nump">$ 2,112,447<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 2,422,323<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
<td class="num">$ (311,673)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594311359240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 135,897<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">11,699<span></span>
</td>
<td class="nump">6,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">96,654<span></span>
</td>
<td class="nump">85,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,952<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">32,365<span></span>
</td>
<td class="nump">15,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">35,871<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(20,124)<span></span>
</td>
<td class="num">(47,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(26,956)<span></span>
</td>
<td class="num">(13,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(24,252)<span></span>
</td>
<td class="num">(15,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">11,434<span></span>
</td>
<td class="nump">4,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">47,812<span></span>
</td>
<td class="nump">51,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">304,352<span></span>
</td>
<td class="nump">175,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(48,265)<span></span>
</td>
<td class="num">(16,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,077,377)<span></span>
</td>
<td class="num">(866,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">1,095,813<span></span>
</td>
<td class="nump">781,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(29,829)<span></span>
</td>
<td class="num">(101,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">18,242<span></span>
</td>
<td class="nump">19,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(15,049)<span></span>
</td>
<td class="num">(26,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="num">(6,438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">277,716<span></span>
</td>
<td class="nump">67,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">598,488<span></span>
</td>
<td class="nump">335,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">5,143<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid liabilities incurred in asset acquisition</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307417256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC) and, in the U.S. only, for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income (loss) from operations, net income (loss), total assets, total liabilities or total stockholders&#8217; equity. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income (Loss).</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307686744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets were zero as of September 30, 2021 and December 31, 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities as of September 30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $6.8 million in revenues in each of the nine months ended September&#160;30, 2021 and 2020, that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, we recognized $48.4 million and $116.2 million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $33.1 million and $115.3 million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$86.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307409592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s now obligated to reimburse us for their share of COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt in and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, collaboration services revenues for the nine months ended September&#160;30, 2021, includes a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the nine months ended September 30, 2021 included $11.9&#160;million recognized in connection with a $12.5&#160;million regulatory milestone we determined was probable of achievement in the second quarter of 2021. The milestone was achieved in the third quarter of 2021 upon submission of a variation application to the European Medicines Agency for CABOMETYX as a treatment for patients with previously treated RAI-refractory DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$44.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the three and nine months ended September&#160;30, 2021 included $18.8&#160;million recognized in connection with a $20.0&#160;million milestone we achieved upon Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $41.7 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $11.5 million and $33.7 million during the three and nine months ended September&#160;30, 2021, respectively, as compared to $7.9 million and $23.7 million in the corresponding periods in 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, in support of our development pipeline, we entered into collaboration and in-licensing arrangements with Adagene Inc. (Adagene), WuXi Biologics Ireland Limited (WuXi Bio), expanded our collaboration with Invenra, Inc. (Invenra), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $28.0&#160;million and will make payments for potential future development milestones of up to $98.0&#160;million, regulatory milestones of up to $229.0&#160;million and commercial milestones of up to $802.5&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales. In addition to the upfront and future milestone payments, we will also pay Invenra, in three equal annual installments, an exclusivity payment of up to $15.0&#160;million to nominate up to 20 additional oncology targets and up to $30.0&#160;million in research program funding in equal quarterly payments over a three-year period, as well as additional fees. As of September 30, 2021, we have paid the first exclusivity installment of $5.0&#160;million and $2.5&#160;million for the first quarterly research and development funding installment. We have the ability to opt in to certain of Invenra&#8217;s other internal research programs in exchange for an option exercise payment of $3.0&#160;million per program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in May 2021, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $5.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $9.0&#160;million payment upon the completion of an initial technology transfer of certain materials and documents specified in the asset purchase agreement. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307530168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of September&#160;30, 2021, restricted cash equivalents included $29.6&#160;million of short-term investments, which is collateral under our January 2021 standby letter of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794,137&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $2.6 million and $4.5 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were 41 and 14 investments in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the nine months ended September&#160;30, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307597960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had one forward contract outstanding to sell &#8364;9.8&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of September&#160;30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months ended September&#160;30, 2021, we recognized $0.5&#160;million of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income (Loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594402937080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307581080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 9,248,609 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we granted 2,032,884 stock options with a weighted average exercise price of $21.81 per share and a weighted average grant&#160;date fair&#160;value of $9.30</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of September&#160;30, 2021, there were 14,357,896 stock options outstanding and $28.6 million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we granted 3,947,355 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $21.50 per share. As of September&#160;30, 2021, there were 8,218,085 RSUs outstanding and $136.3 million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded 1,027,650 (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to an employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2021, there were&#160;7,768,188 PSUs outstanding and $128.6 million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2021, we achieved an additional performance target for 524,307 PSUs granted during 2020 (the 2020 PSUs) and determined that it had become probable that we would achieve an additional performance target for 167,726 PSUs granted during 2018 (the 2018 PSUs) and have recognized $11.4&#160;million of stock-based compensation expense related to the 2020 PSUs and 2018 PSUs during the three months ended September&#160;30, 2021. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307417256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR (BENEFIT FROM) INCOME TAXES</a></td>
<td class="text">PROVISION FOR (BENEFIT FROM) INCOME TAXESThe effective tax rate for the three and nine months ended September&#160;30, 2021 was 28.3% and 22.8%, respectively, as compared to 15.7% and 18.8% for the corresponding periods in 2020. The effective tax rate for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits. The effective tax rate for the three and nine months ended September&#160;30, 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options, the generation of federal tax credits, partially offset by non-deductible executive compensation during the periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309165816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td>
<td class="text">NET INCOME (LOSS) PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, Performance Stock Options, unvested RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307326232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent, each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our <div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patent Nos. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patent Nos. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited (Teva Parent), asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that all of U.S. Patent Nos. 9,724,324, 10,034,873 and 10,039,757 are invalid and not infringed, and on August 23, 2021, we and Teva entered into a stipulation wherein Teva Parent was dismissed without prejudice from this lawsuit and agreed to be bound by any stipulation, judgment, order or decision rendered as to Teva, including any appeals and any order granting preliminary or permanent injunctive relief against Teva. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. A bench trial has been scheduled for June 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397846344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, October&#160;1, 2021 and October&#160;2, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, September&#160;30, 2021 and September&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income (loss) from operations, net income (loss), total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Foreign Currency Forward Contracts for Non-Designated Hedges</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December&#160;31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets were zero as of September 30, 2021 and December 31, 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities as of September 30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594312077496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract liabilities were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div>(1)&#160;&#160;&#160;&#160;Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307523496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594306281400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794,137&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796,112&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307588472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307404872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307563640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307678296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594306246824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 01, 2021 </div>
<div>product </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594310159624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">357,462<span></span>
</td>
<td class="nump">220,401<span></span>
</td>
<td class="nump">1,051,871<span></span>
</td>
<td class="nump">702,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(94,345)<span></span>
</td>
<td class="num">(51,814)<span></span>
</td>
<td class="num">(277,294)<span></span>
</td>
<td class="num">(161,668)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">263,117<span></span>
</td>
<td class="nump">168,587<span></span>
</td>
<td class="nump">774,577<span></span>
</td>
<td class="nump">541,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
<td class="nump">62,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 65,306<span></span>
</td>
<td class="nump">$ 62,505<span></span>
</td>
<td class="nump">$ 209,253<span></span>
</td>
<td class="nump">$ 176,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594400414552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314509816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">266,436<span></span>
</td>
<td class="nump">171,552<span></span>
</td>
<td class="nump">783,583<span></span>
</td>
<td class="nump">549,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,095<span></span>
</td>
<td class="nump">36,006<span></span>
</td>
<td class="nump">162,822<span></span>
</td>
<td class="nump">117,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 23,892<span></span>
</td>
<td class="nump">$ 23,534<span></span>
</td>
<td class="nump">$ 37,425<span></span>
</td>
<td class="nump">$ 50,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594310314376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">259,791<span></span>
</td>
<td class="nump">159,555<span></span>
</td>
<td class="nump">759,000<span></span>
</td>
<td class="nump">522,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">3,326<span></span>
</td>
<td class="nump">9,032<span></span>
</td>
<td class="nump">15,577<span></span>
</td>
<td class="nump">18,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 263,117<span></span>
</td>
<td class="nump">$ 168,587<span></span>
</td>
<td class="nump">$ 774,577<span></span>
</td>
<td class="nump">$ 541,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594310381848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">$ 30,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">275,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(260,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2021</a></td>
<td class="nump">47,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">178,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(171,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2021</a></td>
<td class="nump">16,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">22,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(18,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2021</a></td>
<td class="nump">7,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">17,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">74,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(70,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2021</a></td>
<td class="nump">$ 23,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314574344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Total contract assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">9,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,755,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">16,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,545,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">48,400,000<span></span>
</td>
<td class="nump">$ 33,100,000<span></span>
</td>
<td class="nump">116,200,000<span></span>
</td>
<td class="nump">$ 115,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 86,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309917576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,095<span></span>
</td>
<td class="nump">36,006<span></span>
</td>
<td class="nump">162,822<span></span>
</td>
<td class="nump">117,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25,139<span></span>
</td>
<td class="nump">19,910<span></span>
</td>
<td class="nump">81,246<span></span>
</td>
<td class="nump">71,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
<td class="nump">62,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12,956<span></span>
</td>
<td class="nump">$ 16,096<span></span>
</td>
<td class="nump">$ 81,576<span></span>
</td>
<td class="nump">$ 46,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594417575816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement', window );">Revenue from contract with customer, regulatory milestone probable of achievement</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594310402024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,734<span></span>
</td>
<td class="nump">22,984<span></span>
</td>
<td class="nump">34,291<span></span>
</td>
<td class="nump">49,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,078<span></span>
</td>
<td class="nump">9,780<span></span>
</td>
<td class="nump">23,476<span></span>
</td>
<td class="nump">32,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
<td class="nump">62,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="nump">$ 13,204<span></span>
</td>
<td class="nump">$ 10,815<span></span>
</td>
<td class="nump">$ 16,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307746936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 86.5<span></span>
</td>
<td class="nump">$ 86.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement', window );">Revenue from contract with customer, regulatory milestone probable of achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 41.7<span></span>
</td>
<td class="nump">$ 41.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594315075096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 33.7<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397655448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 3,309<span></span>
</td>
<td class="nump">$ 3,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314211000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments', window );">Collaborative arrangement, maximum aggregate commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate exclusivity payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets', window );">Number of additional oncology targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate research program funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm', window );">Collaborative arrangement, rights and obligations, research program funding payments, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment', window );">Collaborative arrangement, rights and obligations, aggregate research program funding payments, first installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment', window );">collaborative arrangement, rights and obligations, aggregate research program funding payments, second installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment', window );">Collaborative arrangements, rights and obligations, option exercise payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember', window );">Collaborative Agreement With GamaMabs Pharma SA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire assets</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction', window );">Payment upon closing of transaction</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments', window );">Asset acquisition, maximum aggregate development milestone payments</a></td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments', window );">Asset acquisition, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Payment Upon Closing Of Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionPaymentUponClosingOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Aggregate Research Program Funding Payments, First Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments, First Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Research Program Funding Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Number Of Additional Oncology Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Option Exercise Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Research Program Funding Payments Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307630440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,325<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">31,163<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 598,488<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 335,682<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309119400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash short-term investments</a></td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314865432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,459,665<span></span>
</td>
<td class="nump">$ 1,349,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,461,640<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,794,137<span></span>
</td>
<td class="nump">1,532,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,796,112<span></span>
</td>
<td class="nump">1,538,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">886,323<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">886,396<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">503,707<span></span>
</td>
<td class="nump">543,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">505,548<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">58,965<span></span>
</td>
<td class="nump">208,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">58,985<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,670<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,711<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">80,828<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">80,828<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">119,538<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">119,538<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">134,106<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 134,106<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594311243016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 146,326<span></span>
</td>
<td class="nump">$ 56,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">136,319<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">10,007<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594305988456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,103,122<span></span>
</td>
<td class="nump">$ 1,034,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">358,518<span></span>
</td>
<td class="nump">321,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,461,640<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397667368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,461,640<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,461,640<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,715,284<span></span>
</td>
<td class="nump">1,456,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">119,538<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,461,640<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,595,746<span></span>
</td>
<td class="nump">1,415,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">886,396<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">886,396<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">886,396<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">505,548<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">505,548<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">505,548<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">58,985<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">58,985<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">58,985<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">10,711<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">10,711<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">10,711<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">119,538<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">119,538<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">134,106<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 134,106<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594306245400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - 9 months ended Oct. 01, 2021 - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>forward_contract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forward_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397653880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">$ 7,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">28,016<span></span>
</td>
<td class="nump">20,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">11,707<span></span>
</td>
<td class="nump">7,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">50,040<span></span>
</td>
<td class="nump">35,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">28,240<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 21,800<span></span>
</td>
<td class="nump">$ 14,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314486520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
<td class="nump">$ 85,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,487<span></span>
</td>
<td class="nump">18,936<span></span>
</td>
<td class="nump">37,550<span></span>
</td>
<td class="nump">30,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22,479<span></span>
</td>
<td class="nump">$ 36,719<span></span>
</td>
<td class="nump">$ 59,104<span></span>
</td>
<td class="nump">$ 55,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309937176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
<td class="nump">$ 85,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">5,021<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
<td class="nump">15,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,721<span></span>
</td>
<td class="nump">8,816<span></span>
</td>
<td class="nump">40,802<span></span>
</td>
<td class="nump">25,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">14,971<span></span>
</td>
<td class="nump">41,226<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="nump">43,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
<td class="nump">$ 2,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314516936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,248,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,248,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
<td class="nump">$ 85,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,032,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,357,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,357,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">5,021<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
<td class="nump">15,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,947,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,218,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,218,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,721<span></span>
</td>
<td class="nump">8,816<span></span>
</td>
<td class="nump">$ 40,802<span></span>
</td>
<td class="nump">25,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="nump">1,027,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,768,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,768,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,971<span></span>
</td>
<td class="nump">$ 41,226<span></span>
</td>
<td class="nump">$ 37,616<span></span>
</td>
<td class="nump">$ 43,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Achieved And Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedAndProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedAndProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594307375128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - Performance stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 01, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594314304632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">28.30%<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">22.80%<span></span>
</td>
<td class="nump">18.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594397624024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">315,380<span></span>
</td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">313,990<span></span>
</td>
<td class="nump">307,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">6,642<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,094<span></span>
</td>
<td class="nump">10,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">322,022<span></span>
</td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">322,084<span></span>
</td>
<td class="nump">317,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140594309048616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">20,346<span></span>
</td>
<td class="nump">27,033<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
<td class="nump">10,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6U/YUEY^H.4VVQU;2:UEG/T,./.Y,C? ];64^GA@'E!LL([_ U!+ P04
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MYWY\)@R@'%#ZN5U^DY6VAJES*^VM'?.8SQ,V9&N!0?Y* @?;(Z4B7K8?Q5K
MPF=(\Z?]VKNIDO'*TI#.ATG4AH-LZXI3TDL(H5ZROTJ9/>9%825'QPYB43+<
M06=AI]1Z+2)^,?K<[O/B$*/N;;0W=.(=%D3Q:,7'N)@%.'$P[;6(^,6HV^X>
M?F-QH4$0QP$9$K0 "8L9<^11TNL0"5]5*Q0Y7^5%KG/A+1A(KQS$+QWOTU0V
MD#;0EC\;A;/.WR(. 2.C0++ 6,2H8^Z]B!"_B@!%U<!^3&5I9(1W=3FDDI6H
MQ#IWK)E%&"";#<L&&XR0Q%$VD%Y B%]!#ISA09Y"=&F5P^^CY;.2'@M%C*-1
MGK; 0DJ=>;J7$^+7DR]B!55YI])K 1=9(Y"6^_Y *#MGBVH00H?UA05&<90X
M-@;MM87ZM:4/CJ+@*ZFZZ#CC9SJ6#E-3#HLU"XS0((P<G'N%H7Z%^7Q2 9WC
M.I:.,(B#>,AU# O@QU&FTZ,>Q2\PIZ70.:YC*:'1/,3# +;A<!"%CDQ.>\VA
M?LWI*Z(M]!<F$N3:=-N=H"L!97+CH#[6ECGX;TA\C&)QZ"CC:"] U"] 5MJF
M9H)HKAY0(7@MSOI^K#TF*=#A#,:P8(X35TSW D7]G=)0[<^Q'3=" 9X/DX8%
M%5-'FJ.]Y%&_Y'4A?8[@6,P8@\IN%!$6T0L3>I3_3EGVJD?]JG<GRS+O2OJN
MI9>5"091I2[&7GOFG.ZJWO)4W$ZV2M1"[<1D@6RG(/^#H=,Y]ZI)$V^5L]0R
M_;Z1109:\^Y-0DE\W?8+^ME7[-!>X*A?X* ?W:>"VKQIBM[B2XP)U#X*[7C1
MB"DB>(HQ?CE_XHW>2)7_ R/,&E3R<#!5UZ ZUF48"]THK'V0TX.?7@>97P=-
MN$#><,SK&@78,;'K_5RZWKS1M88+"+0KQ$@T93AL'X"D3R,:(Z[14FRU*%="
MO7M#(GS-<'<@UL(^BO3X47=6!@!XY5:T)ZF%]8R"6029#&LU*\A17;)>C)E?
MC-]G66Y2+J0$<U9QD5<HY=L<4H25Z%AF:4 IH\/:P09DT'*[>G[6*S+S*S)4
M/$W9%.WYZ?XL!0IC)3;FT'LG4%[!O;6.9V/9)4$R;&(L**@C' +!CHXF_=)\
M3!L4.4]S:T?-Q@I[ <$7Q2,'6X# ,XQ=6ZE78_::=K!VYB(K;5OG1V@PJM,L
M0)+$<T(<E3#K%9B=.:L<REJ[(__C-,+1::^]T[4!?9TNZ]69^=5YG\B672);
MMNEJBCXY\RVS"#6)(&\-&=MP!'+:@/#LZ".'^<+T)U</>55#$;:&@?@R!@NJ
M^VC3W6BY;;][K*2&+JF]W @._C8 >+Z64K_<F$\IAT]GBW\!4$L#!!0    (
M %2"8E/ET!>9IP(  -X(   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
MK99=;]HP%(;_BA7MHI4VXB1\M8)(*].T39J&BK9=N\F!6'7LS#;0]=?OV$DS
M*.'CHER [9SW]7-.#G$F6Z4?30%@R5,II)D&A;75;1B:K("2F9ZJ0.*5I=(E
MLSC5J]!4&ECN1:4(8TJ'8<FX#-*)7YOK=*+65G )<TW,NBR9_GL'0FVG012\
M+-SS56'=0IA.*K:"!=B?U5SC+&Q=<EZ"-%Q)HF$Y#3Y&M[.(.H&/^,5A:W;&
MQ*7RH-2CFWS-IP%U1" @L\Z"X<\&9B"$<T*./XUIT.[IA+OC%_?//GE,YH$9
MF"GQF^>VF ;C@.2P9&MA[]7V"S0)#9Q?IH3QWV1;QPY' <G6QJJR$2-!R67]
MRYZ:0NP(HOX10=P(XDL%22-(?*(UF4_K$[,LG6BU)=I%HYL;^-IX-6;#I;N-
M"ZOQ*D>=36=*YGA3("<X,DKPG%F<W#'!9 9DX8P-N9HS#=(68'G&Q#7Y0-Z1
MD)@"5\TDM,CAW,*LV?.NWC,^LN>/S/8(C=Z3F,91AWQV6OZ-R6/R$+-O2Q"W
M)8B]7W+$;XZ- UICUECM[/&$8](Z)MZQ?\R1:;)A8@WDBDN2*R&8-J0"79?L
MNJMDM>/(.[K_WB:E/4HQO\UN9<Y%[>'V6]S^2=R%OX^$K6VA-'_&0CCL^NYV
MLM9V@QV*B-:?5[@7!.X1#UKBP27$W)CU>=K! <1KS%,1>WS#EF]XLJ5FJBSQ
M&76NGT:MW>C-^VET43^=B]K#';>XX[?MI_%!_?NTNZ$NB=QCOFF9;]ZNHVX.
M*))HF-#!(6]79#2,1T=Y(_K_P4TO(<:CV5@F<RY7Y[ ;PTNX.T.[P<.=P\>=
M_-^97G%IB( E:FEOA":Z/DSKB565/X\>E,73S0\+? $![0+P^E(I^S)Q1US[
M2I/^ U!+ P04    " !4@F)3F,FW03T&   [&@  &    'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;*59VV[;.!#]%<+H0P(DL4CJ&B0!&MF++=!N@J3=/BL6
M;0N51:](.]F_W]$EDDV.5'?[$DO*F2'/<#AS*-V\RO*'6@NAR=LF+]3M9*WU
M]GHZ58NUV"3J2FY% ?]9RG*3:+@M5U.U+462UD:;?,H<QY]NDJR8W-W4SQ[+
MNQNYTWE6B,>2J-UFDY3_WHM<OMY.Z.3]P5.V6NOJP?3N9INLQ+/0W[:/)=Q-
M.R]IMA&%RF1!2K&\G7RDUW/N5 8UXN],O*J#:U)1>9'R1W7S*;V=.-6,1"X6
MNG*1P,]>Q"+/*T\PCW]:IY-NS,KP\/K=^Q\U>2#SDB@1R_Q[ENKU[22<D%0L
MDUVNG^3KGZ(EY%7^%C)7]5_RVF*="5GLE):;UAAFL,F*YC=Y:P-Q8 !^< /6
M&C#3P!TPX*T!/W4$MS5P3QW!:PUJZM.&>QVX6:*3NYM2OI*R0H.WZJ*.?FT-
M\<J**E&>=0G_S<!.W\6R2&'914K@2LD\2Q,--\\:?B ?M")R23X5"[D1Y.RS
M5.J<7))OSS-R]N&<J'52"D6R@GQ=RYU*BE1=D ]']S=3#;.LQIHNVAG=-S-B
M S/BY(LL]%J1.<PL1>QGX_;1B/T4HM.%B+V'Z)Z-.GQ8Z"OBT O"'$:1^<2G
MF+/:W,'H_-[H\_\]^E$P>)<OO/;'!_P]B;TH=D)=C_AR.U]N[<L=\/55ZB2'
M:M-XQ#*EL?=K^ZKD[>\X"UW&;Z;[PP6P88Q3)V+'L)D-BT(><N<8-K=A 0W<
MT.]@1V2]CJPW&KB'K2@3G14K(MZVU8X;#:'?>?5'0QA+I:L=NI(R503V+[9A
M[AL?W@$C2L/ -:)HH\* >48,;1"/(L\W0FBC6,"XAT<PZ+@&HUR?A!))N5@3
MJ"O0"_;0Y+95B<(8!S9CG_/ 6.H8@05^X)N)8\/<@+IN:+"V83SB7L!PVF%'
M.QRE_0Q-%-+F@JQ$ 2F4U_23%'I!IG254GN!12"TJ3G4\XPYQS8L#&EHKKJ-
MX@YS'2.#YC:,P3:D SLGZ@(0G5 FI+5_,-81DGA^Z!@+&F,P[@?FNMNPD/+0
M,=?=AOF<!@=5ZH@V=?K6[(P2?V^[>=UVEZ7<O$<!6C7:6!UK)A[UJ[9QQ!Z!
M7;K,"XW=,4-P-' <9H1ICN!"+_"'^!]($_H3_EJ OM @**I H(PILM&M)$=0
M4+5<DZZ-\J&/F&2Q$7DPD..4]639*-D'O19ERY2<M3E^?D$*@1:XUMO1&M+(
MY&V#/-_<VZ@G9C9%S%5 !TCW8H+R7\CP%P$''_$> YV\X7N\]7DT%<Y\L[8C
ML$O8O.9NF"$X: *4<S,"",YA 74&@M"K(#HN@QY+N<_J@Q?0)V<O4.:7F:[W
M^_G/@^':L_(<LR''".S2BT(K%C;,=1@WVSLV: 0E;R 2O42BWF@D_A*ZVP%U
M2J",/5L4ALSL13$"N^0 LXJ<C:/<"Z/ Y&SC0@[]?8!S+^"H/ZH++<X$2GQS
MLAH3B+17371<-MTG*EN0,SB4I3+/DU+U ^#Q;=R%!T2=*VIV4 1U"3 SN)@O
MU]I9&(H-95.OF^BX<)IE^:XZR_X"]? DZC8*HX[Y<JW6B:'84#/I%1.-1I/J
M>_U^1*27R1[TPDH0R*\-%)CVP"YW6FF0D:"FQG*,]4J%C2N5/L>:$=#H,ELF
M<.IQ4W;$& Y4)#6JT SU!WW=;%VHO\#E PG&>GW"QO7)88*-\4;4!V.6C(HQ
M',H;]Q>::AS#P4$V&CB&L5ZJL'&I4I6L;2G3W4(/G-Z/'?=R@/W^RP76]U7V
MNZ\7&/+B *0[#<R5L7'4#[TP,%<&>740N%Y@]A($Y[F41D,9V3=0-MY /V>+
M2C:>M"I]AV+C'>JD5>G;$1MO1R>L"G+<CGQ3KL<(C$.#-^4M H,M%9IG_#F*
MXYR& VO2MR$VWH;BJO6\R.;81I0H][!(ZJ0EZNL]&Z_WIRP1[ZLY'Z_F/U^B
MUL'1AO!\JU,B,!9QQY1@""QB/#)/7@C,9Y%U")D>O S?B')5?X50T %WA6[>
M<W9/NR\='^OW^\;S>WH=4^3YC%[/F^\8O?OFL\J7I%QEA2*Y6,)0SE4 V50V
M7RJ:&RVW]:OX%ZFUW-27:Y&DHJP \/^EE/K]IAJ@^UYT]Q]02P,$%     @
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MB(Z)V[%9)=PS&Y8&$=2HCL)4JB?>!3JIKLO4H5CO$BY4 @TK5I]=E:R(>&B
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MGBD<&KU4<'R&@O]T6X)-$9]#B@/] &(<IPY+JCUVJ_T48X+-G7L4>-#@:CH
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M>3 !AW:6I78_.K)?9\*!!?^Y6BDM(7S_G3@D[ X)[2'AR"&?(='+.A<[[G-
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MPA!VD-:9ULR*52]3!+MA%V11BNE0#U<04I"2$3(@/6^1:=[JLNM@^C6@2U^
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M=V]R:W-H965T<R]S:&5E=#DN>&ULM5II4R-'$OTK%6S$!D0(<<QXO?8<$4+
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M98G5A(^X8L.K# @&/Q5#@XUP9&9@^APOE@V,X<BJ->F#E60S$R*\8<&:<./
M@KB"XCLC+ZM[[:UK@EH:7*OK%1O<DS:,-EBKR,?JFE0L]#*L;*U*^!GP <0S
M/7?_T61U.Q\EE-MJ9><6TA#X2E*Z)D0\>@<H& 7;([L$+,N*ABUV>78[4I.?
MWX_4CV?OSEFM&MO%[S=GM_Q_I8.:&U,E#2EX'EG C^/96)T[)T@])9!-<F00
M2^3$0-D]/YWL\:>P,M)7M6&P)JZ<3SA#N*U=Y[-OU71R<@WI?OGYKW\Y^OKE
M*[4[U'=/D74-W-:)1,&E\WO"$7F%0(/0Q1\-NU>NU&KW9CK=&ZFY(V@5KI+
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M>_;ZWZ#]E\EL0J 2AI;OA83?D6,% <%+!'@)8H*< !CI10E[W2IP0N;% *"
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MKWZDFUBN: *^7TH$1/="!PS_F>+%OP%02P,$%     @ 5()B4Y0$*C(-#P
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M)RK9G+^+0S4G&]8G.QX^N>!%7/9$?Q")87\X>&*]48/4B-<;/;:>7<A<_\9
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M9*=B<1.RQ_88JHL;!*)%G@#FVY)VA.N)&ZQ62$M9 'G#X."54',L099CB4W
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M&H#W<P-TP@?:H/D!ZMO_ %!+ P04    " !4@F)3N9YR@+X(  !:&   &0
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M7Z'_&F/($^@/T@9J;MMX1GQZ'+JQ8&1?OV%WHG:B6B%:9G$H;WUH=]'W23M
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M>;A&X;$-O92\EW>BD'?2!.Q+E?4A*IJP2T_YEY9RGX$@F2/VB2%B'PHLU8#
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M=>,&<EKDO71'S=Q7G7FGUCG-0I>.B7:3KZX;5:!@FP.83:4K^1[U4U>LWI(
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M&O^%U=HVB0+(&F-5M7$F!I60ZS]_W>APX- _Y< V#LSS7B_D67[BEH^'6JU
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M#9\RPX4W!7\^G!KO3<8_%TJ"]K0 SV<&_J\NZ(#F>_+Y_P!02P,$%     @
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M>:>L6*^-7 N/0ICIQ1DS]%&V&)\7MA6%O)I  %II'N7DV8&%ADBQ3I:XA]N
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M1#6E>E3E%L)I!T71!QCX ^H["8/O"/S5VGA&>FN^9/8%$/Y+GO_06MF0VXV
MLDL6LP6!2/D./(./=#^:K5:J4L*!5"#KI^*/TEHPXUR;=A\T(<?%GM:/HE=D
M\U\7Y"<I*BP%AX1^JW@@Y*\(9V!.9<%"A;R19BV;$?IP8!*^HO_<NFU-%JTL
M%.R^ZY4M=B3']0$\\CWAO7B0I=BOD%NG"G#)7->M:':0EVJ%_DOW=*@DOHP
MPX@2$U@AU:,O]O\I-E[Q>P6/$5^_@_7=3%?A1]S-T&CLM;?&G9SOG?S[//0V
M0$3_GC>BWAM',D8R9(SDS1EC*/8'707L!F[\4>JU$>U&%;!H#2*/99*C&WVC
MO8 ]UL][&+_'_Z<N_'*^./<I.Z%QE&#*3D,H"5C94JAL/(M\RH;*FN;D_=;
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M3MAYWK@7ZXUU&[W)J.9K7*#]6L\UK7I'E$*46!FA*M"X&G>FX?4L=?R>X9O
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MO+H"1[FPKR>Q0RD>,&8=[:*ES9Z@/2<?M7*5)6]5#OEC_QA#Z./(=G$LLJ.
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MZAD\5#/ 9V9 P&>>JXT$RSQF\0!_,<X/1_BVSD:3$GQ,R0,>-?AGI.X 1+\
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M)E0&&+)$E+]@7=WK=T"X$I*E%5A%D-)L^X]_5HG8 R@[S0!4 =!;0-< ""I
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M+Y LLHR*IUM(^>%Z@ ?/%Y9LLU7F@C>?[>@&5J"^[>Z%/O,:+PG+()>,YTC
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M.G;K_8*O'%=FHPU.2:S4O>N<I].@ZPBAP,2Z"(S^EGB*0KA 1./G.F;0;.F
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MM3.@_952]F'B#NB^A!8_ %!+ P04    " !4@F)3"8$OW/0"  #>"   &0
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M@*!V!K0_5<H^"\Y!]4O3_PE02P,$%     @ 5()B4VH:W5I6 P  40H  !D
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M[N?!9.;==Q@];8R>#AK=2[![!-ZFZY&[+2(M4N )97?"+=(U;W,V%1+IEE$
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MT@!@?RF$?IN85MN^W>D_4$L#!!0    ( %2"8E-7S7FTIP(   D'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;)55[T_;,!#]5ZQH'T "DJ9IMJ&V
M$K2;QJ0Q!&+[,.V#FUP;"\<N]J6%:7_\SD[(NOZ(6#\T=G+OO;MWUGFXUN;!
M%@#(GDJI["@H$)?G86BS DINS_02%'V9:U-RI*U9A'9I@.<>5,HPCJ(T++E0
MP7CHW]V8\5!7*(6"&\-L59;</%^"U.M1T M>7MR*18'N13@>+OD"[@#OES>&
M=F'+DHL2E!5:,0/S47#1.Y^F+MX'?!.PMAMKYBJ9:?W@-E?Y*(A<0B A0\?
MZ;&""4CIB"B-QX8S:"4=<'/]PO[1UTZUS+B%B9;?18[%*'@7L!SFO))XJ]>?
MH*EGX/@R+:W_9^LZ-DT#EE46==F *8-2J/K)GQH?-@#]W@% W #BUP+Z#:"_
M!8@/ 9(&D'AGZE*\#U..?#PT>LV,BR8VM_!F>C25+Y1K^QT:^BH(A^,)MP7C
M*F=7:@46J:%HV2F[YL9PUQ%V- 7D0MKC88BDYU!AUG!?UMSQ >ZO&9ZQJ'?"
MXBCNW=]-V=&;8]'*[.&;=/-]YNK_^*:OR2_V?%'#]R]+2&ZVEL:MI;&G[1^@
MW7#RA$UAAM[?#X^5P&=V!UEE! JP[,?%S**A@_^S0[3?BO:]:') ])8DC<@0
M<I:YEMI"&SQ%,"7[:Y'=U\.:-_6\;DBLQO'[-'*_8;C:DU'29I1T9G2E2)V$
M:3AD(%9\)F&??+(KOZ5>'XW=N&30D>6@S7+0F>5U5<[ ,#W?M(G6U#-6*1JD
M4OPB3Z6VEBVU%7Y8_6:=Q^ZREAQLYMK;*F<WI)?LKR1M*TD[*[F0-,*YRH#1
M9< R [E GS?L;7NZX^>6X].NB#K#<&/NN$OB"S<+H2R3,"=,=/:6ZC/UX*TW
MJ)=^%,TTTF#SRX+N*C N@+[/M<:7C9MN[>TW_@-02P,$%     @ 5()B4]0T
MS3(,!@  XB   !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULQ9IK;]I(
M%(;_R@CU0RN5X+GY4A&DEFQWN]IJJZ;I?C8P!*NVQQT/I-E?OV/C,."Y$ 31
M?@D8WC-^/3/G\>$XXP<N?M0KQB3X5>1E?3U825F]&XWJ^8H5:7W%*U:J;Y9<
M%*E4A^)^5%>"I8LVJ,A'* C"49%FY6 R;C_[(B9COI9Y5K(O M3KHDC%XP>6
M\X?K 1P\?? UNU_)YH/19%RE]^R6R;OJBU!'H]THBZQ@99WQ$@BVO!Z\A^^F
M%#<!K>)[QA[JO?>@N909YS^:@T^+ZT'0.&(YF\MFB%2];-B4Y7DSDO+QLQMT
ML#MG$[C__FGTC^W%JXN9I36;\OR?;"%7UX-X !9LF:YS^94__,&Z"Z+->'.>
MU^U?\-!I@P&8KVO)BRY8.2BR<ON:_NHF8B\ $D< Z@+0<P-P%]#.W&CKK+VL
MFU2FD['@#T T:C5:\Z:=FS9:74U6-LMX*X7Z-E-Q<C)-ZQ5(RP7X5&Y8+=4"
MR1H,#XYFC^"6S=<BDX_@VV/%P.L;)M,LK]\HX=WM#7C]Z@UX!;(2?%OQ=:T&
MJ\<CJ;PU9QC-.Q\?MCZ0P\??<WD% O@6H !!2_C4'_YG6KK"1VI&=M."=M."
MVO&P8[P;-I.@WEYUQFJ0;M0%I[.<#57F#.LT9^\\9\&[L^#V+,1QEO<%%S+[
MERW E-?2-FG;^+"-;S)R,X&$)F%(QZ/-_NQ8=)@D28QVN@.#9&>0> W^+GA=
M@[M2 2)O??ZNP&!=W>TX=,\ @@'JN31%-,'0;I'N+-+3+/ZECIG5(S5./X0H
MZGFTBNP6PYW%T&OQ8YH)\#W-U\SF*C1."$D(0Q+TC%ETF-(D<,Q?M#,7>7=Z
M X"WH,7 ;S_7V49M;97T;\%7E?\BF\MF<SXQHO_97H G&^*=D_C,;(C-*8@2
M G%_#2TZBE&"L'VJDIW!Y$+9D#PG&TR1.QM@H'D>7"H?NI&.)(1=Y;"Y=]N!
M9^1$%]Q;Z1#"_AS:A!3',7$9U#< B+P&I[PHF)AG:0ZJM&+"L\&AYCW$+WA;
M@1K;T,_MXZD$31;'<8CW4J2;8 NSPX30T#&_&MOP1&X[DPF:2(X,FZ8&1ZX]
MH+D-_> ^)9=,//<![I4<.M3PAM$Y:119%SD)^\Y,G5KD&,4.>YKHT(_T*1<5
M%ZED8,:-LO!P3 UAF+Q@#B$-4N0'Z?$<0B89:8"CH$]0FXY@BARKCS1$D1^B
MS\\A9.%D$AI&315%A#AL[M72?I2>D$;=2+V;37^_VE21PZ5F,_(7X_Y4ZH(/
MUYI2$O>M670DCJC+GD8Z\B/][NKV"GQ34UBOQ6-;C=WS#1-E\QMM6%>\K+E0
M4ZN.F*A$9LSOX6DUIA%]R6S3J$5^U#XCVTQ\TC@Q?@E99"B(,7+<L)!&+?*C
M]H1D,W&*8-^F18,=-RRD>8O\O#TET\PB>6B8M&A<--#\1OXJ^DB>6:KB.(F-
M5;94V$&L\M'N#FOJ8S_U/Z_+;)Y5JNH[=L?"&M,8OF0S07,6^SG[C':""4X8
MA%&_4K'(4!S&COL5WFMW^!'[_!3")D9)?W=:-+'C%Q[6F,4G=CS<&83-TMB8
M2%,R=/S"PQK)V%\Y^Q,(FY4P#")H3)XI0W$4.@B$-<>QG^--7\"WF35N\?_=
ME\ :J_C<S@0V21D'^P5T-^L6&8*1X]Z$-5/QI3H3V 2GL6E]DL,VHL8JN5A7
M@IC5<M^A5W+H4$.:G-.0(&9E;%M?F\R]OD23G?C)_IF7[!$4J?C!)%BN_3<F
MHGE,_.V(E\\QLM=I/K=E04R80IA0;"R"J2-!%#JX2S1WR:4Z%L2$J[&%?9)#
M@YJ]Y&+M"G*\7>&5'#K44"?GM"N(61/;%]C4^1988YX<Z58PM0.7V3R5JDCC
M2[!@%:\SZ=O>FM#$W[5X^52C&L;TW,X&-0$+,5&E8O]AB:D+@R!P5.%4PYA>
MJK%!3>+V-[)7<FA0 YE>K*5!S6+:<.B3'#K4;*?GM#.H]8&A98%-G6V!1WL/
MH)NG_Y]3<:\6#.1LJ>*"JTA=FM@^4-\>2%ZUSZ1G7$I>M&]7+%TPT0C4]TO.
MY=-!\YA[]V\-D_\ 4$L#!!0    ( %2"8E/^.EG13 ,  !$,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;,U7WX_:.!#^5ZRH#ZVTD#B$ !4@;5FU
MU^JJ6Y5N[Z'J@PD#6'7LG.U >W_]C4TV_$JX2MV'?2&>>+[Q-S,?@QGOE/YN
M-@"6_,B%-)-@8VWQ.@Q-MH&<F:XJ0.+.2NF<633U.C2%!K;TH%R$<12E8<ZX
M#*9C_^Y>3\>JM()+N-?$E'G.],\W(-1N$M#@\<4GOMY8]R*<C@NVACG8A^)>
MHQ76498\!VFXDD3#:A+<TM<SFCJ ]_C"86>.UL2ELE#JNS/>+R=!Y!B!@,RZ
M$ P?6YB!$"X2\OBG"AK49SK@\?HQ^EN?/":S8 9F2OS-EW8S"88!6<**E<)^
M4KL_H$JH[^)E2AC_27:5;Q20K#16Y148&>1<[I_L1U6((P!-6@!Q!8A_%="K
M #V?Z)Z93^N.638=:[4CVGEC-+?PM?%HS(9+U\:YU;C+$6>G,V8VA,DE>2^W
M8"PVR!K2(6\9U^0+$R7XS7=:&4,>) I%\']A2?Y$&PQ1JQ/<[99QP18".JBO
MSIP)(!P[)<^1Y%X9[KOX\@XL8LPK//-A?D=>OGA%7CC0YXTJ#1YMQJ'%-!W9
M,*M2>K-/*6Y)Z:_,=DE$;T@<Q;0!/KL._\!D&SS$XM85CNL*QSY>KR7>'2PL
MF4-6:DP9S,U9E0Q6Z::U0.B=965>"F8?M[[>+HS5*/]O5\CU:G(]3RYI(7?H
M<U.=]]C48]T\V$YIDO;B=!QNC^MYZ=9/X]&H]CIAEM3,DJO,6B371',?J']T
M?H?&@S.2C4[-%/LUQ?Y5BC.E"Z6Q,V2A+I1Z$C&M(Z;/3RN#FMS@-[0RN*@O
M[:4].CIKPZ5;/$R2?G,CAC6SX5-I9=@D@W-!-S@-FAF.:H:CJPP?NO,N^8S\
M3*E_^I&Z5EO0TLW-CBF4-$HC;[1 %YI?D#\YE$:'X1X]/SW1H]\>^AN*JL G
MDHJBZ/R+W> 6T]&P9?S0P]BF\5.)JHJ4GJCJG&9\*:JDA>-A>M/KX_MC*7G&
M"R;^=P+1P]RER3/4S&'FTNM#]ZIF9A7XN,K]8=HR7NAA+-/TB;0PJR*U:&%_
M?GAT7W.7Y8],K[DT1, *05%W@/SU_OZY-ZPJ_!5NH2Q>"/UR@W=VT,X!]U=*
MV4?#W0KK?P'3_P!02P,$%     @ 5()B4[ED L*= @  1P8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&ULC55=3]LP%/TK5Q$/( 'Y:@I#;24H0]LD
M-$2!/4Q[<-N;QL*QB^VT]-_OV@FAZU+$2^*/>X[//3>^&:R5?C8%HH774D@S
M# IKEQ=A:&8%ELR<JB5*VLF5+IFEJ5Z$9JF1S3VH%&$21?VP9%P&HX%?N].C
M@:JLX!+O-)BJ+)G>7*%0ZV$0!V\+]WQ16+<0C@9+ML )VL?EG:99V++,>8G2
M<"5!8SX,+N.+<>;B?< 3Q[79&H/+9*K4LYM\GP^#R E"@3/K&!B]5CA&(1P1
MR7AI.(/V2 ?<'K^QW_C<*9<I,SA6XA>?VV(8G <PQYQ5PMZK]3=L\O$"9TH8
M_X1U$QL%,*N,564#)@4EE_6;O38^; 'BWAY T@"2SP+2!I#Z1&ME/JUK9MEH
MH-4:M(LF-C?PWG@T9<.EJ^+$:MKEA+.C,3,%,#F'[W*%QE)]K($3N&%<PQ,3
M%8+*P0=]?:GXB@D?L N8;F"LI-54E(H)N&6VTMQNX/ :+>/"'!'EX^0:#@^.
MX "XA(="5898S""TE(73$LX:Q5>UXF2/XI\S>PI1? Q)E,0=\/''\!],[H.'
MY%UK8-(:F'B^= _?E@W'<(U3Z\UQ9E'^$YPY(S@:^'TY-=Z@/Q\<FK:'IO[0
MWIY#:X/EPEFI),(&F0:E0:#I=+1FZWLV=Z]7HSB.TCA)!N%JV[J.N"CMQ5G4
MQOTCM]?*[7U.+LLMZG?%MM"J6A20TTWV*YWB:^YL2U2:G6?Q^8[VCK D/LOB
M;NE9*SW[4/J#LO1!SUU=S7LQV8J^:C85>$)]],30K>@2GOWO9J\?]WO1CO*.
MN#3+OD2[TL.M:^Y:["W3"RX-53TG9'1Z1D2Z;EOUQ*JEO_E39:F/^&%!G1ZU
M"Z#]7"G[-G'-I/UWC/X"4$L#!!0    ( %2"8E/0WY&1K@8  -<R   9
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M\YDW]D!&EGC-](VHOI FH<CRI8(I]P15'1N%'DC72HNB 1L%!>7U&S\W1G0
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M2<QBR;J6UATM2E>.'H4VQ<TU<_/_0:0-,.-+(?1KQU:X]H]F_@=02P,$%
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M27!6\(]47Q//OR2!%_@=^4S?0@\LW>M:SO^+/O_/T5\5(VP,%%J]\(3>BS=
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M_3*G[QUJ9T#/,Z7L?N,"U%_0T1]02P,$%     @ 5()B4S2W=15C @  VP8
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M[1L%)"N-5:(&8P:"R>I+G^H^[ $P3CL@K@'Q(2 ] DAJ0/)6AK0&I&]EZ-4
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MAK1A2#U#<H1AA.+-G?[P,2(+R$K-+$-5S9YJR:ZT$H>"G5$MF5R;/7W^O,'
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M3^(-"GZOS/N%G8ZL^E K[%JSC"^K_C)K!&#L79R=%H58O1-\)G/F)G]PP-&
MKOV"N=+\P4:#4IE: ],DN&?:\.FFY9NFQ2U;FG4Y+3-<<^\(-?_=/,^89)J*
M3=&V]I]SEI^L.+KX5Y*K;Y5=P5Z-]>;\W$6>'X/(^!A$'D5-]H]!9/(L18;U
M!KYQ2M@Z(S36 ,YB0_(93GZB#1I,%EP8+NO>G*<IDX^."I;>T(G](;'%;\>G
M+*,+86X;<$C:]B>6\D6>-*.N(1'UJ+;]$:;7C9N#H(W%9<J6+!W773V;5,W
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M(^H="?2.J'<DT#N./E;^I]ZYG'8I7WN^UWC]_Z2ZG,]-U\M?EM\[1S?4!><
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M]I^ROANS_.L7Z.TUK779'/)9]Y7"Y!-02P$"% ,4    " !4@F)3!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( %2"8E.S_^DU[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %2"8E.97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M5()B4^<&N=X^!0  ;!4  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %2"8E.(=(C7T08  $8;   8
M          " @8$-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !4@F)3Y= 7F:<"  #>"   &               @(&(%   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 5()B4YC)MT$]!@  .QH
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M965T."YX;6Q02P$"% ,4    " !4@F)3KL0\?(,/   4*   &
M    @(%_,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M5()B4YBDKD0[#   6"$  !D              ("!.$(  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !4@F)3E 0J,@T/  ",*@  &0
M            @(&J3@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( %2"8E.YGG* O@@  %H8   9              " @>Y=  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 5()B4^'HAOUE!P
M)A(  !D              ("!XV8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !4@F)3",WFU<<"  #-!0  &0              @(%_
M;@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %2"8E.?
M+140\@@  )87   9              " @7UQ  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ 5()B4Q=TYQ,Q P  "@@  !D
M     ("!IGH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2"8E-:Z$KICP,  &L(   9              "
M@=RB  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 5()B
M4W/RV'D>!@  8A4  !D              ("!HJ8  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !4@F)31@ *1\<#   E"0  &0
M        @('WK   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( %2"8E. #YATRP(  -@%   9              " @?6P  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 5()B4Z,7ITY9!   &@H
M !D              ("!][,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !4@F)3@*^(X[ #  !*"0  &0              @(&'N
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %2"8E.8P7G
MM (  +D'   9              " @6Z\  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ 5()B4[-V)L@2!   _!   !D
M ("!6;\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !4
M@F)3)@P>N\T$  #W'   &0              @(&BPP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %2"8E/$EC X/@,  )T+   9
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M970S-"YX;6Q02P$"% ,4    " !4@F)3P</QN"@#  "A"   &0
M    @(%MW   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M %2"8E.ULB (]P,  /<0   9              " @<S?  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ 5()B4[]XD)PS P  %0D  !D
M             ("!^N,  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !4@F)3"8$OW/0"  #>"   &0              @(%DYP  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %2"8E-J&MU:5@,
M %$*   9              " @8_J  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ 5()B4U=HY.="!   '1   !D              ("!
M'.X  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !4@F)3
M2WC:C-0"  #'!P  &0              @(&5\@  >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %2"8E-7S7FTIP(   D'   9
M      " @:#U  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ 5()B4]0TS3(,!@  XB   !D              ("!?O@  'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !4@F)3_CI9T4P#   1#
M&0              @('!_@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( %2"8E.Y9 +"G0(  $<&   9              " @40" 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 5()B4]#?D9&N
M!@  US(  !D              ("!& 4! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " !4@F)390&<1<@"  "N!@  &0
M@(']"P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( %2"
M8E.(ZV0&T0(  -T(   9              " @?P. 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ 5()B4V<9+;51 P  )0L  !D
M         ("!!!(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " !4@F)32.H&BI(#  "7#@  &0              @(&,%0$ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %2"8E/P-6I3@P8  ' A
M   9              " @549 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ 5()B4U"SHTKF @  30<  !D              ("!#R !
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !4@F)3-+=U
M%6,"  #;!@  &0              @($L(P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( %2"8E-V-M8&HP,  (X,   9
M  " @<8E 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M5()B4W I#G?N @  UP<  !D              ("!H"D! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " !4@F)3SIT=#3@#  !J$P  #0
M            @ '%+ $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %2"8E.7
MBKL<P    !,"   +              "  2@P 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( %2"8E.[%<RI6 0  -LD   /              "  1$Q 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !4@F)3O '6P> !  #L(   &@
M        @ &6-0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !4@F)3%-1QY- !  "M(   $P              @ &N-P$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     /P _ # 1  "O.0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>276</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141108 - Disclosure - Provision For (Benefit From) Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</Role>
      <ShortName>Provision For (Benefit From) Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430420 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20211001.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20211001.htm">exel-20211001.htm</File>
    <File>exel-20211001.xsd</File>
    <File>exel-20211001_cal.xml</File>
    <File>exel-20211001_def.xml</File>
    <File>exel-20211001_lab.xml</File>
    <File>exel-20211001_pre.xml</File>
    <File>exel20210930exhibit311.htm</File>
    <File>exel20210930exhibit312.htm</File>
    <File>exel20210930exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20211001_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20211001.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 276,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20211001_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20211001_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20211001.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20211001_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20211001_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20211001.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 402,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 38,
   "keyStandard": 264,
   "memberCustom": 27,
   "memberStandard": 34,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20211001",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141108 - Disclosure - Provision For (Benefit From) Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes",
     "shortName": "Provision For (Benefit From) Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "ic5cb6b35aa834afe81197ed5f5a2983b_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i174f26ce45354e73a9f4adeb23f35bee_D20210703-20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "iac98a4d51cd54e6993377fc838bb765a_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i3f2514fa13b9413db7b3f86827a216cc_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNet",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i76fbb6c53ef94caba54c3ffa10dd5ab2_I20210101",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i41488a2e36454734af6a6a327ecb17cf_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "idaeb3da2fea64aaa8731abdb42df89d6_D20210102-20211001",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "id1e1880501a749b483269275293c21a5_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "id1e1880501a749b483269275293c21a5_D20210703-20211001",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "if33937ce988840acb055192972fe7d0e_D20210703-20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "if33937ce988840acb055192972fe7d0e_D20210703-20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i01e2f72b11644ef0a4bf820629f67d6a_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430420 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i1060b811968c481ebf2bbc36128837fb_I20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i68ac30fd607b41bc80b50c13706647e4_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i68ac30fd607b41bc80b50c13706647e4_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "icafa823dcfbd4c2a9d8b8df5d69e150d_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i838699b122594d4f9e99ff8f3d9dbddd_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i2bdddb7ab6b049d8af4b51af1589e8a9_I20211001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "ieec069f01d574d05981611f9a549d71e_D20210102-20211001",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "id421b19fea1b414c8e38865109ab0e73_I20211001",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Provision For (Benefit From) Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i7538e59869c24a53ba8e51381b5ca09f_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i17f8aeca77d04c4090ac0e65044f766c_D20210703-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i62c8618c9439454b8cb846aaed306eaa_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i62c8618c9439454b8cb846aaed306eaa_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20211001.htm",
      "contextRef": "i0f87e38c3c00456490dc25089a13aa2c_D20210102-20211001",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedAndProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved And Probable",
        "label": "Achieved And Probable [Member]",
        "terseLabel": "Achieved And Probable"
       }
      }
     },
     "localname": "AchievedAndProbableMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionPaymentUponClosingOfTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "label": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "terseLabel": "Payment upon closing of transaction"
       }
      }
     },
     "localname": "AssetAcquisitionPaymentUponClosingOfTransaction",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementWithGamaMabsPharmaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With GamaMabs Pharma SA",
        "label": "Collaborative Agreement With GamaMabs Pharma SA [Member]",
        "terseLabel": "Collaborative Agreement With GamaMabs Pharma SA"
       }
      }
     },
     "localname": "CollaborativeAgreementWithGamaMabsPharmaSAMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Research Program Funding Payments, First Installment",
        "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Research Program Funding Payments, First Installment",
        "terseLabel": "collaborative arrangement, rights and obligations, aggregate research program funding payments, second installment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAggregateResearchProgramFundingPaymentsFirstInstallment",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate exclusivity payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments, First Installment",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Exclusivity Payments, First Installment",
        "terseLabel": "Collaborative arrangement, rights and obligations, aggregate research program funding payments, first installment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateExclusivityPaymentsFirstInstallment",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Research Program Funding Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Research Program Funding Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate research program funding"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateResearchProgramFundingPayments",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Number Of Additional Oncology Targets",
        "label": "Collaborative Arrangement, Rights And Obligations, Number Of Additional Oncology Targets",
        "terseLabel": "Number of additional oncology targets"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsNumberOfAdditionalOncologyTargets",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsOptionExercisePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Option Exercise Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Option Exercise Payment",
        "terseLabel": "Collaborative arrangements, rights and obligations, option exercise payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsOptionExercisePayment",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Research Program Funding Payments Term",
        "label": "Collaborative Arrangement, Rights And Obligations, Research Program Funding Payments Term",
        "terseLabel": "Collaborative arrangement, rights and obligations, research program funding payments, term"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsResearchProgramFundingPaymentsTerm",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement",
        "label": "Revenue From Contract With Customer, Regulatory Milestone Probable Of Achievement",
        "terseLabel": "Revenue from contract with customer, regulatory milestone probable of achievement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerRegulatoryMilestoneProbableOfAchievement",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20211001",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r168",
      "r259",
      "r265",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r168",
      "r259",
      "r265",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r259",
      "r263",
      "r416",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r259",
      "r263",
      "r416",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r259",
      "r264",
      "r448",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r259",
      "r264",
      "r448",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r55",
      "r56",
      "r436",
      "r454",
      "r455"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r56",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r340",
      "r450",
      "r451",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r303",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r300",
      "r301",
      "r302",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r280",
      "r282",
      "r305",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r282",
      "r296",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "terseLabel": "Share-based payment arrangement, expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r147",
      "r156",
      "r162",
      "r189",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r336",
      "r341",
      "r372",
      "r381",
      "r383",
      "r419",
      "r434"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r48",
      "r92",
      "r189",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r336",
      "r341",
      "r372",
      "r381",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r171",
      "r196"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r430"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r176",
      "r177",
      "r429"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r172",
      "r196",
      "r423"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r284",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r85"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r85",
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r373"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r215",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 316,305 and 311,627 at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r67",
      "r426",
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r369",
      "r370",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r369",
      "r370",
      "r457",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r369",
      "r370",
      "r457",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r369",
      "r370",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r237",
      "r239",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Total contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r416"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r134",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r173",
      "r196",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r182",
      "r197",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r183",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r181",
      "r200",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r184",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r145"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r49",
      "r351",
      "r352",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r344",
      "r346",
      "r348",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Forward Contracts for Non-Designated Hedges"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r259",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r359",
      "r360",
      "r427",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r359",
      "r360",
      "r427",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r128",
      "r190",
      "r235",
      "r236",
      "r300",
      "r301",
      "r302",
      "r316",
      "r317",
      "r358",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r450",
      "r451",
      "r452",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r362",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r364",
      "r365",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r272",
      "r273",
      "r278",
      "r279",
      "r362",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r272",
      "r273",
      "r278",
      "r279",
      "r362",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r204",
      "r205",
      "r230",
      "r234",
      "r357",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r207",
      "r208",
      "r383",
      "r418"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r313",
      "r314",
      "r315",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR (BENEFIT FROM) INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r113",
      "r114",
      "r146",
      "r311",
      "r319",
      "r321",
      "r445"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r82",
      "r414"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r46",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r92",
      "r157",
      "r189",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r337",
      "r341",
      "r342",
      "r372",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r92",
      "r189",
      "r372",
      "r383",
      "r420",
      "r438"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid liabilities incurred in asset acquisition"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r92",
      "r189",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r337",
      "r341",
      "r342",
      "r372",
      "r381",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r57",
      "r60",
      "r65",
      "r66",
      "r84",
      "r92",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r118",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r189",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r360",
      "r372",
      "r425",
      "r442"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r101",
      "r141",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r334",
      "r335",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $193, $453, $949 and $(893), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r51",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r76",
      "r326",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r78",
      "r299"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r209",
      "r383",
      "r431",
      "r440"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r20",
      "r27",
      "r383",
      "r439",
      "r458"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r308",
      "r415",
      "r474"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r13",
      "r89",
      "r460",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash short-term investments"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r16",
      "r89",
      "r460",
      "r461",
      "r462"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r236",
      "r303",
      "r383",
      "r437",
      "r453",
      "r455"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r190",
      "r300",
      "r301",
      "r302",
      "r316",
      "r317",
      "r358",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r168",
      "r258",
      "r259",
      "r416"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r135",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r262",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r282",
      "r295",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r282",
      "r295",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r89",
      "r417",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r284",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137",
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r287",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r421",
      "r422",
      "r433"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r128",
      "r190",
      "r235",
      "r236",
      "r300",
      "r301",
      "r302",
      "r316",
      "r317",
      "r358",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r450",
      "r451",
      "r452",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r128",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r236",
      "r283",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r92",
      "r169",
      "r189",
      "r372",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r186",
      "r187",
      "r188",
      "r230",
      "r234",
      "r357",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r272",
      "r428",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at September\u00a030, 2021",
        "periodStartLabel": "Balance at December\u00a031, 2020"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5291-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r477": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r478": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r479": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r482": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r483": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r484": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r485": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r487": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0000939767-21-000097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-21-000097-xbrl.zip
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MN')"4S!A_%+XOYGIW^S]'S?98@IHB,=  .88!I:T8D#1O-9A#OZO%GXG2JZ
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MK5T^H&>:6SF'I;[! E?!(*@,VA*79MYZC\I;K7Q<0D#GEELY>W"U")8"I>!
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MB.0(XFI4I<:.W02MHK&E@E4I L&<MJ6H *? -2<->>78Z^MOT7 K*7)TZ#V
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M&NQRMF6G7N;0 +,2';$B&Z,5+GJ9Y++YX-W4;K>ZA\]3-_6Q33"OQTZKVZ*
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M4VY)CAHE58^2^\:[-.^<#D>^D3 DED)<GDYG/YV9V)1_29.E!!VK[&197!V
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M.EH]GQJ4UV7_\NJB^R6$GT>K40CI,81TJX 2SG482<A%&:U'H"Q/FI"**%
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M) O'D1 5L-PR*%%/$^N2W[*&R'V\[E# ^53@'.L%+J&.,AD1UHH@$%(BPTU
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ME4#:<HZ,LC2FK=J1W.]\%:2K;*&U$BRA/%8^Z7K6FQS0;'(6?I(NPHCE1FG
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MX!EF98E#_T9WO;&<.]W*D_:#JY>1JSFR","&CRP"L.$CBP!L^,@B !L^L@C
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MI/XRWE1Z[H"6@MN"VX+;Q^-VTFX5-'CJ D'2:X< >T!6*8TX<9%*(K'WK([
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M.*N\AR 358+$TON0E$Q'>7B8,TN#P&<ASXGF C08:DU0"+1,E$G )_*D!.&
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M_>VM G[;W_MM9VOS /[8/X!_=K?;!_O%WMOBS>;^OXNWO^W]N5_4MB,_=7J
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M6$U,?/1"/&]@%M]/)O&7\X_#?&)[;SJ1F[-Y;,#Q3N#H%XD.=U98"<R&>QK
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MR/8.XP<[BMLI1=_D8+@3%G^[4-V>:B\#509A+'+20Y:0=43!Q#H:I"-&Z%Q
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M/3/&)ZDM(QIS%;B3D:?()6,!)(2G6SBY<E@K_-9 8(T@L/UFP=O%F4PA8@?
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M.;$G$?R#_LAV<P^O"61JSHO=S9R14G.=@N0 C-8RQVP220FOA(E!J,93L5+
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MM9)1)<%U0#&4OACMD ,#&5&O<\EUC+U8RMF'9^G";C:W?@091$8&::73-/+
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M/9Q-=C&(AUD77SH,6OS4Z16CH_X8WAB&KUZ_B*.A'*_SVQ^+O/UI2[JNF'F
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M>O3N7'W-!Y%Z7='SN[,(+/HZ;P/WU#%J<(B<P\I )?68>\.TUS+$^1RJ+TZ
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M$_"+P2F&824*45-D@\3LD4B&.+B3D4@6*8^7&%U(T)CA9,!*Y9A['12\W?M
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MD6^>XNRY0'VVAAKFSBBN-"+21,0%TTA+89!5,06>(D"]*)STQQ?27;QJ+!5
MO1* >I[P8050SP90TRABPB$1'R62A&7OVAAD7%#(2DZC$=H&6P 44]=QP50
MM0#*_,8!ZGGB?A5 /1M S;!C4R>P%ACIZ,""8MX!0,6 0I 8C&9M>7(K:ZS.
M\.54S@J@*H!:#(!ZGH!=!5#/!E S<3M-P%FG"1")!\1M\D@K$Y!.W%F7&*/Y
MR FKZR6HI3M/?M[+64TWIS,]<P;HIS$=VKD$T'Z]MM5!9<Y73O^>"7B73$7;
M@X/8J_TYA&]!=6H;,SF6ZYDSHE5PS"Q)'NG&E"GC'OP8+6C?\/BXVRNR_#+S
MSFRFZ7'K..8WE71D!65209W4O9@N5S JC3)6<ROL[% 7*73KP>Y':-96QZ_6
M?AO]]7N]]FWX/ZW:GRT8G/V6[]>V<DH]/.WOUE$KYPC^-OX>+HV_8#AS;RX3
M!!6OV.H 4O9L??2.T9]P8\%)=!0G]\9?K7[)8'53TM]G&+'/IYW8VS^M[8"@
MV.,X!!WLCY\_\_WO1:HF:,CAL#-#I!0MB&3)_]2/%\8DU@[L3Y@E&^";?7CS
MOAW$VO X];IYX.UI>=T@%XW,3;T7>472*C+MF<>8"\D-#IZ"X64L8=;2VVC9
M[D/H>MV.TJ>"<6N]$Z8LD?TO9>?^*?OV=EDN,G?K/BPU*L;H+%(ALR$IRE&N
MAX&8-PYK;G44F;=5W\K;FJ6[8 ([LC_B5')R&N]Q-R?^9X;6-!P,>^?3R"=\
MKP7/U_#XOHPXU(40P#,#2PAS$[2%-5(0FXC0)FIK'L4_>F_A:MA?K:/AT?I8
ME6; ?,HE/!J;-RQZ'W\U/WXG"DN>DD1!&8&X(!192S)+M:#!*Z$C42MKYE;1
MR_1*8\+F5RY.5S%35]+TD336OV-BK'91(,M@0>$PC4@3[)'46%@930@XT_50
M<R<DFV&5?MT2]:[H:+;I*XF:D2B^O?Z=",HDIPP9D4^)":*1L90@+6 2"4O<
M1K:RIC&]@BGP D 5)MB(7F-J9AV#V3\F^<QL%V#(QT%!#W<282&%?\]Q@HX6
MSTO4H(75-R;VR-*9WS(VX0JBS_+&*;/Z>'4N#.IBT2[(/#+W[L1Z+5J;\Y3C
M_PY!"VRGD_]I=?I@";9'=]M\G  <_WYV4D['CWV-:K(Y[>:;5X^9$A-GS5RD
MZ^-W' 0.,3&$+4 N#R$BS;!#F:S.&6^D-F%EC8A;L1>$IM,]RJ0Q<21#UXI0
MJ2[S]3FVFN\?+#+-@IIZ.ZU/*':V.]G;WC_=*5HZ%1C\]@0&-S>^@+"LX^V-
M]=/MC1_?G4K!.X^1-38A+BDLU]8*E *5E&HIM>8YB?4RM]X,A5%W-, CZ"S#
M*:\->L91I7]ZW?V>/7H_+%@$*Q0ZCT*GX,L*$DADD:#('09?UD<$DQB0HHDY
MZ46B!17Y[35(,AOW.)9W7 X[+*(E>R-\5ZZ(\*,WB+WVZ=39[?XL^,U&H@>
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M'-1^U\VXE2MKP6\%44Y1CNA/V\Z%BVJ?#V(L3MZ7=Q[E:DW3!^;@VCT>^GD
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M")*,BLXF$Y\$1C/H_C+MN*BPZ@%8M3U=L"!0[:*T$F&I :M$<DBS1)"6A/%
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M9;N^5<+G26O0++K#WA3.%,?=WB !P'8SI'2'WVZXH-WR@/$GS99O%NW640O
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M4@I:Y^K=Q?FF-=J"@2.!J+:[)_WBGR55Z0Y!24/_MW?7[+E+(',CO-SYQK^
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MM" %&NW:_QEV<_#Y,>A9[!?_''9L.!SVX4^_E4M?YO*,EW@4Y-W*,YFWU)$
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M-GWJG>'.2&MP,"E2J:@!*I J[9]C[2=3_8N,(2X*E%1N>X*M1)90B<"*2=@
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MJRC+<\U@"5$)C &)Q"IX  3D$#V.N!1!E"!MTK-[(>P\GZ(Y);11LW00+'T
M'$-3;>)%^=#SLSQA)EI#()F],17WQ$.P TF=HT]0B9*V#.R<ORB<8/6-(,U(
M*#+\:SC\G!DQY29IH>E2,4])VUWW5@0^D\4J+[UZV[ <Z4[2P-O@'DF[CTPL
M?E)HYRS!.S9%384]+ (&84JX!KA2AIRN<U7="TMY0<,XB2K:+JD;N).%FA@@
M:LB&9H4@"%Q4%88)<@$>&N[8BV;DGE&6SR+0#]#NIR<B,' \D!E\T6@!#H#Z
MNU+?-5<9!@M58>5@P9=AI5J:%98^O1PKYPI8]Q#4;I,C.5AV(:_(X;<"P/H2
MAY$ #==N!0IRG9TIIP*W$E-\YTV:(\?0S2 JO:,*-V0A&!M OQA_J0=?1+ Y
M0!*XT9&7BE(X47T6$&&23MUTG)WAXB>1W+.]T%3G'B-1/'C%OGE59Q\0T#<V
MCJ<3(FAR_.%M+?SII\L#Z1N$$X??PB 'S)J);$XPL0B-X8.*QPL7VZ^X+1&%
MZ26+'),/Y77$%RBJJ=S( _H;E?5J[&'P4K"L=+]DS.YQ'QDQT0R49XI9[%=L
MW"6_6NZAU P@3EI$>O@MD!O9GZY-7^ _3'D2@M+JZ[F3CQ$9E^;LF7.ED(WV
MKSQBACUOHSV@2P0/AD9_+'T5"] 9$#G(<55@5!_""3D3]_COX(UTZ<N\*@7(
MG=9C@;SLD"E!:J4#\2"_AE,9CKI?.E+A?/ *S;@L^FYSFBR4(?I-K'#=$.(N
M=9EP_AP7>W<UW%#,2 ITTHK*RND-"%@&**-!S[CQ4BGRX2&\ICA';&9?\D#Y
M,$$!2Z4DX4+B.F%,:BX#TF(&,T)K[7VF<J"80I8#.F*& G&B!"T0TCSH3CDJ
M<F;#>=\,.1I#?DIOA+_Y(D!;$:^[1JD(YK.7X%=8A@TZ)<?U+WG$504A.'6$
M)_ 7<:1%%!9)\(N-+=:"&L:?CZC(S*/RO369-1V(MRHK_\I!=E'P 5GG+9H*
MIZO5JLK!.CH'\4. E+LK71?03<]M&@[AE;*X!$]R9'*H:6#UR?# 3H0D4:@>
M!,@)6"'<)0K<!%24"-0!^#0AY480+[>,:"]I^:VB T+"@'HG\$*\_S$V04AX
M*?H@!][*4M#9AT!GD<_+UR,NN>AI0(E\G-&R,5"@#%&<9-(1.8W!F*!N"QGG
M(UDX(:]$P.!]$RQT)'0+OP+FC&(>'?,P?VKH?8L3[J_),^H! 5B RLY$D T^
MYU%N$G[#);RXZZ+:'CLQ[PK& #^9@)9*MB6'G;@K^M\!HTOP #62C%@>Z(1?
MA,+U#>1@#$8?9SX@D.#HP$Q\8-/HL^&"3/AV1!Q"A7)@I2*P4^A08<JD@A&C
M0HI\%G P2>F6)6HTC$L"S5 2M?92LC- GL7C;U)\X?G$)W+Q8<Z= %+ DA1%
MMEJ<#OZ)O44(H,#:N;6M*J1P\^(S0I? FWC7K KU>R4.M6Y)'%KMDGV4S*$3
M$& &6&"G7N1QO4Z)"\SHR;F_"._G )3,61H2D;Y7='Q8HN.+@H[/"SK>'KJA
ME=Z D!F'_EJ\%X[[[QP(A27 T"ZH60O*KO>@A8*LL_Y-V2>H%:!P >4YL,9@
M'/!.0<!?)KH177Q"B#GP4%>"Q8Z_ \_Z'HI,$'7]>\7G-X#7R$B1Q-)]P\^3
M1'!UP&R5_9"F^41V'Y(,CJ,V4!/2 'YE> -4S72VS!7"')-"2$?G)J8DKZ]1
M?!,) N'_!I+^2@V.JA3$N0:ZX^)$4" 2*F_=(]TWP%?5$=%-I[U7?2[$@0D<
M"&PG0B?,8_P69C,3-335<PD6\/Q1"+_B]\I524T&!2&Z ?&RB!,B4^>,XN[O
M@%N'9U/.\4+0WT/2DREM@_+M4*6GID4SK@.MPHSS'%?/P+)7,E#V$\I0*[TF
M+^ W>C'>)3]/17PK 2V7"#CE%H;KJBV\+\$+L5] +,V1@:LK])FTXH4;LO06
MA)W3?'L!N"%7I(_LM_@MF F9<7("& ZOY;FH]@'G]K=1&"(V$ !HHI3-4WXQ
M (Z1/<(/&J:BH9(D.2XK4.DOH2;7@3S1( I ('"B4$\(G3D'@^L2]TJJ.H6,
M,N\KZ<_Q8!Q><[T*4"^?DEY-2+;LPO%W"1NB]T;"E<)Z!*9 J23%27:;>09E
M&>))&9*." 0#Q%F/$ A(A]M;T@_$&08>""&MNQ@U..D\%=?W!8O!.P>]46_C
M5L80O6W7W18FC1>@6<>UJW%MNXYKO_"X]A/&IS?D.CJY(P<YB"(4KO."Y?]4
MVN(PQ)(48P;&L\$#VD?,)[<.EU2N2"B;=YY?EGLL''_W1V0^4IH\YWI[E\>'
M^_1>-DA SLV$]&MR?]&Z[/V)K8+S;RSY%K*;70G,"!<:>LDB?-?US!K&('A0
M"PN!6_NCB#Z5&BA7=M ?_8V1U@C\G8T9Q4%)$ -*Q' ',TQA4!$;X<>5P>?P
MAW*417!5$S!7?52H";%0:PI]T!K@BBQR-(-6A1HSUR*D38O\F3MI!TF<H^Y5
MQ%TBV,'8U!Q])+)BW":2:48IT8A[.;FN$=L#S)Q6FZ<']/V#'@._\F5+$&_J
M#<*QWB.D>C349%$1?HMNS9MP/%;9]J1JY^&8+!B2JQ2&%B[;FSCYRO,$4 L2
M80W\@-\!NJ5"DJTDZ;4@AG+)RQZK6Z3_K,3 RY!L!=0E\1XHD3 R['Z_A2GG
M\/%4YK-S95(%&PAL"F( ;.!3PN<!CUP+4R,;$7H8/KR9XBF!'DA4<<B$7:/;
M'-,.E1>8/*LI^E7#="0C/S)_ DT9H=HKY\\UBRGR1&B1\.0"[$49)^. 6RS#
ML7>=CL*I,0%L!"1'MPO8E3_(I1X.3/3:H0,R&H6#,*-D#&."AYXBWLZ2& U/
M S $3.!4<]>?'E^9QL%_/IC&'\>_O:=C34EA)]_"\17]KW+L5E,:R3WY'GU_
M^#->FA&  H'1+%&=\1Z+,_!;N&6 7E2ZL!RL"\G-4Y&SS&'VIG!V OONMMX:
M>_IY]U6JI=H2L@ O^(;8CE!!U/;1AO$]N/<HGGC&WL7AX;YI@+HWHM@9$U8W
M0F< -U,HPN_ X :RMTYG&"J\_&\>#@8H8DJF]-Z[T\M]X_SCT<D?YW*/40@F
M?#[Q!ON\[$%+P28Z@ZV-&)!BC%N#:TCT[?T.V\,MF8:6-@/$/IXM6PSPT O"
MV./,*HP#!/+>Q<')O@4Z2$*VEV:1\RJ:; 3H$ :2,>P=71WNO^6I9'CA%R?_
M7GSCP+R C%CERB7%P 9,+)/P4(T/?>3-^7B,KL?J^T[A?8@UB7 \9K,I=V_S
M'Y016^">]"*'X@^*-!G4MABY'3V<L%WA7!A@$(EY&LJOQZ;@F$ ;YU?''SZ<
M'"I Q8,0[I[@9,[Q@=/C_S,+H'DI^:%+#$(G *!/6"OB 5.2HAA21]<'52YS
MMXVDLPG85H2\W.Q'(<H";K 3UP,,& @-F5/6;PPC?: =R$0+K*VA>)Z("US$
M/OSW-V""TWUC3_U<8.CIR=G9\;L+16\L];XC:@,Q[XN0'::NP=^@Q3)$._PS
M92)UPQA@D63Q,HQBP .QCQVA?412R0#-,I:3=Z@0E$-C!$B;@,*>\D0VXU_>
MU.,&-RC-W'Z&^SORPM ?A<:E%WV=Q9*#F$4\OOR#_5U!X ^,FB.+B*",7Z%V
MQ[Q).8K%&R-K! UL*8(C"U<1)P.%.9(65*X9^SX5K<G)&RM4S2(O,)RR,0]%
M<6E=4<<$U<C8"(M(&TU3+@32"89;I43E.F&(+PC]E#,V3^;,*5*9Q(!2A0(W
M86B A.E$N3/C:)N2JY;:<HNMD$,=4N\EI+;G.+=E_/[+B]#BDW4CMJE*014Y
M%T'419*?BW-DDIA4DJ29Q=%+I_VJ*BUX(6@7Z 0E?Y=2<>!XH FBKL$Q.>59
MMF)72I?@^:U2@:P&>W$SDSB*N?TQ6Z99+-\7'I67CCA-NR/5L7*!V'JK2#L=
M%^HV0-N3=@0J*:$& "KM6W'Y"[EJ^=V@#P'=QEK6XX)#TR]38/M#1GHP$66<
M9L3)T5=/*;F+TD8VW9P'"@TW2*=@=WJ8KU5LV';(F\&YP+7@;6,4@[1!$#$\
MDU!>)[Q 4Y9 !>/V,6H[F@W"N\?SG!E$D)*.;F5 ?8QK=!POJ(@)+@P9)RB!
MN@Z(NE,$K/(:0_J[(F:N8FETS1G+K)(,(557FF81!DS+*[\1MG\IP4I(:9X0
M-2EP[F0*QIG(I#,N#RZ-/?J$FS!7WE<6S.79":FN)=G1S_;)ZT!)3UP9X$N3
MO,0SICR78MGQ2C)3'DJH+607X".D=9C"2R&W=Z<W2!6F8;R+U35H9Z;4!C5#
M18O;B/18E4-"GPAGW3!/2+Q?C^-!V8!>[M>A ,%B?0']B[1>D22":;J^"L<B
M^K.2OP2](@8VR<"L79E+..$.%(I6\?@C2/.&\2D+82.R'E'CX1CT!?U0:"RZ
M81\B2D7BW(5VPM49BENP#+=@B@M%\E;-$WCA+J@>&('BN4,+W4$\TEW@NXGH
MS&-DRWT07#L9>WGD\XUJW@"6)&@:A&+V2P6Q]&0^88<>YPG %^C^4T0V_?$G
M3@^'7N0%GLD%5,$K2Y8XR@TI;W[G,H08:5JP=HVK$Y=?S-JI(D'ZK4C6B"I4
M8N8%PH)5OMH[HV*WZEBZ\QA]QZ7KOIN:(#)XETA2CJN#,J7AQA'<(F]F@BF;
M19\+[C/EHDHFLJH]*<K083M@LU@XDHX_->2+D(X+K[I'+BB1Y*PUU1 $K&[H
M5'E:#_BXG;WCTX-]?4L5=67532SR8U3$%0A$L\C]A7<9E%LK2J'@(VW;>).8
MQQM)TD6YGQ"/0P0@ISHE-Z4IZ4$B"1=# <:?E?1W7)KX(#('3L:F9($*J4Y5
M!11/>,5/),$?*/JC%'6G6:";6O>4.\AF2'6_,V^<@3'\ 9-$>-KRGVP\I#8.
MI[]_^'-_@2JX0F7R\\03-0IYA(Y&GV=WEM4-29.WK59:0FICFGK"P^C"KP-\
M9B(UU(9Q6E;!RO>NKA0W<1[%\Q(5N-"'+&@8>_ M&/9 &D)5GA,B=2RX&@MV
MZEAP'0M^$E1;H*YX2191LR.IFV[$-1<Q2V""91YXFSPNBY[5;'!7+"%-]9%5
M6KIJLU"9EAYC/9@@4W#2?$K1>5']%,A%RQY; 4VN?\(U9E8\M"@H=?O;"\U:
M^?)(]Z!2V%!56V@*/+VEI/H+DU@H/(76GV$%K\B?QV^B7'J0YX*=HUBDG@U8
MQ(9AIM7%R.BQ*@=AHK,5!4WUV!J/&"%N8=@7/8774OPL0D99<R^"Q23]/(PV
M>^78L/ P4H1<%$.AU]( _@H&P75,'R2D$T:8CR4#D51M ;OQDQA4&J77:U>)
M1RK5ARV'K6E0OP%,2B_2P<4K1,DV8/V4$>I3_#S-, &/)_5%Y(7E/N")QPM'
MQ/:D1Q9??1@+^Q! >0'D2(H[A0RUZSB0IKBQ=WAQ@&%#I0">21/KD,/W1-;/
M*P>:^.)*>$**)F78U8QN>>_L\,0ZO#K^N%\DP1:'L<0M("E0,<O>R>75O@01
MVAX8_"@BG]XW+QR+I/7,4WR+2L5+8.+8+W5_RG18@ +2X;3$\N5JL\1_4.[@
MU6QL,4R;+ZY\F_S.MSAJ@9K#;W$F;ZEP?O$86%$" W3*^1B&_@[/+T]/#BT7
M^TU1@'^$',"MK+6$C*E\)T^1G'PV0 Y2T7;G31#=1*THO?F4S(6;>+5/CAP+
M)R6WJ6B3!30=YP(GX.S%T:C9&$@ISO.2<(+N5""_:1QR'3T /3OB 79,<RWR
MDC$U&FVQ":?4(C0;1]801[6E>?(-^_@9>Q_?7ZJB6P"BB OB&P=>&J8*'W4?
MM=["T;'I?@J;NMSB[S++@YG*C290:@>D[D@\#2(K1K32H@?4/Q,P\3+V0Y:1
MB70H">I<^E?V#BX/S_=EHMDIXTH$6319V6[5EB$3MK3*\>4IK$+O!8V+KJJ4
M^CS-"S^/(JWGSO!E8"H"VF3J'(^TL97;V!E.\P[SI4B.4O! \69>527^B =(
M M++,J*\L;)K=$[$AY,)5C6"S>M_Y82I(NXIB([#DW2?B@> /, H9A2_P91Y
M>LS"BM>04B:,+)]@<5ST+4SBB*<6W3#1%A.)(\*.LI@B)'E<"J05\@PZZ5YE
MWZ=C7%W(GP6Q?-YZD!Q51<&7ME+ QN$WJGWE%(O%Q8=XME-,S[/ZQQ?88NU6
M=EMU2Y%"IMTD54;+#!F>&"B:**38=5W>]L*PU)+("07=UE5VR)%@:JQ7"XLY
MS:+0EQ\,>;#H3#?'@X%_(J]!+_A8I=A7ZB9H(%B,"2K%L[S>$H/G\*N"'9]?
M[N-R'A[=$ND6TKT<3HH<?O*T4W$=KY$6K:(HB7+O_.)BGVMLZ2B^D8+E-IC0
MC15 *9>Y"($BJF-HW.=71E%U^(4_D_6=E+VEP,G=MA*@IA'$.==2Z-+0XW-Q
M(4I007M4.018QH+2#?0=+V6Z\.+EYQZL"LI7J_G/9:]J&$=*%RMC[]HRCG**
M#XL_M;KNQXP;ER.GCBW-8^7>+O>U^%.SIS1$E_B/CF38EY*X[MK$"Q^")9&M
M0AA30Q:R#J;A.)S0GT+!6H!Q2Q^94\)6TSX1Q(2BK\PBVR@&G8M0AQC!<93
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MFRH96LDI/S+=B7R32-O(!RF.!>&I%RIBJCCV"JDM;"9^\95D@DKAW%I[56A
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MPRBDP:BJW@Y15J8PSPL-+AM L8BO(V!!5=R]X2.->2 &%_]:E(!JS7Z!A+Z
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MUOMV(C:7IY24T80H4/7T%_,+E7=(Y^1+YJ'PAI@J=47O( &2Q4N",:GX0Q&
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M2$%&/#0\?Q3"S^FW("BPQ0I U0LC_/*VTR>)%UWS\S=> UH[6X[6T[D!\R:
M;.5X3/I0P#1.9D::3Z?CD+T.>+K;!,\3"44@5_^KA=M$L3A!0!*]F<0JO/$X
M]CG] 85>LX@EWAA^ETP1A$P,X0'6M2S68LX%7_ 1^'DX&>1)*MA9B-V5 )5\
M>M--F(V(&RQE /PG%[$_0C[*_!P9*"QRQ'S.O)RFW5^.5(#)U\!I$&S]"D8A
MBCV=TDD@NEJ$%DL#CX^]FQ$R;C]A@!!XHPJN#XJ[:^YE6=S.&,:))LD6"S".
MYX44D]2*V(K/ A+#X:9QA/P%I%0(:\[@K,C7PC@ L0?"=:K8GB:FY?UPO(5M
M([T;61(2:0!!F,9XG5YB].UR^IMZP$F  &= >L.49<9@!D\@_U70F6?!VAL7
M* &'"S=[,PH!P(*O%[P:%H=[1A$.+\Y&81)8N*49DFJ6>'Y6($><7'N@'=#&
M]2U\ YC$">@JHYAX?9QDG+!+^X MR"L--@63!J$@IX?&\0U=-UUPFL9^2' C
MCH$+'IY?GIX<6J[MF/#OLZN#PRNKZ="FQ5> +@"6/$#!9*S5%>XA]U_"KGPZ
M3."V%3X-F0 Q:%77B3>!WX LXCNA[S0T'>2@1;&TK T"V,)O\ @>;=E,-8EA
M]SF,M@_O>51$XW()92G-^^Y $Z : :^"#2[0Y 7M>)'/Q Y@/4!V'[\GDH?#
MA7#7>Q\O/Z7[!L R$C(,11=LP@-Z9[XW84MO!W[+>2!0IO'?'$@3]@*_ 7;7
M-.G$7L)W@S_#]Y1?XS3Y:X!<0(J&A QB?4#UY!ZOMQO&QWG.5*#5',Y7V-J(
M>8$/LB_#[W2^ 6MY'":J+'1.O]!YT<ZH "-6NH!;,U>4!%S/@GLXV2=WF2X6
M/VM*/G.9B#+O(A-+"LLB>7P+.MZ;93\:^JXI?1[P*"7X+I(^YC+18RYF\UQ<
M*80>YGPK -9)F''M?^MEUE(N(HBXW0(JGS<+;\(@&PG/LOZ4B&TTBT>\01J/
MP8A9^L@B=L4-3( ,,-XGYE>N7:E5T?X[2@K;_1JD'X#EJ^4-89-OO/&--TM_
M^J5\-#B7?H]K7(&]LIQH.-SDQ+UU3'ZZ;^ R@NS>D&+"S?K_\9Y["P880</_
M_>D?89<Y0:<_''A!T&EU!D'/8T&O.V1!X 9-N^?_W05)(T7Y(;P0J>]_?O%^
M703,I<CWQ*BV1?KBXTF,90)/O1K%O3#,Q,\N4)^KVC="(54":)G Y#;2K6^M
M+H\ZY&(C\GD,N&5&VXYH?2> @4% $H"[T+Z%[*;LI/?AZ-=Q H="=+Y=+0Q8
MZB?A -WT ] OR'</%QSYX920 /VS(1()*.SC,.. &H* 12L=$''B?27UA/EA
M2K9\PJZ]A""'M+1T T(G .P 53;5E^1.!18E0'G2;JB8_X3=N#PU?/%110K@
MW*1JL'$( L(#10D^\NB]0_B;DKOS,6 (:"B3>7\"WN T1@:'* H@#GWAG%CZ
M+L)5N0Z^!U44EOBX0+'4TL?%$U.6A72IP2P"7/'A1OY$-VH:X]VRU;=87+LP
MKM#3 C@J61EJC #&0DL"DQ(19-98KJ)L%\KC723(SOR<^#$(3U!BPB%<.BIZ
M$]*:Q6E+"#Z$BP=HH\H+F/T#?@V0&B#93+SO@"(_F* :N*$IR[/07PY#6!^L
MUI3 A1Y6_*6)H31/8)4@F_@+\S-N(\,^\T&:>7P!5.B%2WPE/!59WH3CL5 O
M"[:(1\A)*$FL6T!1^ []Q!5O74HX88"V!%=S'1.= F<=>V#K!'-TYOE)#%@S
MP0C-=,QTNF@89W'&9:I8AQP(T<Q"UIW&"?DMB+V*2\+?$/'1719& >WK3<&E
M79.(AF_[W>FEP7_]+22N$H7?0/.=> .ZO' : KW3GT-D?WCX$2 P$YQ>>>N*
M%7D0 -9,X8>2><[;!\)G)MX*</@1C\,?"]ZT*\)#4%)A4A*#B/"UUS,\:I #
M\D[#*86?4)S$^?6HTE-+TI7$*A81U %'P$89&>D$N<TD'C,_'W,8#$)\ ? U
MQ?*Y8%8X-8D#E"RA,/PF#*XU"M-)RI4U;M:>1!QKN'0A<@-ZH!U7-EC8?H4"
M<!US(@[Q[L/AC/"(W:A#%VR95*W@&[KA #/ACPI%_'_VWK6YC>1(&_TK"*_/
MAA31I$GJ/CKO&\&1-!YY/9(LR?;NIQ,-H$"TU>B&^T(*^^M/7JNRNAL74I0$
MCO#%'A% =UVRLO+RY),T$KV#:1AT4N5LTEEUQ06X,:B0!WU3=8(O<;X9&J>H
M+2;_;K-*DZ"1 0IC7&3T7V&O0"U@L) 7#!;?B;S"7,&U;BOV^T$Z83% 6/[7
M646#WUJ,0.&!.*L8@,$,1SFKYV0KN_A6&U(V63&K4KA,8/7:ZBX= 572NZGA
M1;H*9K=&T"JW2#-R'"1X>8-PF;%A*_A=@58VGT?1I;KH[C+-6Y]/C15[0T%
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M].X!9WO V1YPM@><[5ZM^ %G>\ ][AGN\8"S/<C; 6=[QW"VKW'37=U(K.
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MK2IMZD]R'QH+3X1' _N<I AE\E.'U7E9H=0'14IUUT3EPDD'+..#,UC/.&E
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M[YC$5^_$K/8$=81UGFK-84W] *4!($'O+RFJYT.&PAVMH'.G>'C\'@+W+YR
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M$,?,2W4.7S_ZKVSRB9!0'T!IHPU[[_R_/MSWO@"5C:.N'U,*U$?49H2+,6O
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MP;O#U"RPUR]6C1J@D847.=L).=5X6 ^)YV[B^?20>/Y1$\_?6-0F*=&U!6,
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M NU/)1$4K?07CAQ\8Y)^?V-OCPRO+X9_#@9,;2J)'(7)*F'"ITY F3F5HE8
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MX9]+8KU%; 1S^$^YJU);-,.16[/MJJ@J7X974R\5:H%@^MKW<YTSZ=4]2:O
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MUX9,@@9#SZ)6CV2H^._?5T4<'FN?UE6?G$FMFW)!*]?!ZBSA1Z$?X%I&#FI
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M7[]]7]VW&PU*LBF9E/!A)K)$ OV\[WN.U3?.P-:BH? ER3HS-(B>\7:0I:Y
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MPNI=N8EX0D;LQ2E,73HUYN9A,^#38_X/-$AU?J&L%;<)\G^@SP\;$[9''&\
MGI^\)MP@6F>Q+VQH\+8@.KL6J]!EJ,2H^6J2VN^N P5>0.>=<D>WY2L_90[R
M(1=3L"',I7 $JJ%92OE$<]\3<3 '+Q5)X177C<'ZFX 7C)@(4"ECUM$"$<A-
MI!W+YIB0).<_%G,V%TON+005?#.,+"]+FA9T"-N&"'="T/#C/TO&/.BEL!5
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MB>W89C8/XC",8WL1Q1 ALMVOS=EH7A,0\M(ZIY YQ+MDLH?-1@EVF]:!T6/
MM:&5%@8/CZ^%,M)NZ76V=)D[PH"1MY_A7HL['U1N(YH77#OXFV!Y23A=6@S
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MY!)A&!YI$F\Z*\*.?;5NIRP'%&GL3#O;A_H>6Q)[V6U$EEAAVSWVQ4+U\))
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M?0B1&Z;QVD@38R2=Z?*-4></PA'\ * 1Z:CZG__J/STXKO__CJBA=\;L<0B
M$1%VS3OZ[-%V;NY1SZB_<8)!I3\ K9IAV-VF/JR-,K)O2W?J<:_S&W16GQ%I
M\ZNL$K[WA[9#1UNZ0T]ZG?>8Q7N38PH*=,5#VYNGL;TQHQKNF0E"I^'+:CDS
M<U\=;\&&/844#IGT-]JGP&2DOG-KE9;&.-C#HO5YE;Z4'XXA=3E-5B^S'$>#
M7Y)%8%/6+,,QY!4@U<4OP??1G]DZ>_&B]_C@,1AHB]+\;R0O9MNMA[;;_F)4
M_]OSWN/GS7\]Z/6_\F]/'C__JF^N&^N1^>+S9SLRV!>]YX=?]]1VK.U8O\M8
MCXZN]=1]E#'6JQ01^ACE]0** Z8@-__VZ.A1IRPNZ>?#1X$P9/'6GR\ZQD'/
M1AV1ZQSP>GDX_]+I^](58F"A,*3G^*[IK?GP+Z[2(^@EL_YH5!_?>7COD'LQ
M\#%YTZ_8.]F; ]B91]?^VH/9<N,W07QK7K?R-K7 A_W:9W=WU=[8L"U$"P>K
MSD?(FT IT=6+=WLG\AX<QU^R:=J<;?G.@_N[V6*(9T?V.*Y:C@YCJN4Z.\E_
M1'_B'DJ=7XQ'>>V;<JVU6'>-V@7'>]6YKOYLUWW3ZG5_6T7:R1Q+;[]LZ_AN
MKE?;4[L1:0'9TE?)XAOM&5:+W[17D66D-:E%EXKY'0<:CWI]NS[?9NE]XX+$
MSA4M!V[;1O*;5Z_)P743G%X(-241>?S=!L9IS\EB,:]>[N]?7E[VS/AZY\7%
M_DDYG  +\7XZ.D_*?8 ,VW]Q].+9TV?[,$[Z\; //S][NI]^2:? 27SPY/!I
M^N6H7Z;5 @H[AFEOLIB!,*-_=TYAIQ!6!+.+OC<!N4CSH.Q+5G7A3[U(8O5V
M#]LN7+W^P=[O=W3W=F$YS%/WC@X.CYZT:_(=I/,NK,;S_2?[()SN>DEN8@_L
MP#(>]0XWNX*M5M]FK7[X?)]G<M1/9MCVEN0C5NRDU4_HUU@N9#7\S]3Q<6>Z
M? =NSO.]_[NSF[,M<[XEM;P#,]^X\MV%.>\?W8**O:^*M'^')Z35I-^N2:UW
M^^+HP.K$/NE Y]"R!_NAS') >)^"_F/LH/>$'=3YL"RK94(4FZ^_<&_CR7#1
M^;B$6MS^4;+7?_Q#\B-I5/.[3O_)B'YUV^JS_>CM?'2+Y=!?GA"Z%W*U]5!V
M7JX>7BE7?[&@"JU<?; ?W6(Y=._DZF&OC\VT3XY;\;KCXO4P9K965]FM(#:O
M*W_[SQ&IZK1G6W3[1T\.6C&[FQ_=8K%TW\1L_Z#?>_/N; M$[!W-&@LN_OKY
MX]O.FQS:U8=IYQ4#1&UB$0Z?[=+N?YJD'5R+3-9"P++,#\:&S:FS*TU*P5U[
M P-/B!+J%3!Z8:6;H"P O $^;Y&<5XBG .! (PC70R&G?0:RO.('Y7V]>WBO
MSD[_O@7W:IWI<BN72V_OI^0+X%NNC'I?I$3V>S:<I+.D?NE:_;PS']WB>W<?
M]?/IR=M6CM3DB'D'0/,2SDZ6?QXD5425MU)E9SZZQ;?P/DJ55Z]_::5*3:J\
M2L=9GK5"Y;Y\=(LOX7T4*F]/?FZ%2DVHO$T&Z;1J!<I]^.@67\#[*% ^?'S=
M"I2:0/E0I@#<W#H_]^:C6WP-;R16!*@J+S!7N6;FV_?)>SRU]I.W<E3D(P*#
MNP9^8FLD3?O1[?KH[MMIFRS3V:$D\B=@VAIZ%8/)T/+$$1'7[TMDI9D"8A%0
M<@$Y!X"Q=*"?M@NXYY!B':7I+!UUQ@#&0PCND"8]>WV*-3#\H44!I \>@/U@
MU2D%L(%HF)%'F] $:KU03'V$CW:HRR?$CMA_<71$A';47M45VD7U4:_(D;[S
M6'^G\\/E)$4,TQF0S@U2(*%#YIP(X/Q5B_.C69T2.&^(9D*8/X6*,O-ZN*=F
M6,O$C SX>I(L)QAYY(&DU8BDE_<11/.GKP57_>E_!^7^3]\?E?XJ>-2M@*I_
MM@FH^O[!BT?RK1:K_AYCU=_MD8U#_)Z]^?7=R:<_/KX^:[SBVP7"K*LA0=)Z
M3"],\7&E+*<O EA_"8\"3L31TLAGK.X9:6Y)5D= Y GDJCF6_@S223(="W4*
M'A[^ &B%= D:"I^7+!>3HC2S&_6N#^C_Q#\6)4P^MNIWBZC\K-][3-BM-T54
M/GS:>WJP>7S69[W#:^*S?O^G/GG<>W+X]"9@LG=AL#_]6AM40TO=K2UJ@Z0;
M>>F5NH***%^_??/7F[-NYX[)KBA ^ATF_.ZT%PFM-J <[UXL8-..Z"P;C:;I
M'3ME[XH+Y*/L''8[M]<;?E-Y<)<K\//JY0TF?>W=_"YSV:_V.Z>3$HC@Y^!7
M_@/Z.X .["8AZ<VBWGV74^TA ]ZUL-A:U,!0:L?!%;_Y_&R-M-YFJ>/:M_X)
M/).0H,Q&Q+$\,E<X2\=DZ-LV+OJG]'+=Y_VXE<@D/BG&E1[?GA]>@=MU8MVN
M*YOLX/<GPV&Q)%Y7_OB/-PBC/5A>QN?-P:[]03%:F?],%K/I3_\/4$L#!!0
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M#SJXD:1_]:O.-'S8W>_R$ @Z2<JA )<S7O>L! <N,822T+NB!$O,#[K[#6]
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M"9EB/$,(J$"R0&Y<%\=*I^*?FT(<E)_KPJ4^VNKJN,X/0]DE;_WJ'BT<U,W
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MK-\-'?K9Y_4EA@7^]-W_ 5!+ P04    " !5@F)3&]QUCO-(  "?60, %0
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MH+[RIC#"[>M?T7T3N$V+*CH"WD]]10^JOGY5T@!Z:K ]=86M35)29DN[L5%
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M4-$K""9IX#KHI)G.2H<F9'W.P^[,X#W38=]YV+O==Q48>FX%,"M<O<. 7*-
M<DZT B:%5*%1C=AC#]5VHLA&H=HNJCJ 6-HF<)]#M3VH>L>@VC9Z.@!Z&3)K
M4192O(JU'D<7",X7R%&@6UZ6[MKDF Z"5EN%:H=D51?U#-G)<1&6.)\\%FN'
M0K&@M0N@#)+CQ'D PWBQMC!$JW=NYKCVT,,/SG;2WJ;]'+N(OD>?=>W<W,R9
M4DLWQ21&>&($%Y4!+FW&:"371?16;?+(IXYO8_WTHI@><]1WSV3=!-23FSK>
M25,;C9[>1LP#3AUGL0BE(8<*+HHZS% GX-$'IH17B!O-?SQ$W7>=.MZ_ZKM(
MMW\38H''Q^-T?AZ*G&/,BHRF6G<3%&UGC#DPEG,5;"';:=,AC9<_]W#F2W>0
M]+0?,3W$/.NE?W;E@^<'DT:]%^'!94F[R?1:$E1P[Y(+G$=9E';99Z=,$HYQ
MM,3@OJ<IWHMU1Q=X/D=ZVG^=CN?G:EF%/X5#)D(@*QE+HC]\!&^5!R-4,58Z
MYAUN<M!T=W;706KBH+T;'WU<:N';5*CYWS_1+C99O U?EXFNZL.ZXCAD1W_0
M%N,A^LR U,T5&N=,,#OY:_=CV(/[U@LQ-G+4>E9!W_,)N\#^+7P9GYR>O#BB
MUYY^A)=>Z6_3[L[6-!]9%1VW:,!A+1%BU>-%<H"+339;ENFGI7=>=4'XY%C7
M3'U#A9LV6=1M QC/UZ0T(R-,2@@I5!]:"/!%6LB9A*RY\$'=:UVT!/CD&=F7
M\GJ,6>R\II?3DQ.<C5,XOKDF[2/*X#4([\E-4-I *$*#HR/ &VYMB;O%2G<$
M^.0)V9?R;A)2[HV0RP*3>37 OUZL)?*"+CH$YSWYF2JY.M?1@HE:J,2S$>B:
M$_$68$^>@+LJZR;QU&#$^_VTBOI->9'S4I3A^$T->$^/OGX(LR.DE83H8HE&
M 99E$8I/M+LS6HDPW@AI"EZ?M-X#[>Z%]>1(UZ^B;E).[]$:G",A^?AV-CV:
MA9.?3R>ULN[B34I&6R:-!%G'GZDHD=XDK\#F*$K&Y*SJW_?MAO')D;&A"F\R
MTPS&S+N7\0%G)R,I4K(N(J3:@:K(J 67. (+V:@8DDBB\ZRL'G ].0;VK*J;
MK+.'9/O]/)[-%Z\G\T4X/CZK?"=/RSJ5 8/,H(*W9-<:6_-.3@6)0E^?$3&,
M+7@=Z)/C96MEWB2J&XRH&V[W-];'L 3$PD 78T#I3(:)P0!1&"U8XH;9W4;'
M]@CVR1%V"*7>)*T?C+1O/M7_O/J"LS2>GP<&1D%;XY550)8)G0U)Z7K'"P.5
MBTV1V9*<Z)V2MT)Y<H3;72&WA+)W[N6ZL!RF2\G,<%4W4-=3Y34?E<)$%C*"
MT%*"\DR!+Y%#2BSPK'+2>,WRZRD;>2^TATZA-CJXA26[93RN+WH%]^^?II.7
MQ].:'G]3+M4$CC*WG'%TM#GJ6NE)E Z62W!TI"<G$V:SV2"$C@]^Z'1H+NQ;
MF+%;ZN$ZV$Y)/$:N2 @I ;/,U)TO0@R>@V6:&>8-U]IO19,GEV<=3 VW$&BW
M5,%]R._*N=G )6V' :PDYU:QX(GYR8-&'X2SPMJ\65I@!Q!/@CY]*>$6]FP=
M[U\GCK-Z=)=+-J5X4$[;.B:/;/3,-&1A/&-2\US:C.J^%<Y0+;AMC)/=)7PH
M+;'75[(L9$XN29.- EXUJD@[X!A]FP(C9D<?I&TS'.0V-/MJ">E!Q_>PIK.L
M6_0<7L.T*H?>!%7;SM5;<>VG075WO=U#A!V$/APEF Z2X$6P* 4HKCW4LF."
M* WW,B35ZMZP :EP3U/I4$SH(NNVM7SG]>)UX,DOX23\%N+\[<<P.PGO7YRW
M/&09>"3[1F7:#>L5C1 C9Q!$L-HH8=+U-N2-PF?W/WG_AN8VZEH?*NM9U@.U
MEX3YQS#)KR>?R0I>=19<?!F_OL=T.ALOOM9V[%U:1+H_I8\VCQW7=N-&+AN*
M\DX4J>O4:\>8%HG91%Z!RH:/MGA>7V."7GRFCZL6SL_36;UG:/6L,5Z:0!.P
M5K<KLGB*)[-9V0P^9@Y:!#3D$Q<7=),3H!/,G8^_M8]X$>?+X4\CYI7!G!E$
M7219@H$$H5P$71)+,NFB;)NY7?=C&WY/;,>A&X=EOYII, 3N.L*?,"XNH3R9
MSA;C_\;\<CI?_!CF9#O(C+P(F\A_4'4>!<DDTG$!(920I?/9I39#M;HBW<-9
MV[.V[R%3KZIJ897?C3>ETY,:D,+\RVPZG_]],L-P7!?P"\GZ1RS3&=:Q=%8J
MQ@)S8)F@UR_&#,Z*!.@,4]IX$5B;+;P7^$^-A V4VN("@RT744=X?EN$PLA*
MY!9T]/52$*PA=^EJ@1:]>#R6V"BCV@O\9V;NK-0>.R[NE]'5Y8R2C0D)6;VM
M.=98L 97=(:L30XF(6=E:(/N*L)'SZ]>5--C[\3%"$]RR>K_7I'/_YEPDB/V
MCCRRV3@1]^M?O)CDJS^X])L7DK*RE.AJ*I'^#Y1@Y+'[7,"AJI=$T"X=V^1>
M>H'_F'V*X?7;>[QNIQ5<MG-'W#N7LQ<@),E0I:)K&1\#KKDG"R-EG3>L9^\-
MTQ[&3@_/B.G^U7E0K+S%VAUI1RY7=A8PJ'KOM41P+GDPS"054 G4&Q:Y]XSL
MF:%#JK;W1O$>%U-MWY'*ALQ::>@P3E6L*4-(6@$MJ!0,TNNP88=DS\B>>3JD
M:GOO']]E,3^'\>P?X?@4?QK/:W')Z0Q'V;"<"#04S+5(*7N2J)0@598.D\&8
M!MA/;T'VS-,A5=M[N_E.LISD[F'9I*1A0H!,.9'LLX106P=X=B4J)[G5&PY"
M&!CY8_2J#I\"!V4_W+_832/ R6N5(@,=#>DJ1PF>10W1N1B]ER7;#:]9/(3E
M/+\9!T.6@S)C=I# U;"T-=J6A'0B<KF\!2!#9(;^P*(9-\F8?-BORYYS#X_\
M==F>+ _+FAH5[;QW5D#"6"^%)9/1<9W *ZUL84PILV'E7E.<SP1OK]X>9P"=
M"_':ZW8-ZUDY??8%O2\&!")!=)9<%:[(KR8M2X\J<&Q35+P!N*%:5(9+=O2M
MD4-I8OEY/ F3- ['=2;!['0YL;I69EN21ZYA;YV%!!4"!Y]I__9%N*Q,8=JW
MN2!I#:!]M;+TKO=I__)O4#*U; DN./LV[G_9*7P+VGDMJ9W?_E>K&N]-UM*T
M(Z;/U>RGCZ87FER_)W#?.CYTWCH>T4CFP4A+YX45%GR=5VX89]H([@QO=+OE
MP?/UGF:?@Z=K%]4VH.G9J-T*[6V@PVC5H9)LU*[PVO(L/:AZ%W=8%@4)Y4*,
M-??<J-3E-CC#NP[[T_#URI:=U=.@0/[E=/:IMCOAC],JGG.39 6.[ WCA8E0
MBBF@I$;P3!0HR>G@?9*.Q4;<N0/6D^907^IJL/_\_?V'&8;YZ>PKB>F7Z6><
M39;3/,[ %5*48,&!,ZHF!8*&RF\H"FUQ+$BAV]C^=\)ZPESJ3UT-:MA_.YV0
M8#Z%XTKT<WY;QK/RF(!EERLF!X';"#EE)HLVULDVIM-M:)XP<W963H/2\AJ,
M6R'Q+M9A8QYLSK0-9JN(Q-%!\H(IGZR(O$WQ^#<,3Y@<6RJB0:GX;],)?OTM
MS/[ 19V7>4Y4$:KZO 67DJP!.U]3!QX<0Z5]B5[PC>[4[;Z+W(KG"5.E!P4U
M")._Q-EB7,;T:W7I/^&GZ7Q\?BHREI<6.42!9*TS0>=C*)% .E%CO5[(C6Y7
M[;ZUK ?UA G4EZK6CK5O/)GAHEB,?GQ+SA/GTW+IMR_BQ.4L3EQE>O4?O)VN
MQF#T.=BA-<@F<R$&E>RUL1*2G'C#BTZ"&Y7))>.:7'EC<N$LEL!N&2O1&NZ0
M4RF8P\!R8&3^&4&GOI,U9Z%I^\Y.H>(FVC87@Q[(5(J7T\EB/#F=GLYOU\FE
M.H?ZXXMZU9*T#)D)T%Z3M>15!.\E!YYC\;R(Z'*C>8!]+^70ZP.Z,'3S/LDA
M]-X@ GAW+O+VI8P2+Y@]48E.5 =*U-N,?$*00:H8C=:VT>6_VZ ]I%[=04C2
MJ<J@!PTWB"5N@_F:[$86N?:&7FYF4J8EJ S>9 1M/8\J9!]SFSA #^"?.3NL
M_AN$,#<I\M"123J) A15[^E <E)\21%B*DX;P\B4;!,4?[#E5KN<W7UKY.#+
MK52Q"6.=S:"JK Q")(F!1E&LQ%*8;Q.M>(#E5IWTOFFY50?Y'WK9RB9K>2ZW
MVJ[<J@M-FI9;;:'C0^>M%VA8HE-"T8M,?XB:QTP2K,],B5"\#FW&6!T^7[<M
MMSH4NG91[6#E5ME(Q\E$ 2]1U*L,%,22+2 OT@?%F)%M!OH]QG*K3AK>J-RJ
MBWH&+[=RV>=,G@EH*3PH'10MMXZ5=EQH7S0WC2:Z/^9RJ]TXU)>Z!B^WDHDY
MGZ*&%)#3LNL(=*D\6&$U(]Y;H]M$DQ]SN=4N7.I/74.56_D<3$Z:@RDL@[+.
M0.0L $L^6B:,THV&,#["<JM=F+.S<M:66_6:WK[(8?ZVI#F>+7_[3/2=G]=#
MTGASO-?RN\4QETP.]%)&):KVLG!UN";WH<B81G=^\HZAGO.//KMSDZCYZSC$
M\?'J7%H^+K^9O*MGU8SX2K_P^W0R._]V.9_C6S#-VJRQEG:BJ!%:)3W919H!
M>N>D1"6U=$W>\%Z7,=A46F-=R=II$"F4LU*5* RM+U@CC2A&-ZH<.]RIM/OC
MX]8#;+MHL84+<-9&OL'8*&]5,"Y+<,9'4($G"$H**$;QE)53(K9Y.S>&^)3Y
MUD:/K:X/NQ58+&2'(&= IYFHM\1;\(J392(C<XR5%'VC$>_K(#UE0O6CIP;.
M01\B.DNR1)22>XP@D9&?3 (![Q#!\HPN1)%+HQZ@WI8P5%+T<&BY'^T?>FJU
M..<$2PF$"8;6DAA$\O'J91]<!O32-TK<'UAJ=4_LV# !VT5+AY[(VF0MSPG8
MK1*PG6C2,J.UC8X/G;?66BV,E62R&$]KX@9BJK9,%D)HI7RPS_,N'B9=NZAV
MN'D7/I!QS.J-K)[^X,:!U\D!%N^2,=8FV<:I>8P)V$X:WFS>10?U#)Z -3)H
MD:,'D2V!L^C L<B!EV"8X0*9;A/@>\P)V-TXU)>ZAI]WX:QB3$8(/*2SH>^Q
MU(LJK4!E@Y#&M>'28T[ [L*E_M0U5 *6F\)C<)R0N%II94T=#&UIW45:1WLE
MLVWJ01YA G87YNRLG ;S+M;TSCLE4@B1#M54+4*OZ:OHR:E6":71*'VK$2F/
M<;C!3J3974$MKD^\HV.^9"^9Y+30),FO"'4S1)\A2*.*=9$+WJ:I[_$.-]C)
M]NE)50U&9%Q$_7[\>O'EOX]Q1@_Y^/57_(S'2T=56.-B"A:*XY*X7D<".2E
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MF.2Q4:5HK^L8*EAW$#S>(P4.)FZWV\)__'K[!RP],6F#54Y'R&>S'5,!YU"
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MN2AF&UAWET>_@,P+LI2OS46074"_>_8+V.^TAHZ0WA^!=U6E78$'-&XN["C
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M$%T+!Y*0[FWY-,@70=(8G&\:^5@=IBWM!I!"Q.PRUP/Q9!*JI'&\0?.,WV.
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M>#&*II6"+V"KUPW.A\IF*$YK!4,TBJTP+E:QALC9-!P5 /P/9FJX@2??::9
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MQ0*E(U@B!:NLO8BX'*68 R$+^5RXHB9EIF"5_7 M9-:M8H1464&RDHU(I$W
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MT<NBK IS(SK8W&SXGT#L1 &L=19XPM<Y0?^.VHC;TZ?*.9W56WT(-K/#KI]
M#1RLA7]VLG;@R"[\W9G=SG%A^(?SPN"N[W^A[5YD]R*[%]F]R.Y%=B^R>Y'=
MB^Q>9/<BNQ?Y'V@__L$@4,[/F6Y,GS=WQSNCTI3+-3\2#7NH &GJZC*91OD"
M<JD\:$^3J5BJZ5&OLR^=R?8->\XTR#3"--2$F$PL5]6",4^\\W>+*-+55P5
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M!E3ZJ9:P*V3$B.&)X0C"T"-"#,8&;C&!+K-U&N=X<0@P4U24@M*WYR)=#9;
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M>ME'M>A.1/];>8IS.\&2A^>C@T&&7O>[TBC[;?6V;QLSES(=#9^],;<GVX]
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M9O$).B)1.O-ZSHC;E/0LVB-*X%>/Y#K3,.\,AV[^+\C@BIA#*#;)YU]507O
M3&BH3!S=8D"'5!O>."<*?B]CK"T,:7: .Z F1UPX4&-F6)MQK4+W?-[RMB;J
MV?F4,;.'([[!DKJ.]G*RP@%')F/-;HNX)"W;B3\'!'0PP=>V(2E.&1J^3,#7
M@=&")7:C\]71Y+"BCP3X?J<>-Z?O\3/5]-Z2143C\?#97%<5S,#-1%.6YU)U
MV+OZ \^@ T9DKVY7[U>OP:UL2,S2/@=]^!CJ]@$=J[A#145$?K^SXE(O/8Z
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MHZ0AE%>FU=CU&S0])O"B ^6O82)K@PPP@"6@2(<P?JC9CY3W3(#E$WAV>5_
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MTUL)!87] DJH"UCBRHHO=/T:#;R/[RML303%?;,:LBV*!"=:?05&T"JXN#A
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M%R-IDL\QR4'T[< @:E,Y_!F&=-Z6 =JR8$6J<_GK==CA_U2GF?\P/KY]090
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M5U-RACGPG1^6GZ$(>I!0P(E "^DIC"_59(Q43"^;!E#D=\&6[SFF!U">A!<
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MY</BA)F)C?H:*UQX8XU5?>4:V*9/]L;SLM?L5<?F"\66PM+-H"X?!I:;X+H
MO/C37B+'[\)582_,!?(7G>L)^+[KLIOH,VZ),TPQSR+=:/5#E+<FDW0)0C@I
MC)FB>P#S2,-A[-HHVI2JV[;@&3[K#)#A0-C@$)HD*6W<,&%>0@K5BUI+BD#
MT9?B-A\!DK(21YOZOGF,+R!3N_QI[R'C^M0KS@'#BV.=;.3*VR3NB-KM4CC]
MU@]FF@<9H&*AN1BYK618IZR,7'6.\/VN5MX#N1F[M:<./KJ#N0OX$6_ )=WT
M/N3.9'I7N0G1Z_E3,P<6: >$N:VB)>W)U8?P>>J.(/I+@G,P+5TAXD[ZLN92
M@J_Q$D1B('I+&,GG*U2M0I(SX<19+7WNRHW5<>1E@$:P!ZHW+5=LOO3J:R#(
MR%,_*AQ\.^9PBE9UG!:CO'M[X)L0>=GR&>WE 0727=%C7\OGDO9JJ)AR?+S.
MGHX8!)<X!5.$X,(5Q#WII0O7R[<=SCW#&QL\N$<G"!95;'$GU:AFY%2BDCFY
M=7+1H''L1 U@A>3L0@8X%)B^G X+"OHA._4QYXYNS'&B>KBQ@3I%B4F*]"+/
MG'+(%]E([[1&.S! :F3PN&XGT>'<IW%ZJ\XLBEH=/S>SEY:_/#HP5BJQB!^.
MGAK@YM!U=759%"[\V)2D*7KRIR&@4U'7NC208O(C59":ZSIF?ZV5J/$B"='B
M\B'VZ&$F'<)T*Z1@W+ET@4-$*\KV&3>O &_KWHRB<RH[T"?0@^SDDZCM)*D#
M"Q35AFQ[XS%8D/)=CFLU8ZJ/;,]2 E7>YUH\F9(-81_EVD@2(!1]7K7MSL1X
M0,=0*<,0TFI/]W+RIDTPU;W<ZECB0\F^><HKRKO^0@:H[$A-187!URV#*SV.
M:Q:*8Y^[>1;S'$]LE^ZS1)QXS&7(]A@$$GR:JZ^!M&D6$Q>BCKQZDS@VKL%I
M</ _7'<A;U##?/5Y.%CXV+DN7GAI%U4->=?0<V5)&&HP-X\\.@7\T)85G66=
MT$H_BABC2ZO"8ATFF/:4W'<-G;"-_039V+06)*/CZ#^2$Z6?8=YOT[?]G'F[
MLF<_A87PFEWEU9Y56T=_61YTH._WS_1F:^ML '.G5 _(?BQM8 [,:XGS=:IA
M'A9B@&+:SFT.;+QF/G'18?4GKII^*J.\IX F"#])'AD'A]%Y+:SJQDYTPS4R
M^/?$M+D>?Q;QLE!J++2 *LG$?GG>8;.(P-X8?A!^FLBOV/+<(\] K>\X)=:8
M6\KY%"\SWZNGAKB[@NPN#GBI)V""17@0ENW(?ABWF2U=N6>ROCA*=- Y*.R'
MDX'WE;UL7T=A\UW=L>H:<KVTH)1:&3+@&^]N(\L0#UD%-++FDP77'[.2*.IN
M#N4DLUMCKDNS3VO?DAV((W4PWCSEY7WDHH;:$WI5@3WK>_,%F"F7<\V@!:#>
M<R457EIF&IS7_^4C1O_= <Q)[(=ELB1W4"TS59 PX+<(9QVG+#BSVGV9Z[JI
MZR7=*MV<K/X#_T[7X4HT.1#6#%N[2I4!G/@BP!MV6Y$Q$D;DZ<->88@',2&8
MV42R#0/$9+.=%SYQ',F+[%(B=-+W=-(Y*W@V([9*-!#7&:#&BW1I!BC%:QQ%
M945M)X0'^E.M&:!+RPT0,A^$K/^Q(0Z<8VCR38IZ26I2:DL4 1C7#T. IQ;^
MMX_G#SG_?_N/BB\M#S*1,GHA]YV'QD::XV.B;%(M]'Q=;1WSTNR$=LJ#^,O.
MGT]N>GL=:C7R1XX/F\+DQ@<T.[T;N:\D? \Y?F!1T1)]I+Z],::;[;IM)Z%2
M?J_JX/E=?F11BC']4](Q6@1==CZ)E7C .KU$U2-Z.'^PA,]8M#U1)6'7H:B2
MZ%<K[S#)\YL;=!9Q"IL=MK2SSNZ,U8U',![;VTNR?!LXX6>L7\YO]Q-U!#%
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MP(0EB=#>($3LQLX0DE)%$G+M\NHH75\U$6O7T5JAC^L,\)I[=R%FZ VHTO
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MU\4+X0KU8YS8#+M'?&>_RB]C;[)OS;:!5+HX:AUP<,T)-/[*.X,T!NB1P6B
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M6RG0=KT/5+O0BI>-N\@ARN^=*?,8I3\H-CP7S:>$=C:\LB_#XBTX[HVT!Q7
M'Z\W]L+=L;D 5GL>]@!&-#1J1#:,LP\&XU:2+LB)O?[ZIB=3)5!RG\2CR&<
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MBW^Y*$C%(&O;?;&T:/@8L$Z)L\ANU-SHO<H1IDJ.A2Y9"HOJP;>$(];[NZB
M!\"!3#UR*?3*M93&V4&BG>:P>\'">1"V[RB>ZU1SXMF#]]TZ$P]<0(RBZ8CL
M&D0+3+MX_<ZQ"#G'Z-3A]/ST8A7&H[82]-F*7V7Y8[0U!,M  UN$>]]!YJ@
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M+%3B(ZET4DX23^GAA4+%4[J+3=D&5PI6^.>YSB_)Q2D 4F/4]_,_,W;?WJ.
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MS0?04]K$/A#US8B%N49OX$8=KS[&FZE67'$4X$6?2]G?XRT^F+MA6[Z@:._
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M5P.]%NM+:2@Z_I1,>_[@A_T>X+&$2T^QN1>!\/<1MFHY4A$50,?.GQ]M]_\
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M#UT*2G(1CO"1F%,\Z!>+#Z0P,.)F&UTU73#CIX@A=9(:,9],A!?T7LRQ7-*
MR7*3W'79=?P307^B?-[5GXPFG8C&"@6::2B 7";@',;1FW8.O@3YX)V\B3O
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M+)^T<!3]EJ]:-F%S);L9Y?T5)E4A_KEX;/GU757H4^BM/TZ@^3\['A,SO_@
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M$1H\Q^5&S;LT9K*+5]PF:4RT]FYA0\GT!<8</G_W67KH* +;H@V(GW@Z9EM
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M=MR*2=HP[)1'TK_3<:)LXQGJ#K5:G]%,5>P5U,M@$A"YK?-CN<'#*("IQUG
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M;;_EKWQ>MP,L[O%WE7+P6,R5ATEU6=T;]3,3B8=8+'=8DFP#E<\>0L(X5PD
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M8U&JPD4SBEF"4$)5LK<'$<+25DU2']*0<-_CC$3<,ZN-TS^@R;<W3K&<1D*
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MJW,^*2RLZG.^#;7 W@D[ Z363;F-+5:3LXFUW=IS5B0;MU*=33!WZMI9??B
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MXX;D=1.A'-C\._SUI[N?@')=CS S>@: 8[0=FP%; <F=_.!WJ< J*OD,K'0
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M:U/K/&<\,]E JRW+U^2^8<;L1UY*2UDMYM=%$]]]_J3JH<VRF&2$)ASZ:9Q
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MNU1"U-$;H/Y"'/E'4-0AZL"X58J(*T*/((3[Y4(^BW45#=;X;J=9SHPU2X%
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MEY,F7I/3L&WHLUH;\U_)]VQI<Y.L;H4QDIZK8DSOE)Z*Z7J"%:)95@H;,Z,
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M<JU\D.H<;CMZVTPWJS^M$[Y*6MV3SUW?1/CRK:'&:=BBK5=+/:Y2K:$&P;M
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MI\]NI_%FT7USR;^R_@'3K:2> 0-=$+O1S]6P#10<T(B9K!=)(VCRT0$V_V@
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M&7!\.IU>AI!C.#^9 5'=<ZT9LM_>%US/C\\SMC9FE.W[1,*6QAM:R0S+(A=
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MEZ35T3R]DP6U^I6#%^1 GX+CW=IK#O#KG^&$'EO_J[98^(>]<PLNY;"7;[%
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M=)\\,EI/9U.;Z72AW_[CR_]4;+;^]G:Q?%K41;J:+]A88SDKD6%5)@B "A'
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M ,:C1.R$$]L[3H:3<Q>P>1M^?Y%)?-,RO<A6;"VAC,IIJ1,4FV@?](F!PZC
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M;$J#+/SK3]T- QVG)(\691?AP//S9177Q0E<A33IX'PU"2HHU"E!B<S4;(@
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MF)WCA!L2$S,2I,XD)JUI6]<V@R>O3(9@9/*/=:PX'$$[D=<#HHZ"P:*U3CH
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M_%J*R1(=*2@!J=C:A(!S"%(:B!3@U7DOSO%6 ZQO4M))<'.@9N_<3#Q"S/W
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MSS.&T?07X+._V#O$SO?3V?D:\T1XI3!H#76H "C-\L6ZTBGSHKFQ3K<YPWB
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M^OK[)@Z/BR]T4=Q'ZAU$/%?47TBD6O#%O*[<37>X0AI.SC 0VI$%CD+5T[8
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M+&Y&NS[ (2O2)N0:7"9(*1X2N2CT17*6T2BKR2$^)58?H77<CF0=0'4H/7:
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ML^-MBM+^&+?%#G%OAE-8!ZC;]QB;A,5E,:7RHRE@*0Y"G8]72LJ!%>X$^[/
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M#"K #J+N!X[H+*<E83R(>B&Q7B""$&H'I2"Y$[(8V:@YRQ_C!LTA>]-P"NL
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M9?V)$#V6TCO ^S4)/Y^%U6I:IIB_^W39&.H\S'X.ZRJ83]^']6U>DR'\V9+
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MV^9&Y N_!G0(Z@X65 ]@6S_!V"F10HCD.*3J,7M-WT5/49]**(U&Z66;L.2
M<=.G,=7\(, =+JPN;IX]-;FX9"^9Y,2:)"EJ"]5LH\\0I%'%NL@%;W.9X="!
MTZ<Q[?P@;V\@L76!P9N4V.NO-]_^YQ071-;'K[_A%SQ;)1&$-2ZF8*$X+DFW
M@H/@I #-@_(^RF!-FZL'V]$W;AS225IQ>$EVL#&O/1=[O+XKM9;9H.><T[J,
MII#?D8([YR"1LOO  D^F<<7/-F1VD@0?$">;H#BXT'I"Y*^SSQ?GRQ7'^)7Y
MITA>R\P#I#J?4"G#P''ZHGBV@?-B>*/PY FB.D';\%#8!+H#Y=(IQ,2UEXNY
MH+,>B.2:VHR> BMOZO&H9+[P8+%Q/<UCHCK9?D>!V#YRZ0EBK[_>8=O/"_S?
M"YREKY<G1T(ZX4H"H6HWZ*(BN! 07*%P7EENI72MG;Y-Q(V;\>O.XQM$ACW!
M<MV"KF.WC,;:0A&;J)X).2H0*]^T$0IU%D6:>#0G[P%QG6RV0P%B"[_N$.ET
M"KCEC=[>1/5(5IVVBQ)=S9P7 6Y5+EYLU(&ARJ7-H<<VU'4"N:$@L4TH<8A\
M>L+< ;O';S>-9JS-&E6HMYAJ)P(ER?&0F@&26R.)S5*WWJ6'6,:X9RF=[>='
MQT4'2K'U)3YC::O23H-(H=3#2TMVQ1! @S72B&(T/X$[EUW7..X)HGVO9>XB
MT2Z2YE>#=K:8)^JM"L9E"<[X"(JB2PA*"BA&\9254R*V,<Y;D]A)[#XZ6MO(
MM ?#NN+LNH7$4J\WUE,OD\E9TMF"KQ=_@HS,,592]&UJ&3>2=/I1_4"F<Q"9
MG=05]C_"8D%/_H*#W]-Z_.1V-[:>6<4Q[FY9J3&D[,&ZZ.O!38%H%7T1P=8:
M"*=2F\J!T[B[E2)I3G(*HN**''323>=L!EGO@<?@$F.-8_D7?'=K%^RUN[NU
MBX@[V*!_Q 6Y&]5HW-:IO)LN_UJEZU0QQ964 6/RM<VEAI@S@K214S 9D_5M
M3A2?HJH3!!X7*(^:. XDM:X0>-TI<#4[\C)[IV2)0G@)1I8Z$S01DP1'*)I'
MCB+4VYJ-$?B8JK''A0TE^XV@.E 0'8"*HGZ<?IC]]'?Z&&8?:A+@7V&1KS*V
M%#7)5+MC4X#/*>0/#GQP&HQ7H9A4>Z<T2EH^054OH#I4]@\WUJ$$T0.H!@W1
M6"G)*EG7S44=S>,@9&:@2,>E-]II_U)2YUUG< [?C<?#10=*<6LY_KBH2OVF
MW"EX_D\\RQ/FK3#"&1"B=M<3/(%C(D+27HN"6C/3)M/S+&FG[TKN"9N-._\0
M,NP+E/,JSG#VZM/\8G9.6YG(HG@#*3EBE106G$T*F!&HD?8;+D)K+-ZCZ/3M
MY^ 0W%]B72'O/2X^O2G7[M3$<VV4TA;0:R3F!%I'<1Z0QZ(S1N5]J_G:ZREZ
M2>GN89!W@,0Z0-XOH7;Y7A<=+M\N\#S\/<FF]G%3#+P+&52H-Y"\#!"4DY(7
M[8QH4[OV+&FG7X Q#!:'E6&O#?)J9^89@?GK/J<LMW\\R$'*!EH&'$:Q>OIM
MOOHF7>V521H=!;]U0J'"K,"M[NUY9"+X*'2C ] GB#K4!JUY]&UO1YD9:4;6
MD&2IBI$08K81A.<6M<*4&TW1?(JJ\4=%#(&/AW9D,#ET;T+V[P?\\!'#FI.&
M?7^? HWPND1"!V17!_]Y2Z#1!!^!R&4=:YGCR1F5V]&'-R_Y@79>^F[%Y%M@
MLY05!HI*@TRD,=E$\,@]<*F$R\QEVB";+'Y;"OLU-KO@9O-$U 'ET[WA.:!0
MY-$SAC4]K:=K;=RP#*=])#DHJ HH71($)NH--Y]B2"1J;%/[<0R'YBZB:0=5
M:$UF@%B;?;BD@;QQ"[GHZ%0(); V-[W7DM.O5=D%$1M=F+TYWT%,_CJ<A5G"
M/S\BGO]6/UV%4L]IM2@4!WH%9/EJ6[9H("JRAT5K6[PS@?LVA4";*.H$1/L+
M>]Z \YTBZ.I8EE2+"=06?,X)5"DUT> 3Q&ALX+5\/;<99+:9IG%1-(S,MP#2
M'@+H $K72G;;'))Y)YC)!CROK?BX]94O&;3T+@:ELHIMAK,_(J4_X.PCXPU;
MV'X,'Q$QU;F<O#G_B(O?YK,/]+Q/U_,[+MOKN2**20QTP@PJVE4G*P:F2"UY
M]H8%^9P/_/0KQCT5&Q@. W*S(ROR]3;C+2WMTX%Y<-YJ8@K2=U%E<(IIGGQ"
M)]HX,X]I&7\TYK!NS('<[@DO[\*_?@_TW&DX6TZ$8SQS[L#X2(:P-N>,NF20
MGE;@LS5%-<Y3W26G$^=W3QEO@LS>#.\)-?^<+_[Z=?9V,4^X)+ZP*'+B"3BK
MY:W1&0@B2Z!]T[.@G3:Q3?G&>GHZL38#XV9_EO<$G)^GL^GR(^9?YO.\G!B9
M@LHQ0"%K7.^&1(A>*XA2D4?&LY2-.H>OIV?\R;@M@+,_RWL"SB^+.<$>,_I@
M60 O0^W454_<M12UJ:_5,KE@19OFR_?I&+<PHA50=F=QK[=)_SR?I[]>AR7F
M'^:?/N-LN7KB/H<"&YXTR-' -E0.=$!PFP6NE52W+WN'9^2+T/N7Y\L_/Q+Z
M8B7G;?BZ*FZYR1B33X*%8AX(K-Y;KBKB+ ;(+DN;/&=6-ZH5/HCN@ZL&MWW[
MZ[MOOSU9"X+)P"@8C>CJ3 5),:0FU90Y^MJ 2%)\.B[;UA,^\J67XV'U4='A
M$07>ZU'J>JNT?T''D\]K:$<;EGH<B-!@!$IC!62C:[\&G2 Z-,"%9,PR%G*C
MCM3C6M/;@H2?"#?SKXB7+?OQ5J/N$O7J[.PJR?>FO,,T_S";_A\118'S_)+2
M6[53VF91R)/5NE9?EFB E-V#5MZEX&.M:6A<83+PDD[: N^"[\U5*V."9-2.
M4JO$]"T?'NTWK^I5S=J/Z/SKG4+D52;[_<<P>_.YLF-9*Z<O6;1<7GRZ_+\'
MA3\J"YY$1+ B!U R(WA/8N.9&V3%\^3\<];]6,2.F],902&Z1,%I^2Q7Q@'S
MC2E9^[&?_J[?X@&58T.^OJ%'-  _^G"@8K 2@ZD%3')UER.!J]??T2/:;$+
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MX)SPD#VBE)81RML,UWLI/9!3D(4+9<"C13(-7((3BH,5GG86IG@RC8K+OO=
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M0^FU-W)7OZA?ZE"%__BW_P=02P,$%     @ 58)B4YLUV*DK"   (R(  !H
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M>DS"6ODWHA+2N^=2W L3D'X:@YS6T>OU0WVK'\@':L!\E9+QC-RE:BHY&_+
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MN>_%Y[T?-(IK_G7%?.?9_Q=02P$"% ,4    " !5@F)32Y]\I#*' @#? QL
M$0              @ $     97AE;"TR,#(Q,3 P,2YH=&U02P$"% ,4
M" !5@F)3;Q-+K]L1  !.Q0  $0              @ %AAP( 97AE;"TR,#(Q
M,3 P,2YX<V102P$"% ,4    " !5@F)3?-,IT<L9  #% P$ %0
M    @ %KF0( 97AE;"TR,#(Q,3 P,5]C86PN>&UL4$L! A0#%     @ 58)B
M4QO<=8[S2   GUD# !4              ( !:;," &5X96PM,C R,3$P,#%?
M9&5F+GAM;%!+ 0(4 Q0    ( %6"8E-AT2J161$! ,+& 0 4
M  "  8_\ @!E>&5L+3(P,C$Q,# Q7V<Q+FIP9U!+ 0(4 Q0    ( %6"8E.W
M0Y>LE\$  ,\9"  5              "  1H.! !E>&5L+3(P,C$Q,# Q7VQA
M8BYX;6Q02P$"% ,4    " !5@F)3+)Y:&[]T  "5@P4 %0
M@ 'DSP0 97AE;"TR,#(Q,3 P,5]P<F4N>&UL4$L! A0#%     @ 58)B4YLU
MV*DK"   (R(  !H              ( !UD0% &5X96PR,#(Q,#DS,&5X:&EB
M:70S,3$N:'1M4$L! A0#%     @ 58)B4]!A\V8A"   JB$  !H
M     ( !.4T% &5X96PR,#(Q,#DS,&5X:&EB:70S,3(N:'1M4$L! A0#%
M  @ 58)B4Y=A^N:,!0  0AH  !H              ( !DE4% &5X96PR,#(Q
H,#DS,&5X:&EB:70S,C$N:'1M4$L%!@     *  H I (  %9;!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
